

**PCT**

WORLD INTELLECTUAL PROPERTY ORGANIZATION  
International Bureau



INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

<p>(51) International Patent Classification <sup>6</sup> : A01H 1/00, C07H 21/04, C07K 14/00, C12N 5/04, 5/10, C12P 19/34, C12Q 1/68</p>	<p>A1</p>	<p>(11) International Publication Number: <b>WO 98/30083</b>  (43) International Publication Date: 16 July 1998 (16.07.98)</p>
<p>(21) International Application Number: PCT/US98/00615 (22) International Filing Date: 9 January 1998 (09.01.98)  (30) Priority Data: 08/781,734 10 January 1997 (10.01.97) US  (71) Applicant: THE REGENTS OF THE UNIVERSITY OF CALIFORNIA [US/US]; 22nd floor, 300 Lakeside Drive, Oakland, CA 94612 (US).  (72) Inventors: SHEN, Kathy; 44228 Country Club Drive, El Macero, CA 95618 (US). MEYERS, Blake; 904 Drake Drive, Davis, CA 95616 (US). MICHELMORE, Richard, W.; 36757 Russel Boulevard, Davis, CA 95616 (US).  (74) Agents: EINHORN, Gregory, P. et al.; Townsend and Townsend and Crew LLP, 8th floor, Two Embarcadero Center, San Francisco, CA 94111 (US).</p>		<p>(81) Designated States: CA, JP, European patent (AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE).  <b>Published</b> <i>With international search report.</i></p>
<p>(54) Title: RG NUCLEIC ACIDS FOR CONFERRING DISEASE RESISTANCE TO PLANTS</p> <p>(57) Abstract</p> <p>The present invention provides RG nucleic acids and proteins which confer disease resistance to plants. The nucleic acids can be used to produce transgenic plants resistant to pests. Antibodies to proteins of the invention are also provided.</p>		

**FOR THE PURPOSES OF INFORMATION ONLY**

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AL	Albania	ES	Spain	LS	Lesotho	SI	Slovenia
AM	Armenia	FI	Finland	LT	Lithuania	SK	Slovakia
AT	Austria	FR	France	LU	Luxembourg	SN	Senegal
AU	Australia	GA	Gabon	LV	Latvia	SZ	Swaziland
AZ	Azerbaijan	GB	United Kingdom	MC	Monaco	TD	Chad
BA	Bosnia and Herzegovina	GE	Georgia	MD	Republic of Moldova	TG	Togo
BB	Barbados	GH	Ghana	MG	Madagascar	TJ	Tajikistan
BE	Belgium	GN	Guinea	MK	The former Yugoslav Republic of Macedonia	TM	Turkmenistan
BF	Burkina Faso	GR	Greece	ML	Mali	TR	Turkey
BG	Bulgaria	HU	Hungary	MN	Mongolia	TT	Trinidad and Tobago
BJ	Benin	IE	Ireland	MR	Mauritania	UA	Ukraine
BR	Brazil	IL	Israel	MW	Malawi	UG	Uganda
BY	Belarus	IS	Iceland	MX	Mexico	US	United States of America
CA	Canada	IT	Italy	NE	Niger	UZ	Uzbekistan
CF	Central African Republic	JP	Japan	NL	Netherlands	VN	Viet Nam
CG	Congo	KE	Kenya	NO	Norway	YU	Yugoslavia
CH	Switzerland	KG	Kyrgyzstan	NZ	New Zealand	ZW	Zimbabwe
CI	Côte d'Ivoire	KP	Democratic People's Republic of Korea	PL	Poland		
CM	Cameroon	KR	Republic of Korea	PT	Portugal		
CN	China	KZ	Kazakstan	RO	Romania		
CU	Cuba	LC	Saint Lucia	RU	Russian Federation		
CZ	Czech Republic	LI	Liechtenstein	SD	Sudan		
DE	Germany	LK	Sri Lanka	SE	Sweden		
DK	Denmark	LR	Liberia	SG	Singapore		
EE	Estonia						

## RG NUCLEIC ACIDS FOR CONFERRING DISEASE RESISTANCE TO PLANTS

5

The present application is a continuation-in-part application ("CIP") of U.S. Patent Application Serial No. ("USSN") 08/781,734, filed January 10, 1997. The  
10      aforementioned application is explicitly incorporated herein by reference in its entirety and  
for all purposes.

This invention was made with Government support under Grant Nos. 92-37300-7547 and 95-37300-1571, awarded by the United States Department of Agriculture.  
15      The Government has certain rights in this invention.

## FIELD OF THE INVENTION

The present invention relates generally to plant molecular biology. In particular, it relates to nucleic acids and methods for conferring pest resistance in plants.  
20      particularly lettuce.

## BACKGROUND OF THE INVENTION

Recently, several resistance genes have been cloned by several groups from several plants. Many of these genes are sequence related. The derived amino acid  
25      sequences of the most common class, *RPS2*, *RPM1* (bacterial resistances in *Arabidopsis* (Mindrinos *et al.* *Cell* 78:1089-1099 (1994)); Bent *et al.* *Science* 265:1856-1860 (1994); Grant *et al.*, *Science* 269:843-846 (1995)), *L6* (fungal resistance in flax; Lawrence, *et al.*, *The Plant Cell* 7:1195-1206 (1995)), and *N*, (virus resistance in tobacco; Whitham, *et al.*, *Cell* 78:1101-1115 (1994); and U.S. Patent No. 5,571,706), all contain leucine-rich  
30      repeats (LRR) and nucleotide binding sites (NBS).

The NBS is a common motif in several mammalian gene families encoding signal transduction components (e.g., *Ras*) and is associated with ATP/GTP-binding sites.

The NBS is a common motif in several mammalian gene families encoding signal transduction components (e.g., *Ras*) and is associated with ATP/GTP-binding sites.

LRR domains can mediate protein-protein interactions and are found in a variety of proteins involved in signal transduction, cell adhesion and various other functions. LRRs are leucine rich regions often comprising 20-30 amino acid repeats where leucine and other aliphatic residues occur periodically. LRRs can function extracellularly or intracellularly.

Since the onset of civilization, plant diseases have had catastrophic effects on crops and the well-being of the human population. Plant diseases continue to effect enormous human and economic costs. An increasing human population and decreasing amounts of arable land make all approaches to preventing and treating plant pathogen destruction critical. The ability to control and enhance a plant's protective responses against pathogens would be of enormous benefit. Tissue-specific and temporal control of mechanisms responsible for plant cell death would also be of great practical and economic value. The present invention fulfills these and other needs.

What is needed in the art are plant disease resistance genes and means to create transgenic disease resistance plants, particularly in lettuce. Further, what is needed in the art is a means to DNA fingerprint cultivars and germplasm with respect to their disease resistance haplotypes for use in plant breeding programs. The present invention provides these and other advantages.

### SUMMARY OF THE INVENTION

The present invention provides isolated nucleic acid constructs. These constructs comprise an RG (resistance gene) polynucleotide which encodes an RG polypeptide having at least 60% sequence identity to an RG polypeptide selected from the group consisting of: an RG1 polypeptide, an RG2 polypeptide, an RG3 polypeptide, and an RG4 polypeptide. RG1, RG2, RG3, RG4, and the like, represent individual "RG families." Each "RG family," as defined herein, is a group of polypeptide sequences that have at least 60% amino acid sequence identity. Individual members of an RG family, *i.e.*, individual species of the genus, typically map to the same genomic locus. The invention provides for constructs comprising nucleotides encoding the RG families of the



invention, which can include sequences encoding a leucine rich region (LRR), and/or a nucleotide binding site (NBS), or both.

The invention provides for an isolated nucleic acid construct comprising an RG polynucleotide which encodes an RG polypeptide having at least 60% sequence identity to an RG polypeptide from an RG family selected from the group consisting of: an RG1 polypeptide, an RG2 polypeptide, an RG3 polypeptide, an RG4 polypeptide, an RG5 polypeptide, and an RG7 polypeptide. In alternative embodiments, the nucleic acid construct comprises an RG polynucleotide which encodes an RG polypeptide comprising an leucine rich region (LRR), or, an RG polypeptide comprising a nucleotide binding site (NBS). The nucleic acid construct can comprise a polynucleotide which is a full length gene. In another embodiment, the nucleic acid construct encodes a fusion protein.

In one embodiment, the nucleic acid construct comprises a sequence encoding an RG1 polypeptide. The RG1 polypeptide can be encoded by a polynucleotide sequence selected from the group consisting of SEQ ID NO:1 (RG1A), SEQ ID NO:2 and SEQ ID NO:137 (RG1B), SEQ ID NO: 3 (RG1C), SEQ ID NO:4 (RG1D), SEQ ID NO:5 (RG1E), SEQ ID NO:6 (RG1F), SEQ ID NO:7 (RG1G), SEQ ID NO:8 (RG1H), SEQ ID NO:9 (RG1I), and SEQ ID NO:10 (RG1J).

In another embodiment, the nucleic acid construct comprises a sequence encoding an RG2 polypeptide. The RG2 polypeptide can be encoded by a polynucleotide sequence selected from the group consisting of: SEQ ID NO:21 and SEQ ID NO:27 (RG2A); SEQ ID NO:23 and SEQ ID NO:28 (RG2B); SEQ ID NO:29 (RG2C); SEQ ID NO:30 (RG2D); SEQ ID NO:31 (RG2E); SEQ ID NO:32 (RG2F); SEQ ID NO:33 (RG2G); SEQ ID NO:34 (RG2H); SEQ ID NO:35 (RG2I); SEQ ID NO:36 (RG2J); SEQ ID NO:37 (RG2K); SEQ ID NO:38 (RG2L); SEQ ID NO:39 (RG2M); SEQ ID NO:87 (RG2A); SEQ ID NO:89 (RG2B); SEQ ID NO:91 (RG2C); SEQ ID NO:93 (RG2D) and SEQ ID NO:94 (RG2D); SEQ ID NO:96 (RG2E); SEQ ID NO:98 (RG2F); SEQ ID NO:100 (RG2G); SEQ ID NO:102 (RG2H); SEQ ID NO:104 (RG2I); SEQ ID NO:106 (RG2J) and SEQ ID NO:107 (RG2J); SEQ ID NO:109 (RG2K) and (SEQ ID NO:110 (RG2K); SEQ ID NO:112 (RG2L); SEQ ID NO:114 (RG2M); SEQ ID NO:116 (RG2N); SEQ ID NO:118 (RG2O); SEQ ID NO:120 (RG2P); SEQ ID NO:122 (RG2Q); SEQ ID NO:124 (RG2S); SEQ ID NO:126 (RG2T); SEQ ID NO:128 (RG2U); SEQ ID NO:130 (RG2V); and, SEQ ID NO:132 (RG2W).

In other embodiments, the nucleic acid construct comprises a RG3 sequence (SEQ ID NO:68) encoding an RG3 polypeptide (SEQ ID NO:138) (RG3). In other embodiments, the nucleic acid construct comprises an RG4 sequence (SEQ ID NO:69) encoding an RG4 polypeptide (SEQ ID NO:139) (RG4).

5 In other embodiments, the nucleic acid construct comprises a RG5 sequence (SEQ ID NO:134) encoding an RG5 polypeptide (SEQ ID NO:135). The RG5 polypeptide can be encoded by a polynucleotide sequence as set forth in SEQ ID NO:134.

The invention also provides for a nucleic acid construct which comprises an RG7 sequence encoding an RG7 polypeptide. The RG7 polypeptide can be encoded by a polynucleotide sequence as set forth in SEQ ID NO:136.

10 In further embodiments, the nucleic acid construct can further comprise a promoter operably linked to the RG polynucleotide. In alternative embodiments, the promoter can be a plant promoter; a disease resistance promoter; a lettuce promoter; a constitutive promoter; an inducible promoter; or, a tissue-specific promoter. The nucleic acid construct can comprise a promoter sequence from an RG gene linked to a heterologous polynucleotide.

The invention also provides for a transgenic plant comprising a recombinant expression cassette comprising a promoter operably linked to an RG polynucleotide. The expression cassette can comprise a plant promoter or a viral promoter; the plant promoter can be a heterologous promoter. In one embodiment, the transgenic plant is lettuce. In alternative embodiments, the transgenic plant comprises an expression cassette which includes an RG polynucleotide selected from the group consisting of SEQ ID NO:1 (RG1A); SEQ ID NO:2 and SEQ ID NO:137 (RG1B); SEQ ID NO:3 (RG1C); SEQ ID NO:4 (RG1D); SEQ ID NO:5 (RG1E); SEQ ID NO:6 (RG1F); SEQ ID NO:7 (RG1G); SEQ ID NO:8 (RG1H); SEQ ID NO:9 (RG1I) and SEQ ID NO:10 (RG1J); SEQ ID NO:21 and SEQ ID NO:27 (RG2A); SEQ ID NO:23 and SEQ ID NO:28 (RG2B); SEQ ID NO:29 (RG2C); SEQ ID NO:30 (RG2D); SEQ ID NO:31 (RG2E); SEQ ID NO:32 (RG2F); SEQ ID NO:33 (RG2G); SEQ ID NO:34 (RG2H); SEQ ID NO:35 (RG2I); SEQ ID NO:36 (RG2J); SEQ ID NO:37 (RG2K); SEQ ID NO:38 (RG2L); SEQ ID NO:39 (RG2M); SEQ ID NO:87 (RG2A); SEQ ID NO:89 (RG2B); SEQ ID NO:91 (RG2C); SEQ ID NO:93 (RG2D) and SEQ ID NO:94 (RG2D); SEQ ID NO:96 (RG2E); SEQ ID NO:98 (RG2F); SEQ ID NO:100 (RG2G); SEQ ID NO:102 (RG2H); SEQ ID NO:104

(RG2I); SEQ ID NO:106 (RG2J) and SEQ ID NO:107 (RG2J); SEQ ID NO:109 (RG2K) and (SEQ ID NO:110 (RG2K); SEQ ID NO:112 (RG2L); SEQ ID NO:114 (RG2M); SEQ ID NO:116 (RG2N); SEQ ID NO:118 (RG2O); SEQ ID NO:120 (RG2P); SEQ ID NO:122 (RG2Q); SEQ ID NO:124 (RG2S); SEQ ID NO:126 (RG2T); SEQ ID NO:128 (RG2U); SEQ ID NO:130 (RG2V); and, SEQ ID NO:132 (RG2W); SEQ ID NO:68 (RG3); SEQ ID NO:69 (RG4); SEQ ID NO:134 (RG5); or SEQ ID NO:136 (RG7).

The invention provide for a transgenic plant comprising an expression cassette comprising an RG polynucleotide which can encode an RG1 polypeptide selected from the group consisting of SEQ ID NO:11 (RG1A), SEQ ID NO:12 (RG1B), SEQ ID NO:13 (RG1C), SEQ ID NO:14 (RG1D), SEQ ID NO:15 (RG1E), SEQ ID NO:16 (RG1F), SEQ ID NO:17 (RG1G), SEQ ID NO:18 (RG1H), SEQ ID NO:19 (RG1I), or SEQ ID NO:20 (RG1J); or, an RG2 polypeptide selected from the group consisting of SEQ ID NO:22 and SEQ ID NO:41 (RG2A); SEQ ID NO:24 and SEQ ID NO:42 (RG2B); SEQ ID NO:43 (RG2C); SEQ ID NO:44 (RG2D); SEQ ID NO:45 (RG2E); SEQ ID NO:46 (RG2F); SEQ ID NO:47 (RG2G); SEQ ID NO:48 (RG2H); SEQ ID NO:49 (RG2I); SEQ ID NO:50 (RG2J); SEQ ID NO:51 (RG2K); SEQ ID NO:52 (RG2L); SEQ ID NO:53 (RG2M); SEQ ID NO:88 (RG2A); SEQ ID NO:90 (RG2B); SEQ ID NO:92 (RG2C); SEQ ID NO:95 (RG2D); SEQ ID NO:97 (RG2E); SEQ ID NO:99 (RG2F); SEQ ID NO:101 (RG2G); SEQ ID NO:103 (RG2H); SEQ ID NO:105 (RG2I); SEQ ID NO:108 (RG2J); SEQ ID NO:111 (RG2K); SEQ ID NO:113 (RG2L); SEQ ID NO:115 (RG2M); SEQ ID NO:117 (RG2N); SEQ ID NO:119 (RG2O); SEQ ID NO:121 (RG2P); SEQ ID NO:123 (RG2Q); SEQ ID NO:125 (RG2S); SEQ ID NO:127 (RG2T); SEQ ID NO:129 (RG2U); SEQ ID NO:131 (RG2V); and, SEQ ID NO:133 (RG2W); an RG4 polypeptide as set forth by SEQ ID NO:72; an RG5 polypeptide with a sequence as set forth by SEQ ID NO:135; or, an RG7 polypeptide.

The invention also provides for a method of enhancing disease resistance in a plant, the method comprising introducing into the plant a recombinant expression cassette comprising a promoter functional in the plant and operably linked to an RG polynucleotide sequence. In this method, the plant can be a lettuce plant; and, the RG polynucleotide can encode an RG polypeptide selected from the group consisting of an RG1 polypeptide selected from the group consisting of SEQ ID NO:11 (RG1A), SEQ ID NO:12 (RG1B), SEQ ID NO:13 (RG1C), SEQ ID NO:14 (RG1D), SEQ ID NO:15 (RG1E), SEQ ID

NO:16 (RG1F), SEQ ID NO:17 (RG1G), SEQ ID NO:18 (RG1H), SEQ ID NO:19 (RG1I), or SEQ ID NO:20 (RG1J); or, an RG2 polypeptide selected from the group consisting of SEQ ID NO:22 and SEQ ID NO:41 (RG2A); SEQ ID NO:24 and SEQ ID NO:42 (RG2B); SEQ ID NO:43 (RG2C); SEQ ID NO:44 (RG2D); SEQ ID NO:45 (RG2E); SEQ ID NO:46 (RG2F); SEQ ID NO:47 (RG2G); SEQ ID NO:48 (RG2H); SEQ ID NO:49 (RG2I); SEQ ID NO:50 (RG2J); SEQ ID NO:51 (RG2K); SEQ ID NO:52 (RG2L); SEQ ID NO:53 (RG2M); SEQ ID NO:72; SEQ ID NO:74; SEQ ID NO:88 (RG2A); SEQ ID NO:90 (RG2B); SEQ ID NO:92 (RG2C); SEQ ID NO:95 (RG2D); SEQ ID NO:97 (RG2E); SEQ ID NO:99 (RG2F); SEQ ID NO:101 (RG2G); SEQ ID NO:103 (RG2H); SEQ ID NO:105 (RG2I); SEQ ID NO:108 (RG2J); SEQ ID NO:111 (RG2K); SEQ ID NO:113 (RG2L); SEQ ID NO:115 (RG2M); SEQ ID NO:117 (RG2N); SEQ ID NO:119 (RG2O); SEQ ID NO:121 (RG2P); SEQ ID NO:123 (RG2Q); SEQ ID NO:125 (RG2S); SEQ ID NO:127 (RG2T); SEQ ID NO:129 (RG2U); SEQ ID NO:131 (RG2V); and, SEQ ID NO:133 (RG2W). In this method, the promoter can be a plant disease resistance promoter, a tissue-specific promoter, a constitutive promoter, or an inducible promoter.

The invention also provides for a method of detecting RG resistance genes in a nucleic acid sample, the method comprising: contacting the nucleic acid sample with an RG polynucleotide to form a hybridization complex; and, wherein the formation of the hybridization complex is used to detect the RG resistance gene in the nucleic acid sample. In this method, the RG polynucleotide can be an RG1 polynucleotide, an RG2 polynucleotide, an RG3 polynucleotide, an RG4 polynucleotide, an RG5 polynucleotide or an RG7 polynucleotide. In this method, the RG resistance gene can be amplified prior to the step of contacting the nucleic acid sample with the RG polynucleotide, and, the RG resistance gene can be amplified by the polymerase chain reaction. In one embodiment, the RG polynucleotide is labeled.

The invention further provides for an RG polypeptide having at least 60% sequence identity to a polypeptide selected from the group consisting of: an RG1 polypeptide, an RG2 polypeptide, an RG3 polypeptide, an RG4 polypeptide, an RG5 polypeptide, and an RG7 polypeptide.

A further understanding of the nature and advantages of the present invention may be realized by reference to the remaining portions of the specification, the figures and claims.

All publications, patents and patent applications cited herein are hereby expressly incorporated by reference for all purposes.

### DETAILED DESCRIPTION OF THE INVENTION

This invention relates to families of RG genes, particularly from *Lactuca sativa*. Nucleic acid sequences of the present invention can be used to confer resistance in plants to a variety of pests including viruses, fungi, nematodes, insects, and bacteria. Sequences from within the RG genes can be used to fingerprint cultivars or germplasm for the presence of desired resistance genes. Promoters of RG genes can be used to drive heterologous gene expression under conditions in which RG genes are expressed. Further, the present invention provides RG proteins and antibodies specifically reactive to RG proteins. Antibodies to RG proteins can be used to detect the type and amount of RG protein expressed in a plant sample.

The present invention has use over a broad range of types of plants, including species from the genera *Cucurbita*, *Rosa*, *Vitis*, *Juglans*, *Fragaria*, *Lotus*, *Medicago*, *Onobrychis*, *Trifolium*, *Trigonella*, *Vigna*, *Citrus*, *Linum*, *Geranium*, *Manihot*, *Daucus*, *Arabidopsis*, *Brassica*, *Raphanus*, *Sinapis*, *Atropa*, *Capsicum*, *Datura*, *Hyoscyamus*, *Lycopersicon*, *Nicotiana*, *Solanum*, *Petunia*, *Digitalis*, *Majorana*, *Ciahorium*, *Helianthus*, *Lactuca*, *Bromus*, *Asparagus*, *Antirrhinum*, *Heterocallis*, *Nemesis*, *Pelargonium*, *Panieum*, *Pennisetum*, *Ranunculus*, *Senecio*, *Salpiglossis*, *Cucumis*, *Browaalia*, *Glycine*, *Pisum*, *Phaseolus*, *Lolium*, *Oryza*, *Zea*, *Avena*, *Hordeum*, *Secale*, *Triticum*, and, *Sorghum*. In particularly preferred embodiments, species from the family *Compositae* and in particular the genus *Lactuca* are employed such as *L. sativa* and such subspecies as *crispa*, *longifolia*, and *asparagina*.

The nucleic acids of the present invention can be used in marker-aided selection. Marker-aided selection does not require the complete sequence of the gene or precise knowledge of which sequence confers which specificity. Instead, partial sequences can be used as hybridization probes or as the basis for oligonucleotide primers to amplify nucleic acid, e.g., by PCR. Partial sequences can be used in other methods, such as to

follow the segregation of chromosome segments containing resistance genes in plants.

Because the RG marker is the gene itself, there can be negligible recombination between the marker and the resistance phenotype. Thus, RG polynucleotides of the present invention provide an optimal means to DNA fingerprint cultivars and wild germplasm with respect to their disease resistance haplotypes. This can be used to indicate which germplasm accessions and cultivars carry the same resistance genes. At present, selection of plants (e.g., lettuce) for resistance to some diseases is slow and difficult. But linked markers allow indirect selection for such resistance genes. Moreover, RG markers also allow resistance genes to be identified and combined in a manner that would not otherwise be possible. Numerous accessions have been identified that provide resistance to all isolates of downy mildew (*Bremia lactucae*). However, without molecular markers it is impossible to combine such resistances from different sources. The nucleic acid sequences of the invention provide for a fast and convenient means to identify and combine resistances from different sources. The RG markers of the invention can also be used to identify recombinants that have new combinations of resistance genes in *cis* on the same chromosome.

In addition, RG markers may allow the identification of the Mendelian factors determining traits, such as field resistance to downy mildew. Once such markers have been identified, they will greatly increase the ease with which field resistance can be transferred between lines and combined with other resistances.

In another application, primers to RG sequences can be also designed to amplify sequences that are conserved in multiple RG family members. This gives genetic information on multiple RG family members. Alternatively, one or more primers can be made to sequences unique to a single resistance gene genus or a single RG specie. This allows an analysis of individual family groups (an RG genus) or an individual family member (a specie). Primers made to individual RGs at the edge of each cluster can be used to select for recombinants within the cluster. This minimizes the amount of linkage drag during introgression. Classical and molecular genetics has shown that pest resistance genes tend to be clustered in the genome. Pest resistance loci comprise arrays of genes and exhibit a variety of complex haplotypes rather than being simple alternate allelic forms. Pest resistance is conferred by families, or genuses, of related RG sequences, individual members, or species, of which have evolved to have a different specificity.

Oligonucleotide primers can be designed that amplify members from multiple haplotypes, or genuses, or amplify only members of one genus, or only amplify an individual specie. This will provide codominant information and allow heterozygotes to be distinguished from homozygotes.

5 Further, comparison of RG sequences will allow a determination of which sequences are critical for resistance and will ultimately lead to engineering resistance genes with new specificities. Resistance gene sequences were not previously available for lettuce. Marker-aided selection will greatly increase the precision and speed of breeding for disease resistance. Transgenic approaches will allow pyramiding of resistance genes  
10 into a single Mendelian unit, transfer between sexually-incompatible species, substitute for conventional backcrossing procedures, and allow expression of other genes in parallel with resistance genes.

The RG polynucleotides also have utility in the construction of disease resistant transgenic plants. This avoids lengthy and sometimes difficult backcrossing  
15 programs currently necessary for introgression of resistance. It is also possible to transfer resistance polynucleotides between sexually-incompatible species, thereby greatly increasing the germplasm pool that can be used as a source of resistance genes. Cloning of multiple RG sequences in a single cassette will allow pyramiding of genes for resistance against multiple isolates of a single pathogen such as downy mildew or against multiple  
20 pathogens. Once introduced, such a cassette can be manipulated by classical breeding methods as a single Mendelian unit.

Transgenic plants of the present invention can also be constructed using an RG promoter. The promoter sequences from RG sequences of the invention can be used with RG genes or heterologous genes. Thus, RG promoters can be used to express a  
25 variety of genes in the same temporal and spatial patterns and at similar levels to resistance genes.

### **Nucleic acids of the Invention and Their Preparation**

#### ***RG Polynucleotide Families***

30 The present invention provides isolated nucleic acid constructs which comprise an RG polynucleotide. In alternative embodiments, the RG polynucleotide is at least 18 nucleotides in length, typically at least 20, 25, or 30 nucleotides in length, more

typically at least 100 nucleotides in length, generally at least 200 nucleotides in length, preferably at least 300 nucleotides in length, more preferably at least 400 nucleotides in length, and most preferably at least 500 nucleotides in length.

In particularly preferred embodiments, the RG polynucleotide encodes a RG protein which confers resistance to plant pests. This RG protein can be longer, equivalent, or shorter than the RG protein encoded by an RG gene. In various embodiments, an RG polynucleotide can hybridize under stringent conditions to members of an RG family (an RG genus); *e.g.*, it can hybridize to a member of the RG1 RG family, such as an RG1 polynucleotide selected from the group consisting of: SEQ ID NO:1 (RG1A); SEQ ID NO:2 and SEQ ID NO:137 (RG1B); SEQ ID NO:3 (RG1C); SEQ ID NO:4 (RG1D); SEQ ID NO:5 (RG1E); SEQ ID NO:6 (RG1F); SEQ ID NO:7 (RG1G); SEQ ID NO:8 (RG1H); SEQ ID NO:9 (RG1I) and SEQ ID NO:10 (RG1J).

In other embodiments, the polynucleotide can also hybridize under stringent conditions to a member of the RG2 family; such as an RG2 polynucleotide selected from the group consisting of: SEQ ID NO:21 and SEQ ID NO:27 (RG2A); SEQ ID NO:23 and SEQ ID NO:28 (RG2B); SEQ ID NO:29 (RG2C); SEQ ID NO:30 (RG2D); SEQ ID NO:31 (RG2E); SEQ ID NO:32 (RG2F); SEQ ID NO:33 (RG2G); SEQ ID NO:34 (RG2H); SEQ ID NO:35 (RG2I); SEQ ID NO:36 (RG2J); SEQ ID NO:37 (RG2K); SEQ ID NO:38 (RG2L); SEQ ID NO:39 (RG2M); SEQ ID NO:87 (RG2A); SEQ ID NO:89 (RG2B); SEQ ID NO:91 (RG2C); SEQ ID NO:93 (RG2D) and SEQ ID NO:94 (RG2D); SEQ ID NO:96 (RG2E); SEQ ID NO:98 (RG2F); SEQ ID NO:100 (RG2G); SEQ ID NO:102 (RG2H); SEQ ID NO:104 (RG2I); SEQ ID NO:106 (RG2J) and SEQ ID NO:107 (RG2J); SEQ ID NO:109 (RG2K) and (SEQ ID NO:110 (RG2K); SEQ ID NO:112 (RG2L); SEQ ID NO:114 (RG2M); SEQ ID NO:116 (RG2N); SEQ ID NO:118 (RG2O); SEQ ID NO:120 (RG2P); SEQ ID NO:122 (RG2Q); SEQ ID NO:124 (RG2S); SEQ ID NO:126 (RG2T); SEQ ID NO:128 (RG2U); SEQ ID NO:130 (RG2V); and, SEQ ID NO:132 (RG2W).

In alternative embodiments, each RG2 gene can also include an AC15 sequence which hybridizes under stringent conditions to a polynucleotide selected from the group consisting of: SEQ ID NO:56 (AC15-2A); SEQ ID NO:57 (AC15-2B); SEQ ID NO:58 (AC15-2C); SEQ ID NO:59 (AC15-2D); SEQ ID NO:60 (AC15-2E); SEQ ID NO:61 (AC15-2G); SEQ ID NO:62 (AC15-2H); SEQ ID NO:63 (AC15-2I); SEQ ID



NO:64 (AC15-2J); SEQ ID NO:65 (AC15-2L); SEQ ID NO:66 (AC15-2N); SEQ ID NO:67 (AC15-2O).

In other embodiments, an RG polynucleotide can hybridize under stringent conditions to an RG3 (SEQ ID NO:68), an RG4 (SEQ ID NO:69), and RG5 (SEQ ID NO:135), and an RG7 (SEQ ID NO:137), RG family member.

The present invention further provides nucleic acid constructs which comprise an RG polynucleotide which encodes RG polypeptides from various RG families; such as an RG polypeptide having at least 60% sequence identity to an RG polypeptide selected from the group consisting of: an RG1 polypeptide, an RG2 polypeptide, an RG3 polypeptide, and RG4 polypeptide, and RG5 polypeptide, and an RG7 polypeptide.

Exemplary RG1 polypeptides have the sequences shown in SEQ ID NO:2 (RG1A), SEQ ID NO:4 (RG1B), SEQ ID NO:6 (RG1C), SEQ ID NO:8 (RG1D), SEQ ID NO:10 (RG1E), SEQ ID NO:12 (RG1F), SEQ ID NO:14 (RG1G), SEQ ID NO:16 (RG1H), SEQ ID NO:20 (RG1I). Exemplary RG2 polypeptides have the sequences shown in SEQ ID NO:22 and SEQ ID NO:41 (RG2A); SEQ ID NO:24 and SEQ ID NO:42 (RG2B); SEQ ID NO:43 (RG2C); SEQ ID NO:44 (RG2D); SEQ ID NO:45 (RG2E); SEQ ID NO:46 (RG2F); SEQ ID NO:47 (RG2G); SEQ ID NO:48 (RG2H); SEQ ID NO:49 (RG2I); SEQ ID NO:50 (RG2J); SEQ ID NO:51 (RG2K); SEQ ID NO:52 (RG2L); SEQ ID NO:53 (RG2M); SEQ ID NO:88 (RG2A); SEQ ID NO:90 (RG2B); SEQ ID NO:92 (RG2C); SEQ ID NO:95 (RG2D); SEQ ID NO:97 (RG2E); SEQ ID NO:99 (RG2F); SEQ ID NO:101 (RG2G); SEQ ID NO:103 (RG2H); SEQ ID NO:105 (RG2I); SEQ ID NO:108 (RG2J); SEQ ID NO:111 (RG2K); SEQ ID NO:113 (RG2L); SEQ ID NO:115 (RG2M); SEQ ID NO:117 (RG2N); SEQ ID NO:119 (RG2O); SEQ ID NO:121 (RG2P); SEQ ID NO:123 (RG2Q); SEQ ID NO:125 (RG2S); SEQ ID NO:127 (RG2T); SEQ ID NO:129 (RG2U); SEQ ID NO:131 (RG2V); and, SEQ ID NO:133 (RG2W).

An exemplary RG3 polypeptide has the sequence shown in SEQ ID NO:138. An exemplary RG4 polypeptide has the sequence shown in SEQ ID NO:139. RG polynucleotides will have at least 60% identity, more typically at least 65% identity, generally at least 70% identity, and preferably at least 75% identity, more preferably at least 80% identity, and most preferably at least 85%, 90%, or 95% identity at the deduced amino acid level. The regions where substantial identity is assessed can be inclusive or exclusive of the nucleotide binding site or the leucine rich region.

### Vectors and Transcriptional Control Elements

The invention, providing methods and reagents for making novel species and genres of RG nucleic acids described herein, further provides methods and reagents for expressing these nucleic acids using novel expression cassettes, vectors, transgenic plants and animals, using constitutive and inducible transcriptional and translational *cis*-  
5 (e.g., promoters and enhancers) and *trans*-acting control elements.

The expression of natural, recombinant or synthetic plant disease resistance polypeptide-encoding or other (i.e., antisense, ribozyme) nucleic acids can be achieved by operably linking the coding region a promoter (that can be plant-specific or not,  
10 constitutive or inducible), incorporating the construct into an expression cassette (such as an expression vector), and introducing the resultant construct into an *in vitro* reaction system or a suitable host cell or organism. Synthetic procedures may also be used. Typical expression systems contain, in addition to coding or antisense sequence, transcription and translation terminators, polyadenylation sequences, transcription and  
15 translation initiation sequences, and promoters useful for transcribing DNA into RNA. The expression systems optionally at least one independent terminator sequence, sequences permitting replication of the cassette *in vivo*, e.g., plants, eukaryotes, or prokaryotes, or a combination thereof, (e.g., shuttle vectors) and selection markers for the selected expression system, e.g., plant, prokaryotic or eukaryotic systems. To ensure proper  
20 polypeptide expression under varying conditions, a polyadenylation region at the 3'-end of the coding region can be included (see Li (1997) *Plant Physiol.* 115:321-325, for a review of the polyadenylation of RNA in plants). The polyadenylation region can be derived from the natural gene, from a variety of other plant genes, or from T-DNA (e.g., using *Agrobacterium tumefaciens* T-DNA replacement vectors, see e.g., Thykjaer (1997) *Plant*  
25 *Mol Biol.* 35:523-530; using a plasmid containing a gene of interest flanked by *Agrobacterium* T-DNA border repeat sequences; Hansen (1997) "T-strand integration in maize protoplasts after codelivery of a T-DNA substrate and virulence genes," *Proc. Natl. Acad. Sci. USA* 94:11726-11730.

To identify the promoters, the 5' portions of the clones described here are  
30 analyzed for sequences characteristic of promoter sequences. For instance, promoter sequence elements include the TATA box consensus sequence (TATAAT), which is usually 20 to 30 base pairs upstream of the transcription start site. In plants, further

upstream from the TATA box, at positions -80 to -100, there is typically a promoter element with a series of adenines surrounding the trinucleotide G (or T) N G (see, *e.g.*, Messing, in *Genetic Engineering in Plants*, pp. 221-227, Kosage, Meredith and Hollaender, eds. 1983). If proper polypeptide expression is desired, a polyadenylation region at the 3'-end of the RG coding region should be included. The polyadenylation region can be derived from the natural gene, from a variety of other plant genes, or from viral genes, such as T-DNA.

The nucleic acids of the invention can be expressed in expression cassettes, vectors or viruses which are transiently expressed in cells using, for example, episomal expression systems (*e.g.*, cauliflower mosaic virus (CaMV) viral RNA is generated in the nucleus by transcription of an episomal minichromosome containing supercoiled DNA, Covey (1990) *Proc. Natl. Acad. Sci. USA* 87:1633-1637). Alternatively, coding sequences can be inserted into the host cell genome becoming an integral part of the host chromosomal DNA.

Selection markers can be incorporated into expression cassettes and vectors to confer a selectable phenotype on transformed cells and sequences coding for episomal maintenance and replication such that integration into the host genome is not required. For example, the marker may encode biocide resistance, such as antibiotic resistance, particularly resistance to chloramphenicol, kanamycin, G418, bleomycin, hygromycin, or herbicide resistance, such as resistance to chlorosulfuron or Basta, to permit selection of those cells transformed with the desired DNA sequences, see for example, Blondelet-Rouault (1997) *Gene* 190:315-317; Aubrecht (1997) *J. Pharmacol. Exp. Ther.* 281:992-997. Because selectable marker genes conferring resistance to substrates like neomycin or hygromycin can only be utilized in tissue culture, chemoresistance genes are also used as selectable markers *in vitro* and *in vivo*. See also, Mengiste (1997) "High-efficiency transformation of *Arabidopsis thaliana* with a selectable marker gene regulated by the T-DNA 1' promoter," *Plant J.* 12:945-948, showing that the 1' promoter is an attractive alternative to the cauliflower mosaic virus (CaMV) 35S promoter for the generation of T-DNA insertion lines, the 1' promoter may be especially beneficial for the secondary transformation of transgenic strains containing the 35S promoter to exclude homology-mediated gene silencing.

The endogenous promoters from the RG genes of the present invention can be used to direct expression of the genes. These promoters can also be used to direct expression of heterologous structural genes. The promoters can be used, for example, in recombinant expression cassettes to drive expression of genes conferring resistance to any number of pathogens or pests, including fungi, bacteria, and the like.

#### *Constitutive Promoters*

In construction of recombinant expression cassettes, vectors, transgenics, of the invention, a promoter fragment can be employed to direct expression of the desired gene in all tissues of a plant or animal. Promoters that drive expression continuously under physiological conditions are referred to as "constitutive" promoters and are active under most environmental conditions and states of development or cell differentiation. Examples of constitutive promoters include those from viruses which infect plants, such as the cauliflower mosaic virus (CaMV) 35S transcription initiation region; the 1'- or 2'- promoter derived from T-DNA of *Agrobacterium tumefaciens*; the promoter of the tobacco mosaic virus; and, other transcription initiation regions from various plant genes known to those of skill. See also Holtorf (1995) "Comparison of different constitutive and inducible promoters for the overexpression of transgenes in *Arabidopsis thaliana*," *Plant Mol. Biol.* 29:637-646.

#### *Inducible Promoters*

Alternatively, a plant promoter may direct expression of the plant disease resistance nucleic acid of the invention under the influence of changing environmental conditions or developmental conditions. Examples of environmental conditions that may effect transcription by inducible promoters include pathogenic attack, anaerobic conditions, elevated temperature, drought, or the presence of light. Such promoters are referred to herein as "inducible" promoters. For example, the invention incorporates the drought-inducible promoter of maize (Busk (1997) *supra*); the cold, drought, and high salt inducible promoter from potato (Kirch (1997) *Plant Mol. Biol.* 33:897-909).

Embodiments of the invention also incorporate use of plant promoters which are inducible upon injury or infection to express the invention's plant disease resistance (RG) polypeptides. Various embodiments include use of, e.g., the promoter for a tobacco (*Nicotiana tabacum*) sesquiterpene cyclase gene (EAS4 promoter), which is expressed in wounded leaves, roots, and stem tissues, and upon infection with microbial pathogens (Yin

(1997) *Plant Physiol.* 115(2):437-451); the ORF13 promoter from *Agrobacterium rhizogenes* 8196, which is wound inducible in a limited area adjacent to the wound site (Hansen (1997) *Mol. Gen. Genet.* 254:337-343); the Shpx6b gene promoter, which is a plant peroxidase gene promoter induced by microbial pathogens (demonstrated using a fungal pathogen, see Curtis (1997) *Mol. Plant Microbe Interact.* 10:326-338); the wound-inducible gene promoter *wun1*, derived from potato (Siebertz (1989) *Plant Cell* 1:961-968); the wound-inducible *Agrobacterium pmas* gene (mannopine synthesis gene) promoter (Guevara-Garcia (1993) *Plant J.* 4:495-505).

Alternatively, plant promoters which are inducible upon exposure to plant hormones, such as auxins, are used to express the nucleic acids of the invention. For example, the invention can use the auxin-response elements E1 promoter fragment (AuxREs) in the soybean (*Glycine max L.*) (Liu (1997) *Plant Physiol.* 115:397-407); the auxin-responsive Arabidopsis GST6 promoter (also responsive to salicylic acid and hydrogen peroxide) (Chen (1996) *Plant J.* 10: 955-966); the auxin-inducible *parC* promoter from tobacco (Sakai (1996) 37:906-913); a plant biotin response element (Streit (1997) *Mol. Plant Microbe Interact.* 10:933-937); and, the promoter responsive to the stress hormone abscisic acid (Sheen (1996) *Science* 274:1900-1902).

Plant promoters which are inducible upon exposure to chemicals reagents which can be applied to the plant, such as herbicides or antibiotics, are also used to express the nucleic acids of the invention. For example, the maize In2-2 promoter, activated by benzenesulfonamide herbicide safeners, can be used (De Veylder (1997) *Plant Cell Physiol.* 38:568-577); application of different herbicide safeners induces distinct gene expression patterns, including expression in the root, hydathodes, and the shoot apical meristem. Coding sequence can be under the control of, *e.g.*, a tetracycline-inducible promoter, *e.g.*, as described with transgenic tobacco plants containing the *Avena sativa L.* (oat) arginine decarboxylase gene (Masgrau (1997) *Plant J.* 11:465-473); or, a salicylic acid-responsive element (Stange (1997) *Plant J.* 11:1315-1324. Using chemically- (*e.g.*, hormone- or pesticide-) induced promoters, harvesting of fruits and plant parts would be greatly facilitated. A chemical which can be applied to the transgenic plant in the field and induce expression of a polypeptide of the invention throughout all or most of the plant would make an environmentally safe defoliant or herbicide. Thus, the invention also provides for transgenic plants containing an inducible gene encoding for the RG

polypeptides of the invention whose host range is limited to target plant species, such as weeds or crops before, during or after harvesting.

Abcission promoters are activated upon plant ripening, such as fruit ripening, and are especially useful incorporated in the expression systems (*e.g.*, expression cassettes, vectors) of the invention. In some embodiments, when a plant disease resistant polypeptide-encoding nucleic acid is under the control of such a promoter, rapid cell death, induced by expression of the invention's polypeptide, can accelerate and/or accentuate abscission, increasing the efficiency of the harvesting of fruits or other plant parts, such as cotton, and the like. Induction of rapid cell death at this time would accelerate separation of the fruit from the plant, greatly augmenting harvesting procedures. See, *e.g.*, Kalaitzis (1997) *Plant Physiol.* 113:1303-1308, discussing tomato leaf and flower abscission; Payton (1996) *Plant Mol. Biol.* 31:1227-1231, discussing ethylene receptor expression regulation during fruit ripening, flower senescence and abscission; Koehler (1996) *Plant Mol. Biol.* 31:595-606, discussing the gene promoter for a bean abscission cellulase; Kalaitzis (1995) *Plant Mol. Biol.* 28: 647-656, discussing cloning of a tomato polygalacturonase expressed in abscission; del Campillo (1996) *Plant Physiol.* 111:813-820, discussing pedicel breakstrength and cellulase gene expression during tomato flower abscission.

#### *Tissue-Specific Promoters*

Tissue specific promoters are transcriptional control elements that are only active in particular cells or tissues. Plant promoters which are active only in specific tissues or at specific times during plant development are used to express the nucleic acids of the invention. Examples of promoters under developmental control include promoters that initiate transcription only in certain tissues, such as leaves, roots, fruit, seeds, ovules, pollen, pistils, or flowers. Such promoters are referred to as "tissue specific". The operation of a promoter may also vary depending on its location in the genome. Thus, an inducible promoter may become fully or partially constitutive in certain locations.

For example, a seed-specific promoter directs expression in seed tissues. Such promoters may be, for example, ovule-specific, embryo-specific, endosperm-specific, integument-specific, seed coat-specific, or some combination thereof. A leaf-specific promoter has been identified in maize, Busk (1997) *Plant J.* 11:1285-1295. The ORF13 promoter from *Agrobacterium rhizogenes* exhibits high activity in roots (Hansen (1997) *supra*). A maize pollen-specific promoter has been identified in maize (Guerrero (1990)

5 *Mol. Gen. Genet.* 224:161-168). A tomato promoter active during fruit ripening, senescence and abscission of leaves and, to a lesser extent, of flowers can be used (Blume (1997) *Plant J.* 12:731-746). A pistil specific promoter has been identified in the potato (*Solanum tuberosum* L.) SK2 gene, encoding a pistil-specific basic endochitinase (Ficker (1997) *Plant Mol. Biol.* 35:425-431). The Blec4 gene from pea (*Pisum sativum* cv. *Alaska*) is active in epidermal tissue of vegetative and floral shoot apices of transgenic alfalfa, making it a useful tool to target the expression of foreign genes to the epidermal layer of actively growing shoots. The activity of the Blec4 promoter in the epidermis of the shoot apex makes it particularly suitable for genetically engineering defense against insects and diseases that attack the growing shoot apex (Mandaci (1997) *Plant Mol Biol.* 34:961-965).

The invention also provides for use of tissue-specific plant promoters include a promoter from the ovule-specific *BEL1* gene described in Reiser (1995) *Cell* 83:735-742, GenBank No. U39944. Suitable seed specific promoters are derived from the following genes: *MAC1* from maize, Sheridan (1996) *Genetics* 142:1009-1020; *Cat3* from maize, GenBank No. L05934, Abler (1993) *Plant Mol. Biol.* 22:10131-1038; the gene encoding oleosin 18kD from maize, GenBank No. J05212, Lee (1994) *Plant Mol. Biol.* 26:1981-1987; vivparous-1 from *Arabidopsis*, Genbank No. U93215; the gene encoding oleosin from *Arabidopsis*, Genbank No. Z17657; *Atmyc1* from *Arabidopsis*, Urao (1996) *Plant Mol. Biol.* 32:571-576; the 2s seed storage protein gene family from *Arabidopsis*, Conceicao (1994) *Plant* 5:493-505; the gene encoding oleosin 20kD from *Brassica napus*, GenBank No. M63985; *napA* from *Brassica napus*, GenBank No. J02798, Josefsson (1987) *JBL* 26:12196-1301; the napin gene family from *Brassica napus*, Sjodahl (1995) *Planta* 197:264-271; the gene encoding the 2S storage protein from *Brassica napus*, Dasgupta (1993) *Gene* 133:301-302; the genes encoding oleosin a, Genbank No. U09118, and, oleosin B, Genbank No. U09119, from soybean; and, the gene encoding low molecular weight sulphur rich protein from soybean, Choi (1995) *Mol Gen, Genet.* 246:266-268. The tissue specific E8 promoter from tomato is particularly useful for directing gene expression so that a desired gene product is located in fruits. Other suitable promoters include those from genes encoding embryonic storage proteins.

One of skill will recognize that a tissue-specific promoter may drive expression of operably linked sequences in tissues other than the target tissue. Thus, as

used herein a tissue-specific promoter is one that drives expression preferentially in the target tissue, but may also lead to some expression in other tissues as well.

The invention also provides for use of tissue-specific promoters derived from viruses which can include, *e.g.*, the tobamovirus subgenomic promoter (Kumagai (1995) *Proc. Natl. Acad. Sci. USA* 92:1679-1683; the rice tungro bacilliform virus (RTBV), which replicates only in phloem cells in infected rice plants, with its promoter which drives strong phloem-specific reporter gene expression; the cassava vein mosaic virus (CVMV) promoter, with highest activity in vascular elements, in leaf mesophyll cells, and in root tips (Verdager (1996) *Plant Mol. Biol.* 31:1129-1139).

In some embodiments, the nucleic acid construct will comprise a promoter functional in a specific plant cell, such as in a species of *Lactuca*, operably linked to an RG polynucleotide. Promoters useful in these embodiments include RG promoters. In additional embodiments, the nucleic acid construct will comprise a RG promoter operably linked to a heterologous polynucleotide. The heterologous polynucleotide is chosen to provide a plant with a desired phenotype. For example, the heterologous polynucleotide can be a structural gene which encodes a polypeptide which imparts a desired resistance phenotype. Alternatively, the heterologous polynucleotide may be a regulatory gene which might play a role in transcriptional and/or translational control to suppress, enhance, or otherwise modify the transcription and/or expression of an endogenous gene within the plant. The heterologous polynucleotide of the nucleic acid construct of the present invention can be expressed in either sense or anti-sense orientation as desired. It will be appreciated that control of gene expression in either sense or anti-sense orientation can have a direct impact on the observable plant characteristics.

#### *Modifying and Inhibiting RG Gene Expression*

The invention also provides for RG nucleic acid sequences which are complementary to the RG polypeptide-encoding sequences of the invention; *i.e.*, antisense RG nucleic acids. Antisense technology can be conveniently used to modify gene expression in plants. To accomplish this, a nucleic acid segment from the desired gene is cloned and operably linked to a promoter such that the anti-sense strand of RNA will be transcribed. The construct is then transformed into plants and the antisense strand of RNA is produced. In plant cells, it has been shown that antisense RNA inhibits gene expression by preventing the accumulation of mRNA which encodes the enzyme of interest, see, *e.g.*,



Sheehy (1988) *Proc. Nat. Acad. Sci. USA* 85:8805-8809; Hiatt et al., U.S. Patent No. 4,801,340.

Antisense sequences are capable of inhibiting the transport, splicing or transcription of RG-encoding genes. The inhibition can be effected through the targeting of genomic DNA or messenger RNA. The transcription or function of targeted nucleic acid can be inhibited, *e.g.*, by hybridization and/or cleavage. One particularly useful set of inhibitors provided by the present invention includes oligonucleotides which are able to either bind RG gene or message, in either case preventing or inhibiting the production or function of RG. The association can be through sequence specific hybridization. Such inhibitory nucleic acid sequences can, for example, be used to completely inhibit a plant disease resistance response. Another useful class of inhibitors includes oligonucleotides which cause inactivation or cleavage of RG message. The oligonucleotide can have enzyme activity which causes such cleavage, such as ribozymes. The oligonucleotide can be chemically modified or conjugated to an enzyme or composition capable of cleaving the complementary nucleic acid. One may screen a pool of many different such oligonucleotides for those with the desired activity.

#### *Antisense Oligonucleotides*

The invention provides for with antisense oligonucleotides capable of binding RG message which can inhibit RG activity by targeting mRNA. Strategies for designing antisense oligonucleotides are well described in the scientific and patent literature, and the skilled artisan can design such RG oligonucleotides using the novel reagents of the invention. In some situations, naturally occurring nucleic acids used as antisense oligonucleotides may need to be relatively long (18 to 40 nucleotides) and present at high concentrations. A wide variety of synthetic, non-naturally occurring nucleotide and nucleic acid analogues are known which can address this potential problem. For example, peptide nucleic acids (PNAs) containing non-ionic backbones, such as N-(2-aminoethyl) glycine units can be used. Antisense oligonucleotides having phosphorothioate linkages can also be used, as described in WO 97/03211; WO 96/39154; Mata (1997) *Toxicol Appl Pharmacol* 144:189-197; Antisense Therapeutics, ed. Agrawal (Humana Press, Totowa, N.J., 1996). Antisense oligonucleotides having synthetic DNA backbone analogues provided by the invention can also include phosphoro-dithioate, methylphosphonate,

phosphoramidate, alkyl phosphotriester, sulfamate, 3'-thioacetal, methylene(methylimino), 3'-N-carbamate, and morpholino carbamate nucleic acids, as described herein.

Combinatorial chemistry methodology can be used to create vast numbers of oligonucleotides that can be rapidly screened for specific oligonucleotides that have appropriate binding affinities and specificities toward any target, such as the sense and antisense RG sequences of the invention (for general background information, see, *e.g.*, Gold (1995) *J. of Biol. Chem.* 270:13581-13584).

#### *Inhibitory Ribozymes*

The invention provides for with ribozymes capable of binding RG message which can inhibit RG activity by targeting mRNA. Strategies for designing ribozymes and selecting the RG-specific antisense sequence for targeting are well described in the scientific and patent literature, and the skilled artisan can design such RG ribozymes using the novel reagents of the invention. Ribozymes act by binding to a target RNA through the target RNA binding portion of a ribozyme which is held in close proximity to an enzymatic portion of the RNA that cleaves the target RNA. Thus, the ribozyme recognizes and binds a target RNA through complementary base-pairing, and once bound to the correct site, acts enzymatically to cleave and inactivate the target RNA. Cleavage of a target RNA in such a manner will destroy its ability to direct synthesis of an encoded protein if the cleavage occurs in the coding sequence, or, preventing transport of the message from the nucleus to the cytoplasm. After a ribozyme has bound and cleaved its RNA target, it is typically released from that RNA and so can bind and cleave new targets repeatedly.

Catalytic RNA molecules or ribozymes can also be used to inhibit expression of any plant gene. It is possible to design ribozymes that specifically pair with virtually any target RNA and cleave the phosphodiester backbone at a specific location, thereby functionally inactivating the target RNA. In carrying out this cleavage, the ribozyme is not itself altered, and is thus capable of recycling and cleaving other molecules, making it a true enzyme. The inclusion of ribozyme sequences within antisense RNAs confers RNA-cleaving activity upon them, thereby increasing the activity of the constructs. The design and use of target RNA-specific ribozymes is described, *e.g.*, in Haseioff (1988) *Nature* 334:585-591.

In some circumstances, the enzymatic nature of a ribozyme can be advantageous over other technologies, such as antisense technology (where a nucleic acid

molecule simply binds to a nucleic acid target to block its transcription, translation or association with another molecule) as the effective concentration of ribozyme necessary to effect a therapeutic treatment can be lower than that of an antisense oligonucleotide. This potential advantage reflects the ability of the ribozyme to act enzymatically. Thus, a single  
5 ribozyme molecule is able to cleave many molecules of target RNA. In addition, a ribozyme is typically a highly specific inhibitor, with the specificity of inhibition depending not only on the base pairing mechanism of binding, but also on the mechanism by which the molecule inhibits the expression of the RNA to which it binds. That is, the inhibition is caused by cleavage of the RNA target and so specificity is defined as the ratio  
10 of the rate of cleavage of the targeted RNA over the rate of cleavage of non-targeted RNA. This cleavage mechanism is dependent upon factors additional to those involved in base pairing. Thus, the specificity of action of a ribozyme can be greater than that of antisense oligonucleotide binding the same RNA site.

The enzymatic ribozyme RNA molecule can be formed in a hammerhead  
15 motif, but may also be formed in the motif of a hairpin, hepatitis delta virus, group I intron or RNaseP-like RNA (in association with an RNA guide sequence). Examples of such hammerhead motifs are described by Rossi (1992) *Aids Research and Human Retroviruses* 8:183; hairpin motifs by Hampel (1989) *Biochemistry* 28:4929, and Hampel (1990) *Nuc. Acids Res.* 18:299; the hepatitis delta virus motif by Perrotta (1992) *Biochemistry* 31:16;  
20 the RNaseP motif by Guerrier-Takada (1983) *Cell* 35:849; and the group I intron by Cech U.S. Pat. No. 4,987,071. The recitation of these specific motifs is not intended to be limiting; those skilled in the art will recognize that an enzymatic RNA molecule of this invention has a specific substrate binding site complementary to one or more of the target gene RNA regions, and has nucleotide sequence within or surrounding that substrate  
25 binding site which imparts an RNA cleaving activity to the molecule.

#### *Sense Suppression*

Another method of suppression is sense suppression. Introduction of nucleic acid configured in the sense orientation has been shown to be an effective means by which to block the transcription of target genes. For an example of the use of this method  
30 to modulate expression of endogenous genes see, Napoli et al., *The Plant Cell* 2:279-289 (1990), and U.S. Patent No. 5,034,323.

#### *Cloning of RG Polypeptides*

Synthesis and/or cloning of RG polynucleotides and isolated nucleic acid constructs of the present invention are provided by methods well known to those of ordinary skill in the art. Generally, the nomenclature and the laboratory procedures in recombinant DNA technology described below are those well known and commonly employed in the art. Standard techniques are used for cloning, DNA and RNA isolation, amplification and purification. Generally enzymatic reactions involving DNA ligase, DNA polymerase, restriction endonucleases and the like are performed according to the manufacturer's specifications. These techniques and various other techniques are generally performed according to Sambrook *et al.*, *Molecular Cloning - A Laboratory Manual*, Cold Spring Harbor Laboratory, Cold Spring Harbor, New York, (1989).

The isolation of RG genes may be accomplished by a number of techniques. For instance, oligonucleotide probes based on the sequences disclosed here can be used to identify the desired gene in a cDNA or genomic DNA library. To construct genomic libraries, large segments of genomic DNA are generated by random fragmentation, e.g. using restriction endonucleases, and are ligated with vector DNA to form concatemers that can be packaged into the appropriate vector. To prepare a cDNA library, mRNA is isolated from the desired organ, such as roots and a cDNA library which contains the RG gene transcript is prepared from the mRNA. Alternatively, cDNA may be prepared from mRNA extracted from other tissues in which RG genes or homologs are expressed.

The cDNA or genomic library can then be screened using a probe based upon the sequence of a cloned RG gene such as the genes disclosed herein. Probes may be used to hybridize with genomic DNA or cDNA sequences to isolate homologous genes in the same or different plant species.

Those of skill in the art will appreciate that various degrees of stringency of hybridization can be employed in the assay; and either the hybridization or the wash medium can be stringent. As the conditions for hybridization become more stringent, there must be a greater degree of complementarity between the probe and the target for duplex formation to occur. The degree of stringency can be controlled by temperature, ionic strength, pH and the presence of a partially denaturing solvent such as formamide. For example, the stringency of hybridization is conveniently varied by changing the polarity of the reactant solution through manipulation of the concentration of formamide within the range of 0% to 50%.

Alternatively, the RG nucleic acids of the invention can be amplified from nucleic acid samples using a variety of amplification techniques, such as polymerase chain reaction (PCR) technology, to amplify the sequences of the RG and related genes directly from genomic DNA, from cDNA, from genomic libraries or cDNA libraries. PCR and other *in vitro* amplification methods may also be useful, for example, to clone nucleic acid sequences that code for proteins to be expressed, to make nucleic acids to use as probes for detecting the presence of the desired mRNA in samples, for nucleic acid sequencing, or for other purposes.

Oligonucleotides can be used to identify and detect additional RG families and RG family species using a variety of hybridization techniques and conditions. Suitable amplification methods include, but are not limited to: polymerase chain reaction, PCR (PCR PROTOCOLS, A GUIDE TO METHODS AND APPLICATIONS, *ed.* Innis, Academic Press, N.Y. (1990) and PCR STRATEGIES (1995), *ed.* Innis, Academic Press, Inc., N.Y. (Innis)), ligase chain reaction (LCR) (Wu (1989) *Genomics* 4:560; Landegren (1988) *Science* 241:1077; Barringer (1990) *Gene* 89:117); transcription amplification (Kwoh (1989) *Proc. Natl. Acad. Sci. USA* 86:1173); and, self-sustained sequence replication (Guatelli (1990) *Proc. Natl. Acad. Sci. USA*, 87:1874); Q Beta replicase amplification and other RNA polymerase mediated techniques (*e.g.*, NASBA, Cangene, Mississauga, Ontario); see Berger (1987) *Methods Enzymol.* 152:307-316, Sambrook, and Ausubel, as well as Mullis (1987) U.S. Patent Nos. 4,683,195 and 4,683,202; Arnheim (1990) *C&EN* 36-47; Lomell *J. Clin. Chem.*, 35:1826 (1989); Van Brunt, *Biotechnology*, 8:291-294 (1990); Wu (1989) *Gene* 4:560; Sooknanan (1995) *Biotechnology* 13:563-564. Methods for cloning *in vitro* amplified nucleic acids are described in Wallace, U.S. Pat. No. 5,426,039.

The degree of complementarity (sequence identity) required for detectable binding will vary in accordance with the stringency of the hybridization medium and/or wash medium. The degree of complementarity will optimally be 100 percent; however, it should be understood that minor sequence variations in the probes and primers may be compensated for by reducing the stringency of the hybridization and/or wash medium as described earlier.

In some preferred embodiments, members of this class of pest resistance genes can be identified by their ability to be amplified by PCR primers based on the sequences disclosed here. Appropriate primers and probes for identifying RG sequences

from plant tissues are generated from comparisons of the sequences provided herein. See, e.g., Table 1. For a general overview of PCR see *PCR Protocols: A Guide to Methods and Applications*. (Innis, M, Gelfand, D., Sninsky, J. and White, T., eds.), *Academic Press*, San Diego (1990), incorporated herein by reference.

5                    Briefly, the first step of each cycle of the PCR involves the separation of the nucleic acid duplex formed by the primer extension. Once the strands are separated, the next step in PCR involves hybridizing the separated strands with primers that flank the target sequence. The primers are then extended to form complementary copies of the target strands. For successful PCR amplification, the primers are designed so that the  
10                   position at which each primer hybridizes along a duplex sequence is such that an extension product synthesized from one primer, when separated from the template (complement), serves as a template for the extension of the other primer. The cycle of denaturation, hybridization, and extension is repeated as many times as necessary to obtain the desired amount of amplified nucleic acid.

15                   In the preferred embodiment of the PCR process, strand separation is achieved by heating the reaction to a sufficiently high temperature for an sufficient time to cause the denaturation of the duplex but not to cause an irreversible denaturation of the polymerase (see U.S. Patent No. 4,965,188). Template-dependent extension of primers in PCR is catalyzed by a polymerizing agent in the presence of adequate amounts of four  
20                   deoxyribonucleotide triphosphates (typically dATP, dGTP, dCTP, and dTTP) in a reaction medium comprised of the appropriate salts, metal cations, and pH buffering system. Suitable polymerizing agents are enzymes known to catalyze template-dependent DNA synthesis.

                    Polynucleotides may also be synthesized by well-known techniques as  
25                   described in the technical literature. See, e.g., Carruthers *et al.*, *Cold Spring Harbor Symp. Quant. Biol.* 47:411-418 (1982), and Adams *et al.*, *J. Am. Chem. Soc.* 105:661 (1983). Double stranded DNA fragments may then be obtained either by synthesizing the complementary strand and annealing the strands together under appropriate conditions, or by adding the complementary strand using DNA polymerase with an appropriate primer  
30                   sequence.

#### RG Proteins

The present invention further provides isolated RG proteins encoded by the RG polynucleotides disclosed herein. One of skill will recognize that the nucleic acid encoding a functional RG protein need not have a sequence identical to the exemplified genes disclosed here. For example, because of codon degeneracy a large number of nucleic acid sequences can encode the same polypeptide. In addition, the polypeptides encoded by the RG genes, like other proteins, have different domains which perform different functions. Thus, the RG gene sequences need not be full length, so long as the desired functional domain of the protein is expressed.

The resistance proteins are at least 25 amino acid residues in length. Typically, the RG proteins are at least 50 amino acid residues, generally at least 100, preferably at least 150, more preferably at least 200 amino acids in length. In particularly preferred embodiments, the RG proteins are of sufficient length to provide resistance to pests when expressed in the desired plants. Generally then, the RG proteins will be the length encoded by an RG gene of the present invention. However, those of ordinary skill will appreciate that minor deletions, substitutions, or additions to an RG protein will typically yield a protein with pest resistance characteristics similar or identical to that of the full length sequence. Thus, full-length RG proteins modified by 1, 2, 3, 4, or 5 deletions, substitutions, or additions, generally provide an effective degree of pest resistance relative to the full-length protein.

The RG proteins which provide pest resistance will typically comprise at least one of an LRR or an NBS. Preferably, both are present. LRR and/or NBS regions present in the RG proteins of the present invention can be provided by RG genes of the present invention. In some embodiments, the LRR and/or NBS regions are obtained from other pest resistance genes. See, e.g., Yu *et al.*, *Proc. Natl. Acad. Sci. USA*, 93: 11751-11756 (1996); Bent *et al.*, *Science*, 265: 1856-1860 (1994).

Modified protein chains can also be readily designed utilizing various recombinant DNA techniques well known to those skilled in the art. For example, the chains can vary from the naturally occurring sequence at the primary structure level by amino acid substitutions, additions, deletions, and the like. Modification can also include swapping domains from the proteins of the invention with related domains from other pest resistance genes.

Pests that can be targeted by RG genes and proteins of the present invention include such bacterial pests as *Erwinia carotovora* and *Pseudomonas marginalis*. Fungal pests which can be targeted by the present invention include *Bremia lactucae*, *Marssonina panattoniana*, *Rhizoctonia solani*, *Olpidium brassicae*, root aphid, *Sclerotinia sclerotiorum* and *S. minor*, and *Botrytis cinerea* which causes gray mold. RG genes also provide resistance to viral diseases such as lettuce and turnip mosaic viruses.

#### *Fusion Proteins*

RG polypeptides can also be expressed as recombinant proteins with one or more additional polypeptide domains linked thereto to facilitate protein detection, purification, or other applications. Such detection and purification facilitating domains include, but are not limited to, metal chelating peptides such as polyhistidine tracts and histidine-tryptophan modules that allow purification on immobilized metals, protein domains that allow purification on immobilized immunoglobulin, and the domain utilized in the FLAGS extension/affinity purification system (Immunex Corp, Seattle WA). The inclusion of a cleavable linker sequences such as Factor Xa or enterokinase (Invitrogen, San Diego CA) between the purification domain and plant disease resistant polypeptide may be useful to facilitate purification. One such expression vector provides for expression of a fusion protein comprising the sequence encoding a plant disease resistant polypeptide of the invention and nucleic acid sequence encoding six histidine residues followed by thioredoxin and an enterokinase cleavage site (*e.g.*, see Williams (1995) *Biochemistry* 34:1787-1797). The histidine residues facilitate detection and purification while the enterokinase cleavage site provides a means for purifying the desired protein(s) from the remainder of the fusion protein. Technology pertaining to vectors encoding fusion proteins and application of fusion proteins are well described, see *e.g.*, Kroll (1993) *DNA Cell. Biol.*, 12:441-53.

#### *Antibodies Reactive to RG Polypeptides and Immunological Assays*

The present invention also provides antibodies which specifically react with RG proteins of the present invention under immunologically reactive conditions. An antibody immunologically reactive with a particular antigen can be generated *in vivo* or by recombinant methods such as selection of libraries of recombinant antibodies in phage or similar vectors. "Immunologically reactive conditions" includes reference to conditions which allow an antibody, generated to a particular epitope of an antigen, to bind to that



epitope to a detectably greater degree than the antibody binds to substantially all other epitopes, generally at least two times above background binding, preferably at least five times above background. Immunologically reactive conditions are dependent upon the format of the antibody binding reaction and typically are those utilized in immunoassay protocols.

"Antibody" includes reference to an immunoglobulin molecule obtained by *in vitro* or *in vivo* generation of the humoral response, and includes both polyclonal and monoclonal antibodies. The term also includes genetically engineered forms such as chimeric antibodies (e.g., humanized murine antibodies), heteroconjugate antibodies (e.g., bispecific antibodies), and recombinant single chain Fv fragments (scFv). The term "antibody" also includes antigen binding forms of antibodies (e.g., Fab', F(ab')<sub>2</sub>, Fab, Fv, rIgG, and, inverted IgG). See, Pierce Catalog and Handbook, 1994-1995 (Pierce Chemical Co., Rockford, IL). An antibody immunologically reactive with a particular antigen can be generated *in vivo* or by recombinant methods such as selection of libraries of recombinant antibodies in phage or similar vectors. See, e.g., Huse *et al.* (1989) *Science* 246:1275-1281; and Ward, *et al.* (1989) *Nature* 341:544-546; and Vaughan *et al.* (1996) *Nature Biotechnology*, 14:309-314.

Many methods of making antibodies are known to persons of skill. A number of immunogens are used to produce antibodies specifically reactive to an isolated RG protein of the present invention under immunologically reactive conditions. An isolated recombinant, synthetic, or native RG protein of the present invention is the preferred immunogens (antigen) for the production of monoclonal or polyclonal antibodies.

The RG protein is then injected into an animal capable of producing antibodies. Either monoclonal or polyclonal antibodies can be generated for subsequent use in immunoassays to measure the presence and quantity of the RG protein. Methods of producing monoclonal or polyclonal antibodies are known to those of skill in the art. See, e.g., Coligan (1991) *Current Protocols in Immunology* Wiley/Greene, NY; and Harlow and Lane (1989) *Antibodies: A Laboratory Manual* Cold Spring Harbor Press, NY; Goding (1986) *Monoclonal Antibodies: Principles and Practice* (2d ed.) Academic Press, New York, NY.

Frequently, the RG proteins and antibodies will be labeled by joining, either covalently or non-covalently, a substance which provides for a detectable signal. A wide

variety of labels and conjugation techniques are known and are reported extensively in both the scientific and patent literature. Suitable labels include radionucleotides, enzymes, substrates, cofactors, inhibitors, fluorescent moieties, chemiluminescent moieties, magnetic particles, and the like. Patents teaching the use of such labels include U.S. Patent Nos. 3,817,837; 3,850,752; 3,939,350; 3,996,345; 4,277,437; 4,275,149; and 4,366,241.

The antibodies of the present invention can be used to screen plants for the expression of RG proteins of the present invention. The antibodies of this invention are also used for affinity chromatography in isolating RG protein.

The present invention further provides RG polypeptides that specifically bind, under immunologically reactive conditions, to an antibody generated against a defined immunogen, such as an immunogen consisting of the RG polypeptides of the present invention. Immunogens will generally be at least 10 contiguous amino acids from an RG polypeptide of the present invention. Optionally, immunogens can be from regions exclusive of the NBS and/or LRR regions of the RG polypeptides. Nucleic acids which encode such cross-reactive RG polypeptides are also provided by the present invention. The RG polypeptides can be isolated from any number plants as discussed earlier. Preferred are species from the family *Compositae* and in particular the genus *Lactuca* such as *L. sativa* and such subspecies as *crispa*, *longifolia*, and *asparagina*.

"Specifically binds" includes reference to the preferential association of a ligand, in whole or part, with a particular target molecule (i.e., "binding partner" or "binding moiety") relative to compositions lacking that target molecule. It is, of course, recognized that a certain degree of non-specific interaction may occur between a ligand and a non-target molecule. Nevertheless, specific binding, may be distinguished as mediated through specific recognition of the target molecule. Typically specific binding results in a much stronger association between the ligand and the target molecule than between the ligand and non-target molecule. Specific binding by an antibody to a protein under such conditions requires an antibody that is selected for its specificity for a particular protein. The affinity constant of the antibody binding site for its cognate monovalent antigen is at least  $10^7$ , usually at least  $10^8$ , preferably at least  $10^9$ , more preferably at least  $10^{10}$ , and most preferably at least  $10^{11}$  liters/mole. A variety of immunoassay formats are appropriate for selecting antibodies specifically reactive with a particular protein. For

example, solid-phase ELISA immunoassays are routinely used to select monoclonal antibodies specifically reactive with a protein. See Harlow and Lane (1988) *Antibodies, A Laboratory Manual*, Cold Spring Harbor Publications, New York, for a description of immunoassay formats and conditions that can be used to determine specific reactivity. The antibody may be polyclonal but preferably is monoclonal. Generally, antibodies cross-reactive to such proteins as RPS2, RPM1 (bacterial resistances in *Arabidopsis*, L6 (fungal resistance in flax, PRF (resistance to *Pseudomonas syringae* in tomato), and *N*, (virus resistance in tobacco), are removed by immunoabsorbtion.

Immunoassays in the competitive binding format are typically used for cross-reactivity determinations. For example, an immunogenic RG polypeptide is immobilized to a solid support. Polypeptides added to the assay compete with the binding of the antisera to the immobilized antigen. The ability of the above polypeptides to compete with the binding of the antisera to the immobilized RG polypeptide is compared to the immunogenic RG polypeptide. The percent cross-reactivity for the above proteins is calculated, using standard calculations. Those antisera with less than 10% cross-reactivity with such proteins as RPS2, RPM1, L6, PRF, and *N*, are selected and pooled. The cross-reacting antibodies are then removed from the pooled antisera by immunoabsorbtion with these non-RG resistance proteins.

The immunoabsorbed and pooled antisera are then used in a competitive binding immunoassay to compare a second "target" polypeptide to the immunogenic polypeptide. In order to make this comparison, the two polypeptides are each assayed at a wide range of concentrations and the amount of each polypeptide required to inhibit 50% of the binding of the antisera to the immobilized protein is determined using standard techniques. If the amount of the target polypeptide required is less than twice the amount of the immunogenic polypeptide that is required, then the target polypeptide is said to specifically bind to an antibody generated to the immunogenic protein. As a final determination of specificity, the pooled antisera is fully immunosorbed with the immunogenic polypeptide until no binding to the polypeptide used in the immunosorbtion is detectable. The fully immunosorbed antisera is then tested for reactivity with the test polypeptide. If no reactivity is observed, then the test polypeptide is specifically bound by the antisera elicited by the immunogenic protein.

Production of transgenic plants of the invention

Isolated nucleic acid constructs prepared as described herein can be introduced into plants according techniques known in the art. In some embodiments, the introduced nucleic acid is used to provide RG gene expression and therefore pest resistance in desired plants. In some embodiments, RG promoters are used to drive expression of desired heterologous genes in plants. Finally, in some embodiments, the constructs can be used to suppress expression of a target endogenous gene, including RG genes.

To use isolated RG sequences in the above techniques, recombinant DNA vectors suitable for transformation of plant cells are prepared. Techniques for transforming a wide variety of higher plant species are well known and described in the technical and scientific literature. See, for example, Weising *et al. Ann. Rev. Genet.* 22:421-477 (1988).

A DNA sequence coding for the desired RG polypeptide, for example a cDNA or a genomic sequence encoding a full length protein, will be used to construct a recombinant expression cassette which can be introduced into the desired plant. An expression cassette will typically comprise the RG polynucleotide operably linked to transcriptional and translational initiation regulatory sequences which will direct the transcription of the sequence from the RG gene in the intended tissues of the transformed plant.

Such DNA constructs may be introduced into the genome of the desired plant host by a variety of conventional techniques. For example, the DNA construct may be introduced directly into the genomic DNA of the plant cell using techniques such as electroporation, PEG poration, particle bombardment and microinjection of plant cell protoplasts or embryogenic callus, or the DNA constructs can be introduced directly to plant tissue using ballistic methods, such as DNA particle bombardment. Alternatively, the DNA constructs may be combined with suitable T-DNA flanking regions and introduced into a conventional *Agrobacterium tumefaciens* host vector. The virulence functions of the *Agrobacterium tumefaciens* host will direct the insertion of the construct and adjacent marker into the plant cell DNA when the cell is infected by the bacteria.

Transformation techniques are known in the art and well described in the scientific and patent literature. The introduction of DNA constructs using polyethylene glycol precipitation is described in Paszkowski *et al. Embo J.* 3:2717-2722 (1984).

Electroporation techniques are described in Fromm *et al. Proc. Natl. Acad. Sci. USA* 82:5824 (1985). Ballistic transformation techniques are described in Klein *et al. Nature* 327:70-73 (1987).

*Agrobacterium tumefaciens*-mediated transformation techniques are well described in the scientific literature. See, for example Horsch *et al. Science* 233:496-498 (1984), and Fraley *et al. Proc. Natl. Acad. Sci. USA* 80:4803 (1983). Although *Agrobacterium* is useful primarily in dicots, certain monocots can be transformed by *Agrobacterium*. For instance, *Agrobacterium* transformation of rice is described by Hiei *et al. Plant J.* 6:271-282 (1994). A particularly preferred means of transforming lettuce is described in Michelmore *et al., Plant Cell Reports*, 6:439-442 (1987).

Transformed plant cells which are derived by any of the above transformation techniques can be cultured to regenerate a whole plant which possesses the transformed genotype and thus the desired RG-controlled phenotype. Such regeneration techniques rely on manipulation of certain phytohormones in a tissue culture growth medium, typically relying on a biocide and/or herbicide marker which has been introduced together with the RG nucleotide sequences. Plant regeneration from cultured protoplasts is described in Evans *et al., Protoplasts Isolation and Culture, Handbook of Plant Cell Culture*, pp. 124-176, Macmillan Publishing Company, New York, 1983; and Binding, *Regeneration of Plants, Plant Protoplasts*, pp. 21-73, CRC Press, Boca Raton, 1985. Regeneration can also be obtained from plant callus, explants, organs, or parts thereof. Such regeneration techniques are described generally in Klee *et al. Ann. Rev. of Plant Phys.* 38:467-486 (1987).

The methods of the present invention are particularly useful for incorporating the RG polynucleotides into transformed plants in ways and under circumstances which are not found naturally. In particular, the RG polypeptides may be expressed at times or in quantities which are not characteristic of natural plants.

One of skill will recognize that after the expression cassette is stably incorporated in transgenic plants and confirmed to be operable, it can be introduced into other plants by sexual crossing. Any of a number of standard breeding techniques can be used, depending upon the species to be crossed.

#### Detection of RG Resistance Genes

The present invention further provides methods for detecting RG resistance genes in a nucleic acid sample suspected of comprising an RG resistance gene. The means by which the RG resistance gene is detected is not a critical aspect of the invention. For example, RG resistance genes can be detected by the presence of amplicons using RG resistance gene specific primers. Additionally, RG resistance genes can be detected by assaying for specific hybridization of an RG polynucleotide to an RG resistance gene. In some embodiments, the RG resistance gene can be amplified prior to the step of contacting the nucleic acid sample with the RG polynucleotide.

In a typical detection method, the nucleic acid sample is contacted with an RG polynucleotide to form a hybridization complex. The hybridization complex may be detected directly (e.g., in Southern or northern blots), or indirectly (e.g., by subsequent primer extension during PCR amplification). The RG polynucleotide hybridizes under stringent conditions to an RG polynucleotide of the invention. Formation of the hybridization complex is directly or indirectly used to indicate the presence of the RG resistance gene in the nucleic acid sample.

Detection of the hybridization complex can be achieved using any number of well known methods. For example, the nucleic acid sample, or a portion thereof, may be assayed by hybridization formats including but not limited to, solution phase, solid phase, mixed phase, or *in situ* hybridization assays. Briefly, in solution (or liquid) phase hybridizations, both the target nucleic acid and the probe or primer are free to interact in the reaction mixture. In solid phase hybridization assays, probes or primers are typically linked to a solid support where they are available for hybridization with target nucleic in solution. In mixed phase, nucleic acid intermediates in solution hybridize to target nucleic acids in solution as well as to a nucleic acid linked to a solid support. In *in situ* hybridization, the target nucleic acid is liberated from its cellular surroundings in such as to be available for hybridization within the cell while preserving the cellular morphology for subsequent interpretation and analysis. The following articles provide an overview of the various hybridization assay formats: Singer *et al.*, *Biotechniques* 4(3):230-250 (1986); Haase *et al.*, *Methods in Virology*, Vol. VII, pp. 189-226 (1984); Wilkinson, "The theory and practice of *in situ* hybridization" In: *In situ Hybridization*, Ed. D.G. Wilkinson. IRL Press, Oxford University Press, Oxford; and *Nucleic Acid Hybridization: A Practical Approach*, Ed. Hames, B.D. and Higgins, S.J., IRL Press (1987).

The effect of the modification of RG gene expression can be measured by detection of increases or decreases in mRNA levels using, for instance, Northern blots. In addition, the phenotypic effects of gene expression can be detected by measuring nematode, fungal, bacterial, viral, or other pest resistance in plants. Suitable assays for determining pest resistance are well known. Micheltore and Crute, *Trans. Br. mycol. Soc.*, 79(3): 542-546 (1982).

The means by which hybridization complexes are detected is not a critical aspect of the present invention and can be accomplished by any number of methods currently known or later developed. RG polynucleotides can be labeled by any one of several methods typically used to detect the presence of hybridized nucleic acids. One common method of detection is the use of autoradiography using probes labeled with  $^3\text{H}$ ,  $^{125}\text{I}$ ,  $^{35}\text{S}$ ,  $^{14}\text{C}$ , or  $^{32}\text{P}$ , or the like. The choice of radioactive isotope depends on research preferences due to ease of synthesis, stability, and half lives of the selected isotopes. Other labels include ligands which bind to antibodies labeled with fluorophores, chemiluminescent agents, and enzymes. Alternatively, probes can be conjugated directly with labels such as fluorophores, chemiluminescent agents or enzymes. The choice of label depends on sensitivity required, ease of conjugation with the probe, stability requirements, and available instrumentation. Labeling the RG polynucleotide is readily achieved such as by the use of labeled PCR primers.

The choice of label dictates the manner in which the label is bound to the probe. Radioactive probes are typically made using commercially available nucleotides containing the desired radioactive isotope. The radioactive nucleotides can be incorporated into probes, for example, by using DNA synthesizers, by nick translation with DNA polymerase I, by tailing radioactive DNA bases to the 3' end of probes with terminal deoxynucleotidyl transferase, by treating single-stranded M13 plasmids having specific inserts with the Klenow fragment of DNA polymerase in the presence of radioactive deoxynucleotides, dNTP, by transcribing from RNA templates using reverse transcriptase in the presence of radioactive deoxynucleotides, dNTP, or by transcribing RNA from vectors containing specific RNA viral promoters (e.g., SP6 promoter) using the corresponding RNA polymerase (e.g., SP6 RNA polymerase) in the presence of radioactive ribonucleotides rNTP.

The probes can be labeled using radioactive nucleotides in which the isotope resides as a part of the nucleotide molecule, or in which the radioactive component is attached to the nucleotide via a terminal hydroxyl group that has been esterified to a radioactive component such as inorganic acids, *e.g.*, <sup>32</sup>P phosphate or <sup>14</sup>C organic acids, or esterified to provide a linking group to the label. Base analogs having nucleophilic linking groups, such as primary amino groups, can also be linked to a label.

Non-radioactive probes are often labeled by indirect means. For example, a ligand molecule is covalently bound to the probe. The ligand then binds to an anti-ligand molecule which is either inherently detectable or covalently bound to a detectable signal system, such as an enzyme, a fluorophore, or a chemiluminescent compound. Enzymes of interest as labels will primarily be hydrolases, such as phosphatases, esterases and glycosidases, or oxidoreductases, particularly peroxidases. Fluorescent compounds include fluorescein and its derivatives, rhodamine and its derivatives, dansyl, umbelliferone, etc. Chemiluminescers include luciferin, and 2,3-dihydrophthalazinediones, *e.g.*, luminol.

Ligands and anti-ligands may be varied widely. Where a ligand has a natural anti-ligand, namely ligands such as biotin, thyroxine, and cortisol, it can be used in conjunction with its labeled, naturally occurring anti-ligands. Alternatively, any haptenic or antigenic compound can be used in combination with an antibody.

Probes can also be labeled by direct conjugation with a label. For example, cloned DNA probes have been coupled directly to horseradish peroxidase or alkaline phosphatase, (Renz. M., and Kurz, K. (1984) A Colorimetric Method for DNA Hybridization. *Nucl. Acids Res.* 12: 3435-3444) and synthetic oligonucleotides have been coupled directly with alkaline phosphatase (Jablonski, E., *et al.* (1986) Preparation of Oligodeoxynucleotide-Alkaline Phosphatase Conjugates and Their Use as Hybridization Probes. *Nuc. Acids. Res.* 14: 6115-6128; and Li P., *et al.* (1987) Enzyme-linked Synthetic Oligonucleotide probes: Non-Radioactive Detection of Enterotoxigenic *Escherichia Coli* in Faeca Specimens. *Nucl. Acids Res.* 15:5275-5287).

### Definitions

Units, prefixes, and symbols can be denoted in their SI accepted form. Numeric ranges are inclusive of the numbers defining the range. Unless otherwise indicated, nucleic acids are written left to right in 5' to 3' orientation, respectively. The



headings provided herein are not limitations of the various aspects or embodiments of the invention which can be had by reference to the specification as a whole. Accordingly, the terms defined immediately below are more fully defined by reference to the specification as a whole.

5                   As used herein, the term "plant" includes reference to whole plants, plant organs (e.g., leaves, stems, roots, etc.), seeds and plant cells and progeny of same. The class of plants which can be used in the methods of the invention is generally as broad as the class of higher plants amenable to transformation techniques, including both monocotyledonous and dicotyledonous plants.

10                   As used herein, "pest" includes, but is not limited to, viruses, fungi, nematodes, insects, and bacteria.

                  As used herein, "heterologous" is a nucleic acid that originates from a foreign species, or, if from the same species, is substantially modified from its original form. For example, a promoter operably linked to a heterologous structural gene is from a species different from that from which the structural gene was derived, or, if from the same species, one or both are substantially modified from their original form.

15                   As used herein, "RG gene," alternatively referred to as "RLG gene," is a gene encoding resistance to plant pests, such as viruses, fungi, nematodes, insects, and bacteria, and which hybridizes under stringent conditions and/or has at least 60% sequence identity at the deduced amino acid level to the exemplified sequences provided herein. RG genes encode "RG polypeptides," alternatively referred to as "RLG polypeptides," which can comprise LRR motifs and/or NBS motifs. The RG polypeptides encoded by RG genes have at least 55% or 60% sequence identity, typically at least 65% sequence identity, preferably at least 70% sequence identity, often at least 75% sequence identity, more preferably at least 80% sequence identity, and most preferably at least 90% sequence identity at the deduced amino acid level relative to the exemplary RG sequences provided herein. The term "RG family" or "RG family genus" or "genus" includes reference to a group of RG polypeptide sequence species that have at least 60% amino acid sequence identity, and, the nucleic acids encoding these polypeptides. The individual species of a genus, i.e., the members of a family, typically are genetically mapped to the same locus.

25                   As used herein, "RG polynucleotide" includes reference to a contiguous sequence from an RG gene of at least 18, 20, 25, 30, 40, or 50 nucleotides in length, up to

at least about 100 or at least about 200 nucleotides in length. In some embodiments, the polynucleotide is preferably at least 100 nucleotides in length, more preferably at least 200 nucleotides in length, most preferably at least 500 nucleotides in length. Thus, RG polynucleotide may be a RG gene or a subsequence thereof.

5                   As used herein, "isolated," when referring to a molecule or composition, such as, for example, an RG polypeptide or nucleic acid, means that the molecule or composition is separated from at least one other compound, such as a protein, other nucleic acids (*e.g.*, RNAs), or other contaminants with which it is associated *in vivo* or in its naturally occurring state. Thus, an RG polypeptide or nucleic acid is considered isolated  
10 when it has been isolated from any other component with which it is naturally associated, *e.g.*, cell membrane, as in a cell extract. An isolated composition can, however, also be substantially pure. An isolated composition can be in a homogeneous state and can be in a dry or an aqueous solution. Purity and homogeneity can be determined, for example, using analytical chemistry techniques such as polyacrylamide gel electrophoresis (SDS-  
15 PAGE) or high performance liquid chromatography (HPLC).

                  The term "nucleic acid" or "nucleic acid molecule" or "nucleic acid sequence" refers to a deoxyribonucleotide or ribonucleotide oligonucleotide in either single- or double-stranded form. The term encompasses nucleic acids, *i.e.*, oligonucleotides, containing known analogues of natural nucleotides which have similar or  
20 improved binding properties, for the purposes desired, as the reference nucleic acid. The term also includes nucleic acids which are metabolized in a manner similar to naturally occurring nucleotides or at rates that are improved thereover for the purposes desired. The term also encompasses nucleic-acid-like structures with synthetic backbones. DNA backbone analogues provided by the invention include phosphodiester, phosphorothioate, phosphorodithioate, methylphosphonate, phosphoramidate, alkyl phosphotriester,  
25 sulfamate, 3'-thioacetal, methylene(methylimino), 3'-N-carbamate, morpholino carbamate, and peptide nucleic acids (PNAs); see Oligonucleotides and Analogues, a Practical Approach, edited by F. Eckstein, IRL Press at Oxford University Press (1991); Antisense Strategies, Annals of the New York Academy of Sciences, Volume 600, Eds. Baserga and Denhardt (NYAS 1992); Milligan (1993) *J. Med. Chem.* 36:1923-1937; Antisense  
30 Research and Applications (1993, CRC Press). PNAs contain non-ionic backbones, such as N-(2-aminoethyl) glycine units. Phosphorothioate linkages are described in WO

97/03211; WO 96/39154; Mata (1997) *Toxicol Appl Pharmacol* 144:189-197. Other synthetic backbones encompassed by the term include methyl-phosphonate linkages or alternating methylphosphonate and phosphodiester linkages (Strauss-Soukup (1997) *Biochemistry* 36:8692-8698), and benzylphosphonate linkages (Samstag (1996) *Antisense Nucleic Acid Drug Dev* 6:153-156). The term nucleic acid is used interchangeably with gene, cDNA, mRNA, oligonucleotide primer, probe and amplification product. Unless otherwise indicated, a particular nucleic acid sequence includes the complementary sequence thereof.

The term "exogenous nucleic acid" refers to a nucleic acid that has been isolated, synthesized, cloned, ligated, excised in conjunction with another nucleic acid, in a manner that is not found in nature, and/or introduced into and/or expressed in a cell or cellular environment other than or at levels or forms different than the cell or cellular environment in which said nucleic acid or protein is found in nature. The term encompasses both nucleic acids originally obtained from a different organism or cell type than the cell type in which it is expressed, and also nucleic acids that are obtained from the same cell line as the cell line in which it is expressed. invention.

The term "recombinant," when used with reference to a cell, or to the nucleic acid, protein or vector refers to a material, or a material corresponding to the natural or native form of the material, that has been modified by the introduction of a new moiety or alteration of an existing moiety, or is identical thereto but produced or derived from synthetic materials. For example, recombinant cells express genes that are not found within the native (non-recombinant) form of the cell or express native genes that are otherwise expressed at a different level, typically, under-expressed or not expressed at all. The term "recombinant means" encompasses all means of expressing, *i.e.*, transcription or translation of, an isolated and/or cloned nucleic acid *in vitro* or *in vivo*. For example, the term "recombinant means" encompasses techniques where a recombinant nucleic acid, such as a cDNA encoding a protein, is inserted into an expression vector, the vector is introduced into a cell and the cell expresses the protein. "Recombinant means" also encompass the ligation of nucleic acids having coding or promoter sequences from different sources into one vector for expression of a fusion protein, constitutive expression of a protein, or inducible expression of a protein, such as the plant disease resistant, or RG. polypeptides of the invention.

The term "specifically hybridizes" refers to a nucleic acid that hybridizes, duplexes or binds to a particular target DNA or RNA sequence. The target sequences can be present in a preparation of total cellular DNA or RNA. Proper annealing conditions depend, for example, upon a nucleic acid's, such as a probe's length, base composition, and the number of mismatches and their position on the probe, and can be readily determined empirically providing the appropriate reagents are available. For discussions of nucleic acid probe design and annealing conditions, see, *e.g.*, Sambrook and Ausubel.

The terms "stringent hybridization," "stringent conditions," or "specific hybridization conditions" refers to conditions under which an oligonucleotide (when used, for example, as a probe or primer) will hybridize to its target subsequence, such as an RG nucleic acid in an expression vector of the invention but not to a non-RG sequence. Stringent conditions are sequence-dependent. Thus, in one set of stringent conditions an oligonucleotide probe will hybridize to only one specie of the genus of RG nucleic acids of the invention. In another set of stringent conditions (less stringent) an oligonucleotide probe will hybridize to all species of the invention's genus but not to non-RG nucleic acids. Longer sequences hybridize specifically at higher temperatures. Stringent conditions are selected to be about 5<sup>0</sup>C lower than the thermal melting point ( $T_m$ ) for the specific sequence at a defined ionic strength and pH. The  $T_m$  is the temperature (under defined ionic strength, pH, and nucleic acid concentration) at which 50% of the probes complementary to the target sequence hybridize to the target sequence at equilibrium (if the target sequences are present in excess, at  $T_m$ , 50% of the probes are occupied at equilibrium). Typically, stringent conditions will be those in which the salt concentration is less than about 1.0 M sodium ion, *i.e.*, about 0.01 to 1.0 M sodium ion concentration (or other salts) at pH 7.0 to 8.3 and the temperature is at least about 30<sup>0</sup>C for short probes (*e.g.*, 10 to 50 nucleotides) and at least about 60<sup>0</sup>C for long probes (*e.g.*, greater than 50 nucleotides). Stringent conditions may also be achieved with the addition of destabilizing agents such as formamide. Often, high stringency wash conditions preceded by low stringency wash conditions to remove background probe signal. An example of medium stringency wash conditions for a duplex of, *e.g.*, more than 100 nucleotides, is 1x SSC at 45<sup>0</sup>C for 15 minutes (see Sambrook for a description of SSC buffer). An example low stringency wash for a duplex of, *e.g.*, more than 100 nucleotides, is 4-6x SSC at 40<sup>0</sup>C for 15 minutes. a signal to noise ratio of 2x (or higher) than that observed for an unrelated

probe in the particular hybridization assay indicates detection of a "specific hybridization." Nucleic acids which do not hybridize to each other under stringent conditions can still be substantially identical if the polypeptides which they encode are substantially identical. This can occur, *e.g.*, when a nucleic acid is created that encodes for conservative  
5 substitutions. Stringent hybridization and stringent hybridization wash conditions are different under different environmental parameters, such as for Southern and Northern hybridizations. An extensive guide to the hybridization of nucleic acids is found in, *e.g.*, Sambrook, Tijssen (1993) *supra*.

As used herein "operably linked" includes reference to a functional linkage  
10 between a promoter and a second sequence, wherein the promoter sequence initiates and mediates transcription of the DNA sequence corresponding to the second sequence. Generally, operably linked means that the nucleic acid sequences being linked are contiguous and, where necessary to join two protein coding regions, contiguous and in the same reading frame.

15 In the expression of transgenes one of skill will recognize that the inserted polynucleotide sequence need not be identical and may be "substantially identical" to a sequence of the gene from which it was derived. As explained herein, these variants are specifically covered by this term.

In the case where the inserted polynucleotide sequence is transcribed and  
20 translated to produce a functional RG polypeptide, one of skill will recognize that because of codon degeneracy, a number of polynucleotide sequences will encode the same polypeptide. These variants are specifically covered by the term "RG polynucleotide sequence". In addition, the term specifically includes those full length sequences substantially identical (determined as described herein) with an RG gene sequence which  
25 encode proteins that retain the function of the RG protein. Thus, in the case of RG genes disclosed here, the term includes variant polynucleotide sequences which have substantial identity with the sequences disclosed here and which encode proteins capable of conferring resistance to nematodes, bacteria, viruses, fungi, insects or other pests on a transgenic plant comprising the sequence.

30 Two polynucleotides or polypeptides are said to be "identical" if the sequence of nucleotides or amino acid residues, respectively, in the two sequences is the same when aligned for maximum correspondence, as described below. The term

"complementary to" is used herein to mean that the complementary sequence is identical to all or a specified contiguous portion of a reference polynucleotide sequence.

The terms "sequence identity," "sequence similarity" and "homology" refer to when two sequences, such as the nucleic acid and amino acid sequences or the polypeptides of the invention, when optimally aligned, as with, for example, the programs PILEUP, BLAST, GAP, FASTA or BESTFIT (see discussion, *supra*). "Percentage amino acid/nucleic acid sequence identity" refers to a comparison of the sequences of two polypeptides/nucleic acids which, when optimally aligned, have approximately the designated percentage of the same amino acids/nucleic acids, respectively. For example, "60% sequence identity" and "60% homology" refer to a comparison of the sequences of two RG nucleic acids or polypeptides which, when optimally aligned, have 60% identity. For example, in one embodiment, nucleic acids encoding RG polypeptides of the invention comprise a sequence with at least 50% nucleic acid sequence identity to SEQ ID NO:1. In other embodiments, the RG polypeptides of the invention are encoded by nucleic acids comprising a sequence with at least 50% sequence identity to SEQ ID NO:1, or, are encoded by nucleic acids comprising SEQ ID NO:1, or, have at least 60% amino acid sequence identity to the polypeptide of SEQ ID NO:2.

"Percentage of sequence identity" is determined by comparing two optimally aligned sequences over a comparison window, wherein the portion of the polynucleotide sequence in the comparison window may comprise additions or deletions (i.e., gaps) as compared to the reference sequence (which does not comprise additions or deletions) for optimal alignment of the two sequences. The percentage is calculated by determining the number of positions at which the identical nucleic acid base or amino acid residue occurs in both sequences to yield the number of matched positions, dividing the number of matched positions by the total number of positions in the window of comparison and multiplying the result by 100 to yield the percentage of sequence identity.

The term "substantial identity" of polynucleotide sequences means that a polynucleotide comprises a sequence that has at least 55% or 60% sequence identity, generally at least 65%, preferably at least 70%, often at least 75%, more preferably at least 80% and most preferably at least 90%, compared to a reference sequence using the programs described above (preferably BESTFIT) using standard parameters. One of skill will recognize that these values can be appropriately adjusted to determine corresponding

identity of proteins encoded by two nucleotide sequences by taking into account codon degeneracy, amino acid similarity, reading frame positioning and the like. Substantial identity of amino acid sequences for these purposes normally means sequence identity of at least 55% or 60%, preferably at least 70%, more preferably at least 80%, and most preferably at least 95%. Polypeptides having "sequence similarity" share sequences as noted above except that residue positions which are not identical may differ by conservative amino acid changes. Conservative amino acid substitutions refer to the interchangeability of residues having similar side chains. For example, a group of amino acids having aliphatic side chains is glycine, alanine, valine, leucine, and isoleucine; a group of amino acids having aliphatic-hydroxyl side chains is serine and threonine; a group of amino acids having amide-containing side chains is asparagine and glutamine; a group of amino acids having aromatic side chains is phenylalanine, tyrosine, and tryptophan; a group of amino acids having basic side chains is lysine, arginine, and histidine; and a group of amino acids having sulfur-containing side chains is cysteine and methionine. Preferred conservative amino acids substitution groups are: valine-leucine-isoleucine, phenylalanine-tyrosine, lysine-arginine, alanine-valine, and asparagine-glutamine.

Another indication that nucleotide sequences are substantially identical is if two molecules hybridize to each other under appropriate conditions. Appropriate conditions can be high or low stringency and will be different in different circumstances. Generally, stringent conditions are selected to be about 5°C to about 20°C lower than the thermal melting point (T<sub>m</sub>) for the specific sequence at a defined ionic strength and pH. The T<sub>m</sub> is the temperature (under defined ionic strength and pH) at which 50% of the target sequence hybridizes to a perfectly matched probe. Typically, stringent wash conditions are those in which the salt concentration is about 0.02 molar at pH 7 and the temperature is at least about 50°C. However, nucleic acids which do not hybridize to each other under stringent conditions are still substantially identical if the polypeptides which they encode are substantially identical. This may occur, *e.g.*, when a copy of a nucleic acid is created using the maximum codon degeneracy permitted by the genetic code.

Nucleic acids of the invention can be identified from a cDNA or genomic library prepared according to standard procedures and the nucleic acids disclosed here used as a probe. Thus, for example, stringent hybridization conditions will typically include at least one low stringency wash using 0.3 molar salt (*e.g.*, 2X SSC) at 65°C. The washes

are preferably followed by one or more subsequent washes using 0.03 molar salt (e.g., 0.2X SSC) at 50°C, usually 60°C, or mosre usually 65°C. Nucleic acid probes used to identify the nucleic acids are preferably at least 100 nucleotides in length.

As used herein, "nucleotide binding site" or "nucleotide binding domain" ("NBS") includes reference to highly conserved nucleotide-, *i.e.*, ATP/GTP-, binding domains, typically included in the "kinase domain" of kinase polypeptides, such as a kinase-1a, kinase 2, or a kinase 3a motif, as described herein. For example, the tobacco N and Arabidopsis RPS2 genes, among several recently cloned disease-resistance genes, share highly conserved NBS sequence. Kinase NBS subdomains further consist of three subdomain motifs: the P-loop, kinase-2, and kinase-3a subdomains (Yu (1996) *Proc. Acad. Sci. USA* 93:11751-11756). As discussed in detail herein, examples include the *Arabidopsis* RPP5 gene (Parker (1997) *supra*), the *A. thaliana* RPS2 gene (Mindrinos (1997) *supra*), and the flax L6 rust resistance gene (Lawrence (1995) *supra*) which all encode proteins containing an NBS; and Mindrinos (1994) *Cell* 78:1089-1099; and Shen (1993) *FEBS* 335:380-385. Using the teachings disclosed and incorporated herein and standard nucleic acid hybridization and/or amplification techniques, one of skill can identify members having NBS domains, including any of the genus of NBS-containing plant disease resistant polypeptides of the invention.

As used herein, "leucine rich region" ("LRR") includes reference to a region that has a leucine content of at least 20% leucine or isoleucine, or 30% of the aliphatic residues: leucine, isoleucine, methionine, valine, and phenylalanine, and arranged with approximate repeated periodicity. The length of the repeat may vary in length but is generally about 20 to 30 amino acids. An LRR-containing polypeptide typically will have the canonical 24 amino acid leucine-rich repeat (LRR) sequence, which is present in different proteins that mediates molecular recognition and/or interaction processes; as described in Bent (1994) *Science* 265:1856-1860; Parker (1997) *Plant Cell* 9:879-894; Hong (1997) *Plant Physiol.* 113:1203-1212; Schmitz (1997) *Nucleic Acids Res.* 25:756-763; Hipkind (1996) *Mol. Plant Microbe Interact.* 9:819-825; Tornero (1996) *Plant J.* 10:315-330; Dixon (1996) *Cell* 84:451-459; Jones (1994) *Science* 266:789-793; Lawrence (1995) *Plant Cell* 7:1195-1206; Song (1995) *Science* 270:1804-1806; as discussed in further detail *supra*. Using the teachings disclosed and incorporated herein and standard nucleic acid hybridization and/or amplification techniques, one of skill can



identify polypeptides having LRR domains, including any member of the genus of LRR-containing RG polypeptides of the invention.

The term "promoter" refers to a region or sequence determinants located upstream or downstream from the start of transcription and which are involved in recognition and binding of RNA polymerase and other proteins to initiate transcription. A "plant promoter" is a promoter capable of initiating and/or regulating transcription in plant cells; see also discussion on plant promoters, *supra*.

The term "constitutive promoter" refers to a promoter that initiates and helps control transcription in all tissues. Promoters that drive expression continuously under physiological conditions are referred to herein as "constitutive" promoters and are active under most environmental conditions and states of development or cell differentiation; see also detailed discussion, *supra*.

The term "inducible promoter" refers to a promoter which directs transcription under the influence of changing environmental conditions or developmental conditions. Examples of environmental conditions that may effect transcription by inducible promoters include anaerobic conditions, elevated temperature, drought, or the presence of light. Such promoters are referred to herein as "inducible" promoters; see also detailed discussion, *supra*.

The term "abscission-induced promoter" or "abscission promoter" refers to a class of promoters which are activated upon plant ripening, such as fruit ripening, and are especially useful incorporated in the expression systems (*e.g.*, expression cassettes, vectors) of the invention. When the plant disease resistant polypeptide-encoding nucleic acid is under the control of an abscission promoter, rapid cell death, induced by expression of the invention's polypeptide, accelerates and/or accentuates abscission of the plant part, increasing the efficiency of the harvesting of fruits or other plant parts, such as cotton, and the like; see also detailed discussion, *supra*.

The term "tissue-specific promoter" refers to a class of transcriptional control elements that are only active in particular cells or tissues. Examples of plant promoters under developmental control include promoters that initiate transcription only (or primarily only) in certain tissues, such as roots, leaves, fruit, ovules, seeds, pollen, pistils, or flowers; see also detailed discussion, *supra*.

As used herein "recombinant" includes reference to a cell, or nucleic acid, or vector, that has been modified by the introduction of a heterologous nucleic acid or the alteration of a native nucleic acid to a form not native to that cell, or that the cell is derived from a cell so modified. Thus, for example, recombinant cells express genes that are not found within the native (non-recombinant) form of the cell or express native genes that are otherwise abnormally expressed, under expressed or not expressed at all.

As used herein, a "recombinant expression cassette" or "expression cassette" is a nucleic acid construct, generated recombinantly or synthetically, with a series of specified nucleic acid elements which permit transcription of a particular nucleic acid in a target cell. The expression vector can be part of a plasmid, virus, or nucleic acid fragment. Typically, the recombinant expression cassette portion of the expression vector includes a nucleic acid to be transcribed, and a promoter.

As used herein, "transgenic plant" includes reference to a plant modified by introduction of a heterologous polynucleotide. Generally, the heterologous polynucleotide is an RG structural or regulatory gene or subsequences thereof.

As used herein, "hybridization complex" includes reference to a duplex nucleic acid sequence formed by selective hybridization of two single-stranded nucleic acids with each other.

As used herein, "amplified" includes reference to an increase in the molarity of a specified sequence. Amplification methods include the polymerase chain reaction (PCR), the ligase chain reaction (LCR), the transcription-based amplification system (TAS), the self-sustained sequence replication system (SSR). A wide variety of cloning methods, host cells, and *in vitro* amplification methodologies are well-known to persons of skill.

As used herein, "nucleic acid sample" includes reference to a specimen suspected of comprising RG resistance genes. Such specimens are generally derived, directly or indirectly, from lettuce tissue.

The term "antibody" refers to a polypeptide substantially encoded by an immunoglobulin gene or immunoglobulin genes, or fragments or synthetic or recombinant analogues thereof which specifically bind and recognize analytes and antigens, such as a genus or subgenus of polypeptides of the invention, as described *supra*.

It is understood that the examples and embodiments described herein are for illustrative purposes only and that various modifications or changes in light thereof will be suggested to persons skilled in the art and are to be included within the spirit and purview of this application and scope of the appended claims.

5

### EXAMPLES

The following examples are offered to illustrate, but not to limit the claimed invention.

#### Example 1

10 Example 1 describes the use of PCR to amplify RG genes from lettuce.

Multiple primers with low degeneracy, particularly at the 3' end, were designed based on the sequences of two known resistance genes from tobacco and flax.

#### **DNA Templates**

15 Lettuce genomic DNA was extracted from cultivar Diana and a mutant line derived from cultivar Diana using a standard CTAB protocol. To generate cDNA templates, RNA was isolated from cultivar Diana and the mutant following standard procedures; first strand cDNA was synthesized using Superscript reverse transcriptase from 1  $\Phi$ g total RNA as specified by the manufacturer (Life Technologies). BAC (bacterial artificial chromosome) clones from the *Dm3* region were isolated from a BAC library of 20 over 53,000 clones using marker AC15 that was known to be closely linked to *Dm3*. Bacterial plasmids containing clones of *L6* and *RPS2* were used as positive controls.

#### **PCR with degenerate oligonucleotide primers**

25 Oligonucleotide primers were designed based on conserved motifs in the nucleotide binding sites (NBS) of *L6*, *RPS2*, and *N*. Eight primers were made corresponding to the GVGKTT motif in the sense direction; each had 64-fold degeneracy. Six primers were made to the GLPLAL motif in the anti-sense direction; with either 16 or 256-fold degeneracy (Table 1).

30 Oligonucleotides included 14-mer adaptors of (CUA)<sub>4</sub> at the 5' end of the sense primers and (CAU)<sub>4</sub> at the 5' end of the antisense primers to allow rapid cloning of the PCR products into pAMP1 (Life Technologies).

PCR amplification was performed in 50  $\Phi$ l reaction volume with 1  $\Phi$ M of each of a pair of sense and antisense primers. The templates were denatured by heating to 94EC for 2 min. This was followed by 35 cycles of 30 sec at 94EC, 1 min at 50EC, 2 min at 72EC, with a single final extension of 5 min at 72EC. 25 ng of genomic DNA or cDNA was used. BAC clones as templates required less. The final dNTP concentration was 0.2 mM;  $MgCl_2$  was 1.5 mM.

Forty-eight combinations of sense and antisense primers were tested on a panel of nine templates consisting of two genomic DNA samples, two cDNA preparations, three BAC clones and plasmids containing *L6* and *RPS2* as positive controls.

Amplification from *L6* and *RPS2* resulted in fragments of 516 and 513 respectively. Seven combinations of primers resulted in fragments of approximately this size with multiple templates (Table 2). Primers that gave RLG products were: PLOOPAA, PLOOPAG, PLOOPGA, PLOOPGG, PLOOPAC, GLPL3, GLPL4.

(Intentionally left blank)

Table 1

## DEGENERATE PRIMER SEQUENCES for NBS PCR

Sense primers based on GVGKTT amino acid sequence from L6, N and rps2 PLOOP motif:

PLOOPAG 5' GGN GTN GGN AAA ACG AC 3'

PLOOPAA 5' GGN GTN GGN AAA ACA AC 3'

PLOOPAT 5' GGN GTN GGN AAA ACT AC 3'

PLOOPAC 5' GGN GTN GGN AAA ACC AC 3'

PLOOPGG 5' GGN GTN GGN AAG ACG AC 3'

PLOOPGA 5' GGN GTN GGN AAG ACA AC 3'

PLOOPGT 5' GGN GTN GGN AAG ACT AC 3'

PLOOPGC 5' GGN GTN GGN AAG ACC AC 3'

Antisense primers based on GLPLAL amino acid sequence:

GLPL1 5' AGN GCN AGN GGN AGG CC 3'

GLPL2 5' AGN GCN AGN GGN AGA CC 3'

GLPL3 5' AGN GCN AGN GGN AGT CC 3'

GLPL4 5' AGN GCN AGN GGN AGC CC 3'

GLPL5 5' AAN GCC AAN GGC AAA CC 3'

GLPL6 5' AAN GCC AAN GGC AAT CC 3'

TABLE 2. Characteristics of RLGs isolated from lettuce.

	Template	Primers	Number <sup>a</sup>	Size <sup>b</sup> (bp)	Copy number <sup>c</sup>	Dm linkage
5	RLG1	genomic DNA	PLOOPGA+GLPL6	6/6	522	DM4,
		cDNA	PLOOPGA+GLPL6	1/5		DM13
		genomic DNA	PLOOPAA+GLPL6	5/5		
		cDNA	PLOOPAA+GLPL6	1/1		
	RLG2	BACH8	PLOOPGG+GLPL3	3/3	510	DM1, Dm3
	RLG3	gemonic DNA	PLOOPGA+GLPL4	3/6	461	Dm5 Dm8
10	RLG4	genomic DNA	PLOOPGA+GLPL4	1/6	524	

<sup>a</sup> Number of RLG sequences out of total number of clones sequenced.

<sup>b</sup> Size of fragment amplified from the nucleotide binding domain.

<sup>c</sup> Estimated copy number from genomic Southern blot analysis and numbers of clones in the BAC library.

### Example 2

Example 2 describes the genetic analysis used to obtain a preliminary indication of the linkage relationships of the amplified products and known clusters of resistance genes.

Bulked segregant analysis was performed to obtain a preliminary indication of the linkage relationships of the amplified products and known clusters of resistance genes. DNA from individuals were pooled for each susceptible and resistant bulk. Amplified products were then mapped by RFLP analysis from our intraspecific mapping population. Resistances from four clusters of resistance genes as well as over six hundred markers have now been mapped on this population. Linkage analysis was done using JIONMAP or MAPMAKER mapping programs. Due to a suppression of recombination in the *Dm3* region, sequences were mapped relative to *Dm3* using a panel of deletion mutants that provided greater genetic resolution than the mapping population (Anderson *et al.* 1996). All blots were washed twice at 63EC in 2x SSC/1% SDS for 20 min, followed by one wash at 63EC in 1x SSC/0.1% SDS for 10 or 30 min.

Most of the RLG sequences were analyzed by bulked segregant analysis (BSA) using pools of resistant and susceptible individuals for each of the four clusters of resistance genes. In genomic Southern analyses, all the RLGs revealed numerous fragments of varying intensity. The numbers of bands was highly dependent of the stringency of hybridization. BSA demonstrated that RLG1 was linked to the *Dm4*, 7 and *Dm13* clusters. Segregation analysis confirmed this linkage.

RLG2 was derived from BAC H8 that was known to be from the *Dm3* region. BSA with RLG2 demonstrated that the polymorphic bands that distinguished the parents of our mapping population mapped to the *Dm1*, *Dm3* cluster. Several bands absolutely cosegregated with *Dm1* or *Dm3*. To provide finer genetic resolution, RLG2 was also mapped using a panel of *Dm3* deletion mutants. A number of fragments were missing in largest deletion mutant demonstrating that several RLG2 family members are physically located very close to *Dm3*. No fragment was missing in all deletion mutants; however, this is not unexpected as there is extensive duplication within the region.

### Example 3

Example 3 describes the screening of a bacterial artificial chromosome library.

Over 53,000 BAC clones containing lettuce genomic DNA were screened with two of the amplified products. High density filters each containing 1536 clones were hybridized to  $^{32}\text{P}$  labelled probes. Filters were washed at 65EC with 40 mM  $\text{Na}_2\text{PO}_4$ /0.1 % SDS for 5 min followed by 20 min in the same solution.

To isolate additional RLG sequences we screened our genomic BAC library. Clones were identified that hybridized to RLG1 and RLG2. Nearly all the clones that hybridized to RLG2 also hybridized to marker AC15 that had already been shown by deletion mutant analysis to be clustered around *Dm3*. This provided further evidence for clustering of RLG2 sequences.

Using primers conserved within each family, part of the NBS was amplified from each unique BAC clone and sequenced. This revealed that members within each family varied from 64% identical at the deduced amino acid level. The most divergent members only weakly cross-hybridized to each other. Currently, RLG sequences are

considered to be part of the same family of sequences if they are at least 55% identical at the deduced amino acid level and map to the same region of the chromosome.

**Example 4:**

5                    Example 4 describes the cloning, identification, sequencing and characterization of RG polynucleotide sequences; including use of RG sequences from plasmid and PCR products.

                    Doubled stranded plasmid DNA clones and PCR products were sequenced using an ABI377 automated sequencer and fluorescently labelled di-deoxy terminators.  
10                   Sequences were assembled using Sequencher (Genecodes), DNASTar (DNASTar) and Genetics Computer Group (GCG, Madison, WI) software. Database searches were performed using BLASTX and FASTA (GCG) algorithms.

                    Sequences flanking the NBS region for RLG2 and for some of RLG1 were obtained by a series of IPCR and the products sequenced directly. IPCR worked less well  
15                   for RLG1. Therefore RLG1 was subcloned from a BAC clone into pBSK (Stratagene) and the double stranded plasmid sequenced by long range sequencing.

                    Initially, a total of 30 clones were sequenced. Three of these seven primer combinations yielded sequences that comprised continuous open reading frames with sequence identity to the NBS of known resistance genes. Seven out of 10 clones amplified  
20                   from genomic DNA with the primer pair PLOOPGA/GLP6 were 522 bp long; they were identical to each other and named RLG1. All six clones amplified from genomic DNA or cDNA using the primers PLOOPAA/GLP6 were similar/the same as RLG1. All three clones sequenced from BAC clone H8 were 510 bp long, identical to each other but different from RLG1 and were therefore designated RLG2. The 11 clones sequenced from  
25                   four other primer combinations had no similarity to any NBS motifs and therefore were not studied further. Therefore, sequencing resulted in the identification of clones containing NBS motifs representing four RLG sequences.

                    Comparison of the deduced amino acid sequences of RLG1 and RLG2 to those of known resistance genes revealed that RLG1 and RLG2 are as similar to each other  
30                   as they are to resistance genes from other species and that this is the same level of identity shown between the known resistance genes (Table 3). The percent identity (upper quadrant) and percent identity (lower quadrant) were determined using the MEGALIGN



routine of the DNASTAR package. Identity refers to the proportion of identical amino acids; identity refers to the proportion of identical and similar amino acids and takes into account substitutions of amino acids with similar chemical characteristics. RG1 and RG2 are as similar to each other and to cloned resistance genes as cloned resistance genes from a variety of species are to each other. L6, resistance to *Melampsora lini* in flax (Lawrence *et al.*, 1995). N, resistance to tobacco mosaic virus in tobacco (Whitham *et al.*, 1994). PRF, required for resistance to *Pseudomonas syringae* in tomato. RPS2, resistance to *Pseudomonas syringae* in *Arabidopsis thaliana* (Bent *et al.*, 1994; Mindrinos *et al.*, 1994). RPM1, resistance to *Pseudomonas syringae* pv. *maculicola* in *A. thaliana* (Grant *et al.*, 1995). The initial RG1 and RG2, sequences were amplified from lettuce using degenerate primers.

Table 3

## IDENTITIES OF

## RESISTANCE GENE HOMOLOGUES

		RG1	RG2	RG3	RG4	N gene	RPS2
Lettuce	RG1	***	22.7	15.0	29.2	25.4	23.8
Lettuce	RG2		***	32.2	21.6	22.7	33.0
Lettuce	RG3			***	17.2	15.0	32.8
Lettuce	RG4				***	44.3	22.7
Tobacco	N gene					***	21.6
<i>Arabidopsis</i>	RPS2						***

The regions homologous to the primers are included in this analysis as the genomic sequences for RLG1 and RLG2 were determined by IPCR. Interestingly, the genomic sequences for RLG1 exactly matched that of the primers used.

To obtain further evidence that we had amplified resistance genes, we amplified the regions flanking the NBSs of RLG1a and RLG2a by IPCR of BAC clones. These products were then directly sequenced without cloning to minimize the introduction of PCR artifacts. Sequence analysis of the 5' regions failed to detect any homology to known resistance genes. However, the sequence of the 3' region contained leucine-rich

repeats (LRRs). When this sequence was used to search GENBANK using BLASTX, it detected identity to the *Arabidopsis* resistance gene, *RPS2*. This region does not contain as regular LRRs as in some resistance genes; however, the repeat structure seems to be consistent with that of the flax resistance gene, *L6*. Therefore, the presence of an LRR region is further evidence that the sequences we amplified using degenerate oligonucleotide primers are probably resistance genes.

The sequences of the IPCR products also provided the genomic sequences of the regions complementary to the sequences of the degenerate oligonucleotide primers.

The genomic sequences for RLG1 were identical to one of the primers in the mixture.

The RLG sequences are resistance genes as supported by three criteria: the presence of multiple sequence motifs characteristic of resistance genes, genetic cosegregation with known resistance genes, and their existence as clustered multi-gene families. The presence of LRR regions in a similar position relative to the NBS as in cloned resistance genes provides stronger evidence than relying solely sequence similarity between NBS regions.

The clustering of RLG sequences at the same position as the known clusters of resistance genes make them strong candidates for encoding resistance genes. The hybridization patterns and genetic distribution of the RLG sequences are similar to that of cloned resistance genes in other species. Most of these hybridize to small multigene families and preliminary genetic evidence indicates that they are clustered in the genome. Therefore, the degenerate primers that we designed from other resistance genes seemed to have been specific enough to amplify resistance genes rather than P-loop containing proteins in general.

(intentionally left blank)

# SEQ ID NO: 1

## FLG1A (Strand)

```

1   ATCGTAACCGTTGCTACGAG  ANCGCTGTCCTCTTCATC  TTTTGTCAATGTCATATTC  TCATNATNTMGCCACATNT
81  AATTTTGTGGTTATTTTAAA  TTAATTTTATTCACATGT  CATTTTATGAGTTTTCAT  TTTATTGAGTTTCACATAAT
161 ATTTAAATGTAATAACAATA  AATGCATATTTATTTTCTT  TAAATAAACGCATATAATAT  ATAGATTAAAAATCATATAAT
241 ACATAGGTTAAACTCATATA  ATACATATGTTTCATCCCCAG  TTTATTATATGTCCTCATCC  TTAATTTATTTATTTATTTAT
321 TTATTAGAGTAGATGATCTT  TGTGATATTAATAATTAAT  TTGTTCAAAATTTAAATTA  TTAATAATCCCAATTTGA
401 ATAAAAATTAATAAATGGN  CCCACCATTAGTCCATCACT  TTTTCAGCTCATCAATATCG  TGAGTATCTCTCTGTTTC
481 CACCCTAATCAATATTTCCA  GCGAATGACAGACTCTTACG  CGGTTTCTGAATTTGCGTTC  CGACACTGTTTCATTGAAGGA
561 GATAATAAATCAATGGAGC  TGCTCCAATGTTTCATGCTG  ATGAAAGGTGAATTTGTATGT  GAAGANAATGTCAGCGATCN
641 ATCTCCATCGGAACCCACC  ACATTATCAGTGTACCACCA  AACCCTCAAACGGYGGAA  GTAGRRAKACWRAAAGTCA
721 TGAAGAATAGATTATTTTGG  TCCTCATGGGCTGACTGAGG  AGCGGGTTTAGTTCATCATT  TTTCTTTGANCAAGAATTA
801 TCGGTCCATCGAATTTTAC  ATCGACAAAGAAGTTTCACT  TCGCAATGTTTGTAAACA  ATTTTAATCTTTTATCTT
881 TCGTGAAGACTCTCAATT  GCAACTTGCAACTTGCAACT  TTGGGGCCCAAAATTTGTG  GTGGGCGTTAATTTATCCA
961 CATATTCACGTAAACAATA  ATTCAAATCGATCTCTGTT  ATCCAAATCATCAACATCTC  TTGATAATTTGAATCATTCG
1041 CGCTTCATCCATTTTCATCCA  CATCTATACTATATTTCTG  CTCTTATCATATTAACGAT  GGCTGAATCGTTCTTTCTG
1121 CCTTCTTGACAGTGGTGT  GAAAAGCTGGCATTTGAAGC  CTGGAAGAAGATTTGTCGCT  CCAAAAGAATTGAATCTGAG
1201 CTTAAGAAATGAAGGAGAC  ATTAGACCAAAATCCAAGATC  TGCTTAACGATGCTTCCCG  AAGGAAGTAACATGAAGC
1281 CGTTAAAGATGGCTGAATG  ATCTCCAACATTTGGCTTAT  GACATAGACGACCTACTTGA  TGATTTGCAACTGAAGCTG
1361 TTCACGCTGAGTTGACCGAG  GAGGGTGGAGCCTCTCCAG  TATGGTAAGAAACTAATCC  CAAGTTGTGTCACAAGTTTC
1441 TCACAAAGTAATAGGATGCA  TGCCAAAGTTAGATGATTTG  CCHCCAGGTTACAAGAACTG  GTAGAGGCAAAAATATCT
1521 TGGTTTAAAGTGTGATAACAT  ATGAAAGCCAAAAATGAA  AGGTATGAGGCGCTTTTGGT  AGATGAAAGCGGTACTGTGCG
1601 TACGTGAAGACTCTCAATT  AAATGCTGGAGAAGCTGTT  GGGGATAAAGATGAATCAG  GGAGTCAAAACTTCAGCATC
1681 GTGCCATAGTTGGTATGGG  TGGAGTTGGTAAACAACCTC  TAGCTAGACTTTTGTATGAT  GAAAAGAAAGTGAAGGATCA
1761 CTTCGAACTCAGGGCTTGGG  TTTGTGTTTCTGATGAGTTC  AGTGTTCCTCAATATAAGCAG  AGTTATTTATCAATCTGTGA
1841 CTGGGAAAGAAAGGAGTGT  GAAGACTTAAATCTGCTTCA  AGAAGCTCTTAAAGAGAAAC  TTAGGAACCAAGCTATTTCTA
1921 ATAGTTTGTGATGATGTTG  GTCTGAAAGCTATGGTGATT  GGGAGAAATTAGTGGGCCCA  TTCCTTGGGGGTCTCTCTGG
2001 AAGTGAATATCATGACAA  CTCCGAAGGAGCAATTGCTC  AGAAGCTGGGCTTTTCTCA  TCAAGACCTCTCGAGGGTTC
2081 TATCAACAGATGATGCTTTG  TCTTTGTTTGTCTCAACAGC  ATTTGGTGTACCAACTTTG  ATTCACATCCAACCTAAGG
2161 CCACATGGAGAGTGTTTGT  GAAGAAATGTGATGGCTTAC  CTCTAGCTTTAAGAACACTT  GGAAGGTTTATAGGCAAAA
2241 AACAGACGAGGAACATGGA  AGGAGCTGTGGATAGTGAG  ATATGGAGGTTAGGAAAGAG  CGATGAGATTTGTTCCGGCTC
2321 TTAGACTAAGCTACATGAT  CTTTCTGCCCTTTTGAAGCT  RTTCTTGCATATGCTCTCT  TGTTCCTCAAGGACTATGAG
2401 TTTGACAAAGGAGGTGTGAT  TCTATTTGCGATGGCAGAG  GGTTTTTCACCAACCACT  AYAAACAAGTCAAGGCAACG
2481 KTTGGGTCTTGAATATTTT  AAGAGTTRTGTCAAGRTCR  TTTTTCACATGCTCTCTAA  TRRCAATCTSTGTTTGTGA
2561 TGCATGACCTAATGAATGAT  TTGGCTACATTTGTTGCTGG  AGAATTTTTCAGGTTAG  ACATAGAGATGAAGAAGGAA
2641 TTTAGGATGSAATCTTTGGA  RAAGCACCGACATATGTCAT  TTGTATGTGAGRATTACATA  GGTTCACAAARGTTTCGAGCC
2721 ATTTAGAGGAGCTAAAAAT  TGAGAACATTTTTCAGATG  TCTGTGGGGTGGTAGAAGA  TTGGAAGATGTTTACTTAT
2801 CAAACAGGCTCTGAATGAC  WTACTTCARGATTTACCATT  GTTAAGGGTCTTRAKTTTGA  TTRTCTTAYAAATASYRAG
2881 GTACCAAAATCGTSGGTAG  TATGAASCACTTGGCGTATC  TTAATCTATCWGRAACTTWA  ATCACMCACTTACCGGAAWA
2961 TKTCTGCAATCTTTATAAT  TACARACCTGATTTGTCTCT  GGCTGTGAMTATTTAGTTAA  KTTGCCCAARACCTTCTCAA
3041 ASCTTAAAAATTTGCASCAT  TTTGACATGAGGGTACTCC  KAAKTTRAARAACATGCCCT  TARGGATTTGGTARTTGAAA
3121 ARTCTACAAACTCTCTTVMG  TAACATTTGGCATAGCAATA  CCGAGCTTAAGAACTTGCAM  AAYCTCCATGGGAAATTTG
3201 TATTGGCGGGCTGGGAAAA  TGGAAAATGCMGTGGATGC  ACGTTAAGCGAACTTGTCTC  AAAAAAGGTTWAATGARITA
3281 NAAACTCGRVTGCGGGTGA  TRAATTTAATGTTTTCGGAA  ATGGGAACACTTGAAGAAAG  AGTCCCTCAATGAAGTATGC
3361 CTCATAATGGTACTCTANAA  AAAACCCANAATTTATGCTA  TAGGGGTATAGAGTTTCCA  AATTGGGTGGTTTCACTAA
3441 GGGTTTCTGAAACTAGAGAT  GTGTTCTAGGTGTATGAAAA  AGANTGTTTACGTAGTTTC  ATCAATCACCAGTGGGAAA
3521 TAGATGATATTTTCAGGGCY  TACTGATGAGATGTGGAGAG  GTATGATAGGGTTCCTGGG  GCGGTAGAAGAAATAGCAT
3601 CCATTCTTGTAAATGAATAA  GATATTTGTGGGAATCAGAA  GCAGAGGCAAGTAAGGTTCT  TATGAATTTAAGAAGTTTG
3681 ATTTAGGTGAATGTGAAAA  TTGGTGAGTTTGGGGAGAA  AAAGGAGGATAATCATAATA  TTAATAGTGGGAGCAGCTTA
3761 ACATCTTTTAGGAGGTTGAA  TGTATGGAGATGTAAACAGCT  TGGAGCATTCAGGTTGTCCA  GATAGCATGGAGAATTTGTA
3841 TATGCAATGTGTGATTCAA  TNACATCCGCTCTCTTCCCA  ACAGGAGGAGGACAGAAGAT  CAAGTCACTTACCATCACTG
3921 ATTGCAAGAGCTTTCCGAA  GAGGAGTTGGGAGGAGCAGA  GAGGACAAAGATGCTTATA  ACTCAAAAAATCAGATGCTT
4001 GAATCAATAGATATACGTAA  TTGGCCAAATCTGAAATCTA  TCAGTGAATTGAGTTGCTTC  ATTCACCTGAACAGATTATA
4081 TATATCAAACTGTCGAGTR  TGGAGTCATTTCTGACCAT  GAGTTGCCAAATCTCACCTC  CTTAACAGATCGAAGGAGAG
4161 GACAGCGAATTTGCTACGAA  CGGTACGATTCGACTGGCC  GTCGTTTT

```

SEQ ID NO: 2

RLG1B

[Strand]

```
1  AACCGTTCGT ACGAGAATCG CTGTCCCTCTC CTTCCTGTAA TATAATGATA AGAAAAATA TGATTAAAGG
71  TTAAATCCA AAATCCATTA TTCCACCGGT GATATGATGC ACTAGCTGTA GTATGCAAAA ACAGTATTAT
141 AAATGCTAAC CAAAACAGCA GCTAAGAAAC AATATAAATA ATGGTTTGAA TCGTCCCTTC TCGGTACAQT
211 CATTTCTTCC AAATCCCTAT CATTCATACA TACAAGTGCT CCCATATTAG GTTTTCACTA TAAGCAATGG
281 CTGAAATCCT TGGTTCGTGG TTCTTTGCGG TGTCTTTTGA AAAGCTTGCT TCTGAAGCCT TGAAGAGGGT
351 TGCTTGCTCC AAAGTAATTG ACAAGGAGCT CGAGAAATTG AATAGCTCAT GAATCAATAT AAAAGCTCTG
421 CTCAATGATG CTTCTCAGAA GGAAATAAGT AAGGAAGCTG TTAAAGAATG GTTGAATGCT CTTCAACATT
491 TGCTTACGA CATAGATGAT CACTTGGGG ATTTGGCAAC CAAAGCTATC CATCGTAAGT TCTCTGAGGA
561 ATACGGGGCC ACCATCAACA AGGTACGAAA GTTAATTCCA TCTGTTCCT CTAGTTTGTG AAGTACTAAG
631 ATGCGCAACA AGATACATAA TATTACCAGC AAGTTACAAG AACTATTAGA AGAGAGAAAT AATCTTGGAT
701 TATGTGAAT TGGTGAAAGC CGAAAACCTC GAAATAGAAA ATCAGAGACC TCINTGCTAG ATCCATCTAG
771 TATGTTGGA CGCACAGATG ATAAGGAAGC GTTGTCTCTC AAGCTATATG AACCATGTGA TAGAACTTT
841 AGCATCTTGC CNATAGTTGG TATGGGTGGG TTAGATAAGA CCACCTTAGG TAGACTTTTG TATGATNAAA
911 TGCAAGTGAA GGATCACTTC GAACTCAAGG CGTGGGTTTG TGTTCCTGAT GAGTTTGATA TCTTCGGTAT
981 AAGCAAAACC ATTTTCGAAT CGATAGAGGG GGGAAACCAA GAGTTTAAGG ATTTAAATCT GCTTCAGGTG
1051 GCTTTAAAGG AGAAAATCTC AAAGAAACGA TTCTTGTGTG TTCTTGATGA TGTATGGAGC GAGAGCTATA
1121 CTGATTGGGA AATTCTAGAA CGTCCATTTC TAGCAGGAGC ACCAGGAAGT AAAGTAATCA TCACAACCCG
1191 CAAGTTGTG TGTCTAAACC AATTGGGTCA TGATCAACCA TACCAATTGT CTGATTTGTC ACATGACAA
1261 GCTCTATCTC TATTTGTGTA ACACGCATTT GGTGTAATA GCTTTGATTC ACATCCGATA CTTAAACCAC
1331 ATGGTGAAGG TATTGTTGAA AAATGTGATG GTTTGCCATT GGCTTTGATT GCACITGGGA GGTATTGAG
1401 GACAAAAGA GATGAGGAAG AATGGAAGGA ACTATTGAAT AGTGAGATAT GGAGTTAGG AAAGAGAGAT
1471 GAGATTATTC CGGTCCTAG ACTAAGCTAT AATGATCTTT CTGCTCTTT GAAGCAGTTG TTTGCATATT
1541 GCTCCTTGT CCCCAGAGAC TATGTGTTCA ACAAGGAGAA GTTGATTTTA TTATGGATGG CAGAAGGGTT
1611 TTTGCACAA GAAAATACAA ACAAGTCAAT GGAACGCTTA GNTCTTGAAT ATTTTGACGA CTTGTGTGTA
1681 AGGTCAATTT TTCAACATGC ACTCGATGAC AAATCGTGTG TTGTGGTGCA CGACCTCATG AATGACTTGG
1751 CCACATCTGT TGCTGGAGAT TATTTTTTAA GATTAGACAT TGAAATGAAA AAGGAAGCTT TGGAAAAATA
1821 CCGACATATG TCATTGTTT GTGAGAGTTA CATGGTTTAC AAAAGGTTTG AACCATTATA AGGAGCTAAA
1891 AAATTGAGAA CTTTCTTAGC AATGCCCTGT GGGATGATAA AAAGTTGGAC AACATTTTAC TTATCAAATA
1961 AGGTCTTGA TGACTTACT CACGAATTAC CATGTGTGAG AGTTCCTAAGT TTGAGTTATC TTAGCATCAA
2031 GGAGGTACCT GAAATAATAG GCAATTTGAA ACACTTGGCG TATCTTAATT TATCACACAC GAGTATCACA
2101 CATTTACCAG AAAATGTCTG CAATCTTTAC AACTTACAAA CATTGATCCT TTGTGGCTGT TGTMTTATA
2171 CCAAGTTTCC CAACTCTTC TTAAAGCTTA GAAATTTACG GCATTTGGAC ATTAGCGATA CTCCCGGTTT
2241 GAAGAGATG TCCTCGGGA TTGGTGAATT GAAGAACCTA CACACVCTCT CCAAGCTCAT TATTTGAGGT
2311 GAAAATAGAC TAAACGAGCT TAAGAACTTA CAAAATCTCC ATG
```

RLG1b - Diana  
[Strand]

```
1  TACTACTACT AGAATTCGGT GTTGGTAAGA CGACTCTAGC TAGACTTTTG TATGAGGAAA TGCAAGGGAA
71  GGATCACTTC GAACTTAAGG CGTGGGTATG TGTTCCTGAT GAGTTTGATA TCTTCAATAT AAGCAAAATT
141 ATCTTACAAT CGATAGGTGG TGGAAACCAA GAATTTACGG ACTTAAACCT GCTTCGAGTA GCTTTAAABAG
211 AGAAGATCTC AAAGAAAAGa TTTCTTCTTG TTCTTGATGA TGTTTGGAGT GAAAGCTATA CCGATTGGGA
281 AATINTAGAA CGCCCATTTT TTGCAGGGGC ACCTGGAAGT AAGATTATTA TCACCACCCG GAAGCTGTCA
351 TTGTAAACA AACTCGGTTA CAATCAACCT TACAACCTTT CGGTTTGTG ACATGAGAAT GCTTTGTCTT
421 TATTCTGTCA GCATGCATTG GGTGAAGATA ACTTCAATTC ACATCCAACA CTTAAACCAC ATGGCGGAGG
491 TATTGTTGAA AAATGTGATG GATTGCCATT GGCATTGTG ACATGATGAT GATG
```

SEQ ID 137

# SEQ ID NO: 3

RLG1C  
[Strand]

```
1   TCCCGTGCAA CGTATATCAT TCAGAAGNGC CCAAGACCA NAGATNTGTT TAANGNTGNT TMTCAGAAGG
71  AAGTAATTGA TGAAGCTGTA AAAAGATGGC TGATTGATNT CCAACAATTG GCTTACGACA CTGANGACNA
141 ACTTGATGAT NTGCGCAACAG AAGCTATTCA TCGTGAGTTG ATCCGTGAAA CTGGAGCTTC CICCAGCATG
211 GTAAGAAAGC TAATCCCAAG TTGTTGCACA AGTTTCTCAC AAAGTAATAG GATGCATGCC AGGTTAGATG
281 ATATTGCCGC TAAGTNACAA GAACTGGTAG AGGCGAAAAA TAATCTTGGT TTAAGTGTGA TAACATACGA
351 AAAACCCAAA ATTGAAAGAG ATGAGGCGTN TTTGGTAGAT GCAAGTGGTA TCATTGGACG TGAAGATGAT
421 AAGAAAAAAT TGCTTCAGAA GCTGTTGGGG GATACCTATG AATCAAGTAG TCAAAACTTC AACATCGTGC
491 CCATAGTTGG TATGGGTGGG GTAGGTAAAA CAACTCTAGC TAGACTTTTG TATGATGAAA AAAAAAGTGA
561 GGATCACTTC GAACTCAGGG TTTGGGTTTG TGTTCTGAT GAGTTCAGTG TTCCCAATAT AAGCAGAGTT
631 ATCTATCAAT CTGTGACTGG TGA AAACAA GAATTTGCAG ATTTAAATCT GCTTCAAGAA GCCCTTAAAG
701 AGAAACTTCA GAACAACTA TTCTTAATAG TTTTAGATGA TGTATGGTCT GAAAGCTATG GTGATTGGGA
771 GAAATTAGTG GGCCCATTTT ATGCTGGGAC TTCTGGAAGT AGAATAATCA TGACTACTCG GAAGGAGCAA
841 TTACTCAAAC AGCTGGGTTT TTCTCATGAA GACCTCTGCG ATAGTATAGA CTCCCTGCAA CGTCTATCAC
911 AAGAAGATGC TTTGTCTTTG TTTCTCAAC ACGCATTTGG TGTACCTAAC TTTGATTTCAC ATCCAACACT
981 AAGGCCATAT GGGGAACAGT TTGTGAAAAA ATGTGGGGGA TTGCCTTTGG CCTTGT
```

SEQ ID NO:4

RLG1D

[Strand]

```
1  CHTACCCATTC TAGGAGATCG CTGTCCCTCC TCGATCTGCT TAACGATGCT TCCCAGAAGG AAGTNACTAA
71  TGAAGCCGTT AAAAGATGGC TGAATGATCT CCAACATTTC GCTTATGACA TANACGACCT ACTTGATGAT
141 CTTGCCACAS AAAGCTATTC TTCSTGAGTT GACCGANGAA GGTGGAGCCT CCACCAGTAT GGTAGAAAAA
211 CTAATCCCAA GTTGTTCAC AAGTTTCTCA CAAAGTTATA GGATGCATGC CAAGTTAGAT GATATTGCCA
281 CCAGGTACA AGAACTGGTA GAGGCAAAAA ATAATCTTGG TTAAAGTGTG ATAACATATG AAAAGCCCCA
351 AATTGAAAGG TATGAGGCAT CTTGGTAGA CGAAAGTGGT ATTTTGGAC GTTNAGATGA TNAGAAAAAA
421 TTGATGGAGA AGCTGTTGGA GGATAAAGAT GAATCCGGAG TCNAACTTC AGCATCCTGC CCATAATTGG
491 TATGGGTGGA GTTGGCNAAA CAACTCTAGC TAGACTCTTG TTTGATGAAA AGACAGTGAA GGATCACTTC
561 GAACCTAGGG CTTGGGTTTG TGTTCCTGAT GAATTCAGTA TTCTCAACAT AAGCAAAGTT ATCTATCAAT
631 CTGTGACCGG GGAAAGAGAA GAGTTTGAAG ACTTAAATCT GCTTCAAGAA GCTCTTAGAG GGAAACTACA
701 AAACAATACTA TTCTAATAG TTTGGATGA TGTATGGTCG GAAAGCTATG GTGATTGGGA GAAATTAGTG
771 GGCCCATTTT ATGCTGGGAC TTCTGGAAGT AGAATAATCA TGACTIONG GAAGGAGCAA TTACTCAAAC
841 AGTTCGGTTT TTCTCATCAA GACCCCTCTG GTTGTATAGA CTCCCTGCAA CGTCTATCAC AAGATGATGC
911 TTTGTCTTTG TTTGCTCAAC ACGCAITTTG TGWCCA
```

RIG1E  
[Strand]

```
1  TCTAGCTAGA CTTTGTGATG ACGAGATGCA AGAGAAGGAT CACTTCGAAC TCAAGGCGTG GGTTTGTTGT
71  TCTGATGAGT TTGATATATT CAATATAAGC AAAATTATTT TCCAATCGAT AGGAGGTGGA AACCAAGAAT
141 TTAAGGACTT AAATCTCCTT CAAGTAGCTG TAAAAGAGAA GATTTCAAAG AAACGATTTC TACTTGTTC
211 TGATGATGTT TGGAGTGAAA GCTATGCGGA TTGGGAAATT CTGGAACGCC CATTTCCTGC AGGGGCAGCC
281 GGAAGTAAA TTATCATGAC GACCCGGAAG CAGTCATTGC TAACCAAAC CGGTTACAAG CAACCTTACA
351 ACCTTTCCGT TTGTGCACAT GACAGTGCTC TCTCTTTATT CTGTCAGCAT GCATTGGGTG AAGATAACTT
421 CGATTCCAT CCAACACTTA AACCACATGG CGAAGGCATT GTTGAAAAAT GTGCT
```

SEQ ID NO:5



RLGIF  
[Strand]

```
1   ATTTTCNGCT  CNAACAAAN  AAAAGCAATG  GCTGAAATCT  TTCTTTCNGC  ATTCTAGACC  AGTATTCTTT
71  GAAAAAGNTGG  CTTCCTGAAGC  CTTGAAGAAG  ATCGCTCGCT  TCCATCGGAT  TGATTCTGAG  CTCAAGAAAC
141 TGAAGAGGTC  ATTAATCCAG  ATCAGATCTG  TGCTTAATGA  TGCTTCTGAG  AAGGAAATAA  GTGATGAAGC
211 TGTTAAGAA  TGGCTGAATG  GTCTCCAACA  TTGTCTTAC  GACATAGACG  ACCTACTTGA  TGATTGGCA
281 AOCGAAACTA  TGCATCGTGA  GTTGACCCAC  GGATCTGGAG  CCTCCACCAG  CTTGTAAGAA  AGATAATCCC
351 AACTTGTTC  ACAGATTCT  CACTAAGTAG  TAAGATGCGT  AACAAAGTTAG  ATAATATTAC  CATCAAGTTA
421 CAAGAACTGG  TAGAGGAAAA  AGATAATCTT  GGCTTAAGTG  TGAAGGTGA  AAGCCCAAAA  CATACCAACA
491 GAAGATTACA  GACCTCTTTG  GTAGATGCAT  CTAGCATTAT  TGGTCGTGAA  GGTGATAAGG  ATGCATTGCT
561 CCATAAGCTG  CTGGAGGATG  AACCAGTGA  TAGAAACTTT  AGCATCGTGC  CAATAGTTGG  TATGGGTGGT
631 GTGGGTAAGA  CGACTCTAGC  TAGACTTTTG  TATGACGAGA  TGCAAGAGAA  GGATCACTTC  GAACTCAAGG
701 CGTGGGTTTG  TGTTCCTGAT  GAGTTTGATA  TCTTCAATAT  AAGCAAAGTT  ATCTTCCAAT  CGATAGGTGG
771 TGGARACCA  GAATTTAAGG  ACTTAAATCT  CCTTCAAGTA  GCTGTAAAAG  AGAAGATTTC  AAAGAAACGA
841 TTTCTTNTTG  TTCTGGATGA  TGTTTGGAGT  GAAAGCTATA  CAGAATGGGA  AATTCTAGCA  CGTCCATTTC
911 TTGCAGGGGC  ACCAGGAAGT  AAGATTATCA  TGACGACCCG  GAAGTTGTGG  TTGCTAACCA  AACTCGGTTA
981 CAATCAACCT  TACAACCTTT  CSGTTTGTGC  ACATGATAAT  GCTTGTCTTT  TATTCTGTCA  GCAYGCATTG
1051 GGTGAAGATA  ACTTCGATTC  ACATCCAACA  CTTAAACCAC  ASGGTGAAAG  TATTGTTGAA  AAATGTGACG
1121 GTTTACCATT  GGCCTTTRAT  GCACCTGGGA  GRTTGTGAR  GACAAAAACA  GATGAGGAAG  AATGGAARGA
1191 AGTGTGAAT  AGTGAATAT  GGGGTCAGG  AAAGGGAGAT  GAGATTGTTT  CGGCTCTTAA  ACTAAGCTAC
1261 AATGATCTCT  CTGCCTCTTT  GAAGAAGTTG  TTGCATACT  GCTCCTTGTT  CCCAAAAGAC  TATGTTGTCG
1331 ATAAGGAGGA  GTTGATTTTG  TTGTGGATGG  CAGAAGGGTT  TTTGCACCAA  TCAACCACAA  GCAAGTCBAT
1401 GGAACGCTTG  GGHCATGAAG  GTTTTGATGA  ATTGTGTGCA  AGATCATTTT  TTCAACATGC  CCTGTATGCC
1471 AAATCGATGT  TTGTGATGCA  TGACCTGATG  AATGACTTGG  CHACATCTGT  TGCTGGAGAT  TTTTTCCAA
1541 GGATGGACAT  TGAGATGAAG  AARGAATTTA  GGAAGGAAGC  TTTGSAAAAG  YAYCGCCATA  TGTCAATTGT
1611 TTGTGAKGAT  TACATGGTKK  ACAAAGGTT  CRAGCCATTS  ACAAGGAGCT  AG
```

SEQ ID NO: 6

RLG1G  
[Strand]

```
1  GTGAAGGATC ACTTCGAACT CAGGGCTTGG GTTTGTGTTT CTGATGAATT TAATATCCTC AATATAAGCA
71  AAGTAATTTA TCAATCTGTA ACCGGGGAAA AAAAGGAGTT TGAAGACTTA AATCTGCTTC AAGAAGCTCT
141 TAAAGAAAAA CTTTGGAATC AGTTATTTCT AATAGTTCTG GATGATGTGT GGTCTGAAAG CTATCGTGAT
211 TGGGAGAAAT TAGTGGGCCC ATTTTITTCG GGGTCTCCTG GAAGTATGAT TATCATGACA ACTCGGAAGG
281 AGCAATTGCC AAGAAAGCTG GGTTTTCCTC ATCAAGACCC TTGCAAGGT CTATCACATG ACGATGCTTT
351 GTCCTTGTTT GCTCAACAGC CATTGGTGT ACCA
```

SEQ ID NO:7

RLG1H  
[Strand]

```
1   TCTAGCTAGA CTTTGTATG AGGAAATGCA AGGGAAGGAT CACTTGAAC TCAAGGCGTG GGTATGTGTT
71  TCTGATGAGT TTGATATCTT CAATATAAGC AAAATTATCT TACAATCGAT AGGTGGTGGA AACCAAGAAT
141 TTACGGACTT AAACCTGCTT CAAGTAGCTT TAAAAGAGAA GATCTCAAAG AAAAGATTTC TTCTGTTCCT
211 TGATGATGTT TGGAGTGAAA GCTATACCGA TTGGGAAATT CTAGAACGCC CATTTCCTTC AGGGGCACCT
281 GGAAGTAAGA TTATTATCAC CACCCGGAAG CTGTCATTGT TAAACAAACT CGGTTACAAT CAACCTTACA
351 ACCTTTCGGT TTGTCACAT GAGAATGCTT TGTCTTTATT CTGTCAGCAT GCATTGGGTG AAGATAACTT
421 CAATTCACAT CCAACACTTA AACCACATGG CGAAGGTATT GTTGAAAAAT GTGAT
```

SEQ ID NO: 8

RLG1  
[Strand]

```
1  TCTAGCTAGA CTTGTGTATG ATGAGATGCA AGAGAAGGAT CACTTTGAAC TCAAGGCGTG GGTATGTGTT
71  TCTGATGAGT TTGATATATT CAATATAAGC AAAATTATTT TCCAAATCGAT AGGAGGTGGA AACCAGAAT
141 TTAAGGACTT AAACCTCCTT CAAGTAGCTG TAAAAGAGAA GATTTTAAAG AACGATTTC TTCTGTTCCT
211 TGAAGACGTT TGGAGTGAAA GCTATGCCGA TTGGGAAATT NTGGAACGCC CATTTCTTGC AGGGGCAGCC
281 GGAAGTAAAA TTATCATGAC AACCCGAAAG CAGTCATTGC TAACCAACT CGGTACAAG CACCTTACA
351 ACCTTCCGT TTTGTACAT GACAGTGCTC TGTCTTTATT CTGTCAGCAT GCATTGGGTG AAGGTAACTT
421 CGATTACAT CCAACACTTA AACCACATGG CGAAGGCATT GTTGAAAAAT GTGCTGGATT GCCATTGGCA
491 TTGTCGACA
```

SEQ ID NO. 9

RLGLJ  
[Strand]

```
1  TACTACTACT AGAATTCGGT GTTGGTAAGA CGACTCTAGC TAGACTTTTG TATGAGGAAA TGCAAGGGAA
71  GGATCACTTC GAACTTAAGG CGTGGGTATG TGTTCCTGAT GAGTTTGATA TCCTCAATAT AAGCAAAATT
141 ATCTTACAAT CGATAGGTGG TGGAAACCAA GAATTTACGG ACTTAAACCT GCTTCGAGTA GCTTTAAAAG
211 AGAAGATCTC AAAGAAAAGA TTCTCTCTTG TTCTTGATGA TGTTTGGAGT GAAAGCTATA CCGATIGGGA
281 AATINTAGAA CGCCCATTC TTGCAGGGGC ACCTGGAAGT AAGATTATTA TCACCACCCG GAAGCTGTCA
351 TTGTTAAACA AACTCGGTTA CAATCAACCT TACAACCTTT CGGTTTGTG ACATGAGAAT GCTTTGTCTT
421 TATTCTGTCA GCATGCATTG GGTGAAGATA ACTTCAATTC ACATCCAACA CTTAAACCAC ATGGCGGAGG
491 TATTGTGGAA AAATGTGATG GATTGCCATT GGCATGTGTC ACATGATGAT GATG
```

SEQ ID NO:10

RLGIA aa.

IVTVRTR?LSLLHLLSYVIFS?I?PH?ILWLF.INFYSTCHFMSFSILLSFT.YLNVITINAYLFFFK.THIYR  
LKSynt.VKLI.YICSSPVLYVSSLIYLLFIY.SR.SL.Y.KFNLFKI.NY..SHNLNKIKKNGPTISPSLFQJINIV  
SILLRFHPNQYFQRMtdSYGVSEFAFRHCSLKEIINQMELLOCSLLMKGELYVK?MSAI?LHPEPTTLsv  
YHQTTONGGSr?T?KS.RIDYFCPHGLTEERV.FIIFL?KNYRSIEFLHRQRSFTSQCFVKQFJFLSFR.NS  
SIATCNLQLLGPQICGGR.FNPHIHCKQ.FKSISVHPIHQHLLIEIIHASSISSTSILYSLLLSY.TMAEIVLS  
AFLTVVFEKLA?EALKKIVRSKRIESELKKLKETLDQIQDLLNDASQKEVTNEAVKRWLNDLQHLAYDID  
DLLDD?ATEAV?RELTEGGASSSMVRKLIPSCCTSFSQSNRMHAKLDDIATRLQELVEAKNNLGLSVI  
TYEKPkieryEASLVDESGTVGREDDKKKLEKLLGDKDESGSQNFSIVPIVGMGGVGKTTLARLLYDEK  
KVKDHFELRAWVCVSEFSVPNISRVYQSVTGEKKEFDNLQEQALKEKLRNQLFLVDDVWSESY  
GDWEKLVGPFLAGSPGSRIMTTRKEQLLRKLGFSHQDPLEGLSQDDALSFAQHAFGVNFDShPTLR  
PHGELFVKKCDGLPLALRTLGRLLRKTDEEQWKELLDSEIWRLGKSDEIVPALRLSYNDLSA?LKLFA  
YCSLFPKDYEFdKEELLLWMAEGFLHQPT?NKSQRGLGEYF?ELLSRSFFQHAPN?KSLFVMHDLMDND  
LATFVAGEFFSRLDIEMKKEFRM?SLEKHRHMSFVCE?YIGYK?FEPFRGAKNLRFTLALSVGVVEDWK  
MFYLSNKVLND?LQDLPLLRVL?LI?L?I?VP??VGSM?HLRYLNLS?T?ITHLPE??CNLYNLQTLIV  
SGC?YLV?LPKTFS?LKNL?HFDMR?TP?LKNMPL?IGELK?LQTLF?NIGIAITELKNL?NLHGK?CIGG  
LGKMENAVGCTLSELVSKV?..??NW??G..I.CFPKWEHLKKKSSMK.CLIMVL?KKP?IMSIGGIEFPN  
WVGLRVSETRDVFMVYEK?CFT.FHQSPSGK.MIFSG?TDEMWRGMIG?LGAVEEISIHSCNEIRYLWE  
SEAEASKVLMNLKKLDLGECENLVSLGEKKEDNHNINSGSSLTSFRRLNVWRCNSLEHCRCPDSMENLY  
MHMCDS?TSVSFPTGGGQKIKSLTITDCKLSEELGGRERTRVLINSKMQMLESVDIRNWPNLKSISEL  
SCFIHLNRLYISNCPS?ESFPDHELPNLTSLTDRRRRGQRFSYERLRFDWPSF

SEQ ID NO:11

RLGIB a.a.

NRSYENRCPLLPVI...EKI.LKV.IQNPLFHR.YDALAVVCKNSIINANQNSS.ETI.IMV.IVLSPTYTHFFQIPII  
HTYKCSHIRFSLAMAEILGSAFFAVFFFEKLASEALKRVACSKVIDKELEKLNSS.INIKALLNDASQKEIS  
KEAVKEWLNALQHLPYDIDDLGDLATKAIHRKFSEYGATINKVRKLIPSCFSSLSSTKMRNKIHNTS  
KLQELLEERNNLGLCEIGESRKLNRKSETS?LDPSSIVGRTDDKEALLKLYEPCDRNFSILPIVGMGGL  
DKTTLGRLLYD?MQVKDHFELKAWVCVSDEFDIFGISKTIFESIEGGNQEFKDLNLLQVALKEKISKKRFL  
VLDDVWSESYTDWEILERPFLAGAPGSKVIITTRKLSLLNQLGHDQPYQLSDLSHDNALSIFCQHAFG  
VNSFDSHPILKPHGEGIVEKCDGLPLALIALGRLLRTKRDEEEWKELLNSEIWRLGKRDEIIP?LRLSYND  
LSASLKQLFAYCSLFPKDYVFNKEKLILLWMAEGFLHNENTNKS MERL?LEYFDDLLSRFFQHALDDKS  
LFVVHDLMLNDLATS VAGDYFLRLDIEMKKEALEKYRHMSFVCESYMVYKRFEPFKGAKKLRTFLAMPV  
GMIKSWTTTFYLSNKVLDLHLLHELP LLRVLSLSYSIKEVPEIIGNLKHLRYLNL SHTSITHLPENVCNLYN  
LQTLILCGCCFITKFPNNFLKLRNLRLHLDISDTPGLKKMSSGIGELKNLHTLSKLIIGGENRLNELKNLQNL  
H

SEQ ID NO:12

RLG 1c a.a.

SRAT?IIQK?PKT?D?F????QKEVIDEAVKRWLID?QQLAYDT?D?LDD?ATEAIHRELIRETGAS?S  
MVRKLIPSCCTSFSSQSNRMHARLDDIAAK?QELVEAKNNLGLSVITYEKP KIERDEA?LVDASGIIGRED  
DKKKLLQKLLGDTYESSQNFNIVPIVGMGGVGKTTLARLLYDEKKVKDHFELRVWVCVSDEFSVPNIS  
RVIYQSVTGENKEFADLNLLQEALKEKLQNKLFLLVDDVWSESYGDWEKLVGPFFHAGTSGSRIIMTTR  
KEQLLKQLGFSHEDPLHSIDSLQRLSQEDALSLFSQHAFGVNFD SHPTLRPYGEQFVKKCGGLPLAL

SEQ ID NO:13



RLGID

?T?LRDRCPSSICLTMLPRRK?LMKPLKDG.MISNIWLMT?TTYLMILQ?KAI??ELT?EGGASTSMVRK  
LIPSCCTSFSQSYRMHAKLDDIATRLQELVEAKNNLGLSVITYEKP KIERYEASLVDESGIFGR?DD?KK  
LMEKLLEDKDESGVKLQHLP IIGMGGVG?TTLARLLFDEKTVKDH FELRAWVCVSDEFSILNISKVIYQS  
VTGEKKEFEDLNLLQEALRGKLQNKLFVLDDVWSESYGDWEKLVGPFHAGTSGSRIIMTTRKEQLLK  
QLGFSHQDPLRCIDSLQRLSQDDALSLFAQHAFG?

SEQ ID NO: 14

RLGIE

LARLLYDEMQEKDHFELKAWVCVSDEFDIFNISKIIFQSIGGGNQEFKDLNLLQVAVKEKISKKRFLVLD  
DVWSESYADWEILERPFLAGAAGSKIIMTTRKQSLTKLGYKQPYNLSVLSHDSALSFCQHALGEDNF  
DSHPTLKPHGEGIVEKCA

SEQ ID NO: 15

RLGIF

FSA?NK?KQWLKSFF?HSRPVFFEK?ASEALKKIARFHRIDSELKKLKRSUQIRSVLNDASEKEISDEA  
VKEWLNGLQHLSYDIDDLDDLATETMHRELTDDLEPPPACKKDNPTCCTDFSLSSKMRNKLDNITIKL  
QELVEEKDNLGLSVKGESPKHTNRRLQTSVLDASSIIGREGDKDALLHKLLEDEPSDRNFSIVPIVGMGG  
VGKTTLARLLYDEMQUEKDHFEKAWVCVSDEFDIFNISKVIFQSIGGG?QEFKDLNLLQVAVKEKISKKR  
FL?VLDDVWSESYTEWEILARPFLAGAPGSKIIMTTRKLSLLTKLGYNQPYNLSVLSHDNALSLFCQHA  
LGEDNFDSHPTLKP?GESIVEKCDGLPLALIALGRLL?TKTDEEEWKEVLNSEIWGSGKGDEIVPALKLS  
YNDLSASLKKLFAYCSLFPKDYVFDKEELJLLWMAEGFLHQSTTSKSMERLGHEGFDELLSRFFQHAPD  
AKSMFVMHDLMLNDLATS VAGDFFSRMDIEMKKEFRKEAL?K?RHMS?VC?DYMV?KRF?P?TRS.

SEQ ID NO: 16

RLG1 G

VKDHFE LRAWVCVSDEFN ILNISKVIYQSVTGEKKEFEDLNLLQEALKEKLWNQLFLIVLDDVWSESYR  
DWEKLVGPFFSGSPGSMIIMTTRKEQLPRKLGFPHQDPLOGLSHDDALSLFAQHAFGVP

SEQ ID NO: 17

RLG 1 H

LARLLYEEMQKDHFKAWVCVSDEFDIFNISKIILQSIGGGNQEFTDLNLLQVALKEKISKKRFLVLD  
DVWSESYTDWEILERPFLAGAPGSKIITTRKLSLLNKLGYNQPYNLSVLSHENALSFCQHALGEDNFN  
SHPTLKPHGEGIVEKCD

SEQ ID NO: 18

RLGI I

LARLVYDEMQEKDHFELKAWVCVSDEFDIFNISKIIFQSIGGGNQEFKDLNLLQVAVKEKILKKRFLVLD  
DVWSESYADWEI?ERPFLAGAAGSKIIMTTRKQSLTKLGYKQPYNLSVLSHDSALSFCQHALGEGNF  
DSHPTLKPHGEGIVEKCAGLPLALST

SEQ ID NO: 19

RLG 15

EFGVGKTTLARLLYEEMQGKDHFELKAWVCVSDEFDIFNISKIILQSIGGGNQFTDLNLLRVALKEKISK  
KRFLVLDDVWSESYTDWEI?ERPFLAGAPGSKIITTRKLSLLNKLGYNQPYNLSVLSHENALSIFCQH  
ALGEDNFNSHPTLKPHG?GIVEKCDGLPLALS

SEQ ID NO: 20

SEQ ID NO: 21  
RLG 2A

```
1   TTNACACCAT AAATCTCINA CCTGNGGGGA CAAAAACCTA AAAATGGTCC ATAATGCNCA AATCAGNAAG
71  GTTGANAAGG CTCTAAGTTT TTNACCTCCA NCTGATGCNC NMTCCTCNTA AAGTTCANAT CCAAGCTTGC
141 CCTCCAACCTC TANCNCTTC AATGGCACCT CCTTCTCTTC AAAAGCACAC AAGAACACTT TCAAGCTCAA
211 CCACACTCAC ACAAGCTCTA GAACNAGGGT TAGGGGCACAT TTAGGGTTTT GCTCTCTGGA AATGGTGTCT
281 AAAAGTGAGG CCATAATGTT CCTTATATAA GGCTCACTCC CACAATTAGG CTITCAATCT GAACGTANTA
351 CGCCCACTGT ACACATATGGT ACGCCCAACG TACTCGGTAG TCTCCGCGTC AANAATACAC TCATGAGTAC
421 GCGCAACGTA CTTTCCCTTA CGCCCAAGCT ACTCAAAAGC CAAACATCTT TTTCAAGGAC TAAATTTTGAC
491 AACTTGAGGA AAGAAAAGGA TCAAGANAT ATACTTGAAT TCCGGGATGT TACAATGAAG TTGANACCTT
561 GGCTAAAAAA TTAAATTGGT TGTGGAAGCC GTTGGCTGAG CAAGCAACAA GGGTAAAAAT CGTAATCTAC
631 AAATGGTGTG ATTTTCTATT TCTTCTTATT ATTTTACTTG ATTTACGGGT AGTTTTTTTT TCTTACAAAA
701 AATATTAAAG TTGATAAAGT ATAGCCACTA AAATTGACTT TTTCCAAAAC ATAATGTCAA ATGGTGCSTA
771 TATGTATCAT GTTGATTAN ATAATGAATA TGATGATNCT GTTCTATTTA ANCCGAAAAA ATTATCTAAT
841 GATTTTATAT TGGAAAACAA AGTTGTGATT TTTNGCATAA TATAATCAA TCCNCTTTTG TNGGGAGGT
911 CGATAAATGT GGTAAATTTA NAACAAGTGT TTNACNTTG AAGGGTNGG AAAGGTTGAA AAAAGTTAAA
981 ATGATAAAAT GTTTACACAA ATGTTGTATC CGACTGAATA TNAATGTTAA GGATNATTGT ATTAAATTGT
1051 TGATATATAG TAAGCATAAA TATTTAGAAT TGTGACTTAA ATTTATAAGT TATNCNACT GGATTGAAAC
1121 ATTTTGTGATA TANATTAGGA ATGAAAATGA GCAACCCATA CATACTTATC TTTGGTAGTT TGGTTATTAT
1191 ATTTTATATA NAATATAGAA NCATCCCTTT ATTTTAAACC CATATGTGG ACGGACTTGA ATAAATGGGA
1261 AAAATGTACC TTGCTATTTA GCACAAAAAA ATTATAAAAA TGTACATTGC TATTTAGCAC AAACAAAAAA
1331 AAAAAACTTA TCCTTTTTCG ATTAGGTGAC AAAGAAATAT AAAATGGGAA ATGTGTGTCT ATTTAATGCA
1401 CTAAGAGAAA CTATTTTGCC TTTATTAACC CGGGTAAACC AATAGAAAAA TGGAAAGTAA TTGTCATTTA
1471 GCATGAAAAA AAATAACTTT CCATTTTTCG CATCCGGTCA CAATAATAGA AAAATGAAAG TAGCTTGTCTA
1541 TTTAGCGAAA CTAATCTCCT TTTTCTTTT TGGCATCGTA TCATAAAATA TAGACTAAAA TAGCTTAGTT
1611 TTACTATTTT AATACATTGA AATGTCTAAT CCACATGTTA TTCTATAAAA AGGGAATGT AATTTACTTA
1681 TTCTTTGATT CTTTGGCTTC TTTTATGATC CCAAAACATC CCTCTATCCA TCTATTCCAA CTAATAATAT
1751 GAAACTATA TTCTTCCAT TGTAGGGATG TTATAAATTT TGTAAATGTT TTTATGCAAA AAAGTGTTTT
1821 TTGTTAACTA GATTACGAG ATTCATTTT CAGCATTTTA GGAGAAGTTC ATCCATCTTT TGGATATGAA
1891 GTGCAAGCCA AGTTCCTTAA CATGGAATAT GAGGTCCCTA TATGCTCAAA AAATAGCAAA TGAGAAATTT
1961 TTTAAATTTG ATCCCATATA AAGAAATTT GTTAATGTTT GTTTAATAT TGGTCAATGT GTCCACCGGA
2031 TGAGCATTAAT ACTAGTTTAT AAGGGGTAAA GGTGGGTTTG GTGGGCCCAT TTATCTTTAT TAITTCTAAA
2101 AGTCAGAATT AAGTAAAAAA AATTATAAGA TAAATACCAT AAGGATAAAA AATCATTTTA TTTGGACCAA
2171 AGACCAAGT TGTTAAGGGG CTGTTTGTG TTTTGTGAA GAGCTGTGCA ACCACTTTTG TCTCGCGCCG
2241 ACAGACAACG TGCAGACATA TGCCCTCGCA GAGTGTTTGT TTTTGAAGG TGCGCAGACC AAAAAACGT
2311 CTGCGCGAGG TCATCTGCGC GCATATATGT GTCACTGTCT TCAAAGGTCT TCAGACCTCA TTTTAACCAA
2381 AAAAAAAGG GACCACCGGT TTTTTTTTT TTTTNTTCT TTCTCTGTA GCTGAAAATG CATTTTAAAT
2451 CTTTATGACA TGAATTAAG TTTGAAAAAT TAATTTATTT CAACAGCTGT AGACGTTAAA AACAAACAGT
2521 CTTCCTTGTG CAGACTGTGG ACATTTGGTC CACCTCTTCT ACCGCAGAGA CTTCGAGATG TGGTCCGAG
2591 ACTGCAGACA TTTTGGCTTC AAATAAACAA ACATCACCTA ATTTGACTAC ACCACACGGA CCTCCAATGT
2661 AACAAAAAAA AGGTTGAAAC AAAGTTGCC ATTTCTCCAT ATCCAGGGGC CATTTATGTA AGAGTTATCT
2731 AAATTTTAGT TCGGTAGATC AGTTCACACA TTTTAAACGG GTAAAGTGTG TGTGTGTACG CGCGCACCTG
2801 AAAGGTTTGA ANGTAACCTC CAACTGAAN CAANAATCGA TATGAAGTAT CAAGTTAGAG GTTCAATTGG
2871 TGAAGGAATC AGCTGGAGGT TGGGGAATCG AGCTTCCACT ATTAAGGTAA AATCCATAAC CCTAAATGTT
2941 GGTACGCTCA TATATCAAA TCGCTGTMTT GTTGAATGAA AAAAGCATGC TCAAAAAACC AGTGTAAAGG
3011 ACGGTATATG ACATATTTAT AGTTACTGAT AACAAATAT GATAATTTTG GGTTTACGTA AGTTAGGATT
3081 CGTACTTCAA CCAAAATGTA TAGTTTGTG GAGTCTATCT ATGTATTTTG GGAATCACAT TAGCAACGGG
3151 ATTGTACTAG TAATTGAAA AAGTCTTTTA AATAATTTT CTGTTTATA TTTATGAATA GTTTTAGCGA
3221 CATCTAATAT TAAATAGAAT GTATCTGATA TTGAATTAAT GTCCTTAATG TGAACATAGA CCTTTTCCAT
3291 TTACTAATGC CTAATTATTA GTTCTAATC AATAAATTTT AATTTCTGTT TTATGCTTCT AAGACAATAA
3361 AAATCCATAT TTTACCTTTA AATATTAACA AAAATGACCA TAAATAAATA AAAAATTAGG ATACCAAAAC
3431 CCCCCGCAAT GCCCAATGTC TAAATATCT TGAATGCTTT GCTTTTCCCT CTTTTCCTTG TTAGTCTATT
3501 ATTCCTGAGA GTTTGAGAGA GTTTCATACA AGAAATTTT AAGAAGAAAG CAAAGGTCCA GGTATTCTCT
3571 TTTCTEATTT ATGTATTAA TTAACAAGAT TTTTACACG ATCCATGGTT TTTTGTGTAT GTTTTTCAAA
3641 TTGAAACTAG ATTGGGACTT TTGCCCTTGA TGATTCATAA GATATTGCAT GGAAGTTGAGA TTGTGTAAGA
3711 AAAGTGTGTA ATAGAAAGAG CAAGTGAATC CAGATATAGT ATTTGGTAATA TATGATGATG AGATAGAGAT
3781 ATGTTTAAAC TGGCTAGAAA ATTGTTTAA TTTGAAATTT AGGTTGTGTA ATTTGAAAGA TACCAAGCTA
3851 ATAACTAATT AGTTATGCTA AATAGTTATA AAGAACAACA AACTCGTAGT TTTTPTTCA TGATTTTCAA
3921 CTTCTCTGTA CCAAACTAAA TTATAACAAA ATTTGAATATC ATTCCTGCA ATCAATTTTA ACTTTTGTTA
3991 TTATCATCAT GTCTAAATTT GCCACAAGTT TATTTTCATA GTCATATTGG ATTATGAAAG GACTATTTTT
4061 ACCAATTACA TCTTTACTTT ATGGCCAAAG CTAATACAAT CCGACTAAAC TAAAGGATTC TAGGATGCAT
```



SEQ ID NO: 2/  
RLG 2A cont.

4131 ATAGTTTGCT CCCCATTAT AGATTTCAT CTAATTGTC TATTGTAATA ATTTAGGTGC CACCACAAGT  
4201 AAATTCCTGA AATGGATGTC GTTAATGCCA TTCTTAAACC AGTTGTCGAG ACTCTCATGG TACCCGTAA  
4271 GAAACACATA GGGTACCTCA TTCTCTGCAG GCAATATATG AGGGAATATG GTATCAAAAT GAGGGGATTG  
4341 AATGCTACAA GACTTGGTGT CGAAGAGCAC GTGAACCGGA ACATAAGCAA CCAGCTTGAG GTTCCAGCCC  
4411 AAGTCAAGGG TTGGTTTGAA GAAGTAGGAA AGATCAATGC AAAAGTGGAA AATTCCCTA GCGATGTTGG  
4481 CAGTTGTTTC AATCTTAAGG TTAGACACGG GGTCCGAAAG AGAGCCTCCA AGATAATTGA GGACATCGAC  
4551 AGTGTCTATG GAGAACACTC TATCATCATT TGGAAATGATC ATTCCATTCC TTTAGGAAGA ATTTGATTCA  
4621 CGAAAGCATC CACCTCAATA CCATCAACCG ATCATCATGA TGAGTTCCAG TCAAGAGAGC AAATTTTCAC  
4691 AGAAGCACTA AACGCACTCG ATCTTAACCA CAAATCCAC ATGATAGCCT TATGGGGAAT GGGCGGAGTG  
4761 GGAAGACGA CAATGATGCA TCGGCTCAAA AAGGTTGTGA AAGAAAAGAA AATGTTTAAAT TTTATATTG  
4831 AGGCGGTTGT AGGGGAAAA ACAGACCCCA TTGCTATTCA ATCAGCTGTA GCAGATTACC TAGGTATAGA  
4901 GCTCAATGAA AAAACTAAAC CAGCAAGAAC TGAGAAGCTT CGGAAATGGT TTGTGGACAA TTCTGGTGGT  
4971 AAGAAGATCC TAGTCATACT CGACGATGTA TGGCAGTTTG TGGATCTGAA TGATATTGGT TTAAGTCCCT  
5041 TACCAATCA AGGTGTCGAC TTCAAGGTGT TGTGACATC ACGAGACAAA GATGTTTGCA CTGAGATGGG  
5111 AGCTGAAGTT AATTCAACTT TTAATGTGAA AATGTTAATA GAAACAGAAG CACAAAGTTT ATTCCACCAA  
5181 TTTATAGAAA TTTCCGATGA TGTGATCCT GAGCTCCATA ATATAGGAGT GAATATTGTA AGGAAGTGTG  
5251 GGGGTCTACC CATTTGCCATA AAAACCATGG CGTGTACTCT TAGAGGAAAA AGCAAGGATG CATGGAAGAA  
5321 TGCACCTTCTT CGTTTAGAGC ACTATGACAT TGAAAATATT GTTAATGGAG TTTTAAAT GAGTTACGAC  
5391 AATCTCCAAG ATGAGGAGAC TAAATCCACC TTTTGTCTTT GTGGAATGTA TCCCGAARAC TTTGATATT  
5461 TTACCCGAGG GTTGGTGAGG TATGGATGGG GGTGGAATTT ATTTAAAAA NIGTATACTA TAGGAGAAGC  
5531 AAGAACCCAG CTCAACACAT GCATTGAGCG GCTCATTCAT ACAATTTGT TGATGGAAGT TGATGATGTT  
5601 AGGTGCACTA AGATGCATGA TCTTGTCTGT GCTTTTGTGT TGGATATGTA TTCTAAAGTC GAGCATGCTT  
5671 CCATTGTCAA CCATAGTAAT ACACATAGAT GGCATGCAGA TAATATGCAC GACTCTTGTA AAAGACTTTC  
5741 ATTAACATGC AAGGGTATGT CTAAGTTTCC TACAGACCTG AAGTTTCCAA ACCTCTCCAT TTTGAAACTT  
5811 ATGCATGAAG ATATATCATT GAGGTTTCCC AAAAATCTTT ATGAAGAAAT GGAGAAGCTT GAGGTTATAT  
5881 CCTATGATAA AATGAAATAT CCATTGCTTC CCTCATCACC TCAATGTTC GTCAACCTTC CGGTGTTTCA  
5951 TCTACATAAA TGCTCGTTAG TGATGTTTGA CTGCTCTGT ATTGGAATC TGTCGAATCT AGAAGTGCTT  
6021 AGCTTTGCTG ATTTCTGCAT TGACCGTTTG CCTTCCACAA TCGGAAAGTT GAAGAAGCTA AGGCTACTGG  
6091 ATTTGACGAA TTGTATGTT GTTCGTATAG ATAATGTTGT CTTAAAAAA TTGGTCAAAAC TGGAGGAGCT  
6161 CTATATGACA GTGGTTGATC GAGGTCGAAA GCGGATTAGC CTCACAGATG ATAAGTCAA GGAGATGGCA  
6231 GAGGCTTCAA AAGATATTTA TGATATGAA CTGAGTTCT TTGAAAACGA TGCTCAACCA AAGAATATGT  
6301 CATTTGAGAA GCTACAACGA TTCCAGATCT CAGTGGGCG CTATTTATAT GGAGATTCCA TAAAGAGTAG  
6371 GCACCTGAT GAAAACACAT TGAAGTTGGT TCTTGAAAAA GGTGAATTAT TGGAGCTCG AATGAACGAG  
6441 TTGTTTAAAG AAAACAGAGG GTTATGTTTA AGTGTGGGAG ATATGAATGA TCTTGAAGAT ATTGAGGTTA  
6511 AGTCACTCTC ACAACTTCTT CAATCTTCTT CGTTCAACAA TTTAAGAGTC CTGTCTGTTT CAAAGTGTGC  
6581 AGAGTTGAAA CACTTCTTCA CACCTGGTGT TGCAAAACAT TTAAGAAAGC TTGAGCATCT TGAAGTTTAC  
6651 AAATGTGATA ATATGGAAGA ACTCATAGT AGCAGGGGTA GTGAAGAAGA GACGATTACA TTCCCCAAGC  
6721 TGAAGTTTAT ATCTTTGTGT GGGCTACCAA AGCTATCGGG TTTGTGCGAT AATGTCAAAA TAATTGAGCT  
6791 ACCACAATCT ATGGAGTTGG AACTTGACGA CATTTCCAGG TTCAACAGCA TATATCCCAT GAAAAAGTTT  
6861 GAAACATTTA GTTTGTTGAA GGAAGAGGTA AATATAAAT TTTAATGCTA ATACATTACA AAGGATCTTT  
6931 TCAAGTAAAT CTTTCAAAAT ATATTGTAAT TTGATTGTAT GGGGTATTAT TGTGGATGG GACTATTAAAT  
7001 AAATGATTAT CTGTCAGGTT CTGATTCCTA AGTTAGAGAA ACTGCATGTT AGTAGTATGT GGAATCTGAA  
7071 GGAGATATGG CCTTCCGAAT TTAATATGAG TGAGGAAGTT AAGTTACAG AGATTAAAGT GAGTAAGTGT  
7141 GATAAGCTTG TGAATTTGTT TCCGCACAAG CCCATATCTC TGCTGCATCA TCTTGAAGAG CTTAAAGTCA  
7211 AGAATTTGGG TTCCATTGAA TCGTTATTCA ACATCCATTT GGATTGTTT GGTGCAACTG GAGATGAATA  
7281 CACAACACAGT GGTGTAAGAA TTATTAAAGT GATCAGTTGT GATAAGCTTG TGAATCTCTT TCCACACAAT  
7351 CCCATGTCTA TACTGCATCA TCTTGAAGAG CTTGAAGTGG AGAATTGTTG TTCCATTGAA TCGTTATTCA  
7421 ACATTGACTT GGATTGTGCT GGTGCAATTG GCAAGAAGA CAACAGCATC AGCTTAAAGAA ACATCAAAGT  
7491 GGAGAATTTA GGAAGCTAA GANAGGTGT GAGGATAAAA GGTGGAGATA ACTCTCGTCC CCTTGTTCAT  
7561 GGCTTTCAAT CTGTTGAAAG CATAAGGTT ACNAAATGTN AGAAGTTTAG AAATGTATT ACACCTACCA  
7631 CCACAAATTT TAATCTGGGG GCACTTTGG AGATTTCAT AGATGACTGC GAGAGAAAACA GGGGAAATGA  
7701 CGAATCGGAA GAGAGTAGCC ATGAGCAAGA GCAGGTAAAG ATTTCAATTT CACTGTCTTA ATTAATGATT  
7771 AAGCTCTGCG TTTTGAATA AAAAAGGAC AAACCATTT ATGACTTAAT GTAGCAATAC AAGTCATGTA  
7841 TAAGAGTGAC CAACTCTTT TTATTATATA AATGACTACA AAATATTTT TTCTATTAGA GATCATGTAT  
7911 AAATGTGACT AATTTTTCAT CACCTAATCT TAGTTGATAA ATCTTTATAA ATGTCACTAG TTACTTTTCA  
7981 GTAAATAAAC AAATTTAATA AATTATCAAC AAAAGCATC AACTAAAAA ATCCCAACAC CCGTAATAT  
8051 TTAATAATAA AGGATTTAAC ATCTAATACG AACAAATTTT TTCTAAACA TGATTGGAC CAAATATCAC  
8121 CAGCAACTCA AGTTTGAAT CGATTCAAGT TAAACTTGA CCAGCATAAT TAGATAGATG AGAGTTGAAG  
8191 CTAAGTGCC TATATAAGTT CGTTTCATCT TTTTCTTGA TCTTGATAGC AAGTTGAATG ATTTCTTCT

RLG 2A cont.

8261 TCAAAATGGA TAAAAATCTA CATTATAAAG AGACTAGCTT GAAAAAAAAT GGTCTAGGTG GGTCTTGGGT  
8331 TCTGCTAGAT GAAGATGGAA GGGGAGAGTA TGATTTCAAA GACACAACAC ATCCTTCATT TTATTTATTT  
8401 ATTATATTATTA TTATTTTITG ATATCTTGCT CATATTTGTT ACAGATATGT GAGGTCTATT AATCTTTTAA  
8471 AATATATAAA AAAATAAATA ACATAAATGA GAAAAATTAA TAAAGAATAA ATTAATAAGG GCACAATAGT  
8541 CTTTTTAGGT AAGACAAGGA CCAAAACCGC AACAAAAATA AACAGTAGGG ACCATCCGAT TTAACAAAAA  
8611 TAATTAGGGA CCAAAACCAT AAATTCCCCC AAACCATAGG GACCATTCTT GTAAATTTACT CTTACTTTTC  
8681 GTTTTGTTC AATTTGGGTA ACTATTTTIT TTGTACACAT CTAGGTAACG AACTTGTGTA AGTGTTCCTA  
8751 TTTAGGATGT GACCTACTAC AACCGATCAT AATAGTCATA TGTGAACACT TAATTACCTT AGCAAGTTAT  
8821 GGTGTGTACA AAAAAACAAT AGTTACCATG ATGTGAACAT ACTGAAAAAT TAATTACCTT AGCAAGTTAT  
8891 TTTCCCATTT AGGTTGTATG GAAACAGTTC CGTGAGACCG TGACTTGGAT GGTAGATAAA TTTAGTAAAC  
8961 TTAACCTTTC AATTAACCTA CCTTTTCTTT ATTTAACTCA TTTCAACCTA AATTCTGATT CTTGTTTGAA  
9031 AGTAAGTTGC ATCTTTATTT TTGTATTATC TTGTTCGATA GGATCCTTAG CATCTTTTAA TAATTTATTT  
9101 GAAGGTGAAA GATCCAACTA TTTTAACTCT GTTGGCATTT TCCATCATTT GCAACTGTTT CTTGAAAAAA  
9171 AAATACCTAA AATCAAAATA ACCATTTTCA AATCCAAAT TATAAGAGAG AATTGTAAAT GGACATGGAA  
9241 TCATAAATCA TTAACACAGT TCAGTAAACA AGTTGCTAAT TACATTTCTT GCTGTGCAGA TTGAAATCTT  
9311 ATCAGAGAAA GAGACATTAC AAGAAGCCAC TGACAGTATT TCTAATGTTG TATTCCTATC CTGTCTCATG  
9381 CACTCTTTTC ATAACCTCCA GAAACTTATA TTGAACAGAG TTAAAGGAGT GGAGGTGGTG TTTGAGATAG  
9451 AGAGTGAGAG TCCAACAAGT AGAGAATTGG TAACAACCTA CCATAACCAA CAACAACCTA TTACTTTCC  
9521 CAACTCCAG GAATTGATTC TATGGAATAT GGACAACATG AGTCAATGTT GGAAGTGCAG CAACTGGAAT  
9591 AAATCTTCA CTCTTCCAAA ACAACAATCA GAATCCCCAT TCCACAACCT CACAACCTA AAAATTTATG  
9661 ATTGCAAAAG CATTAAGTAC TTGTTTTCGC CTCTCATGGC AGAATCTCTT TCCAACCTAA AGCATATCAA  
9731 GATAAGAGAG TGTGATGGTA TTGGAGAAGT TGTTTCAAAC AGAGATGATG AGGATGAAGA AATGACTACA  
9801 TTTACATCTA CCCACACAAC CACCCTTTG TTCCCTAGTC TTGATTCTCT CACTCTAAGT TTCTGGAGA  
9871 ATCTGAAGTG TATTGGTGGG GGTGGTGCCA AGGATGAAGG GAGCAATGAA ATATCTTTCA ATAATACCAC  
9941 TGCAACTACT GCTGTCTTTG ATCAATTTGA GGTATGCTTT GTACATATTC AATTATTTAT TTAATTTCTT  
10011 TTTTATTTTG CAATATTCTA TAAATAATAC ATTTTATACC CACTATACTA AGATAATAAT TACCTAGAGG  
10081 TAGGATGCT ATGACACAGC TGCTACACTT CAGAACTCT AGTAAGGGCA GTTATGGAAG TTCAATAAAA  
10151 TGATAATGGC ATCTTTTGAT GGGTAATATA GGCAATTTAA GTTTTATTTT TGTAAAGCA GTATTTAGCA  
10221 AGTACTGGCC AGTAGGAGAG GAGAATATCA CCTTTTGTA AAATCTGGTC ATTTGACCCA GAATTTAGTT  
10291 AAATGTACA TTTTAGATAT CAGGGGTCAT CAGGTGACAG ATATTGTAGA ATAGAACAAT ATATAATATC  
10361 ACCCAAACT ATTTTTCCTA AGGTTATCT GTTAAATATG TGCTTTCTTG TTTTCATINGA ATTINGCATTC  
10431 GTATATTTTA GGTGTTAAAG TGATTTTNTC TTCAATAAAT CCGGAAATTA ATTAACAAAA AAAAACAAAA  
10501 AGTACATTTT TGATGTGGAG AGCACTGGTA TCACTTAGTA TATAAAAAGC TTGATTTTGA ATTAACCTTC  
10571 TTATACAAAA GTTGTGTATA TAGTTTAAAT AGTTTACAT CATTTTCCA TGTGGTGTG CAGTTGTCTG  
10641 AAGCAGGTGG TGTTCCTGG AGCTTATGCC AATACGCTAG AGAGATGAGA ATAGAATCTT GCAATGCTAT  
10711 GTCAAGTGTA ATTCATGTT ATGCAGCAGG ACAAATGCAA AAGCTGAAGG AGAGGACAGC GATTCTCGTA  
10781 CGAACGGTTA CGATTGACT GGCCTGCTT TTACA

SEQ ID NO: 21

RLGIA a.a.

MDVVNAILKPVVETLMVPVKKHIGYLISCRQYMREMGIKMRGLNATRLGVEEHVNRNISNQLEVPQV  
RGWFEEVGKINAKVENFPSDVGSCFNKVRHGVGKRASKIIEDIDSVMREHSIIWNDHSIPLGRIDSTK  
ASTSIPSTDHHDEFQSREQTFTEALNALDPNHKSHMIALWGMGGVGKTTMMHRLKKVWKEKKMFNFII  
EAVVGEKTDPIAIQSAVADYLGIELNEKTKPARTEKLRKWFVDNSGGKKILVILDDVWQFVDLNDIGLS  
PLPNQGVDFKVLTSRDKDVCTEMGAEVNSTFNVKMLIETEAQSLFHQFIEISDDVDPELHNIGVNIVRK  
CGGLPIAIKTMACTLRGKSKDAWKNAALLRLEHYDIENIVNGVFKMSYDNLQDEETKSTFLLCGMYPE?FD  
ILTEELVRYGWGLKLFKK?YTIGEARTRLNTCIERLIHTNLLMEVDDVRCIKMHDLVRAFVLDMYSKVEH  
ASIVNHSNTLEWHADNMHDSCKRLSLTCKGMSKFPTDLKFPNLSILKLMHEDISLRFPKNFYEEEMKLE  
VISYDKMKYP LLPSSPQCSVNLRVFHLHKCSLVMFDCSCIGNLSNLEVLFSADSAIDRLPSTIGKLLKLR  
LLDLTNCYGVRIIDNGVLKLVKLEELYMTVDRGRKAISLTDDNCKEMAERSKDIYALEFFENDAQPK  
NMSFEKLQRFQISVGRYLYGDSIKSRHSYENTLKLVLKELLEARMNELFKKTEVLCLSVGDMNDLEDIE  
VKSSSQLLQSSSFNNLRVLVWSKCAELKHFFTPGVANTLKKLEHLEVYKCDNMEELIRSRGSEEETITFP  
KLKFLSLCGLPKLSGLCDNVKIIELPQLMELELDDIPGFTSIYPMKKFETFSLLKEEVLPKLEKLHVSSM  
WNLKEIWPCEFNMSSEVKFREIKVSNCDKLVNLFPHKPISLHHLEELKVKNCGSIESLFNIHLDCVGAT  
GDEYNNSGVRIIKVISCDKLVNLFPHNPMSILHHLEEELEVENCGSIESLFNIDLDCAGAIGQEDNSISLRNI  
KVENLGKLR?VWRIKGGDNSRPLVHGFQSVESIRVTKC?KFRNVFTPTTTNFNLGALLEISIDDCGENR  
GNDESEESSHEQEIEILSEKETLQEATDSISNVFSPCLMHSFHNLOKLILNRVKGVEVVFIESESPTS  
RELVTTTHHNQQQPIILPNLQELILWNMDNMSHWKCSNWNKFFTLPKQQSESPPHNLTTIKIMYCKSIKY  
LFSPLMAELLSNLKHIKIRECDGIGEVVSNRDEDEEMTTFTSTHTTTTLFPSLDSLTLSFLENLKCIGGG  
GAKDEGSNEISFNNTTATTAVLDQFEVCFVHIQLFI.

SEQ ID NO:22

RLG 2B

SEQ ID NO: 23

1 AGTTTTTTTTT TTTCCCAATA TCCATTATATA TGGGATTAT TTTCTGAAATA ATTTTATCAA AACGCAGGAA  
71 ACAATGTAGA ATAATACTGG TATAATTAAT TATATAAAGT TATTAGGCTG AAATCTTGAG GCTACTATAA  
141 TTTAATTATC ATAATTGAA AATCATCAAA TTGTATTCCA TGTATATTTA TGTATACAGA TAAATTAATA  
211 TATGTGAGCC ACACAAATCC ACATCATCAG ACACCCACC TTATTGTCGG CTACCTCACC ACTTGCATGA  
281 TCCCGACATC TTCCCAACCC CACCGACGAC TTGGGGTCTC CTTAATATAT CAATTATTTT CTGTAAGTAT  
351 TTATTGTGT AAATGTGTAA TGTCAITTTA CCTTTTTTCT AATATATACA GAAACATAAA TTTTAAATGA  
421 AATTCACCTG CGTTTCATTC TTGCATTAAA AAAAAAGACT GTACTGTGTG CAATATTTTA CTATTAACCT  
491 GATTAAATTA TTAAGCGTA ATTGCATAAT TTGCATTAGG TTGTAATTTT GTGTTTTATA GGGAGGGTGA  
561 GGGTCACCGG GAATCAAAGC ACTTATGTAA AAGCAGGGGA AATACAAAAA ATTTACTCGA AACAAATTTT  
631 ATTCAATTTA AGTGAGATAA TAAATGTCTG ATTAGATTAT GAGAACTAGG AGATTAAAGT GATATATCCC  
701 ATTTAAAAAG AATTGCATTA TTAATTTTGG ATCTCTTGAT GATGACAAAA TTAACCTCGT ACAGGTATATA  
771 TATCATATAC AAAATGAGTG GCTATGCTTT CGCTTTCCAA AAAGCAATTA TAGTTATACT ACACCTACAA  
841 ATTTTAAAG GGGTTAAACA TATCAAAATA CTTGATAAGT AATTATATAA ATATGCATTT AACCTCTTAA  
911 AGAAAAATGCT ACTAAGCTTG GACCATCTCA GAATTACAAAT CATACCCCTC CCCTCAAAAA AGATTCTGAT  
981 ATATCATGTC ATTTGGCATT CATTTCTTTT TCACAATTCA TAGTTCTATT CTCAAAAAAT TCGAGTTCTC  
1051 GTATTGTGTA GGAAGATCAG AAGAGACTGT TCACACAGGT ACTCTCTTTT ATTTATIGAT TCACATTCAT  
1121 ATATGTTATT GTTTTCTTGC TTAATGGTTT CGTCAGTCTA ACTGCGCTTG CTGATTAAAA TTTCTTCACT  
1191 TTCTTCCACG GATTTTTTAA ATATTAGTTT ATAAGGGTAT ATGCTAAAT GAACTATGCC CATTCACCTT  
1261 TTTTCTAAAG TAAACCTAGA TACTTAGGTT ATAAGGGTAT ATGCTAAAT GAACTATGCC CATTCACCTT  
1331 TGCCCTTTCT TTTACTTTT AGTTTTTAGA ATCCAAAGTT TCATATGTAT CTCGATGTGT GAGAAGAATA  
1401 GGCATTAGAA AGGTAAAGGA CGTACATAAA ATTGATTAAT TAGTGAATGT TCTTTGATAT CATTAATTTT  
1471 ACTCTCATAA AAAGCATATA GATCAACAC AAATTGCTAC TTGTTAGTGT AACAACTTCG ACTTAATAAT  
1541 GTTAATAATC AAGATTCTCT TGATTTCAC TATTTTCTAA CCGAACAAGC TCCTAAAAA CTCATATTGC  
1611 TTGAGTCTG AGTGGTTTAT ATTTGGGGTT TTACATTTAA TTTTTTGTG ATGAATGTGA AAATAGACTG  
1681 CTTATTGATT CTTTGTGTTT CATTTGAGTTT ATTTTCATTA TTACTACCTT ACAAATTGCT CAGTGATAGA  
1751 TTTCCATTAA TTTGCTAATT CGGTGTCTTC TAAATATGTA GGAGCTACTA AAAGCAAAAA TATCGAGCAA  
1821 TGTCGGACCC AACGGGGATT GCTGGTGCCA TTATTAACCC AATTGCTCAG ACGGCTTGG TTTCCGTTAC  
1891 GGACCAATGA GGTCTACATGA TTTCCCTGAG AAAATATGTG AGGGTCTAGC AGATGAAAA GACAGAGTTG  
1961 AATACCTCAA GAATCAGTGT AGAGGAACAC ATTAGCCGGA ACACAAGAAA TCATCTTCAG TTCCATCTCA  
2031 AACTAAGGAA TGGTTGGACC AAGTAGAAGG GATCAGAGCA AATGTGAAA ACTTTCCGAT TGATGTCATC  
2101 ACTTGTGTGA GTCTCAGGAT CAGGCACAAG CTTCGACAGA AAGCMTTCAA GATAACTGAG CAGATTGAAA  
2171 GTCTAACGAG ACAACTCTCC CTGATCAGTT GGACTGATGA TCCAGTTCTT CTAGGAAGAG TTGGTTCCAT  
2241 GAATGCAATC ACCTCTGCAT CATTAAAGTA TGATTTCCCA TCAAGAGAGA AAACCTTTTAC ACAAGCACTA  
2311 ATAGCACTCG AACCCAACCA AAAATTCCAC ATGGTAGCCT TGTGTGGGAT GGGTGGAGTG GGGAGACTA  
2381 GAATGATGCA AAGGCTGAAG AAGGCTGHTG AAGAAAAGAA ATTGTTAAT TATATTGTTG GGGCAGTTAT  
2451 AKGGGAAAGC ACGGACCCCT TTGCCATTCA AGAAGCTATA GCAGATTACC TCGGTATACA ACTCAATGAA  
2521 AAAACATAGC CAGCAAGAGC TGATAAGCTT CGTGAATGGT TCAAAAAGAA TTCAGATGGA GGTAAAGACTA  
2591 AGTTCTTCAT AGTACTTGAC GATGTTTGGC AATTAGTTGA TCTTGAAGAT ATTGGGTTAA GTCCCTTTCC  
2661 AAATCAAGGT GTCGACTTCA AGGTCTTGTT GACATCAGCA GACTCACAAG TTTGCACTAT GATGGGGTT  
2731 GAAGCTAATT CAATTATTAA CGTGGGCCCT CTAAGCTGAAG CAGAAGCTCA AAGTCTGTTT CAACAATTTG  
2801 TAGAACTTTC TGAGCCCGAG CTCCAGAAGA TAGGAGAGGA TATCGTAAGG AAGTGTGCG GTCTACCTAT  
2871 TGCCATAAAA ACCATGGCAT GTWCTCTTAG AAATAAAGAA AAGGATGCAT GGAAGGATGC ACTTTCCGCC  
2941 ATAGAGCACT ATGACATTCA CAATGTGCG CCCAAAGTCT TTGAAACGAG CTACCACAA CTCCAAGAA  
3011 AGGAGACTAA ATCCACTTTT TTAATGTGTG GTTTGTTTCC CGAAGACTTC GATATTCTTA CTGAGGAGTT  
3081 GATGAGGTAT GGTATGGGCT TGAAGCTATT TGATAGAGTT TATACGATTA GAGAAGCAAG AACCGAGCTC  
3151 AACACCTGCA TTGAGCGACT GGTGCAGACA AATTGTGTTA TTGAAAGTGA TGATGTTGGG TGTGTCAGA  
3221 TGCAATGATCT GGTCCGTGCT TTGTGTTTGG GTATGTTTTC TGAAGTCTGAG CATGCTTCTA TTGTCACCA  
3291 TGGTAATATG CTTGGGTGGC CTGATGAAAA TGATATGATC GTGCACTCTT GCAAAAGAA TTTCAATTA  
3361 TGCAAGGGTA TGATTGAGAT TCCAGTAGAC CTCAAGTTTC CTAAGTTAAC GATTTTGAAG CTTATGCAATG  
3431 GAGATAAGTC GCTAAGGTTT CCTCAAGACT TTTATGAAGG AATGGAAGG CTCCATGTTA TATCATACGA  
3501 TAAAAAGAAG TACCCATTGC TTCCCTTGGC ACCTCGATGC TCCACCAACA TTCCGGTGTCT TCACTCTACT  
3571 GAATGTTTAT TAAAGATGTT TGATTGCTCT TCTATCGGAA ATCTATCGAA TCTGGAAGTG CTGAGCTTTG  
3641 CAAATTTCTCA CATTTGAATG TTACCTTCCA CAGTCAGAAA TTTAAAGAG CTAAGGTTTAC TTGATCTGAG  
3711 ATTTTGTGAT GGTCTCCGTA TAGAACAGGG TGCTCTGAAA AGTTTTGTCA AACTTGAAGA ATTTTATATT  
3781 GGAGATGCTAT CTGGGTTTAT AGATGATAAC TGCAATGAGA TGGCAGAGCG TTCTTACAAC CTTCTGCAAT  
3851 TAGAACTCCG GTTCTTTAAT AACAAAGCTG AAGTGAAAAA TATGTCATTT GAGAATCTTG AACGATTCAA  
3921 GATCTCAGTG GATGCTCTT TTGATGAAAA TATCAATATG AGTAGCCACT CATACGAAAA CATGTTGCAA  
3991 TTGGTGACCA ACAAGGTGA TGTATTAGAC TCTAACTTA ATGGGTTATT TTTGAAAAA GAGGTGCTTT  
4061 TTTTAAAGTGT GCATGGCATG AATGATCTTG AAGATGTTGA GGTGAAGTCG ACACATCCTA CTCAGTCTTC

RLG 2B cont.

SEQ ID NO: 23

```
4131 TTCATTCTGC AATTAAAAAG TTCTTATTAT TTCAAAGTGT GTAGAGTTGA GATACCTTTT CAAACTCAAT
4201 CTGCAACA CTTTGTCAAG ACTTGAGCAT CTAGAAGTTT GTGAATGTGA GAATATGGAA GAACTCATAC
4271 ATACTGGAAT TGGGGGTGTG GGAGAAGAGA CAATTACTTT CCCTAAGCTG AAGTTTTTAT CTTTGAGTCA
4341 ACTACCGAAG TTATCAAGTT TGTGCCATAA TGCAACATA ATTGGGCTAC CACATCTCGT AGACTTGATA
4411 CTTAAGGGCA TTCCAGGTTT CACAGTCATT TATCCGCAGA ACAAGTTGCG AACATCTAGT TTGTTGAAGG
4481 AAGGGGTAGA TATATGTTCT TTATGTTAAT ACAATTAAAA TAATATTTTC AACCAAATTT TCATAATATA
4551 TCTGTAATTT GATTGTATGA TGTGTTATTG TTTATATGTG GCTATTAAGG GATGATTATT TTGCAAGTTG
4621 TGATTCTTAA GTTGGAGACA CTTCAAATTG ATGACATGGA GAACCTAGAA GAAATATGGC CTTGTGAATT
4691 TAGTGGAGGT GAGAAAGTTA AGTTGAGAGC GATTAAAGTG AGTAGCTGTG ATAAGCTTGT GAATCTATTT
4761 CCGCGCAATC CCATGCTCTT GTTGCATCAT CTTGAAGAGC TTACAGTCGA GAATTGCGGT TCCATTGAGT
4831 CGTTATTCAA CATTGACTTG GATTGTGTG GTGCAATTGG AGAAGAAGAC AACCAAGAGCC TCTTAAGAAG
4901 CATCAACGTG GAGAATTTAG GGAAGCTAAG AGAGGTGTGG AGGATAAAAG GTGCAGATAA CTTGATCTC
4971 ATCAACGGTT TTCAAGCTGT TGAAGCATA AAGATTGAAA AATGTAAGAG GTTTAGAAAT ATATTCACAC
5041 CTATCACCGC CAATTTTTAT CTGGAGGCAC TTTTGGAGAT TCAGATAGAA GGTTCGGGAG GAAATCAGCA
5111 ATCAGAAGAG CAGGTAACGC TTTCAATTTT ACTTTCTTAA TTAATTAAGG ACTAAGCTCC TGTTTTTTGA
5181 ATAATAAAGA GGTGGGATGA CTAAACTTGG GCATCACAAT TGCAACAAAA TGTACAAAC CATGAAACGT
5251 TCAAAACATT TCTTGAATTA AGGTTTCAAT ACAAGTCATT TAAAAATATG GCTTAAATTT TTTTATATT
5321 TATGTATCAA CATGATTTT CATTAGAGAT CATTATTATA ATAGTAAGTT TAAAGCAATT TAAATCAGAA
5391 CTAATTCTAA CTTTAGCTAA TAAATCGTTA TAAATGTAAA TAATTACTTT TTAGTGAAAT AAGCAACGGA
5461 TTTAATAAGT TAACAACCTA AATGTCAATT CTAACAAAA AAAACTTTTG TTCAGAAAA CCGCAATTCA
5531 AGATACTAA AATAAAAAATA TTTGACATTC ACTAAGAGCA TTTTTTTTTC TAAATATGAT TGCAAAATGA
5601 TAAAACTTAA ATTTATACAG AAAATTCTTT TATATATGTT ATACAAAAAT TACAAATGTA AATTGGATAT
5671 GTTAATTAA GGTTTATAAT TCTGGTATCA CAAAGGGATA TATAATAAAA TATTATTTTC TGTAGTCATT
5741 TGTAAATGTA CTAGTTTATA ACCCGTGGGA ACCATGAGTT CTAAAATTAG TTAACCTTTC ATAATAAAAA
5811 TTTATAATTA TTATTATT TTAAATAAAT ATTAATTAAAG AGATATATCA AAAATTAAAA GTTATTATAA
5881 CTTCAAATTT AACATATAAT TAGAAAAAT ATGATCATAA CTCTGCACT CTCTTTGTAT AAATGCAGAG
5951 AAGCTATTAG TATATTTCTA ATCAAGTCCA AACCTAATGA AGCCTATATA ATTTTGTGAA AACTCAATTA
6021 GCATTAGGTT TTAAGAGTCA CCAAAATCAA AGAATAATCC AATGCTTTCA TTACCACAT GAGAAAAATA
6091 TTTTCTTAGT TTAATGAAA TGAACAAAA CATTCAAAT AATTGTTGCT TATTAAACCA AAGACCCATT
6161 ACTTAGCCAA GAGTTTAA CAAAAAAATT ACATTCAATG ATCATTATT CAGGGAATTC CTCAAAATAA
6231 ATGAAGGGAG TTTTATAGA AAATATAATC ATAGATATTC AACATAACTT CAGGGAATTC CTCAAAATAA
6301 CCAAGTTATT CAAGAAATTA CATCCAAATC AACCAAGAG AAGTTTAGCC TAGCATGGCT AAACCTCAAGA
6371 AACTAAAAATA AGGATTAGAA GTACCAAAACA TGTAGTAAGA ATCAGAGTAA AAGATGATGT TGTCTTGTAT
6441 GTTCTTCTAA GTTCTTCAAG TCTCCAGTTG CTCTTAATAA TGCAAGGAG AGCCATTAAA TTCGTATGTA
6511 TTGATCCCTT CAAAAGCTGC ACCAACCTCC CTTAAATAAC ACTCAAAGCA AAAATGACAA AATGCCCTGA
6581 AGGACCCCTAT GTGGGTGCGT TCGCGGGGTG GAGCTGCATA CGAAAGGTCT TTGCTCTTTG TGAGGGTGTAT
6651 GTTGTGCGGG ATAGCTTGTG GCATGCTTCC GCGGGTTTCA CGCACATGTG CACAGGTGAT GCATGGTGTG
6721 TGGCTTCTTG AGTTTGTAGC CTCGGATGCT TAGTCCACTT GGCCCAATTC GAGTCCAATC AGCTTATAAC
6791 CCATTTTCTT TCAAGTTATC TTCAAGTTAA GCCCAATTTG GCTTCTCCAA ATCATCCATA ACTTCACAGA
6861 ATCGCCCGTT CATCTTAATC CCGGATGCAC AATTATTCTC CCGTCTTCAT TTTAAGCAAG ATACACCTT
6931 CTTCAATGCTT CATCCATCAA TAGTACACTT CATGTATCAT CTCTACTAGT TATTTAGTCC ACAAACTCTT
7001 GTTGTCTTCC AAATTTAATT ATCTCAATTA GTTCCCGTT CCGTACTTT CTTAAAAAT TGAATTAAG
7071 CTCAGAGAAA TATTAAGTAC CCGAAATGGT CATAAAATTA ACAAAGGA AAATGCATGA AGATTAACTA
7141 AATGATGAAC GAAATATGCT AAAATAGACT ATAAAATGAA GTAAATAAAA TGAATTTATC GCACTCCGAC
7211 CACCCCTTATG GCTTGTAGTC CACCCACCTT TCATTCTTTG TACCAATATG GGATGGAAAC ATCATTAATT
7281 AAGCCAAAAA GCTAACATAT AAGGGTTTAG TGACAAAGGT AAGTACTAAA GATGAAAAATA ATCCATTTT
7351 CTTGTTTTTA CACAACACAC ACATAGGGC AGACGTAGGA TTTCAAAGTA CAGATTGTTG GTGGCACATA
7421 AGTGTGCTG GTGACATTTT TTTTCTCTT TTACGTGGTG GCACAACAGT AGGAAAAACG AAAAATTCGA
7491 AATTTTTTAT AATTGTCTTT AAAAAAACA GGGGTGTGTG GTGCCACTAT GGCAACAAA GTTGAAGTGC
7561 CCTACGCGCG CACACACACA CACACACATA GAGAGAGAGA GAGAGAGAGA GAGAGAGAGA AAGAAAGAAA
7631 GAGAGAGAGA GTTGGGATG TGATACTTCT TTTAGGAAAA TGGAGTTATA TCTTTGATAT TGTATTTT
7701 TAAATGTAAT TATNTATTTA ATCATTTTAG TTTATAAGTT NTATTTATTN GGNATGAAA AAAAAGTCT
7771 TTTATACATT GGATTTAACA TAAAAATCCA ACAATATTAA TCAAAAAGAC CAAACATGTG GACATTTATG
7841 TATATAATTA ATTCACAATA GTCTTTAGGA ATAGTATTAT ATATATAATT AATTCTCAAT GGTCTTAGGA
7911 ATAGTAAGTT CTTATATTTC AAACCTTTTG CACAATTCTT TGCTTACTTT GACACTTTTC CTTCTAACT
7981 TTACATATAT ATATATATTA AAGCGCAAGG GTCTAGGAA TATAATATTT TCTATTATTC TACGTTTTCG
8051 CACAAAAGTT TGACACATTT GCCACTTTT GTCCCTCTCT AACCTTTTCA ATGTTTTGCG ACAAAAGTTC
8121 CAAAACCTTG CCACCTTGAT CATTCCTCAA CTTTTCACCG CATTAGTTTG TGGAGTTGGC AGTTTTGGTC
8191 CCTTAACTT CGATATTCTC TACTGCTAGC CAAAAGGGT TCCAGAGTTT CACACTTTTG GTCCCTGACA
```

RLG 2B cont.

8261 GTAACCAAT GTGAGATGTC AAATTTTTCG CACATTAGTT TGTGGAGTTG TCCCTTTTGG TCCCCCACA  
8331 TTCCGATATC TACTATACGA TCTTATTTTT CTCAAATAAC AACACGTATA TTTTCATC:CT AATTGGAAAA  
8401 AGAGTTTTAA AA:AAATAAC GACTAGG:: G:GC:GAGTT TTTTIT:ACA AGTTTGTATC AAATCATATC  
8471 AAAATTTAAG GTGGAACGGT GACCACATTA ACCAGAAATG TAATTTATTC TTTGATTTTG ATAATTTTTA  
8541 ATATTTTGTG GTGATCTATG TATTTAAAG TAAACAACAA AGAACATAAT CCAAAACCCCT AAATGCAAG  
8611 TCTCGCCCAA TTTCTCTATC ACTAGTCCTC ACTTACGATG GCGTTACGTC GCTCTCTCAC TGCTTACAAC  
8681 CCTTTGTGTC TACTCATTAC AATAACGAAA AGTTGAATAT CCATATATTT ATTTGGATGT GGAATGAAC  
8751 GAATCTCGTC AAAATTTTGA TTTTGTGAT GGATTTGAGT AGAAGTTTGG GCAGAACGGG AATGATGGTC  
8821 TGCAAGTGGT TATAAACTTG ATTCTGAGTT ATTACTATAT ATGTAGCCTC TTTACAACGA CCAAGGTTTC  
8891 TTCCAGGTAC CATTTGATCT TTTTAGAAT TAGTTTTCG AAACACCCCTG ATTTGGATCA AATATCACCA  
8961 ACAACTCTTA AAAACTTGAT TAATCAATG TTTTCTTCAT CTGTATAACA AGTGGAAATGA TTTTCTACTT  
9031 AGATTAACTT GAAAAAAAG GTCCATGTGC GTCTGGTGA TCTGGTAAAT GAAGATGGAA GGGAGAGCTG  
9101 ACTTTAAAGA CACAAACACG TCACCATATC TCTTATTTTA TTTTAAATTT GCTTTTGGTG TATTTCTTTT  
9171 TTTCTTATTT CTTCCTTTCT TGATCTCCAG ATGGTATGTG GTGTGGATAA TTTACACCTA GAGATTGGGA  
9241 ACGATGGGAA GGGGTCTGTG ATTTATGGCT GGCCGAGTTT TACTTATTA CTCAATTTCA ACCTAAATTC  
9311 TGATTCTTGT TTGAAAAATA GTTGCATCTT TATTTTGTGA TTATCTTGT GCATAGGATC CTTAGCATCT  
9381 TTTAATAATT TATTTGAAG TGAAAGATCC AACTATTTT TAGCTGTGG CATTTTCCAT CATTTGCAAC  
9451 TGTTCTTGA AAAAAAATA CCTAAAATA AAATAACCAT TTTCAAATCC AAAATTATAA GAGAGAATTG  
9521 TAAATGGACA TGAATCATA AATCATTAAC ACAGTTCAGT AAACAAGTTG CTAATTACAT TCTTGTCTGT  
9591 GCAGATTGAA ATTCTATCAG AGAAAGAGAC ATTACAAGAA GCCACTGGCA GTATTTCAAA TCTTGTATTC  
9661 CCATCCTGTC TCATGCACTC TTTTCATAAC CTCCGTGTGC TTACATTGGA TAATTATGAA GGAGTGGAGG  
9731 TGGTATTTGA GATAGAGAGT GAGAGTCCAA CATGTAGAGA ATTGGTAACA ACTCGCAATA ACCACAACA  
9801 GCCTATTATA CTTCCTTACC TCCAGGATTT GTATCTAAG AATATGGACA ACACGAGTCA TGTGTGGAAG  
9871 TGCAGCAACT GGAATAAATT CTTCACCTCT CCAAAACAAC AATCAGAATC CCCATTCCAC AACCTCACAA  
9941 CCATAAATAT TCTTAAATGC AAAAGCATTA AGTACTTGT TTTCCCTCTC ATGGCAGAAC TTTTTCCAA  
10011 CCTAAAGGAT ATCCGGATAA GTGAGTGTGA TGGTATTAAA GAAGTTGTTT CAAACAGAGA TGATGAGGAT  
10081 GAAGAAATGA CTACATTTAC ATCTACCCAC ACAACCACCA CTTTGTTCCT TAGTCTTGAT TCTCTCACTC  
10151 TAAGTTTCTT GGAGAATCTG AAGTGTATTG GTGGAAGTGG TGCCAAGGAT GAGGGGAGCA ATGAAATATC  
10221 TTTCAATAAT ACCACTGCAA CTACTGCTGT TCTTGATCAA TTTGAAGTAT GCTTTGTACA TATTCCATTA  
10291 TTTATTTAAT TTCTTTTIT ATTTGCAATA TTCTATAAAT AATACATTTT ATACCCACTA TACTAAGATA  
10361 ATAATTACCT AGAGGGATGG ATGCTATGAC ACAGCTGCTA CACTTCAGAA ACTCTARTAA GGGCAGTTAT  
10431 GGAAGTTCAA TAAATGATA ATGGCATCTT TTGATGGGTA ATATAGGCAA TTTAAGTTT ATTTCTGTTA  
10501 AAGCAATATT TAGCAAGTAC TGGCCAGTAG GAGAGGAGAA TATCACCTTT TGTGAAAATC TGGTCATTGT  
10571 ACCCAGAATT TAGTTAAATG TAACATTTTA GATATTAGGG GTTATCAGGT GACAGATATT GTAGAATAGA  
10641 ACAATATGTA ATATTACCA AACTATTTT TTCTAAGGT GCTCTGTAA ATATGTGCTT TCTTGATTC  
10711 ATTGAATTTG CATTCCTATA TTTTAGGTGG TAAAGTGATT GTCTCTCAA TAAATCCCGA AATTTTITAA  
10781 TTTAAAAAAA AAAAAACAA AGTAAATTTT TGATATGGAG AGCACTGGTA TCATTTAGTA TATAAAAAAC  
10851 AGATTTTGA TTAAGTTTCT TATATAAAG CTGTGTATAT AGTTTAAATTA GTTTTACATC ATTTTCCAT  
10921 GTGGTGTGTC AGTTGTCTGA AGCAGGTGGT GTTCTTGTGA GCTTATGCCA ATACCTAGA GAGATAAAAA  
10991 TAGGCAACTG CCATGCATTG TCAAGTGTGA TTCCATGTTA TGCAGCAGTA CAAATGCAGA AAGCTT

SEQ ID NO: 23

RLG2 B a.u.

MSDPTGIAGAIINPIAQTALVPVTDHVGYMISCRKYVRVMQMKMTELNTSRISVEEHISRNTRNHLOIP  
SQTKEWLDQVEGIRANVENFPIDVITCCSLRIRHKLQKAFKITEQIESLTRQLSLISWTDDPV?LGRVG  
SMNASTSASLSDDFPSREKTFTQALIALEPNQKFHMVALCGMGGVGKTRMMQRLKKA?EEKLNFYIV  
GAVI?EKTDPFQIAQEIADYLGQILNEKTKPARADKLREWFKKNSDGGKTKFLIVLDDVWQLVDLEDIGL  
SPFPNQGVDFKVLTSRDSQVCTMMGVEANSIINVGLL TEAEASLFFQOFVETSEPELQKIGEDIVRKC  
CGLPIAKTMAC?LRNKRKDAWKDALSRIEHYDIHNVAPKVFETSYHNLQEEETKSTFLMCGLPEDFDI  
PTEELMRYGWGLKLFDRVYTIREARTRLNTCIERLVQTNLLIESDDVGCVKMHDLVRAFVLGMFSEVEH  
ASIVNHGNMPGWPDENMIVHSCKRISLTCKGMIEIPVDLKFPLTILKLMHGDKSLRFPQDFYEGMEKL  
HVISYDKMKYPLLPLAPRCSTNIRVLHLTECSLKMFDCCSIGNLSNLEVLSFANSHIEWLPSTVRNLKKL  
RLDLRFCDGLRIEQGVKSFVKLEEFYIGDASGFDDNCNEMAERSYNLSALEFAFFNNKAEVKNMSFE  
NLERFKISVGCSDENINMSSHYSYENMLQLVTNKGVDLDSKLNGLFLKTEVLFLSVHGMNDLEDVEVKS  
THPTQSSSFCNLKVLISKVELRYLFLKLNLANLTSRLEHLEVCECENMEELIHTGIGGCGETITFPKLKF  
LSLSQLPKLSSLCHNVNIIIGLPHLVDLILKGIPGFTVIYPQNKLRSSLLKEGVVIPKLETLOIDDMENLEE  
IWPCELSGGGEKVKLRAIKVSSCDKLVNLFPRNPMSLLHLEELTVENCGSIESLFNIDLDCVGAIGEEDN  
KSLLRSINVENLGKLREVWRIKGADNSDLINGFOAVESIKIEKCKRFRNIFTPTANFYLEALLEIQIEGCG  
GNHESEEQVTLSSLS

SEQ ID NO: 24

SEQU ID NO:

→ 25

10  
 11  
 12  
 13  
 14  
 15  
 16  
 17  
 18  
 19  
 20  
 21  
 22  
 23  
 24  
 25  
 26  
 27  
 28  
 29  
 30  
 31  
 32  
 33  
 34  
 35  
 36  
 37  
 38  
 39  
 40  
 41  
 42  
 43  
 44  
 45  
 46  
 47  
 48  
 49  
 50  
 51  
 52  
 53  
 54  
 55  
 56  
 57  
 58  
 59  
 60  
 61  
 62  
 63  
 64  
 65  
 66  
 67  
 68  
 69  
 70  
 71  
 72  
 73  
 74  
 75  
 76  
 77  
 78  
 79  
 80  
 81  
 82  
 83  
 84  
 85  
 86  
 87  
 88  
 89  
 90  
 91  
 92  
 93  
 94  
 95  
 96  
 97  
 98  
 99  
 100  
 101  
 102  
 103  
 104  
 105  
 106  
 107  
 108  
 109  
 110  
 111  
 112  
 113  
 114  
 115  
 116  
 117  
 118  
 119  
 120  
 121  
 122  
 123  
 124  
 125  
 126  
 127  
 128  
 129  
 130  
 131  
 132  
 133  
 134  
 135  
 136  
 137  
 138  
 139  
 140  
 141  
 142  
 143  
 144  
 145  
 146  
 147  
 148  
 149  
 150  
 151  
 152  
 153  
 154  
 155  
 156  
 157  
 158  
 159  
 160  
 161  
 162  
 163  
 164  
 165  
 166  
 167  
 168  
 169  
 170  
 171  
 172  
 173  
 174  
 175  
 176  
 177  
 178  
 179  
 180  
 181  
 182  
 183  
 184  
 185  
 186  
 187  
 188  
 189  
 190  
 191  
 192  
 193  
 194  
 195  
 196  
 197  
 198  
 199  
 200  
 201  
 202  
 203  
 204  
 205  
 206  
 207  
 208  
 209  
 210  
 211  
 212  
 213  
 214  
 215  
 216  
 217  
 218  
 219  
 220  
 221  
 222  
 223  
 224  
 225  
 226  
 227  
 228  
 229  
 230  
 231  
 232  
 233  
 234  
 235  
 236  
 237  
 238  
 239  
 240  
 241  
 242  
 243  
 244  
 245  
 246  
 247  
 248  
 249  
 250  
 251  
 252  
 253  
 254  
 255  
 256  
 257  
 258  
 259  
 260  
 261  
 262  
 263  
 264  
 265  
 266  
 267  
 268  
 269  
 270  
 271  
 272  
 273  
 274  
 275  
 276  
 277  
 278  
 279  
 280  
 281  
 282  
 283  
 284  
 285  
 286  
 287  
 288  
 289  
 290  
 291  
 292  
 293  
 294  
 295  
 296  
 297  
 298  
 299  
 300  
 301  
 302  
 303  
 304  
 305  
 306  
 307  
 308  
 309  
 310  
 311  
 312  
 313  
 314  
 315  
 316  
 317  
 318  
 319  
 320  
 321  
 322  
 323  
 324  
 325  
 326  
 327  
 328  
 329  
 330  
 331  
 332  
 333  
 334  
 335  
 336  
 337  
 338  
 339  
 340  
 341  
 342  
 343  
 344  
 345  
 346  
 347  
 348  
 349  
 350  
 351  
 352  
 353  
 354  
 355  
 356  
 357  
 358  
 359  
 360  
 361  
 362  
 363  
 364  
 365  
 366  
 367  
 368  
 369  
 370  
 371  
 372  
 373  
 374  
 375  
 376  
 377  
 378  
 379  
 380  
 381  
 382  
 383  
 384  
 385  
 386  
 387  
 388  
 389  
 390  
 391  
 392  
 393  
 394  
 395  
 396  
 397  
 398  
 399  
 400  
 401  
 402  
 403  
 404  
 405  
 406  
 407  
 408  
 409  
 410  
 411  
 412  
 413  
 414  
 415  
 416  
 417  
 418  
 419  
 420  
 421  
 422  
 423  
 424  
 425  
 426  
 427  
 428  
 429  
 430  
 431  
 432  
 433  
 434  
 435  
 436  
 437  
 438  
 439  
 440  
 441  
 442  
 443  
 444  
 445  
 446  
 447  
 448  
 449  
 450  
 451  
 452  
 453  
 454  
 455  
 456  
 457  
 458  
 459  
 460  
 461  
 462  
 463  
 464  
 465  
 466  
 467  
 468  
 469  
 470  
 471  
 472  
 473  
 474  
 475  
 476  
 477  
 478  
 479  
 480  
 481  
 482  
 483  
 484  
 485  
 486  
 487  
 488  
 489  
 490  
 491  
 492  
 493  
 494  
 495  
 496  
 497  
 498  
 499  
 500  
 501  
 502  
 503  
 504  
 505  
 506  
 507  
 508  
 509  
 510  
 511  
 512  
 513  
 514  
 515  
 516  
 517  
 518  
 519  
 520  
 521  
 522  
 523  
 524  
 525  
 526  
 527  
 528  
 529  
 530  
 531  
 532  
 533  
 534  
 535  
 536  
 537  
 538  
 539  
 540  
 541  
 542  
 543  
 544  
 545  
 546  
 547  
 548  
 549  
 550  
 551  
 552  
 553  
 554  
 555  
 556  
 557  
 558  
 559  
 560  
 561  
 562  
 563  
 564  
 565  
 566  
 567  
 568  
 569  
 570  
 571  
 572  
 573  
 574  
 575  
 576  
 577  
 578  
 579  
 580  
 581  
 582  
 583  
 584  
 585  
 586  
 587  
 588  
 589  
 590  
 591  
 592  
 593  
 594  
 595  
 596  
 597  
 598  
 599  
 600  
 601  
 602  
 603  
 604  
 605  
 606  
 607  
 608  
 609  
 610  
 611  
 612  
 613  
 614  
 615  
 616  
 617  
 618  
 619  
 620  
 621  
 622  
 623  
 624  
 625  
 626  
 627  
 628  
 629  
 630  
 631  
 632  
 633  
 634  
 635  
 636  
 637  
 638  
 639  
 640  
 641  
 642  
 643  
 644  
 645  
 646  
 647  
 648  
 649  
 650  
 651  
 652  
 653  
 654  
 655  
 656  
 657  
 658  
 659  
 660  
 661  
 662  
 663  
 664  
 665  
 666  
 667  
 668  
 669  
 670  
 671  
 672  
 673  
 674  
 675  
 676  
 677  
 678  
 679  
 680  
 681  
 682  
 683  
 684  
 685  
 686  
 687  
 688  
 689  
 690  
 691  
 692  
 693  
 694  
 695  
 696  
 697  
 698  
 699  
 700  
 701  
 702  
 703  
 704  
 705  
 706  
 707  
 708  
 709  
 710  
 711  
 712  
 713  
 714  
 715  
 716  
 717  
 718  
 719  
 720  
 721  
 722  
 723  
 724  
 725  
 726  
 727  
 728  
 729  
 730  
 731  
 732  
 733  
 734  
 735  
 736  
 737  
 738  
 739  
 740  
 741  
 742  
 743  
 744  
 745  
 746  
 747  
 748  
 749  
 750  
 751  
 752  
 753  
 754  
 755  
 756  
 757  
 758  
 759  
 760  
 761  
 762  
 763  
 764  
 765  
 766  
 767  
 768  
 769  
 770  
 771  
 772  
 773  
 774  
 775  
 776  
 777  
 778  
 779  
 780  
 781  
 782  
 783  
 784  
 785  
 786  
 787  
 788  
 789  
 790  
 791  
 792  
 793  
 794  
 795  
 796  
 797  
 798  
 799  
 800  
 801  
 802  
 803  
 804  
 805  
 806  
 807  
 808  
 809  
 810  
 811  
 812  
 813  
 814  
 815  
 816  
 817  
 818  
 819  
 820  
 821  
 822  
 823  
 824  
 825  
 826  
 827  
 828  
 829  
 830  
 831  
 832  
 833  
 834  
 835  
 836  
 837  
 838  
 839  
 840  
 841  
 842  
 843  
 844  
 845  
 846  
 847  
 848  
 849  
 850  
 851  
 852  
 853  
 854  
 855  
 856  
 857  
 858  
 859  
 860  
 861  
 862  
 863  
 864  
 865  
 866  
 867  
 868  
 869  
 870  
 871  
 872  
 873  
 874  
 875  
 876  
 877  
 878  
 879  
 880  
 881  
 882  
 883  
 884  
 885  
 886  
 887  
 888  
 889  
 890  
 891  
 892  
 893  
 894  
 895  
 896  
 897  
 898  
 899  
 900  
 901  
 902  
 903  
 904  
 905  
 906  
 907  
 908  
 909  
 910  
 911  
 912  
 913  
 914  
 915  
 916  
 917  
 918  
 919  
 920  
 921  
 922  
 923  
 924  
 925  
 926  
 927  
 928  
 929  
 930  
 931  
 932  
 933  
 934  
 935  
 936  
 937  
 938  
 939  
 940  
 941  
 942  
 943  
 944  
 945  
 946  
 947  
 948  
 949  
 950  
 951  
 952  
 953  
 954  
 955  
 956  
 957  
 958  
 959  
 960  
 961  
 962  
 963  
 964  
 965  
 966  
 967  
 968  
 969  
 970  
 971  
 972  
 973  
 974  
 975  
 976  
 977  
 978  
 979  
 980  
 981  
 982  
 983  
 984  
 985  
 986  
 987  
 988  
 989  
 990  
 991  
 992  
 993  
 994  
 995  
 996  
 997  
 998  
 999  
 1000



RLG2A  
RLG2B  
RLG2C  
RLG2D  
RLG2E  
RLG2F  
RLG2G  
RLG2H  
RLG2I  
RLG2J  
RLG2K  
RLG2L  
RLG2M

[illegible]

RLG2A  
RLG2B  
RLG2C  
RLG2D  
RLG2E  
RLG2F  
RLG2G  
RLG2H  
RLG2I  
RLG2J  
RLG2K  
RLG2L  
RLG2M

[illegible]

[illegible]

ACGACCTTCGAGTGGCTTCATCTCCATCGAATGTTTCATTAAGCATGTTGATTTGCTCTCTCTATTCGAAATCTTTTGAATCTCGAAGTGGCTTCAGCTTTGCTA	1210	1220	1230	1240	1250	1260	1270	1280	1290	1300
GTCAACCTTCGCGTGTTCATCTACATAATGCTCTCTTGAATGCGAATCTCTGCAATCTGCAATCTGCAAGTGGCTTCAGCTTTGCTG	1271									
ACGACATTCGCGTGGCTTCATCTCACTCAATGTTTCATTAAGCATGTTGATTTGCTCTCTCTATTCGAAATCTTGAATCTCGAAGTGGCTTCAGCTTTGCTA	1275									
ACCAACATTCGCGTGGCTTCATCTCACTCAATGTTTCATTAAGCATGTTGATTTGCTCTCTCTATTCGAAATCTTGAATCTCGAAGTGGCTTCAGCTTTGCTA	1267									
ACCAACATTCGCGTGGCTTCATCTCACTCAATGTTTCATTAAGCATGTTGATTTGCTCTCTCTATTCGAAATCTTGAATCTCGAAGTGGCTTCAGCTTTGCTA	1245									
ATCAACCTTCGAGTGGCTTCATCTCACTCAATGTTTCATTAAGCATGTTGATTTGCTCTCTCTATTCGAAATCTTGAATCTCGAAGTGGCTTCAGCTTTGCTA	1264									
ACCAACCTTCGAGTGGCTTCATCTCACTCAATGTTTCATTAAGCATGTTGATTTGCTCTCTCTATTCGAAATCTTGAATCTCGAAGTGGCTTCAGCTTTGCTA	1269									
ACCAACCTTCGAGTGGCTTCATCTCACTCAATGTTTCATTAAGCATGTTGATTTGCTCTCTCTATTCGAAATCTTGAATCTCGAAGTGGCTTCAGCTTTGCTA	1282									
ACCAACCTTCGAGTGGCTTCATCTCACTCAATGTTTCATTAAGCATGTTGATTTGCTCTCTCTATTCGAAATCTTGAATCTCGAAGTGGCTTCAGCTTTGCTA	1260									
ACCAACCTTCGAGTGGCTTCATCTCACTCAATGTTTCATTAAGCATGTTGATTTGCTCTCTCTATTCGAAATCTTGAATCTCGAAGTGGCTTCAGCTTTGCTA	1274									
ACCAACCTTCGAGTGGCTTCATCTCACTCAATGTTTCATTAAGCATGTTGATTTGCTCTCTCTATTCGAAATCTTGAATCTCGAAGTGGCTTCAGCTTTGCTA	1258									
ACCAACCTTCGAGTGGCTTCATCTCACTCAATGTTTCATTAAGCATGTTGATTTGCTCTCTCTATTCGAAATCTTGAATCTCGAAGTGGCTTCAGCTTTGCTA	1274									
ACCAACCTTCGAGTGGCTTCATCTCACTCAATGTTTCATTAAGCATGTTGATTTGCTCTCTCTATTCGAAATCTTGAATCTCGAAGTGGCTTCAGCTTTGCTA	1214									
ACCAACATTCGCGTGGCTTCATCTCACTCAATGTTTCATTAAGCATGTTGATTTGCTCTCTCTATTCGAAATCTTGAATCTCGAAGTGGCTTCAGCTTTGCTA	1249									
ATTCGCGATTCGATTCGCTTCAGCTTCGACATTCGAAATTCGAAAGCTTAAGGCTTACCTTCGATTCGACAAATTCGATTCGCTTCGCTATAGAAATTCGCTG	1310	1320	1330	1340	1350	1360	1370	1380	1390	1400
ATTCGCGATTCGATTCGCTTCAGCTTCGACATTCGAAATTCGAAAGCTTAAGGCTTACCTTCGATTCGACAAATTCGATTCGCTTCGCTATAGAAATTCGCTG	1371									
ATTCGCGATTCGATTCGCTTCAGCTTCGACATTCGAAATTCGAAAGCTTAAGGCTTACCTTCGATTCGACAAATTCGATTCGCTTCGCTATAGAAATTCGCTG	1375									
ATTCGCGATTCGATTCGCTTCAGCTTCGACATTCGAAATTCGAAAGCTTAAGGCTTACCTTCGATTCGACAAATTCGATTCGCTTCGCTATAGAAATTCGCTG	1367									
ATTCGCGATTCGATTCGCTTCAGCTTCGACATTCGAAATTCGAAAGCTTAAGGCTTACCTTCGATTCGACAAATTCGATTCGCTTCGCTATAGAAATTCGCTG	1345									
ATTCGCGATTCGATTCGCTTCAGCTTCGACATTCGAAATTCGAAAGCTTAAGGCTTACCTTCGATTCGACAAATTCGATTCGCTTCGCTATAGAAATTCGCTG	1364									
ATTCGCGATTCGATTCGCTTCAGCTTCGACATTCGAAATTCGAAAGCTTAAGGCTTACCTTCGATTCGACAAATTCGATTCGCTTCGCTATAGAAATTCGCTG	1369									
ATTCGCGATTCGATTCGCTTCAGCTTCGACATTCGAAATTCGAAAGCTTAAGGCTTACCTTCGATTCGACAAATTCGATTCGCTTCGCTATAGAAATTCGCTG	1382									
ATTCGCGATTCGATTCGCTTCAGCTTCGACATTCGAAATTCGAAAGCTTAAGGCTTACCTTCGATTCGACAAATTCGATTCGCTTCGCTATAGAAATTCGCTG	1360									
ATTCGCGATTCGATTCGCTTCAGCTTCGACATTCGAAATTCGAAAGCTTAAGGCTTACCTTCGATTCGACAAATTCGATTCGCTTCGCTATAGAAATTCGCTG	1374									
ATTCGCGATTCGATTCGCTTCAGCTTCGACATTCGAAATTCGAAAGCTTAAGGCTTACCTTCGATTCGACAAATTCGATTCGCTTCGCTATAGAAATTCGCTG	1358									
ATTCGCGATTCGATTCGCTTCAGCTTCGACATTCGAAATTCGAAAGCTTAAGGCTTACCTTCGATTCGACAAATTCGATTCGCTTCGCTATAGAAATTCGCTG	1374									
ATTCGCGATTCGATTCGCTTCAGCTTCGACATTCGAAATTCGAAAGCTTAAGGCTTACCTTCGATTCGACAAATTCGATTCGCTTCGCTATAGAAATTCGCTG	1314									
ATTCGCGATTCGATTCGCTTCAGCTTCGACATTCGAAATTCGAAAGCTTAAGGCTTACCTTCGATTCGACAAATTCGATTCGCTTCGCTATAGAAATTCGCTG	1349									

RLG2A  
RLG2B  
RLG2C  
RLG2D  
RLG2E  
RLG2F  
RLG2G  
RLG2H  
RLG2I  
RLG2J  
RLG2K  
RLG2L  
RLG2M

RLG2A  
RLG2B  
RLG2C  
RLG2D  
RLG2E  
RLG2F  
RLG2G  
RLG2H  
RLG2I  
RLG2J  
RLG2K  
RLG2L  
RLG2M

1410 1420 1430 1440 1450 1460 1470 1480 1490 1500  
 CTTAAAGAAATTTGGTCAAACTTCGAGGAGCTCTATAT-CACAGTG-----GTT-----CAT-----CGAGGTGAAAGG-----CGA----- 1437  
 CTTGAAAGCTTTTGGTCAAACTTCGAGGAGCTCTATATTTGGAGATGCAATCTGGGTTTATAGATGATTAACCTGCAATGAGATGGCAGAGCGTTCTTACAACTT 1475  
 CTTGAAAGCTTTTGGTCAAACTTCGAGGAGCTCTATATTTGGAGATGCAATCTGGGTTTATAGATGATTAACCTGCAATGAGATGGCAGAGCGTTCTTACAACTT 1417  
 CTTGAAAGCTTTTGGTCAAACTTCGAGGAGCTCTATATTTGGAGATGCAATCTGGGTTTATAGATGATTAACCTGCAATGAGATGGCAGAGCGTTCTTACAACTT 1411  
 CTTGAAAGCTTTTGGTCAAACTTCGAGGAGCTCTATATTTGGAGATGCAATCTGGGTTTATAGATGATTAACCTGCAATGAGATGGCAGAGCGTTCTTACAACTT 1432  
 CTTGAAAGCTTTTGGTCAAACTTCGAGGAGCTCTATATTTGGAGATGCAATCTGGGTTTATAGATGATTAACCTGCAATGAGATGGCAGAGCGTTCTTACAACTT 1437  
 CTTGAAAGCTTTTGGTCAAACTTCGAGGAGCTCTATATTTGGAGATGCAATCTGGGTTTATAGATGATTAACCTGCAATGAGATGGCAGAGCGTTCTTACAACTT 1466  
 CTTGAAAGCTTTTGGTCAAACTTCGAGGAGCTCTATATTTGGAGATGCAATCTGGGTTTATAGATGATTAACCTGCAATGAGATGGCAGAGCGTTCTTACAACTT 1420  
 CTTGAAAGCTTTTGGTCAAACTTCGAGGAGCTCTATATTTGGAGATGCAATCTGGGTTTATAGATGATTAACCTGCAATGAGATGGCAGAGCGTTCTTACAACTT 1442  
 CTTGAAAGCTTTTGGTCAAACTTCGAGGAGCTCTATATTTGGAGATGCAATCTGGGTTTATAGATGATTAACCTGCAATGAGATGGCAGAGCGTTCTTACAACTT 1449  
 CTTGAAAGCTTTTGGTCAAACTTCGAGGAGCTCTATATTTGGAGATGCAATCTGGGTTTATAGATGATTAACCTGCAATGAGATGGCAGAGCGTTCTTACAACTT 1423  
 CTTGAAAGCTTTTGGTCAAACTTCGAGGAGCTCTATATTTGGAGATGCAATCTGGGTTTATAGATGATTAACCTGCAATGAGATGGCAGAGCGTTCTTACAACTT 1398  
 CTTGAAAGCTTTTGGTCAAACTTCGAGGAGCTCTATATTTGGAGATGCAATCTGGGTTTATAGATGATTAACCTGCAATGAGATGGCAGAGCGTTCTTACAACTT 1441

1510 1520  
 TCTGCAATAGAAATTCGGTCTCTTTA -TTA -SEQ ID NO: 27  
 -TTA -SEQ ID NO: 28  
 -TTA -SEQ ID NO: 29  
 -TTA -SEQ ID NO: 30  
 -TTA -SEQ ID NO: 31  
 -TTA -SEQ ID NO: 32  
 -TTA -SEQ ID NO: 33  
 -TTA -SEQ ID NO: 34  
 -TTA -SEQ ID NO: 35  
 TCGAATTCGAGGAGCTTTTTCGA -SEQ ID NO: 36  
 -TTA -SEQ ID NO: 37  
 -TTA -SEQ ID NO: 38  
 -TTA -SEQ ID NO: 39

1439  
 1500  
 1417  
 1412  
 1432  
 1438  
 1466  
 1420  
 1442  
 1474  
 1437  
 1398  
 1441

SEQ ID NO:

40

GETT-----LKEVVEKQKFNIVIAVIGKTDPTAIQQAVADYIGIELKSTPRADKIREMFAESQSGKNEFLVLDVWQSVLDIGLSPFNQ 100  
 10 20 30 40 50 60 70 80 90 100  
 RLG2A protein GKTTHMRLKVKVKEKHNF IIEAVGCKTDPDIAIQSAVDYIGIELKSTPRADKIREMFAESQSGKNEFLVLDVWQSVLDIGLSPFNQ 98-41  
 RLG2B protein GKTTHMRLKVKVKEKHNF IIEAVGCKTDPDIAIQSAVDYIGIELKSTPRADKIREMFAESQSGKNEFLVLDVWQSVLDIGLSPFNQ 100-42  
 RLG2C protein NTRX--AKAEVAVKKEGFYIIEAVIGELISDPIAQVADYIGIELKSTPRADKIREMFAESQSGKNEFLVLDVWQSVLDIGLSPFNQ 98-43  
 RLG2D protein EVAK--AK--FKYIIEAVIGELISDPIAQVADYIGIELKSTPRADKIREMFAESQSGKNEFLVLDVWQSVLDIGLSPFNQ 90-44  
 RLG2E protein GRND--AKYEEVAKENHNFIVIAVIGKTDPTAIQQAVADYIGIELKSTPRADKIREMFAESQSGKNEFLVLDVWQSVLDIGLSPFNQ 99-45  
 RLG2F protein LEUTMQRLLKVKVKEKHNF IIEAVGCKTDPDIAIQSAVDYIGIELKSTPRADKIREMFAESQSGKNEFLVLDVWQSVLDIGLSPFNQ 100-46  
 RLG2G protein GRUDD--EELKEVVEKQKFNIVIAVIGKTDPTAIQQAVADYIGIELKSTPRADKIREMFAESQSGKNEFLVLDVWQSVLDIGLSPFNQ 97-47  
 RLG2H protein CKXS-----KVVVEKQKFNIVIAVIGKTDPTAIQQAVADYIGIELKSTPRADKIREMFAESQSGKNEFLVLDVWQSVLDIGLSPFNQ 94-48  
 RLG2I protein ERGR-----GKQKFNIVIAVIGKTDPTAIQQAVADYIGIELKSTPRADKIREMFAESQSGKNEFLVLDVWQSVLDIGLSPFNQ 89-49  
 RLG2J protein ERGR-----GKQKFNIVIAVIGKTDPTAIQQAVADYIGIELKSTPRADKIREMFAESQSGKNEFLVLDVWQSVLDIGLSPFNQ 89-50  
 RLG2K protein LEUTMQRLLKVKVKEKHNF IIEAVGCKTDPDIAIQSAVDYIGIELKSTPRADKIREMFAESQSGKNEFLVLDVWQSVLDIGLSPFNQ 100-51  
 RLG2L protein AEE-----AAEKKLNFYIVIAVIGKTDPTAIQQAVADYIGIELKSTPRADKIREMFAESQSGKNEFLVLDVWQSVLDIGLSPFNQ 92-52  
 RLG2M protein AEE-----AAEKKLNFYIVIAVIGKTDPTAIQQAVADYIGIELKSTPRADKIREMFAESQSGKNEFLVLDVWQSVLDIGLSPFNQ 92-53

VDFKVLITSRDSHUCTMAGVEANSILNGLLIEAEQSLFQFVETS--E---PELQKIGEDIVRKCQGLPIAKTHACTLRKRKQKADKALSRLEHYD 196  
 110 120 130 140 150 160 170 180 190 200  
 RLG2A protein VDFKVLITSRDSHUCTMAGVEANSILNGLLIEAEQSLFQFVETS--E---PELQKIGEDIVRKCQGLPIAKTHACTLRKRKQKADKALSRLEHYD 196  
 RLG2B protein VDFKVLITSRDSHUCTMAGVEANSILNGLLIEAEQSLFQFVETS--E---PELQKIGEDIVRKCQGLPIAKTHACTLRKRKQKADKALSRLEHYD 193  
 RLG2C protein VDFKVLITSRDSHUCTMAGVEANSILNGLLIEAEQSLFQFVETS--E---PELQKIGEDIVRKCQGLPIAKTHACTLRKRKQKADKALSRLEHYD 185  
 RLG2D protein VDFKVLITSRDSHUCTMAGVEANSILNGLLIEAEQSLFQFVETS--E---PELQKIGEDIVRKCQGLPIAKTHACTLRKRKQKADKALSRLEHYD 193  
 RLG2E protein VDFKVLITSRDSHUCTMAGVEANSILNGLLIEAEQSLFQFVETS--E---PELQKIGEDIVRKCQGLPIAKTHACTLRKRKQKADKALSRLEHYD 195  
 RLG2F protein VDFKVLITSRDSHUCTMAGVEANSILNGLLIEAEQSLFQFVETS--E---PELQKIGEDIVRKCQGLPIAKTHACTLRKRKQKADKALSRLEHYD 197  
 RLG2G protein VDFKVLITSRDSHUCTMAGVEANSILNGLLIEAEQSLFQFVETS--E---PELQKIGEDIVRKCQGLPIAKTHACTLRKRKQKADKALSRLEHYD 189  
 RLG2H protein VDFKVLITSRDSHUCTMAGVEANSILNGLLIEAEQSLFQFVETS--E---PELQKIGEDIVRKCQGLPIAKTHACTLRKRKQKADKALSRLEHYD 194  
 RLG2I protein VDFKVLITSRDSHUCTMAGVEANSILNGLLIEAEQSLFQFVETS--E---PELQKIGEDIVRKCQGLPIAKTHACTLRKRKQKADKALSRLEHYD 189  
 RLG2J protein VDFKVLITSRDSHUCTMAGVEANSILNGLLIEAEQSLFQFVETS--E---PELQKIGEDIVRKCQGLPIAKTHACTLRKRKQKADKALSRLEHYD 195  
 RLG2K protein VDFKVLITSRDSHUCTMAGVEANSILNGLLIEAEQSLFQFVETS--E---PELQKIGEDIVRKCQGLPIAKTHACTLRKRKQKADKALSRLEHYD 177  
 RLG2L protein VDFKVLITSRDSHUCTMAGVEANSILNGLLIEAEQSLFQFVETS--E---PELQKIGEDIVRKCQGLPIAKTHACTLRKRKQKADKALSRLEHYD 187



[illegible]

[illegible]



AC15-2A  
AC15-2B  
AC15-2C  
AC15-2D  
AC15-2E  
AC15-2G  
AC15-2H  
AC15-2I  
AC15-2J  
AC15-2L  
AC15-2N  
AC15-2O

AC15-2A  
AC15-2B  
AC15-2C  
AC15-2D  
AC15-2E  
AC15-2G  
AC15-2H  
AC15-2I  
AC15-2J  
AC15-2L  
AC15-2N  
AC15-2O

AC15-2A	1	2	3	4	5	6	7	8	9	10	11	12	13	14	15	16	17	18	19	20	21	22	23	24	25	26	27	28	29	30	31	32	33	34	35	36	37	38	39	40	41	42	43	44	45	46	47	48	49	50	51	52	53	54	55	56	57	58	59	60	61	62	63	64	65	66	67	68	69	70	71	72	73	74	75	76	77	78	79	80	81	82	83	84	85	86	87	88	89	90	91	92	93	94	95	96	97	98	99	100	101	102	103	104	105	106	107	108	109	110	111	112	113	114	115	116	117	118	119	120	121	122	123	124	125	126	127	128	129	130	131	132	133	134	135	136	137	138	139	140	141	142	143	144	145	146	147	148	149	150	151	152	153	154	155	156	157	158	159	160	161	162	163	164	165	166	167	168	169	170	171	172	173	174	175	176	177	178	179	180	181	182	183	184	185	186	187	188	189	190	191	192	193	194	195	196	197	198	199	200	201	202	203	204	205	206	207	208	209	210	211	212	213	214	215	216	217	218	219	220	221	222	223	224	225	226	227	228	229	230	231	232	233	234	235	236	237	238	239	240	241	242	243	244	245	246	247	248	249	250	251	252	253	254	255	256	257	258	259	260	261	262	263	264	265	266	267	268	269	270	271	272	273	274	275	276	277	278	279	280	281	282	283	284	285	286	287	288	289	290	291	292	293	294	295	296	297	298	299	300	301	302	303	304	305	306	307	308	309	310	311	312	313	314	315	316	317	318	319	320	321	322	323	324	325	326	327	328	329	330	331	332	333	334	335	336	337	338	339	340	341	342	343	344	345	346	347	348	349	350	351	352	353	354	355	356	357	358	359	360	361	362	363	364	365	366	367	368	369	370	371	372	373	374	375	376	377	378	379	380	381	382	383	384	385	386	387	388	389	390	391	392	393	394	395	396	397	398	399	400	401	402	403	404	405	406	407	408	409	410	411	412	413	414	415	416	417	418	419	420	421	422	423	424	425	426	427	428	429	430	431	432	433	434	435	436	437	438	439	440	441	442	443	444	445	446	447	448	449	450	451	452	453	454	455	456	457	458	459	460	461	462	463	464	465	466	467	468	469	470	471	472	473	474	475	476	477	478	479	480	481	482	483	484	485	486	487	488	489	490	491	492	493	494	495	496	497	498	499	500	501	502	503	504	505	506	507	508	509	510	511	512	513	514	515	516	517	518	519	520	521	522	523
---------	---	---	---	---	---	---	---	---	---	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----

[illegible]

SEQ ID NO:

AC15-2A  
AC15-2B  
AC15-2C  
AC15-2D  
AC15-2E  
AC15-2G  
AC15-2H  
AC15-2I  
AC15-2J  
AC15-2L  
AC15-2N  
AC15-2O

810 820  
TAAGTACTTGTTTCACTCTCAAGG - 56  
TAAGTACTTGTTTCACTCTCAAGG - 57  
TAGTACTTGTTTCACTCTCAAGG - 58  
TAGTACTTGTTTCACTCTCAAGG - 59  
TAAGTACTTGTTTCACTCTCAAGG - 60  
TAAGTACTTGTTTCACTCTCAAGG - 61  
TAAGTACTTGTTTCACTCTCAAGG - 62  
TAAGTACTTGTTTCACTCTCAAGG - 63  
TAAGTACTTGTTTCACTCTCAAGG - 64  
TAAGTACTTGTTTCACTCTCAAGG - 65  
TAAGTACTTGTTTCACTCTCAAGG - 66  
TAAGTACTTGTTTCACTCTCAAGG - 67

779  
777  
777  
788  
721  
781  
738  
722  
786  
699  
778  
763

SEQ ID NO:68

RLG3 (real RLG3)

[Strand]

```
1  AATGGCAAAA GAAGTCGGAG CAAGAGCTAA GTTAGAGCAT CTATTGACG TCATTATCAT GGTAGATGTC
71  ACTCAAGCAC CCAACAAGAA CACAATTCAA AGTAGTATTT CAGAACAGTT GGGATTAAAA CTGCAAGAAG
141 AGAGCTTGTG GGTAAAGAGCA GCTAGGGTAA GTGCGAGSTT AAAAAATGCTT ACAAGGGTGC TGGTGATATT
211 AGACGATATA TGGTCAAGGC TTGACATGGA GGAACCTGGG ATTCCCTTTG GATCAGATAG ACAACACCAC
281 GGCTGCAAAA TCTTGTTGAC TTCAAGAAGT ATTAGTGCTT GTAACCAGAT GAGAGCTGAT AGAATCTTTA
351 AAATAAGAGA AATGCCACTG AATGAAGCAT GGCTTCTTTT CGAAAGAACA GCTAAAAAAG CTCCGAATCT
421 GCATCAAGTA GCAAGAGATA TCGTGGAGGA GTGTGGTGGG C
```



RLG4  
SEQ ID NO: 69

```
1 GAATTCGGTG TTGGTAAGAC AACTCTTGCC TCTTCTGTTT ATGATGAAAT CTCTAGCAAG TTGATGGTT
71 GCTGCTTTCT AAAAATATCT GCGAGGAATC AAGTAATAAA GACGGTATAG AAAGATTGCA AGAAAAAATC
141 ATTTGTGATG TTTTGAAACA AGAGCAAGTG GCGGTAGGGA GAGTTGAAGA AGGAAAGCGC ATGATAAAGG
211 ATAGGTTACA ACATAGAAG GTATTGATTG TGCTTGATGA TGTCGACAAC GTTGAGCAGC TAGCTAGAAC
281 AGTTGGGCTGG ATCACAATGAT TGGTTTGGTG AAGGTAGCCG CATAATAATC ACAACTAGAG ATGAACATGT
351 ATTAATTGCA CACAAAGTAG ATGTGATACA CAATATAAGC TTGTTAAACA ACGATGAAGC TATGCATCTC
421 TTCTGCAAGC AAGCACCACG GGGTCACAAA CGTATACAAG ATTATGAGCA ACTTTTAAAA CATGTGGTTT
491 CTTATGCTGG TGGGCTTCCA CTAGCACTGT CGAC
```

SEQ. ID NO: 70  
RLG1-E169  
[Strand]

```
1  ATCGTAACCG  TTGCTACGAG  ANCGCTGTCC  CTCCTTCATC  TTTTGTGATA  TGTGATATTC  TCATNATTN
71  TGCCACATCT  AATTTTGTGG  TTATTTTAAA  TTAATTTTFA  TTCCACATGT  CATTTTATGA  GTTTTCTAT
141  TTTATTGAST  TTCACATAAT  ATTAAATGT  AATAACAATA  AATGCATATT  TATTTTCTT  TAAATAAACG
211  CATATAATAT  ATAGATTAAA  ATCATATAAT  ACATAGGTTA  AACTCATATA  ATACATATGT  TCATCCOCAG
281  TTTATTTATA  TGCTCATCC  TTAATTTATT  TATTATTAT  TTATTAGAGT  AGATGATCTT  TGTGATATTA
351  AAAATTTAAT  TTGTTCAAAA  TTAAATTTA  TTAATAATCC  CACAATTIGA  ATAAATTTAA  AAAAAATGNN
421  CCCACCATTA  GTCCATCACT  TTTTCAGCTC  ATCAATATCG  TGAGTATICT  CCTTCGTTTC  CACCCTAATC
491  AATATTTCCA  GCGAATGACA  GACTCCTACG  GCGTTTCTGA  ATTTGCGTTC  CGACACTGTT  CATTTGAAGGA
561  GATAATAAAT  CAAATGGAGC  TGCTCCAATG  TTCAATTGCTG  ATGAAAGGTG  AATTTGATGT  GAAGANAATG
631  TCAGCGATCN  ATCTCCATCC  GGAACCCACC  ACATTATCAG  TGTACCACCA  AACCACCTCA  AACGSGGAA
701  GTAGRRKAC  WRKAAAGTCA  TGAAGAATAG  ATTATTTTGG  TCCTCATGGG  CTGACTGAGG  AGCGGTTTA
771  GTTCATCAAT  TTCTTTTGAN  CAAAGAATTA  TCGTCCATC  GAAATTTTAC  ATCGACAAAG  AAGTTTCACT
841  TCGCAATGTT  TTGTTAAACA  ATTTTAAATC  TTTTATCTTT  TTGTTTGAAG  CTCTCAATTT  GCAACTTGCA
911  ACTTGCAACT  TTTGGGCCCA  CAAATTTGTG  GTGGGCGTTA  ATTTAATCCA  CATATTCACT  GTAAACAATA
981  ATTCAAAATG  ATCTCTGTT  ATCCAAATCA  TCAACATCTC  TTGATAATTG  AAATCATICA  CGCTTCATCC
1051  ATTTCATCCA  CATCTATACT  ATATTCTCTG  CTCTATCAT  ATTTAAAGAT  GGCTGAAATC  GTTCTTCTG
1121  CCTTCTTGAC  AGTCTGTTT  GAAAGCTGG  CATYTGAGC  CTGGAAGAG  ATTTGTTCGT  CCAAAAGAT
1191  TGAATCTGAG  CTTAAGAAAT  TGAAGGAGAC  ATTAGACCAA  ATCCAAGATC  TGCTTAAAG  TGCTTCCAG
1261  AAGGAAGTAA  CTAATGAAGC  CGTTAAAGA  TGGCTGAATG  ATCTCCAACA  TTTGGCTTAT  GACATAGAGG
1331  ACCTACTTGA  TGAATTTGCA  ACTGAAGCTG  TTCACGCTGA  GTTGACCGAG  GAGGGTGGAG  CCTCTCCAG
1401  TATGGTAAGA  AAATCTAATC  CAAATTTGTT  CACAAGTTTC  TCACAAAGTA  ATAGGATGCA  TGCCAAGTTA
1471  GATGATATTC  CCACCAAGTT  ACAAGAACTG  GTAGAGGCAA  AAAATAATCT  TGGTTTAAAT  GTGATAACAT
1541  ATGAAAAGCC  AAAAATGAA  AGGTATGAGG  CSTCTTTGTT  AGATGAAAGC  GGTACTGTCC  GACSTGAAGA
1611  TGATAAGAAA  AAATTCCTGG  AGAAGCTGTT  GGGGGATAAA  GATGAATCAG  GGAGTCAAAA  CTTTCAGATC
1681  GTGCCCATAG  TTGCTATGGG  TGGAGTTGGT  AAAACAACCT  TAGCTAGACT  TTTGTATGAT  GAAAAGAAAG
1751  TGAAGGATCA  CTTGAACTC  AGGGCTTGGG  TTTGTGTTTC  TGATGAGTTC  AGTGTTCCTA  ATATAAGCAG
1821  AGTTATTTAT  CAATCTGTC  CTGGGGAAGA  GAAGGAGTTT  GAAGACTTAA  ATCTGCTTCA  AGAAGCTCTT
1891  AAAGAGAAAC  TTAGGAACCA  GCTATTCTTA  ATAGTTTGG  ATGATGTGTG  GTCTGAAAGC  TATGGTGATT
1961  GGGGAAATTT  AGTGGGCCA  TTCTTGGGG  GGTCTCTCTG  AAGTAGAATA  ATCATGACAA  CTGGGAAGGA
2031  GCAATTCCTC  AGAAGCTGG  GCTTTTCTCA  TCAAGACCTT  CTGGAGGTC  TATCACAAGA  TGAATGCTTTG
2101  TCTTTGTTG  CTCACACCC  ATTTGGTGTA  CCAAACCTTG  ATTCACATCC  AACACTAAGG  CCACATGGAG
2171  AACTGTTTGT  GAAGAAATGT  GATGGCTTAC  CTCTAGCTTT  AAGAACACTT  GGAAGGTAT  TAAGGACAAA
2241  AACAGACGAG  GAACAAATGA  AGGAGCTGTT  GATAGTGAG  ATATGGAGGT  TAGGAAAGAG  CGATGAGATT
2311  GTTCCGCTTC  TTAGACTAAG  CTACAATGAT  CTTTCTGCCW  CTTTGAAGCT  RTTCTTTGCA  TATGTCTCTT
2381  TGTTCCTCAA  GGACTATGAG  TTTGACNAGG  AGGAGTTGAT  TCTATTTGTT  ATGGCAGAAG  GGTMTTTGCA
2451  CCAACCAACT  AYAAACAAGT  CAAAGCAAGG  KTTGGGTCCT  GAATATTTTR  AAGAGTTTTR  GTCAAGTCTR
2521  TTTTTCACAC  ATGCTCTTAA  TRRCAAATCS  TTGTTTGTGA  TGCATGACCT  AATGAATGAT  TTGGCTACAT
2591  TTGTTGCTGG  AGAATTTTTC  TCAAGGTTAG  ACATAGAGAT  GAAGAAGGAA  TTTAGGATGS  AATCTTTGGA
2661  RAAGCACCGT  CATATGTCAT  TTGATGTGTA  GRATTACATA  GGTACAAAA  RGTTCGAGCC  ATTTAGAGGA
2731  GCTAAAAAT  TTGAAACATT  TTTAGCATTC  TCTGTTGGGG  TGGTAGAAGA  TTGGAAGATG  TTTTACTTAT
2801  CAAACAAGGT  CTGAAATGAC  WTACTTCARG  ATTTACCATT  GTTAGGGTTC  CTRAKTTTGA  TTRRTCTTAY
2871  AATAASYRAG  GTACCARAAC  TCGTSGGTAG  TATGAASCAC  TTGCGGTATC  TTAATCTATC  WGRAACTTWA
2941  ATCACHCAT  TACCGGAAWA  TRCTTGCAAT  CTTTATAATT  TACARACCTT  GATTGTNCT  GCTGTGAMT
3011  ATTTAGTTAA  KTTGCCCAAR  ACCTTCTCAA  ASCTTAAAAA  TTTGCASCAT  TTTGACATGA  GGGTACTCC
3081  KAAKTTRAAR  AACATGCCCT  TARGGATTGG  TGARTTGAAG  ARTCTACAAA  CTCTCTTMM  TAACATTGGC
3151  ATAGCAATTA  CCGAGCTTAA  GAACCTTGAM  AAYCTCCATG  GGAAATTTTG  TATTGGGGGG  CTGGGAAAAA
3221  TGGAAAATGC  NGTGGGATGC  ACGTTAAGCG  AACTTGTCTC  A:AAAAAGGT  TWAATGARTT  ANAACTGGR
3291  WTKGGGGTGG  ATRAATTTAA  TGTTTTCCGA  AATGGGAACA  CTGAAAAAAA  NAAGGTCTCT  AATCAATTGA
3361  ATGCTCTACA  ATGGTAYTCY  AAWWAARRRY  YWTAARWAT  TWKAWRRK  GKGTTYATRR  TKTTMYRAAW
3431  WAGRTKTTT  TATAGGTTT  TCATCCARTC  ACCCAAGTGG  GAAATAGAT  GATATTTTCA  GGGCTTACTG
3501  ATGAGATGTT  GAGAGGTATG  ATAGGTTNVC  TTGGGGCGGT  AGAAGAAATA  AGCATCCATT  CTGTGATTA
3571  AATAAGATAT  YTGTTGGGAT  CAGAAGCAGA  GGCAGTAAAG  GTTCTTATGA  ATTTAAAGAA  GTTGGATTTA
3641  GGTGAATGTT  AAAATTTGGT  GAGTTTAGGG  GAGAAAAAGG  AGGATAATCA  TAATATTAT  AGTGGGAGCA
3711  GCTTAACAT  TTTTAGAGG  TTGAATGTAT  GGAGATGTAA  CAGCTTGGAG  CATTCGAGGT  GTCCAGATAG
3781  CATGGAGAA  TTGTATATGC  ACATGTGTGA  TTCAATNACA  TCCCTCTCT  TCCCAACAGG  AGGAGGACAG
3851  AAGATCAAGT  CACTTACCAT  CACTGATTCG  AAGAAGCTTT  CGGAAGAGGA  GTTGGGAGGA  CGAGAGAGGA
3921  CAAGAGTCT  TATAAATCT  AAAATGCAGA  TGCTTGAATC  AGTAGATATA  CGTAATTTGG  CAAATCTGAA
3991  ATCTATCACT  GAATTAGATT  GCTTCATICA  CCTGAACAGA  TTATATATAT  CAAACTGTCC  GAGTGTGGAG
4061  TCAATTCCTG  ACCATGAGTT  GCCAATCTC  ACCTCTCTAA  CAGATCGAAG  GAGAGGACAG  CGATTTTCTG
```

RLG1-E169  
[Strand]

4131 ACGAACGGTT ACGATTGAC TGGCCGTCTT TTT

SEQ ID NO: 70

*Further Characterization of RG2 Family Members:*

Further sequencing of cloned RG2 polynucleotide sequences, as discussed above, identified additional RG2 species, listed below. Additionally, further sequencing of the 5' sections of RG2 sequences listed above resulted in modified and/or new sequence information, also listed below. The AC15 sequences found in the 3' sections of RG2 family have not changed.

Listed below are: four full length species, RG2A, RG2B, RG2C and RG2S; two near complete, but with a gap in the largest intron, RG2D and RG2J; three nearly complete RG2 gene sequences, RG2K, RG2N, and RG2O. The deduced translation products (polypeptides) encoded by these RG2 species are listed below. The polynucleotide sequences do not contain any gaps (as with some of the polynucleotide sequences), because all of the gaps in the sequences are in introns, *i.e.*, there are no gaps in exon, or coding, sequences.

They include: an RG2A polynucleotide sequence (SEQ ID NO:87) and its deduced polypeptide sequence (SEQ ID NO:88); an RG2B polynucleotide sequence (SEQ ID NO:89) and its deduced polypeptide sequence (SEQ ID NO:90); an RG2C polynucleotide sequence (SEQ ID NO:91) and its deduced polypeptide sequence (SEQ ID NO:92); an RG2D polynucleotide sequence (SEQ ID NO:93) and (SEQ ID NO:94), and its deduced polypeptide sequence (SEQ ID NO:95); an RG2E polynucleotide sequence (SEQ ID NO:96) and its deduced polypeptide sequence (SEQ ID NO:97); an RG2F polynucleotide sequence (SEQ ID NO:98) and its deduced polypeptide sequence (SEQ ID NO:99); an RG2G polynucleotide sequence (SEQ ID NO:100) and its deduced polypeptide sequence (SEQ ID NO:101); an RG2H polynucleotide sequence (SEQ ID NO:102) and its deduced polypeptide sequence (SEQ ID NO:103); an RG2I polynucleotide sequence (SEQ ID NO:104) and its deduced polypeptide sequence (SEQ ID NO:105); an RG2J polynucleotide sequence (SEQ ID NO:106) and (SEQ ID NO:107), and its deduced polypeptide sequence (SEQ ID NO:108); an RG2K polynucleotide sequence (SEQ ID NO:109) and (SEQ ID NO:110), and its deduced polypeptide sequence (SEQ ID NO:111); an RG2L polynucleotide sequence (SEQ ID NO:112) and its deduced polypeptide sequence (SEQ ID NO:113); an RG2M polynucleotide sequence (SEQ ID NO:114) and its deduced polypeptide sequence (SEQ ID NO:115); an RG2N polynucleotide sequence (SEQ ID NO:116) and its deduced polypeptide sequence (SEQ ID NO:117); an RG2O

polynucleotide sequence (SEQ ID NO:118) and its deduced polypeptide sequence (SEQ ID NO:119); an RG2P polynucleotide sequence (SEQ ID NO:120) and its deduced polypeptide sequence (SEQ ID NO:121); an RG2Q polynucleotide sequence (SEQ ID NO:122) and its deduced polypeptide sequence (SEQ ID NO:123); RG2S polynucleotide sequence (SEQ ID NO:124) and its deduced polypeptide sequence (SEQ ID NO:125); an RG2T polynucleotide sequence (SEQ ID NO:126) and its deduced polypeptide sequence (SEQ ID NO:127); an RG2U polynucleotide sequence (SEQ ID NO:128) and its deduced polypeptide sequence (SEQ ID NO:129); and RG2V polynucleotide sequence (SEQ ID NO:130) and its deduced polypeptide sequence (SEQ ID NO:131); and, an RG2W polynucleotide sequence (SEQ ID NO:132) and its deduced polypeptide sequence (SEQ ID NO:133).

*Characterization of New RG Family Groups and RG Species:*

Further BAC insert characterization and sequencing, as discussed above, identified new RG polynucleotide sequences. The new sequences were characterized as belonging to new RG families; designated RG5 and RG7. These RG polynucleotides sequences, and their predicted translation products (the polypeptides which are encoded by these sequences) are summarized and listed below.

Identified and listed below is an RG5 family member, designated as the RG5 polynucleotide sequence set forth in SEQ ID NO:134, and its deduced polypeptide sequence (SEQ ID NO:135). This sequence contains an NBS region sequence.

Also identified and listed below is an RG7 family member, designated as the RG7 polynucleotide sequence set forth in SEQ ID NO:136. No deduced polypeptide sequence is given for the new RG7 family member as this sequence appears to be a pseudogene.

**RG2A polynucleotide sequence (SEQ ID NO:87)**

AAAGTTCATATCCAAGCTTGCCCTCCAACTCTAGCTCCTTCAATGGCACC  
TCCTTCTCTTCAAAAGCACACAAGAACTTTCAAGCTCAACCACACTCA  
CACAAAGCTCTAGAACGAGGGTTAGGGCACATTTAGGGTTTTGCTCTCTGG  
AAATGGTGTCTAAAAGTGAGGCCATAATGTTCTTATATAAGGCTCACTC  
CCACAATTAGGCTTTCAATCTGAACGTANTACGCCCAGTGTAACACTATGG  
TACGCCCAACGTACTCGGTAGTCTCCGCGTCAANAATACTCATGAGTA

CGCGCAACGTACTTTCCCTTACGCCCAGCGTACTCAAAAGCCAAACATTC  
TTTTCAAGGACTAATTTTGACAACTTGAGGAAAGAAAAGGATCAAAGANA  
TATACTTGAATTCGGGATGTTACAATGAAGTTGANACCTTGGCTAAAAA  
ATTA AATTGGTTGTGGAAGCCGTTGGCTGAGCAAGCAACAAGGGTAA AAT  
5 TCGTAATCTACAAATGGTGTTATTTTCTATTTCTTCTTATTATTTTACTT  
GATTTACGGGTAGTTTTTTTTTCTTACAAAAAATATTAAAGTTGATAAAG  
TATAGCCACTAAAATTGACTTTTTTCCAAAACATAATGTCAAATGGTGCGT  
ATATGTATCATGTTGTATTANATAATGAATATGATGATNCTGTTCTATTT  
AANCCGAAAAAATTATCTAATGATTTTATATTGGAAAACAAAGTTGTGAT  
10 TTTTNGCATAATATAATCAAATCCNCTTTTGTNTGGGAGGTGGATAAATG  
TGGTAAATTTANAACAAGTGTTTTNACNTTGAAGGGTNTGGAAAGGTTGA  
AAAAAGTTAA AATGATAAAATGTTTACACAAATGTTGTATCCGACTGAAT  
ATNATGTTTAAGGATNATTGTATTAAATGTTGATATATAGTAAGCATAA  
ATATTTAGAATTGTGACTTAAATTTATAAGTTATNCNAACTGGATTGAAA  
15 CATTTTTGATATANATTAGGAATGAAAATGAGCAACCCTAACATACTTAT  
CTTTGGTAGTTTGGTTATTATATTTTTATTANAATATAGAANCATCCCTT  
TATTTTAAACCCATATTGTGGACGGACTTGAATAAATGGGAAAAATGTAC  
CTTGCTATTTAGCACAAAAAATTATAAAAATGTACATTGCTATTTAGCA  
CAAACAAAAA AAAAAA AACTTATCCTTTTTGCATTAGGTCACAAAGAAATA  
20 TAA AATGGGAAATGTGTGCTATTTAATGCACTAAAAGAACTATTTTGC  
CTTTATTAAACCGGGTAAACCAATAGAAAAATGGAAGTACATTGTCAATT  
AGCATGAAAAA AATAACTTTCCATTTTTTGCATCCGGTCACAATAATAG  
AAAAATGAAAGTACGTTGCTATTTAGCGAACTAACTTCCTTTTTTCTTT  
TTGGCATCGTATCATAAAATATAGACTAAAATACGTTAGTTTTACATTTT  
25 TAATACATTGAAATGTCTAATCCACATGTTATTCTATAAAAAGGGAAATG  
TAATTTACTTATTCTTTGATTCTTTGGCTTCTTTTAGTACCCAAAACAT  
CCCTCTATCCATCTATTCCAATAAATAATGAAAATATATTCTTCCA  
TTGTAGGGATGTTATAAATTTTGTAATTGTTTTTATGCAAAAAAGTGTTT  
TTTGTTAACTAGATTAACGAGATTCATTTTTCAGCATTTTAGGAGAAGTT  
30 CATCCATCTTTTGATATGAAGTGCAAGCCAAGTTCTTTAACATGGAATA  
TGAGGTCCCTATATGCTCAAAAAATAGCAAATGAGAAATTTTTTAAATTG  
GATCCCATAAAAGAAAATTTGTTAATGGTTGTTTTAATATTGGTCAATG  
TGTCCACCGGATGAGCATAATACTAGTTTATAAGGGGTAAAGGTGGGTTT  
GGTGGGCCCATTTATCTTTATTATTTCTAAAAGTCAGAATTAAGTAAAAA  
35 AAATTATAAGATAAATACCATAAGGATAAAAAATCATTTTATTGGACCA  
AAGACCAAAGTTGTTAAGGGGCTGTTTGTTTTTTTTTGTAAGAGCTGTGC  
AACCACTTTTGTCTGCGCCGCACAGACAACGTGCAGACATATGCCCTCGC  
AGAGTGTTTGTTTTTTGAAAGTGCGCAGACCAAAAAAACGTCTGCGCGAG  
GTCATCCTGGCGCATATATGTGTCACTGTCTTCAAAGGTCTTCAGACCTC  
40 ATTTTAAACCAAAAAA AAAAAAGACCACGGTTTTTTTTTTTTTTTTNTTC  
TTTCTCTGTAGCTGAAAATGCATTTTAAATCTTTATGACATGAAATTAA  
GTTTGAAAAATTAATTTATTTCAACAGCTGTAGACGTTAAAAACAAACAG  
TCTTCTTGTTGCAGACTGTGGACATTTGGTCCACCTCTTCTACCGCAGAG

ACTTGCAGATGTGGTCCGCAGACTGCAGACATTTTGGCTTCAAATAAACA  
AACATCACCTAATTTGACTACACCACACGGACCTCCAATGTAACAAAAAA  
AAGGTTGAAACAAAGTTGCCTATTTCTCCATATCCAGGGGCCATTTATGT  
AAGAGTTATCTAAATTTTAGTTTCGGTAGATCAGTTCTCACATTTTAACCG  
5 GGTAAAGTGTATGTGTGTACGCGCGCACCTGAAAGGTTTGAANGTAACTT  
CCAAACTGAANCAANAATCGATATGAAGTATCAAGTTAGAGGTTCAATTG  
GTGAAGGAATCAGCTGGAGGTTGGGGAATCGAGCTTCCACTATTAAGGTA  
AAATCCATAACCCTAAATGTTGGTACGCTCATATATCAAATTGCGTGTTT  
TGTTGAATGAAAAAAGCATGCTCAAAAAACCAGTGTAAGGCACGGTATAT  
10 GACATATTTATAGTTACTGATAACAAATTATGATAATTTTGGGTTTACGT  
AAGTTAGGATTCGTA CT TCAACCAAATGTAATAGTTTTTGTGAGTCTATC  
TATGTATTTGGGGAATCACATTAGCAACGGGATTGTACTAGTAATTCGAA  
AAAGTCTTTTAAATAATTTTCTGTTTATAATTTATGAATAGTTTTAGCG  
ACATCTAATATTAAATAGAATGTATCTGATATTGAATTAATGTCCTTAAT  
15 GTG.AACATAGACCTTTTCCATTTACTAATGCCTAATTATTAGTTTCTAAT  
CAATAAATTTTAATTTCTGTTTTATGCTTCTAAGACAATAAAAAATCCATG  
ATTTACCTTTAAATATTAACAAAAATGACCATAAATAAAAAAATTAG  
GATACCAAACCCCCCGCCATGCCCAATGTCTAAATATTCTTGATGCTTT  
TGCTTTTCCCTCTTTTCTTGTAGTCTATTATTCTGGAGAGTTTGAGAG  
20 AGTTTCATACAAGAAAATTTCAAGAAGAAAGCAAAGGTCCAGGTATTCTC  
TTTTCTTAATTATGTATTAACCTTACAAGCATTTTTTACACGATCCATGGT  
TTTTTGTGTATGTTTTTCAAATTGAACTAGATTGGGACTTTTGCCCTTG  
ATG.ATTCATAAGATATTGCATGGAGTTGAGATTGTGTAAGAAAAGTGGTG  
AATAGAAAGAGCAAGTGAATCCAGATATAGTATTGGTAATATATGATGAT  
25 GAG.ATAGAGATATGTTAAAACTGGCTAGAAAATTGTTTTAATTTGAAATT  
TAGGTTGTTGAATTTGAAAGATACCAAGCTAATAACTAATTAGTTATGCT  
AAATAGTTATAAAGAACAACAACTCGTAGTTTTTTTTTTCATGATTTTCA  
ACCTCTTCGTACCAAACCTAAATTATAACAAAATTGAATATCATTCTCTGC  
AATCAATTTTAACTTTTGTATTATCATCATGTCTAAAATTGCCACAAGT  
30 TTATTTTCATAGTCATATTGGATTATGAAAGGACTATTTTACCAATTAC  
ATCTTTACTTTATGGCCAAAGCTAATACAATCCGACTAAACTAAAGGATT  
CTAGGATGCATATAGTTTGCTCCCCGATTATAGATTTCTATCTAATTTGT  
CTATTGTACTAATTTAGGTGCCACCACAAGTAAATTCCTGAAATGGATGT  
CGTTAATGCCATTCTTAAACCAGTTGTCGAGACTCTCATGGTACCCGTTA  
35 AGAAACACATAGGGTACCTCATTTCTGCAGGCAATATATGAGGGAAATG  
GGT.ATCAAAATGAGGGGATTGAATGCTACAAGACTTGGTGTGCAAGAGCA  
CGTGAACCGGAACATAAGCAACCAGCTTGAGGTTCCAGCCCAAGTCAGGG  
GTTGGTTTGAAGAAGTAGGAAAGATCAATGCAAAAGTGGAATTTCCCT  
AGCGATGTTGGCAGTTGTTTCAATCTTAAGGTTAGACACGGGGTCGGAAA  
40 GAGAGCCTCCAAGATAATTGAGGACATCGACAGTGTGATGAGAGAACACT  
CTATCATCATTTTGAATGATCATTCCATTCCTTTAGGAAGAATTGATTCC  
ACG.AAAGCATCCACCTCAATACCATCAACCGATCATCATGATGAGTTCCA  
GTC.AAGAGAGCAAACCTTTCACAGAAGCACTAAACGCACTCGATCCTAACC

ACAAATCCCACATGATAGCCTTATGGGGAATGGGCGGAGTGGGGAAGACG  
ACAATGATGCATCGGCTCAAAAAGGTTGTGAAAGAAAAGAAAATGTTTAA  
TTTTATAATTGAGGCGGTTGTAGGGGAAAAAACAGACCCCATTGCTATTC  
AATCAGCTGTAGCAGATTACCTAGGTATAGAGCTCAATGAAAAAACTAAA  
5 CCAGCAAGAACTGAGAAGCTTCGGAAATGGTTTGTGGACAATTCTGGTGG  
TAAGAAGATCCTAGTCATACTCGACGATGTATGGCAGTTTGTGGATCTGA  
ATGATATTGGTTTAAGTCCTTTACCAAATCAAGGTGTGCACTTCAAGGTG  
TTGTTGACATCACGAGACAAAGATGTTTGCCTGAGATGGGAGCTGAAGT  
TAATTCAACTTTTAATGTGAAAATGTTAATAGAAACAGAAGCACAAGTT  
10 TATTCCACCAATTTATAGAAATTTCCGGATGATGTTGATCCTGAGCTCCAT  
AATATAGGAGTGAATATTGTAAGGAAGTGTGGGGGTCTACCCATTGCCAT  
AAAAACCATGGCGTGTACTCTTAGAGGAAAAAGCAAGGATGCATGGAAGA  
ATGCACTTCTTCGTTTAGAGCACTATGACATTGAAAATATTGTTAATGGA  
GTTTTTAAAATGAGTTACGACAATCTCCAAGATGAGGAGACTAAATCCAC  
15 CTTTTTGCTTTGTGGAATGTATCCCGAAGACTTTGATATTCTTACCGAGG  
AGTTGGTGAGGTATGGATGGGGGTGAAATTATTTAAAAAAGTGTATACT  
ATAGGAGAAGCAAGAACCAGGCTCAACACATGCATTGAGCGGCTCATTCA  
TACAAATTTGTTGATGGAAGTTGATGATGTTAGGTGCATCAAGATGCATG  
ATCTTGTTCTGTGCTTTTGTGTTTGGATATGTATTCTAAAGTCGAGCATGCT  
20 TCCATTGTCAACCATAGTAATACACTAGAGTGGCATGCAGATAATATGCA  
CGACTCTTGTAAGAACTTTTCAATTAACATGCAAGGGTATGTCTAAGTTTC  
CTACAGACCTGAAGTTTCCAAACCTCTCCATTTTGAACTTATGCATGAA  
GATATATCATTGAGGTTTCCCAAAAACCTTTATGAAGAAATGGAGAAGCT  
TGAGGTTATATCCTATGATAAAATGAAATATCCATTGCTTCCCTCATCAC  
25 CTCATGTTCCGTCAACCTTCGCGTGTTCATCTACATAAATGCTCGTTA  
GTGATGTTTGACTGCTCTTGATTGGAAATCTGTGCAATCTAGAAGTGCT  
TAGCTTTGCTGATTCTGCCATTGACCGGTTGCCTTCCACAATCGGAAAGT  
TGAAGAAGCTAAGGCTACTGGATTTGACGAATTGTTATGGTGTTTCGTATA  
GATAATGGTGTCTTAAAAAATTTGGTCAAACTGGAGGAGCTCTATATGAC  
30 AGTGGTTGATCGAGGTCGAAAGGCGATTAGCCTCACAGATGATAACTGCA  
AGGAGATGGCAGAGCGTTCAAAAGATATTTATGCATTAGAAGCTGAGTTC  
TTTGAAAACGATGCTCAACCAAGAATATGTCATTGAGAAGCTACAACG  
ATTCCAGATCTCAGTGGGGCGCTATTTATATGGAGATTCCATAAAGAGTA  
GGCACTCGTATGAAAACACATTGAAGTTGGTTCTTGAAAAAGGTGAATTA  
35 TTGGAAGCTCGAATGAACGAGTTGTTTAAGAAAACAGAGGTGTTATGTTT  
AAGTGTGGGAGATATGAATGATCTTGAAGATATTGAGGTAAAGTCATCCT  
CACAACTTCTTCAATCTTCTTCGTTCAACAATTTAAGAGTCCTTGTCGTT  
TCAAAGTGTGCAGAGTTGAAACACTTCTTCACACCTGGTGTTGCAACAC  
TTTAAAAAAGCTTGAGCATCTTGAAGTTTACAAATGTGATAATATGGAAG  
40 AACTCATACGTAGCAGGGGTAGTGAAGAAGAGACGATTACATCCCCAAG  
CTGAAGTTTTTATCTTTGTGTGGGCTACCAAAGCTATCGGGTTTGTGCGA  
TAATGTCAAAATAATTGAGCTACCACAACCTCATGGAGTTGGAAGTTGACG  
ACATTCCAGGTTTCACAAGCATATATCCCATGAAAAAGTTTGAAACATTT



AGTTTGTGAAGGAAGAGGTAATATAAAATTTTAAATGCTAATACATTAC  
AAAGGATCTTTTCAGTTAAATCTTTCAAAATATATTGTAATTTGATTGTA  
TGGGGTATTATTGTTGGATGGGACTATTAATAAATGATTATCTTGCAGGT  
TCTGATTCTTAAGTTAGAGAACTGCATGTTAGTAGTATGTGGAATCTGA  
5 AGGAGATATGGCCTTGCGAATTTAATATGAGTGAGGAAGTTAAGTTCAGA  
GAGATTAAAGTGAGTAACTGTGATAAGCTTGTGAATTTGTTTCCGCACAA  
GCCCATATCTCTGCTGCATCATCTTGAAGAGCTTAAAGTCAAGAATTGTG  
GTTCCATTGAATCGTTATTCAACATCCATTTGGATTGTGTTGGTGCAACT  
GGAGATGAATACAACAACAGTGGTGTAAGAATTATTAAAGTGATCAGTTG  
10 TGATAAGCTTGTGAATCTCTTTCCACACAATCCCATGTCTATACTGCATC  
ATCTTGAAGAGCTTGAAGTCGAGAATTGTGGTTCCATTGAATCGTTATTC  
AACATTGACTTGGATTGTGCTGGTGCAATTGGGCAAGAAGACAACAGCAT  
CAGCTTAAGAAACATCAAAGTGGAGAATTTAGGGAAGCTAAGAGAGGTGT  
GGAGGATAAAAGGTGGAGATAACTCTCGTCCCCTTGTTTCATGGCTTTCAA  
15 TCTGTTGAAAGCATAAGGGTTACAAAATGTAAGAAGTTTAGAAATGTATT  
CACACCTACCACCACAAATTTTAATCTGGGGGCACTTTTGGAGATTTCAA  
TAGATGACTGCGGAGAAAACAGGGGAAATGACGAATCGGAAGAGAGTAGC  
CATGAGCAAGAGCAGGTAAGGATTTCAATTTCACTGTCTTAATTAATGAT  
TAAGCTCCTGCTTTTTGAATAAAAAAGGGACAAACCATTTTCATGACTTAA  
20 TGTAGCAATACAAGTCATGTATAAGAGTGACCAACTCTTTTTTATTATA  
AAATGACTACAAAATATTTTTTTTCATTAGAGATCATGTATAAATGTGAC  
TAATTTTTTCATCACCTAACTTTAGTTGATAAATCTTTATAAATGTCACTA  
GTTACTTTTCAGTAAAATAACAAATTTAATAAATTATCAACAAAAAGCAT  
CAACTAAAAAATCCCACAACCCGTAATAATTTAAAAATAAAAGGATTTAA  
25 CATCTAATACGAACAATTTTTTTTCTAAACATGATTTGGACCAAATATCA  
CCAGCAACTCAAGTTTGAATCGATTGAGCTTAAACTTGACCAGCATAA  
TTAGATAGATGAGAGTTGAAGCTAAAGTGCCTATATAAGTTTCGTTTCATC  
TTTTTTCTTGATCTTGATAGCAAGTTGAATGATTTTCTTCTTCAAAATTG  
ATAAAAATCTACATTATAAAGAGACTAGCTTGAAAAAAATGGTCTAGGT  
30 GGGTCTTGGGTTCTGGTAGATGAAGATGGAAGGGGAGAGTAGATTTCAA  
GACACAACACATCCTTCATTTTATTTATTATTATTATTATTTTGTG  
ATATCTTGCTCATATTTGTTACAGATATGTGAGGTCTATTAATCTTTTA  
AATATATAAAAAAATAAATAACATAAATGAGAAAATTAAATAAAGAATAA  
ATTAAATAAGGGCACAATAGTCTTTTTAGGTAAGACAAGGACCAAACACGC  
35 AACAAAAATAAACAGTAGGGACCATCCGATTTAAAAAAATAATTAGGGA  
CCAAAAACATAAATCCCCCAAACCATAGGGACCATTCATGTAATTTACT  
CTTACTTTTCGTTTTGTTTCATATTTGGGTAACATTTTTTTTGTACACAT  
CTAGGTAACGAACCTTGTGGAAGTGTTCCCATTTAGGATGTGACCTACTAC  
AACCGATCATAATAGTCATATGTGAACACTTCCAACAACCTTTATTACTTA  
40 GGTGTGTACAAAAAACAATAGTTACCATGATGTGAACATACTGAAAAAT  
TAATTACCTTAGCAAGTTATTTTCCCATTTAGGTTGTATGGAAACAGTTC  
CGTGAGACCGTGACTTGGATGGTAGATAAATTTAGTAACTTAACCTTC  
AATTAACCTACCTTTTTCTTATTAACCTCAATTTCAACCTAAATTCTGATT

CTTGTTTGAAAGTAAGTTGCATCTTTATTTTTGTATTATCTTGTTGCATA  
GGATCCTTAGCATCTTTTAATAATTTATTTGAAGGTGAAAGATCCAACTA  
TTTTTAATCTGTTGGCATTTCATCATTTGCAACTGTTTCTTGAAAAA  
AAATACCTAAAAATCAAAATAACCATTTTCAAATCCAAAATTATAAGAGAG  
5 AATTGTAAATGGACATGGAATCATAAATCATTAAACACAGTTCAGTAAACA  
AGTTGCTAATTACATTTCTTGCTGTGCAGATTGAAATTCTATCAGAGAAA  
GAGACATTACAAGAAGCCACTGACAGTATTTCTAATGTTGTATTCCCATC  
CTGTCTCATGCACTCTTTTCATAACCTCCAGAACTTATATTGAACAGAG  
TTAAAGGAGTGGAGGTGGTGTGTTGAGATAGAGAGTGAGAGTCCAACAAGT  
10 AGAGAATTGGTAACAACTCACCATAACCAACAACAACCTATTATACTTCC  
CAACCTCCAGGAATTGATTCTATGGAATATGGACAACATGAGTCATGTGT  
GGAAGTGCAGCAACTGGAATAAATTCTTCACTCTTCCAAAACAACAATCA  
GAATCCCCATTCCACAACCTCACAACCATAAAAAATTATGTATTGCAAAAG  
CATTAAAGTACTTGTTTTCGCCTCTCATGGCAGAACTTCTTTCCAACCTAA  
15 AGCATATCAAGATAAGAGAGTGTGATGGTATTGGAGAAGTTGTTTCAAAC  
AGAGATGATGAGGATGAAGAAATGACTACATTTACATCTACCCACACAAC  
CACCACCTTTGTTCCCTAGTCTTGATTCTCTCACTCTAAGTTTCCTGGAGA  
ATCTGAAGTGTATTGGTGGAGGTGGTGCCAAGGATGAGGGGAGCAATGAA  
ATATCTTTCAATAATACCACTGCAACTACTGCTGTTCTTGATCAATTTGA  
20 GGTATGCTTTGTACATATTCAATTATTTATTTAATTTCCCTTTTTTATTTG  
CAATATTCTATAAATAATACATTTTATACCCACTATACTAAGATAATAAT  
TACCTAGAGGGATGGATGCTATGACACAGCTGCTACACTTCAGAACTCT  
AGTAAGGGCAGTTATGGAAGTTCAATAAAATGATAATGGCATCTTTTGAT  
GGGTAATATAGGCAATTTAAGTTTATTTCTGTAAAGCAGTATTTAGCA  
25 AGTACTGGCCAGTAGGAGAGGAGAATATCACCTTTTGTGAAAATCTGGTC  
ATTGTACCCAGAATTTAGTTAAATGTAACATTTTAGATATCAGGGGTCAT  
CAGGTGACAGATATTGTAGAATAGAACAATATATAATATCACCCAAAAC  
ATTTTTTCTAAGGTTATTCTGTAAATATGTGCTTTCTTGTTTTCATNGA  
ATTNGCATTCGTATATTTTAGGTGTTAAAGTGATTTTNTCTTCAATAAAT  
30 CCCGAAATTAATTAAAAAAAAAAAAAACAAAAGTACATTTTGATGTGGAG  
AGCACTGGTATCACTTAGTATATAAAAAGCTTGATTTTGAATTAACCTTC  
TTATACAAAAGTTGTGTATATAGTTTAATTAGTTTTACATCATTTTTCCA  
TGTGGTGTGTCAGTTGTCTGAAGCAGGTGGTGTCTTGAGGCTTATGCC  
AATACGCTAGAGAGATGAGAATAGAATTCTGCAATGCATTGTCAAGTGTA  
35 ATTCCATGTTATGCAGCAGGACAAATGCAAAAGCTTCAAGTGCTGACAGT  
AAGTGATTGCAAAGGGATGAAGGAGGTATTTGAACTCAATTAAGGAGGA  
GCAGCAACAAAAACAACAAGAGTGGTGCAGGTGAGGAAGGAATTCCAAGA  
GTAAATAACAATGTTATTATGCTTTCTGGTCTGAAGATATTGGAAATCAG  
CTTTTGTGGGGGTTTGGAACATATATTCACATTCTCTGCACTTGAAAGCC  
40 TGAGACAGCTCCAAGAGTTAAAGATAACATTTTGCTACGGAATGAAAGTG  
ATTGTGAAGAAGGAAGAAGATGAATATGGAGAGCAGTAAACAACAACAAC  
AACACAATAACGAAGGGGGCATCATCATCATCTTCTTCATCTTCTA  
AGGAGGTTGTGGTCTTTCCTCGTCTCAAATCCATTGAACTAAATGATGTA

CCAGAGCTGGTAGGATTCTTCTTGGGGAAGAATGAGTTCCGGTTGCCTTC  
ATTGGAAGAAGTTACCATCAAGTATTGCTCAAAAATGATGGTGTTCAG  
CTGGTGGGTCCACAGCTCCCCAACTCAAGTATATACACACAGAATTAGGC  
AGACATGCTCTTGATCAAGAATCTGGCCTTAACTTTCATCAGGTATATAT  
5 ATTTCTTTAATTGGCATCATCTAATTAAGAAAGATATCATTCCCTGCCAAG  
TAAATTTACTTCAAACACATTACACTGGTTTCAGTCTAAGTTTATGTTG  
TTCTAGGAAGGCCAAAATGGGAAAGCAAGATAGGGAAAAATAGTGTATTT  
CAGTGGAAAGGGTATTTTAGGTATTTTCTGTCAAAAGTTGTTATTGCAGG  
CTTTTTAGTACCTGGAATCGTGTGTGGGAGGAGCATTATTATTCTGATTT  
10 GCTTGTTTCTTTATCATTTTTTCTTAGCCTCTGGAACAGCTAGAAACCCT  
TTTAACTTTTGATTTTCAATGACAAAATTTTCCCTGTTACTACATTTGA  
TTGTTGTTCTTCATGGTTCTAAGTGAGTTATTGGCTCATCTGTTACTTCT  
TTTGATTGTTATTTTCATATCATGTTAGTCACTTGAATCAAGCTTTTCTA  
TTTTCAACCAGGGCAAAAGGTCAAAAGTAACCTACTTTATGAGATCAAAA  
15 ACAGCAACCCATCGGATAACTTTTAGTTGGAGTTAATAGTTACAATTACC  
ATTGTGATTAATAATTATAATATCTTGTATTAATTCATAAAAATTGGTAC  
AGCACATATATGACATTTCAAAGGTTTTTGTGTTGACATATATATGCCTCT  
GGCGTTTTCTTTATTGGACATGCAGACCTCATTCCAAAGTTTATACGGTG  
ACACCTTGGGCCCTGTAACCTCAGAAGGGACAACCTGTTCTTTTCATAAC  
20 TTGATCGAATTATATATGGAATTTAATGATGCTGTTAAAAAGATTATTCC  
ATCCAGTGAGTTGCTGCAACTGCAAAAGCTGGAAAAGATTCATGTGACTT  
ATTGTAATTGGGTAGAGGAGGTATTTGAAACTGCATTGGAAGCAGCAGGG  
AGAAATGGAAATAGTGGAATTGGTTTTGATGAATCGTCACAAACAACCTAC  
CACTACTCTTGTCAATCTTCCAAACCTCAGAGAAATGAAGTTATGGTATC  
25 TAAATTGTCTGAGGTATATATGGAAGAGCAATCAGTGGACAGCATTTGAG  
TTTCCAAACCTAACAAGAGTCGATATATGGGGATGTGATAGGTTAGAACA  
TGTATTTACTAGTTCCATGGTTGGTAGTCTATTGCAACTCCAAGAGCTAC  
GCATATGGAAGTGCAGTCAGATAGAGGTCGTGATTGTTTCAGGATGCAGAT  
GTTTGTGTAGAAGAAGACAAAGAGAAAGAAATCTGATGGCAAGACGAATAA  
30 GGAGATACTTGTGTTACCTCGTCTAAAGTCCTTGATATTAAACACCTTC  
CAWGTCTTAAGGGGTTTAGCTTGGGGAAGGAGGATTTTTCATTCCCATTA  
TTGGATACYTTGGAAATCTACRAATGCCCAGCAATAACCACCTTCACCAA  
GGGAAATTCCRCTACTCCACAGCTAAAAGAAATTGAAACAMATTTTGGCT  
TCTTTTATGCTGCAGGGGAAAAAGACATCAACTCCTCTATTATAAAGATC  
35 AAACAACAGGTAAACCAGATCTTTGTTGCTTNNATAATTCTTAAACNACA  
TNTGAAAAGCTTCATGCAAGTTTTTTTNGTTATATNGTCAAAAACCGCAA  
CCTACATTTTCAGCTTTANATTTATGTACTTTATGCAGGATTTCAAACAA  
GACTCTGATTAATGTGAAGTGAATATTAAGGTAAATTATATTTTCATGT  
TCCTAGTNGCCTATTAATTAAGGCCTTTTAGTTCGNGATTTTGGATGT  
40 ATTCTTCATGATGATGTCAATCTTCTAATACCCCATTCATTGTTTGGTTG  
AATGTTGACTCTATGTCAGGATGAATATTCAAGGGAAGAATTGTTTCATCA  
TATGAAGGACATTAAAGAACATGGATGCTCTGAAGATGTTGGGAACACA

**RG2A deduced polypeptide sequence (SEQ ID NO:88)**

MDVVNAILKPVVETLMVPVKKHIGYLISCRQYMREMGIKMRGLNATRLGVEEHVN  
RNISNQLEVPAQVRGWFEVVGKINAKVENFPSDVGSCFNLKVRHGVGKRASKIIEDI  
DSVMREHSIIIWNDHSIPLGRIDSTKASTSIPSTDHHDEFQSREQTFTEALNALDPNHK  
5 SHMIALWGMGGVGKTTMMHRLKKVVEKKMFNFIEAVVGEKTDPIAIQSAVADY  
LGIELNEKTKPARTEKLRKWFVDNSGGKKILVILDDVWQFVDLNDIGLSPLNQGV  
DFKVLLTSRDKDVCTEMGAEVNSTFNVKMLIETEAQSLFHQFIEISDDVDPELHNIG  
VNIVRKCGGLPIAKTMACTLRGKSKDAWKNAALLRLEHYDIENIVNGVFKMSYDNL  
QDEETKSTFLLCGMYPEDFDILTEELVRYGWGLKLFKKVYTIGEARTRLNTCIERLI  
10 HTNLLMEVDDVRCIKMHDLVRAFLDMYSKVEHASIVNHSNTLEWHADNMHDSC  
KRLSLTCKGMSKFPTDLKFPNLSILKLMHEDISLRFKPNFYEEMEKLVISYDKMKY  
PLLPSQPQCSVNLRVFHLHKCSLVMFDCSCIGNLSNLEVLSFADSAIDRLPSTIGKLG  
KLRLDLTLNCGYVRIDNGVLKLVKLEELYMTVVDRGRKAISLTDDNCKEMAERS  
KDIYALELEFFENDAQPKNMSFEKLQRFQISVGRYLYGDSIKSRHSYENTLKLVLK  
15 GELLEARMNELFKKTEVLCLSVGDMNDLEDIEVKSSSQLQSSSFNNLRVLVVSCK  
AELKHFFTPGVANTLKKLEHLEVYKCDNMEELIRSRGSEETITFPKLKFLSLCGLP  
KLSGLCDNVKIIELPQLMELELDDIPGFTSIYPMKKFETFSLKEEVLIPKLEKLHVSS  
MWNLKEIWPCEFNMSSEVKFREIKVSNCDKLVNLFPHKPISLLHHLEELKVKNCGSI  
ESLFNIHLDCVGATGDEYNNSGVRIIKVISCDKLVNLFPHNPMSILHHLEEELEVEN  
20 GSIESLFNIDLDCAGAIGQEDNSISLRNIKVENLGKLREVWRIKGGDNSRPLVHGFQS  
VESIRVTKCKKFRNVFTPTTTNFNLGALLEISIDDCGENRGNDESEESSHEQEIEILS  
EKETLQEATDSISNVVFPSCLMHSFHNLQKLILNRVKGVVFEIESESPTSRELVT  
HHNQQPILPNLQELILWNMDNMSSHVWKCSNWNKFFTLPKQQSES PFHNLTTKI  
MYCKSIKYLFSPLMAELLSNLKHIKIRECDGIGEVVSNRDEDEEMTTFTSTHTTTT  
25 LFPSLDSLTLFLENLKCIGGGGAKDEGSNEISFNNTTATTAVLDQFELSEAGGVSW  
SLCQYAREMRIEFCNALSSVIPCYAAGQMQLQVLTVSDCKGMKEVFETQLRRSSN  
KNNKSGAGEEGIPRVNNNVIMLSGLKILEISFCGGLEHIFTFSALESRLQELKITFC  
YGMKVIVKKEEDEYGEQ.TTTTTTTITKGASSSSSSSSKEVVVFPRLKSIELNDVPELV  
GFFLGKNEFRLPSLEEVTIKYCSKMMVFAAGGSTAPQLKYIHTELGRHALDQESGL  
30 NFHQTSFQSLYGDTLGPVTSEGTTCFHNLIELYMEFNDAVKKIIPSELLQLQKLEK  
IHVTYCNWVEEVFETALEAAGRNGNSGIGFDESSQTTTTLVNLPNLREMKLWYL  
NCLRYIWKSNQWTAFFPNLTRVDIWGCDRLEHVFTSSMVGSLQLQELRIWNCSQ  
IEVVTVQDADVCVEEDKEKESDGKTNKEILVLPRLKSLILKHLPCLGFSLGKEDFSF  
PLDITLEIYKCPAITTFTKGNSTTPQLKEIETHFGFFYAAGEKDINSSIIKIKQQDFKQ  
35 DSD.CEVNIK

**RG2B polynucleotide sequence (SEQ ID NO:89)**

TTTTTTAAGATCAGGGATTCAAATTCAGCCCTAGTGATTACAATTGTGTC  
TAAACTTTCCCATACCTTCACATTATTGTAAGTATACTTTCTCAGTTTCT  
40 CTCTTGGAAGCTTCCTTGGTATTTAACTCGTGTTCTAATATTAACTCT  
GATAGTTATTTTGGCCAATCTACTATCTGCATGTCCGGTTATTGAATCCG  
AAGGCACTGGAATCTTGGATTCCATTCCGTTGTGTGTTGGTTGCCAAAT

GAACGGAATTGAATTATGTAAGATTCCCTTCAAAAATCCATGTTTAGGTATA  
TCGTTGTTTCTTGGGATGGATGGTAAAGAACGGAATTTCTCCTGTTCAATT  
TTTTAATGAAAGACCAAATTGACCTTATAAACCTGTTAAAAAAATTACAT  
TCCAGTTTCTTAACAAACTGAAAATGGTAAAGGAGTGTGATTGAATTCC  
5 AATCTGTTTCCTGTCCAAAACACGTGACGGAATATTACAATTCCTTCAAA  
TTTCATTTTCTTAAATTGTTATTCCCTTTCTTACAAAAACAAGGTAAACG  
AAACACCCGCTTACTTAATCATACTCCTACATGATGTAAATGAAAAGGGT  
ATAAATGGTATTTTATTACAGGGATGAGTCACCATGGTCATGAAAGAAT  
CATTAACCGCCCTTACCCAATTCATGTTTGCCCTAAAATATGATTTAAA  
10 GTAATATTGGCTTATGGGATTCAAGTTGACTTTTTTGTGGCGAAGAAATA  
ATGAAAATCTTCATTTCTAAAGTGCTTCTACCACTGACATTTTCTAAGA  
AAGAACTTGCTAGAAGAAGGTGGGTGTTTAGTCTTTTACTCTTTAAAT  
GTGAAGACTGTTGAGTTATTATTATTATTTTGCCAACTATGGACAACCTG  
TTTAGTTTTTTTTTTTCCCAATATCCATTTATATGCGATTTATTTCTGA  
15 AATAATTTTATCAAAACGCAGGAAACAATGTAGAATAATACTGGTATAAT  
TAATTATATAAAGTTATTAGGCTGAAATCTTGAGGCTACTATAATTTAAT  
TATCATAATTTGAAAATCATCAAATTGTATTCCATGTATATTTATGTTAT  
CAGATAATTAATAATATGTGAGCCACACAAATCCACATCATCAGACACCC  
CACCTTATTGTGCGCTACCTCACCACTTGATGATCCCGACATCTTCCCA  
20 ACCCCACCGACGACTTGGGGTCTCCTTAATATATCAATTATTTTCTGTAA  
GTATTTATTGTGTAAATGTGTAATGTCATTTTACCTTTTTTCTAATATA  
TACAGAAACATAAATTTTAAATGAAATTCAACTGCGTTTCATTCTTGAT  
TAA.AAAAAAAGACTGTACTGTTGTCAATATTTTACTTATAACCTGATTAA  
TTA.ATTAAAGCGTAATTGCATAATTTGCATTAGGTTGTAATTTTGTGTTT  
25 TATAGGGAGGGTGAGGGTCACCGGAATCAAAGCACTTATGTAAAAGCAG  
GGAAATACAAAAAATTTACTCGAAACAAATTTTATTCAATTTAAGTGAGA  
TAATAATGTTCTGATTAGATTATGAGAACTAGGAGATTTAAGTGATATAT  
CCC.ATTTAAAAGAAATTGCATTATTAATTTTGGATCTCTTGATGATGACA  
AAATTAACCTCGTGACAGGTTATATATCATATACAAAATGAGTGGCTATGC  
30 TTTCGCTTTCCAAAAAGCAATTATAGTTATACTACACCTACAAATTTTAA  
AAGGGGTAAACATATCAAAATACTTGATAAGTAATTATATAAATATGCA  
TTT.AACCCTCTAAAGAAAATGCTACTAAGCTTGGACCATCTCAGAATTAC  
AATCATACCCTTCCCCTCAAAAAAGATTTCGTATATATCATGTCATTTGGC  
ATTCATTTCTTTTTTACAAATTCATAGTTCTATTCTCAAAAAATTCGAGTT  
35 CTCGTATTTGTAAGGAAGATCAGAAGAGACTGTTACACAGGTAATCTCT  
TTT.ATTTATTGATTCACATTCATATATGTTATTGTTTTCTTGCTTAATGG  
TTTCGTCACTTAACTGCGCTTGCTGATTTAAATTTCTTCACTTTCTTCC  
ACGGATTTTTTAAATATTAGTTTTGTGAATGAACAATTGGTGAAGGAAAG  
AAACATGGGAGTCTTTTCTAAAGTAAACCTAGATACTTAGGTTATAAGGG  
40 TATATGCTAAATGAACTATGCCATTACCTTTGCCTTTTCTTTTACTT  
TTTAGTTTTTAGAATCCAAGTTTTTCATATGTATCTCGATGTGTGAGAAGA  
ATAGGCATTAGAAAGGTAAAGGACGTACATAAAATTGATTAATTAGTGAA  
TGTTCTTTGATATCATTATTTTACTCTCATAAAAAGCATATAGATCAAA

CACAAATTGCTACTTGTTAGTGTAACAACTTCGACTTAATAATGTTAATA  
ATC.AAGATTCTCTTGATTTCAACTATTTTCTAACCGAACAAGCTCACTAA  
AAACTCATATTGCTTTGAGTCTGAGTGGTTTATATTTGGGGTTTTACATT  
TAATTTTTTGTGCATGAATGTGAAAATAGACTGCTTATTGATTCTTTGTG  
5 TTTCATTGAGTTGATTTTCATTATTACTACCTTACAAATTGCTCAGTGAT  
AGATTTCCATTAATTTGCTAATTCGGTTGCTTCTAAATATGTAGGAGCTA  
CTAAAGCAAAAATATCGAGCAATGTCGGACCCAACGGGGATTGCTGGTG  
CCATTATTAACCCAATTGCTCAGACGGCCTTGGTTCCCGTTACGGACCAT  
GTAGGCTACATGATTTCCCTGCAGAAAATATGTGAGGGTCATGCAGATGAA  
10 AATGACAGAGTTGAATACCTCAAGAATCAGTGTAGAGGAACACATTAGCC  
GGAACACAAGAAATCATCTTCAGATTCCATCTCAAATAAGGAATGGTTG  
GACCAAGTAGAAGGGATCAGAGCAAATGTGGAATACTTTCCGATTGATGT  
CATCACTTGTTGTAGTCTCAGGATCAGGCACAAGCTTGGACAGAAAGCCT  
TCAAGATAACTGAGCAGATTGAAAGTCTAACGAGACAACTCTCCCTGATC  
15 AGTTGGACTGATGATCCAGTTCCTCTAGGAAGAGTTGGTTCCATGAATGC  
ATCCACCTCTGCATCATTAAAGTGATGATTTCCCATCAAGAGAGAAAACCT  
TTACACAAGCACTAAAAGCACTCGAACCCAACCAAAAATTCCACATGGTA  
GCCTTGTTGGGATGGGTGGAGTGGGGAAGACTAGAATGATGCAAAGGCT  
GAAGAAGGCTGCTGAAGAAAAGAAATTGTTTAATTATATTGTTGGGGCAG  
20 TTATAGGGGAAAAGACGGACCCCTTTGCCATTCAAGAAGCTATAGCAGAT  
TACCTCGGTATACAACCTCAATGAAAAAACTAAGCCAGCAAGAGCTGATAA  
GCTTCGTGAATGGTTCAAAAAGAATTCAGATGGAGGTAAGACTAAGTTCC  
TCATAGTACTTGACGATGTTTGGCAATTAGTTGATCTTGAAGATATTGGG  
TTAAGTCCTTTTCCAAATCAAGGTGTCGACTTCAAGGTCTTGTTGACATC  
25 ACGAGACTCACAAGTTTGCATATGATGGGGGTTGAAGCTAATTCAATTA  
TTAACGTGGGCCTTCTAACTGAAGCAGAAGCTCAAAGTCTGTTCCAACAA  
TTTGTAGAACTTCTGAGCCCGAGCTCCAGAAGATAGGAGAGGATATCGT  
AAGGAAGTGTTGCGGTCTACCTATTGCCATAAAAACCATGGCATGTACTC  
TTAGAAATAAAAAGAAAGGATGCATGGAAGGATGCACTTTCGCGCATAGAG  
30 CACTATGACATTCACAATGTTGCGCCCAAAGTCTTTGAAACGAGCTACCA  
CAATCTCCAAGAAGAGGAGACTAAATCCACTTTTTTAATGTGTGGTTGT  
TTCCCGAAGACTTCGATATTCTACTGAGGAGTTGATGAGGTATGGATGG  
GGCTTGAAGCTATTTGATAGAGTTTATACGATTAGAGAAGCAAGAACCAG  
GCTCAACACCTGCATTGAGCGACTGGTGCAGACAAATTTGTTAATTGAAA  
35 GTG.ATGATGTTGGGTGTGTCAAGATGCATGATCTGGTCCGTGCTTTTGT  
TTGGGTATGTTTTCTGAAGTCGAGCATGCTTCTATTGTCAACCATGGTAA  
TATGCCTGGGTGGCCTGATGAAAATGATATGATCGTGCACTCTTGCAAAA  
GAATTTTCATTAACATGCAAGGGTATGATTGAGATTCCAGTAGACCTCAAG  
TTTCCTAAACTAACGATTTTGAAACTTATGCATGGAGATAAGTCGCTAAG  
40 GTTTCCTCAAGACTTTTATGAAGGAATGGAAAAGCTCCATGTTATATCAT  
ACGATAAAAATGAAGTACCCATTGCTTCCTTTGGCACCTCGATGCTCCACC  
AACATTGCGGTGCTTCATCTCACTGAATGTTCAATTAAGATGTTTGATTG  
CTCTTCTATCGGAAATCTATCGAATCTGGAAGTGCTGAGCTTTGCAAATT

CTCACATTGAATGGTTACCTTCCACAGTCAGAAATTTAAAGAAGCTAAGG  
TTACTTGATCTGAGATTTTGTGATGGTCTCCGTATAGAACAGGGTGTCTT  
GAAAAGTTTTGTCAAACCTGAAGAATTTTATATTGGAGATGCATCTGGGT  
TTATAGATGATAACTGCAATGAGATGGCAGAGCGTCTTACAACCTTTCT  
5 GCATTAGAATTCGCGTTCTTTAATAACAAGGCTGAAGTGAAAAATATGTC  
ATTTGAGAATCTTGAACGATTCAAGATCTCAGTGGGATGCTCTTTTGATG  
AAAATATCAATATGAGTAGCCACTCATACGAAAACATGTTGCAATTGGTG  
ACC.AACAAAGGTGATGTATTAGACTCTAACTTAATGGGTTATTTTTGAA  
AACAGAGGTGCTTTTTTTAAGTGTGCATGGCATGAATGATCTTGAAGATG  
10 TTGAGGTGAAGTCGACACATCCTACTCAGTCCTCTTCATTCTGCAATTTA  
AAAGTTCCTATTATTTCAAAGTGTGTAGAGTTGAGATACCTTTTCAAAC  
CAATCTTGCAAACACTTTGTCAAGACTTGAGCATCTAGAAGTTTGTGAAT  
GTG.AGAATATGGAAGAACTCATACATACTGGAATTGGGGGTGTGGAGAA  
GAGACAATTACTTTCCCTAAGCTGAAGTTTTTATCTTTGAGTCAACTACC  
15 GAAGTTATCAAGTTTGTGCCATAATGTCAACATAATTGGGCTACCACATC  
TCGTAGACTTGATACTTAAGGGCATTCCAGGTTTCACAGTCATTTATCCG  
CAGAACAAGTTGCGAACATCTAGTTTGTGAAGGAAGGGGTAGATATATG  
TTCTTTATGTTAATAACAATTTAAATATATTTTCAACCAAATTTTCATAA  
TATATCTGTAATTTGATTGTATGATGTGTTATTGTTTATATGTGGCTATT  
20 AAGGGATGATTATTTTGCAGGTTGTGATTCCTAAGTTGGAGACACTTCAA  
ATTGATGACATGGAGAACTTAGAAGAAATATGGCCTTGTGAACTTAGTGG  
AGGTGAGAAAGTTAAGTTGAGAGCGATTAAAGTGAGTAGCTGTGATAAGC  
TTGTGAATCTATTTCCGCGCAATCCCATGTCTCTGTTGCATCATCTTGAA  
GAGCTTACAGTCGAGAATTGCGGTTCCATTGAGTCGTTATTCAACATTGA  
25 CTTGGATTGTGTCGGTGCAATTGGAGAAGAAGACAACAAGAGCCTCTTAA  
GAAGCATCAACGTGGAGAATTTAGGGAAGCTAAGAGAGGTGTGGAGGATA  
AAAGGTGCAGATAACTCTCATCTCATCAACGGTTTTCAAGCTGTTGAAAG  
CAT.AAAGATTGAAAAATGTAAGAGGTTTAGAAATATATTCACACCTATCA  
CCGCCAATTTTTATCTGGTGGCACTTTTGGAGATTCAGATAGAAGGTTGC  
30 GGAGGAAATCACGAATCAGAAGAGCAGGTAACGCTTTCAATTTCACTTTC  
TTA.ATTAATTAAGGACTAAGCTCCTGTTTTTTGAATAATAAAGAGGTGGG  
ATG.ACTAAACTTGGGCATCACAATTGCAACAAAATGTTACAAACCATGAA  
ACGTTCAAACCATTTCTTGAATTAAGGTTTCAATACAAGTCATTTAAAAA  
TATGGCTTAAATTTTTTTTATATTTATGTATCAACATGATTTTTTCATTAG  
35 AGATCATTATTATAATAGTAAGTTTAAAGCAATTTAAATCAGAACTAATT  
CTAACTTTAGCTAATAAATCGTTATAAATGTAAATAATTACTTTTTAGTG  
AAATAAGCAACGGATTTAATAAGTTAACAACCTTAAATGTCATTTCCCTAAC  
AAAAAAAACCTATTTGGTTCAGAAAAACCGTAATTCAAGATAACTAAAATA  
AAAATATTTGACATTCCTAAGAGCATTTTTTTTTCTAAATATGATTGCA  
40 AATGAATAAAACTTAAATTTATACAGAAAATCTTTTATATATGTTATAC  
AAAATTTACAAATTGAAATTGGATATGTTAATTAACGGTTTATAATTCTG  
GTATCACAAAGGGATATATAATAAAATATTATTTCTGTAGTCATTTGTA  
ATTGTACTAGTTTATAACCCGTGGGAACCATGAGTTCTAAAATTAGTTAA

[illegible]



TNGCCACAATTCTTTGKTTACTTGWGACACTTYCCTCTCTCTAATTATATA  
TATATATATATATATATATATATATATATACACACACACACACACACTAG  
ATGTGTGCCCCGCGCAAAGCAGTGACGTNNNGGAGAANACTTTCTTAAGCA  
TAAATAATTATTATATTTTTTTATTGGGTATTATATAATAAAAAATTACAA  
5 CTTTAAATAAAATATTTATGTTTATACTTTATATTTATATTGCTTGTAT  
ACTATTAATATAATAAATTAATATTTATGTCTAATTTATGAAATGTAAAT  
TAATTTAAATACATGAATTTAATATTTTTTAAAATTTTCAGTTTGCTTCAA  
ATTGAGTTTCTTAATTATTTTTTTTTTAAATTCANGTATTCAAACCTTTTGGTA  
AGTATTAAGAATTATTTATGCATAATTGATTTATACAAAAAATTTGTA  
10 ACTTATACATCTTAAATTCAGATATACTAACATGTTTACAATATAT  
AT  
TAAAGCGCAAAGGTCATAGGAATAGAATATTTTCTATTATTCTACGTTTT  
GCCACAAAAGTTTGAACACTTTGCCACTTTTTGTCCCTCCTTAACCTTTT  
CAATGTTTTGCGACAAAAGTTCCAAAACCTTTGCCACTTTGATCATTCCTC  
15 AACTTTTCACCGCAATTAGTTTGTGGAGTTGGCAGTTTTGATCCCCCTAA  
CTTCGATATTCTCTACTGCTAGCCAAAAAGGGTCCAGAGTTTCACACTT  
TTGGTCCCTGACAGTAACCAAATGTGAGATGTCAAATTTTTGCCACATTA  
GTTTGTGGAGTTGTCCCTTTTGGTCCCCCACCATTTCGATATTCTANTATA  
CGACCTTATTTTTNTCAAATAACAACACGTATATTTAATTACCAATTATA  
20 GAAATAGATATCAAATAAAGTATTTGTAACTGTGTAAGAACGGTGCTA  
CTATAGGTAAAAATAAACATTTCAAAGTACGATATCCTAATTGAAAAAAG  
AGTTTTAAAAAATAACGACTAGGGGCGAGTTTTTTTTACAAGTTTGTAT  
CAAATCATATCAAATTTAAGGTGGAACGGTGACCACATTAACCAGAAAT  
GTAATTTATTCTTTGATTTTGATAATTTTTAATATTTTGTGTGATCTAT  
25 GTATTTAAAGTAAACAACAAGAACATAATCCAAAACCCTAAATTGCAA  
GTCTCGCCCAATTTCTCTATCACTAGTCCCTCACTTACGATGGCGTTACGT  
CGCTCTCTCACTGCTTACAACCCTTTGTTGCTACTCATTACAATAACGAA  
AAGTTGAATATCCATATATTTATTTGGATGTGGAATTGAACGAATCTCGT  
CAAATTTTGTATTTTGTGATGGATTTGAGTAGAAGTTTGGGCAGAACGG  
30 GAATGATGGTCTGCAAGTGTTTATAAATCTGATTCTGAGTTATTACTATA  
TATGTAGCCTCTTTACAACGACCAAGGTTTCTTCCAGGTACCATTTGATC  
TTTTTAGAACTTAGTTTTCTGAAACACCCTGATTTGGATCAAATATCACC  
AACAACTCTTAAAAACTTGATTAATCAATTGTTTTCTTCATCTTGATAAC  
AAGTGGAATGATTTTCTACTTAGATTAACCTGAAAAAAGGTCCATGTG  
35 CGTCTGGTGGATCTGGTAAATGAAGATGGAAGGGAGAGCTGACTTTAAAG  
ACACAAACACGTCACCATATCTCTTATTTTATTTTAAATTTGCTTTTGGT  
GTATTTTCTTTTTTCTTATTTCTTTCTTTGATCTCCAGATGGTATGT  
GGTGTGGATAATTTACACCTAGAGATTGGGAACGATGGGAAGGGGTCTGT  
GATTTATGGCTGGCCGAGTTTTACTTATTAATCAATTTCAACCTAAAT  
40 CTGATTCTTGTGTTGAAAATAAGTTGCATCTTTATTTTTGTATTATCTTGT  
TGCATAGGATCCTTAGCATCTTTAATAATTTATTTGAAGGTGAAAGATC  
CAACTATTTTTTAGCTGTTGGCATTTTCCATCATTTGCAACTGTTTCTTG  
AAAAAAAATACCTAAAATAAAAAATAACCATTTTCAAATCCAAAATTATA

[illegible]

CAGGTATATATATATTTCTTTAATTGGCATCATCTAATTAAGAAAGATAT  
CATTCCTGCCAAGTAAATTTACTTCAAACACATTCACTGGTTTCAGTC  
TAAGTTTATGTTGTTCTAAGAAGGCCAAAATGGGAAAGCAAGATAGGGAA  
AAATAGTGTATTTCAAGTGGAAAGGGTATTTAGGCATTTTCTGTCAAAAG  
5 TTGTTATTGCAGGCTTTTTAGTACCTGGAATCGTGTGTGGGAGGAGCATT  
ATT.ATTCTGATTTGCTTGTTTCTTTATCATTTTTTCTTAGCCTCTCGAAC  
AGCTAGAAACCCTTTTAATCTTTTGATTTTCAATGACGAAATTTTCCCT  
GTTACTCCATTTGATTGTTGTTCTTCATGGTTCTAAGTGAGTTATTGGCT  
CATCTGTTACTTCTTTTGATTGTTATTTTCATATCATGTTGTCCTTTGAA  
10 TCAAGCTTTTCCATTTTCAACCAGGGCAAAAGGTCAAAAGTAACCTACTT  
TATGAGATCAAAAACAGCAACCCATCGGATAACTTTTAGTTGGAGTTAAT  
AGTTACAATTACCATTGTGATTAATAATTATAATATCTTGTATTAATTCA  
TAAAAATTGGTACAGCACATATATGACATTTCAAAGGTTTTTGTGTTGACA  
TAT.ATATGCCTCTGGCGTTTTCTTTATTGGACTTGCAGACCTCATTCCAA  
15 AGTTTATACGGTGACACCTTGGGCCCTGCTACTTCAGAAGGGACAACCTG  
GTCTTTTCATAACTTTATCGAATTAGATGTGGAAGGTAATCATGATGTTA  
AAAAGATTATTCCATCCAGTGAGTTGCTGCAACTGCAAAAGCTGGAAAAG  
ATT.AATGTAAGGTGGTGTAAGGGGTAGAGGAGGTATTTGAACTGCATT  
GGAAGCAGCAGGGAGAAATGGAAATAGTGGAAATTGGTTTTGATGAATCGT  
20 CAC.AAACAACCTACCACTACTCTTGTCAATCTTCCAAACCTTAGAGAAATG  
AACTTATGGGGTCTAGATTGTCTGAGGTATATATGGAAGAGCAATCAGTG  
GACAGCATTGAGTTTCCAAACCTAACAAGAGTTGATATCTATAAATGTA  
AAAGGTTAGAACATGTATTTACTAGTTCCATGGTTGGTAGTCTATCGCAA  
CTCCAAGAGCTACATATATCCAAGTGCAGTGAGATGGAGGAGGTGATTGT  
25 TAAGGATGCAGATGATTCTGTAGAAGAAGACAAAGAGAAAGAATCTGATG  
GGGAGACGAATAAGGAGATACTTGTGTTACCTCGTCTAAACTCCTTGATA  
TTA.AGAGAACTTCCATGTCTTAAGGGGTTTAGCTTGGGGAAGGAGGATTT  
TTC.ATTCCCATTATTGGATACTTTAAGAATTGAGGAATGCCCAGCAATAA  
CCACCTTCACCAAGGGAAATCCGCTACTCCACAGCTAAAAGAAATTGAA  
30 ACACATTTTGGCTCGTTTTGTGCTGCAGGGGAAAAAGACATCAACTCTCT  
TAT.AAAGATCAAACAACAGGTAAATCAGATCTTTGTTGCTTTAATAATTC  
TTAAACTACATTTGAAAAGCTTCATGCAAGTTTTTTTTTGTATATTGTCA  
AAAACCGCAACCTACATTTTCAGCTTTATATTTATGTACTTTATGCAGGA  
GTTCAAACAAGACTCTGATTAATGTGAAGTAAATACTAAAGGTAAATTAT  
35 ATTTTCATGTTTCTAGTTGCCTATTAATTAATTGCCTTTTAGTTCATGAT  
TTTTGGATGCATTCTTCATGATGATGTCAATCTTCTAATACCCCATTCAT  
TGTTTTGGTTGAATGTTGACTCTATGTCTTGATGAATATTCAAGGGAAGAA  
TTGTTTCATCATATGAAGGACATTAAAGAAGAACATGGATGCTATGAAGAT  
GTGGGAAAACAA  
40

## RG2B deduced polypeptide sequence (SEQ ID NO:90)

MSDPTGIAGAIINPIAQTALVPVTDHVGYMISCRKYVRVMQMKMTELNTSRISVEE  
HISRNTRNHLQIPSQTKEWLDQVEGIRANVENFPIDVITCCSLRIRHKLQKAFKITE  
QIESLTRQSLISWTDDPVPLGRVGSMNASTSASLSDDFPSREKTFTQALKALEPNQK  
5 FHMVALCGMGGVGKTRMMQRLKKAEEKKLFNYIVGAVIGEKTDPFAIQEAIADY  
LGIQLNEKTKPARADKLREWFKKNSDGGKTKFLIVLDDVWQLVDLEDIGLSPFPNQ  
GVDFKVL LTSRDSQVCTMMGVEANSIINVGLLTEAEAQSLFQQFVETSEPELQKIGE  
DIVRKCCGLPIAKTMACTLRNKRKDAWKDALSRIEHYDIHNVAPKVFETSYHNLQ  
EEETKSTFLMCGLPEDFDIPTEELMRYGWGLKLFDRVYTIREARLNTCIERLVQ  
10 TNLLIESDDVGCVMHDLVRAFVLGMFSEVEHASIVNHGNMPGWPDENDMIVHSC  
KRISLTCKGMIEIPVDLKFPKL TILKLMHGDKSLRFPQDFYEGMEKLHVISYDKMKY  
PLLPLAPRCSTNIRVLHLTECSLKMFDCCSIGNLSNLEVLSFANSHIEWLPSTVRNLK  
KLRLDLRFCDGLRIEQGVLSFVKLEEFYIGDASGFIDDNCNEMAERSYNLSALEF  
AFFNKAAEVKNMSFENLERFKISVGCSDENINMSSHSEYENMLQLVTNKGDVLDK  
15 LNGLFLKTEVFLSVHGMNDLEDVEVKSTHPTQSSSFCNLKVLISKVELRYLFLK  
NLANTLSRLEHLEVCECENMEELIHTGIGGCGEETITFPKLKFLSLSQLPKLSSLCHN  
VNIIGLPHLVDLILKGIPGFTVIYPQNKLR TSSLLKEGVVIPKLET LQIDDMENLEEIW  
PCELSGGEKVKLRAIKVSSCDKLVNLFPRNPMSLLHHLEELTVENCGSIESLFNIDLD  
CVGAIGEEDNKSLLRSINVENLGKLRVWRIKGADNSHLINGFQAVESIKIECKRFR  
20 NIFTPITANFYLVALLEIQIEGCGGNHESEEQIEILSEKETLQEATGSISNLVFPSCLMH  
SFHNLRVLTLDNYEGVEVVFEIESESPTCRELV TTRNNQQPIILPYLQDLYLRNMD  
NTSHVWKCSNWNKFFTLPKQQSESPFHNLT TINILKCKSIKYLFSPLMAELLSNLKDI  
RISECDGIKEVVSNRDDEDEEMTTFTSTHTTTTLPFSLDSLTSFLENLKICGGGGAK  
DEGSNEISFNNTTATTAVLDQFELSEAGGVSWSLCQYAREIEIVGCYALSSVIPCYAA  
25 GQMQL

## RG2C polynucleotide sequence (SEQ ID NO:91)

ATAATATTACACAAAGGTAACGTCATTAATTAATTACGATACGAGACAGA  
CTTTTTCCTCGGACATNAACGGTCTATTCCTAACTTNANNTAATTNAAT  
30 GAATTTAGGATGTGCTAATATGCATGTAANATTCGCTACCGTCATCTTTC  
AAATGACCATATTTTTATGTATTTATAATGAATCAATGAAAAACCGGATT  
TCT.ATTTAAATTCCTTAAACTTCATCTTTTAAGCCAGGGTGAATACAAT  
TGCTAGATCCACTGTTAATTTCCATCGAATTATGCCTGATCAATTGTTGG  
CTGCCTACGATGCAGGTGCTACCACAAGAATATGGCCATGGAACTGCTA  
35 ATGAAATTATAAAACAAGTTGTTCCAGTTCTCATGGTTCCTATTAACGAT  
TACCTACGCTACCTCGTTTCCTGCAGAAAGTACATCAGTGACATGGATTT  
GAAAATGAAGGAATTAAGAAGCAAAAGACAATGTTGAAGAGCACAAAGA  
ATCATAACATTAGTAATCGTCTTGAGGTTCAGCAGCTCAAGTCCAGAGC  
TGGTTGGAAGATGTAGAAAAGATCAATGCAAAAGTGGAAGTGTTCCTAA  
40 AGATGTCGGCTGTTGCTTCAATCTAAAGATTAGGTACAGGGCCGGAAGGG  
ATGCCTTCAATATAATTGAGGAGATCGACAGTGT CATGAGACGACACTCT  
CTG.ATCACTTGGACCGATCATCCCATTCTTTGGGAAGAGTTGATTCCGT

GATGGCATCCACCTCTACGCTTCAACTGAACACAATGACTTCCAGTCAA  
GAGAGGTAAGGTTTAGTGAAGCACTCAAAGCACTTGAGGCCAACACATG  
ATAGCCTTATGTGGAATGGGGGGAGTGGGGAAGACCCACATGATGCAAAG  
GCTGAAGAAGGTTGCCAAAGAAAAGAGGAAGTTTGGTTATATCATCGAGG  
5 CGGTTATAGGGGAAATATCGGACCCCATTTGCTATTCAGCAAGTTGTAGCA  
GATTACCTATGCATAGAAGTGAAGAAAGCGATAAGAAAACAAGAGCTGA  
GAAGCTTCGTCAAGGGTTCAAGGCCAAATCAGATGGAGGTAACACTAAGT  
TCCTCATAATATTGGATGATGTCTGGCAGTCCGTTGATCTAGAAGATATT  
GGTTTAAGCCCTTCTCCAATCAAGGTGTGCGACTTCAAGGTCTTGTTGAC  
10 TTCACGAGACGAACATGTTTGCTCAGTGATGGGGGTTGAAGCTAATTCAA  
TTATTAACGTGGGACTTCTAATTGAAGCAGAAGCACAAAGATTGTTCCAG  
CAATTTGTAGAACTTCTGAGCCCCGAGCTCCACAAGATAGGAGAAGATAT  
TGTTAGGAGGTGTTGCGGTCTACCCATTGCCATCAAACCATGGCGTGTA  
CTCTAAGAAATAAAAGAAAGGATGCATGGAAGGATGCACCTTCTCGTTTA  
15 CAACACCATGACATTGGTAATGTTGCTACTGCAGTTTTTAGAACCAGCTA  
TGAGAATCTCCCGGACAAGGAGACAAAATCTGTTTTTTGATGTGTGGTT  
TGTTTCCCGAAGACTTCAATATTCCTACCGAGGAGTTGATGAGGTATGGA  
TGGGGCTTAAAGTTATTTGATAGAGTTTATACAATTATAGAAGCAAGAAA  
CAGGCTCAACACCTGCATTGACCGACTGGTGCAGACAAATTTACTAATTG  
20 GAAGTGATAATGGTGTACATGTCAAGATGCATGATCTGGTCCGTGCTTTT  
GTTTTGGGTATGTATTCTGAAGTCGAGCAAGCTTCAATTGTCAACCATGG  
TAATATGCCTGGGTGGCCTGATGAAAATGATATGATCGTGCACTCTTGCA  
AAAGAATTTCAATTAACATGCAAGGGTATGATTGAGTTTCCAGTAGACCTC  
AAGTTTCCTAAACTAACGATTTTGAACTTATGCATGGAGATAAATCGCT  
25 AAAGTTTCCTCAAGAATTTTATGAAGGAATGGAAAAGCTCCGGGTTATAT  
CATACCATAAAATGAAGTACCCATTGCTTCCTTTGGCACCTCAATGCTCC  
ACCAACATTTCGGGTGCTTCATCTCACGGAATGTTCAATTAAGATGTTTGA  
TTGCTCGTGTATTGGAAATCTATCGAATCTGGAAGTGCTGAGCTTTGCTA  
ATTCTTGCAATTGAGTGGTTACCTTCCACGGTCAGAAATTTAAAAAAGCTA  
30 AGGTTACTTGATTTGAGATTGTGTTATGGTCTCCGTATAGAACAGGGTGT  
CTTGAAAAGTTTGGTCAAACCTGAAGAATTTTATATTGGAAATGCATATG  
GGTTTATAGATGATAACTGCAAGGAGATGGCAGAGCGTTCTTACAACCTT  
TCTGCATTAGAATTCGCGTTCTTTAATAACAAGGCTGAAGTGAAAAATAT  
GTCATTTGAGAATCTTGAACGATTTAAGATCTCAGTGGGATGCTCTTTTG  
35 ATGGAAATATCAATATGAGTAGCCACTCATACGAAAACATGTTGCGATTG  
GTGACCAACAAAGGTGATGTATTAGACTCTAACTTAATGGGTTATTTTT  
GAAAACAGAGGTGCTTTTTTTAAGTGTGCATGGCATGAATGATCTTGAAG  
ATGTTGAGGTGAAGTCGACACATCCTACTCAGTCCTCTTCATTCTGCAAT  
TTAAAAGTCCTTATTATTTCAAAGTGTGTAGAGTTGAGATACCTTTTCAA  
40 ACTCAATGTTGCAACACTTTGTCAAGACTTGAGCATCTAGAAGTTTGTA  
AATGCAAGAATATGGAAGAACTCATACATACTGGGATTGGGGGTTGTGGA  
GAAGAGACAATTACTTTCCCAAGCTGAAGTTTTATCTTTGAGTCAACT  
ACCGAAGTTATCAGGTTTGTGCCATAATGTCAACATAATTGGGCTACCAC

ATCTCGTAGACTTGAACTTAAGGGCATTCCAGGTTTCACAGTCATTTAT  
CCGCAGAACAAGTTGCGAACATCTAGTTTGTGAAGGAAGAGGTAGATAT  
ATGTTCTTTATGTTAATACAATTTAAACAATATTTTCAACCAAATTTTCA  
TAATATATCTGTAATTTGATTGTATGATGTGTTATTGTTTATATGTGGCT  
5 ATTAAGGGATGATAATTTTGCAGGTTGTGATTCCTAAGTTGGAGACACTT  
CAAATTGATGACATGGAGAAGTTAGAAGAAATATGGCCTTGTGAAGTTAG  
TGGAGGTGAGAAAGTTAAGTTGAGAGAGATTAAAGTGAGTAGCTGTGATA  
AGCTTGTGAATCTATTTCCGCGCAATCCCATGTCTCTGTTGCATCATCTT  
GAAGAGCTTACAGTCGAGAATTGCGGTTCCATTGAGTCGTTATTCAACAT  
10 TGACTTGGATTGTGTCGGTGCAATTGGAGAAGAAGACAACAAGAGCCTCT  
TAAGAAGCATCAACGTGGAGAATTTAGGGAAGCTAAGAGAGGTGTGGAGG  
ATAAAAGGTGCAGATAACTCTCATCTCATCAATGGTTTTCAAGCTGTTGA  
AAGCATAAAGATTGAAAAATGTAAGAGGTTTAGAAATATATTCACACCTA  
TCACCGCCAATTTTTATCTGGTGGCACTTTTGGAGATTCAGATAGAAGGT  
15 TGCGGAGGAAATCACGAATCAGAAGAGCAGGTAACGCTTTCATTTCACT  
TTCTTAATTAATTANGGACTAAGCTCCTGTTTTTTGAATAATAAAGAGGT  
GGGATGACTAACTTGGGCATCACAATTGCAACAAAATGTTACAAACCAT  
GAAACGCTCAAACCATTTCTTGAATTAAGGTTTCAATACAAGTCATTTAA  
AAATATGGCTTAAATTTTTTTATATTTATGTATCAACATGATTTTTTCATT  
20 AGAGATCATTATTATAATAGTAAGTTTAAAGCAATTTAAATTAGAAGTAA  
TTCTAACTTTAGCTAATAAATCGTTATAAATGTAAATAATTACTTTTTAG  
TGAAATAAGCAACGGATTTAATAAGTTAACAACCTTAAATGTCATTTCCCTA  
ACAAAAAAACTATTTGGTTCAGAAAACTGTAATTCAAGATAACTAAAA  
TAAAAATATTTGACATTCCTAAGAGCATTTTTTTCTAAATATGATTGCA  
25 AATGAATAAACTTAAATTTATACAGAAAAGATTTTTATATATGTTATAC  
AAAATTTACAAATTGAAATTGGATATGTTAATTAACGGTTTATAATTCTG  
GTATCACAAGGGATATATAATAAAATATTATTTTTCTGTAGTCATTTAT  
AATTGTACTAGTTTATAACCCGTGGGAACCATGAGTTCTAAAATTAGTTA  
AACTTTCATAATAAAAAATTTATAATTATTATTTATTTTAAATAAATTATT  
30 AATTAAGAGATATATCAAAAAATTTAAAGTTATTATAACTTCAAATTTAAC  
ATATAATTAAAAAATATATGATCATAACTTTCCGCAACTCTTCTTTTGTA  
TTAAATGACCAGAGAAGCTCTTAGTATATTTTCTAAATCAAAGTCACAA  
AACTAATGAAGCATATAATTTTGTGAAAATCAATTAGCATTAGGTTTTAA  
GAGTCACCAAATTCAAAGAGTAATCCAATGCTTTTCATTACCACTATGGAG  
35 AAAATATTTTCTTAGTTTAAATGAAATGAAAACAAACATTCAAACCTAATT  
GTTGCTTATTAAACCAAAGACCCATTACTTAGCCAAGAGTTTAACCAAAA  
AAAATTACATTCATGTATCATTATTAATGACTAGATATATATGAATATGA  
AGGGAGTTTTTATAGAAAATATAATCATAGATATTCAACATAACTTCATG  
GAATTCCTCAAAATAACCAAGTTATTCAAGAAATTACATCCAAGTCAACC  
40 AAAGAGAAGTTTAGCCTAGCATGGCTAAACTCAAGAAAATAAAATAAGGA  
TTAGAAGTACCAACATGTAGTAAGAATCACAGTAAAAGATGATGTTGTT  
CTTGATGTTCTTCTAAGTTCTTCAAGTCTCCAGTTGCTCCTAATAATGCA  
AAGGAGAGCCATTAAATTCGTATGTATTGATCCCTTCAAAGCTGCACCA

ACCTCCCTTAAATAAACTCAAAGCAAAAATGACAAAATTGCCCTGAAG  
GACCCTATGCGGGTGCCTTGCGCGGGTGGAGCTGAATATGAAAGGTCTTT  
GGTCTTTGTGAGGGTGATGTTGTGCGGGTTAGCTTGTGCGCATGCTTCCGC  
GCGGTTGCGGCACATGTGCACAGGTGATGCATGGTGTGTACGTTCTTGAC  
5 TTTTGAGCCTCCGATGCTTAGTCCACTTGGCCCAATTCGAGTCCAATCAA  
CTTATGACCCATTTTTCTTCAAGTTATCTTCAAGTTAAGCCCAATTTGCC  
TTCTCCAAATCATCCATAACTTCACAGAATCGCCCGTTCATCTTAATCCC  
GAATGAACAATTATTCTCCCGTCTTCATTTTAAGCAAGATACCACCTTCT  
TCATGCTTCATCCATCAATAGTACACTTCATGTATCATCTCTACTAGTTA  
10 TTTAGTCCACAGTCCTTGTTGTCCTCCAAATTTAATTATCTCATTTAGTT  
CCCGTTCCGCTAGTTTCCTTAAAATTTGCAATTAAGCTCACAGAAATATT  
AAGTACCCGAAATGGTCATAAAAATAACAGAAAGGAAAATATGCATGAAGA  
TAACTAAATGATGAACGAAATATGCTAAAATAGACTATAAAATGAAGTA  
AATAAAATGAAATTATCGCACTCCGACCACCCTTATAGGCTTGTAGTCCA  
15 CCCACCCTTCATTCTTGTACCAATATGGGATGGAAACATCATTAAATTA  
GCCAAAAAATAACATATAAGGGGTGAGTGACAAAGGTAAGTACTAAAGA  
TGAAAAAAATCCATTTTTCTTGTATATACACAACACACACATAGGGGCAG  
ACGTAGGATTTTCATAGTACAGATTGTTGGTGGCACATAAGTGTTGCTAGT  
GACATTTTTTTTTCTTTTACGTAGTGGCACAACAGTARAAAAAACRAAA  
20 AATTCGAAATTTTTTACAATGTGCCTAAAAAAAACAGTGGTTGTTGGTGC  
CACTATGGACACCAAAGTTGAAGTGGCCCTGCGCGCGCACACACACACAC  
ACATAAAGTTTG  
GGATGTGATACTTCTTTTGGGAAAATGGAGTTATATCTTTGATATTGTAT  
TTTTTTAATGTAATTTATATATTTAATCATTTTAGTTTATAAGTTTATT  
25 TATTTKGATATGAAAAAAAAGTCTTTTATACATTGGATTTAACATAAAA  
ATCCAACAATATTAATCAAAAAGACCAAACATGTGGACAATTATGTATAT  
AATTAATTCACAATAGTCTTTAGGAATAGNATTATATATATAATTAATTC  
TCAATGGTCTTAGGAATAGTAAGTTCTTATATTTCAAACNTTTGCCACAN  
TTCTTTGNTTACTTNGACACTTTYCTCTMWNNANWMWWTWATATATATAT  
30 ATATATATATATAHAHAHAHAVACACACACACTAGATGTGTGCCMGCGCA  
AAGCAGTGACGTNNNGAGAANACTTTCTTAAGCATAAATAATTATTATA  
TTTTTTATTGGGTATTATATAATAAAAAATTACAACTTTAAATAAAATA  
TTTATGTTTATACTTTATATTTATATTGCTTGTATACTATTAATATAATA  
AATTAATATTTATGTCTAATTTATGAAATGTAAATTAATTTAAATACATG  
35 AATTTAATATTTTTAAAATTTTCAGTTTGCTTCAAATTGAGTTTCTTAAT  
TATTGACCAAACATGTGGACAATTATGTATATAATTAATTCACAATAGTC  
TTTAGGAATAGTATTATATATATAATTAATTCTCAATGGTCTTAGGAATA  
GTAAGTTCTTATATTTCAAACCTTTTGCCACAATTCTTTGCTTACTTTGAC  
ACTTTTCCTTCCTAACTTTACATATATATATATATTAAGCGCAAAGGTC  
40 ATAGGAATATAATATTTTCTATTATTCTACGTTTTGCCACAAAAGTTTGA  
ACACTTTGCCACTTTTTGTCCCTCCTTAACCTTTTCAATGTTTTGCGACA  
AAAGTTCCAAAACCTTTGCCACTTTGATCATTCCTCAACTTTTCACCGCAT  
TAGTTTGTGGAGTTGGCAGTTTTGGTCCCTCTAACTTCGATATTCTCTAC

TGCTAGCCAAAAAGGGTTCCAGAGTTTCACACTTTTGGTCCCTGACAGTA  
ACCAAATGTGAGATGTCAAATTTTTGCCACATTAGTTTGTGGAGTTGTCC  
CTTTTGGTCCCCCACATTCGATATTCTACTATACGATCTTATTTTTCTC  
AAATAACAACACGTATATTTAATTACTAATGATAGAAATAGATATCAAAT  
5 AAAGTATTTGTAACTGTGTAGAGTTTTTTTTTACAAGTTTGTATCAAA  
TCATATCAAAATTTAAGGTGGAACGGTGACCACATTAACCAGAAATGTAA  
TTTATTCTTTGATTTTGATAATTTTAAATTTTTGTTGTGATCTATGTAT  
TAAAAAGTAAACAACAAGAACAATAATCCAAAACCCTAAATTGCAAGTCT  
CGCCCAATTTCTCTATCACTAGTCCTCACTTACGATGGCGTTACGTCGCT  
10 CTCTCACTGCTTACAACCCTTTGTTGCTACTCATTACAATAACGAAAAGT  
TGAATATCCATATATTTATTTGGATGTGGAATTGAACGAATCTCGTCAAA  
TTTTTGATTTAGTTGATGGATTTGAGTAGAAGTTTGGGCAGAACGGGAAT  
GATGGTCTGCAAGTGGTTATAAACTTGATTCTGAGTTATTACTATATATG  
TAGCCTCTTTACAACGACCAAGGTTTCTTCCAGGTACCATTTGATCTTTT  
15 TAGAACTTAGTTTTCTGAAACACCCTGATTTGGATCAAATATCACCAACA  
ACTCTTAAAACTTGATTAATCAATTGTTTACTTCATCTTGATAACAAGT  
GGAATGATTTTCTACTTGAAAAAAAAGGTCCATGTGCGTCTGGTGGATCT  
GGTAAATGAAGATGGAAGGGAGAGCTGACTTTAAAGACACAAACACGTCA  
CCATATCTTTTATTTTATTTTAAATTTTCTTTTTTCTTATTTCTTTCTTT  
20 CTTGATCTCCAGATGGTATGTGGTGTGGATAATTTACACATAGAGATTGG  
GAACGACTGTGATTTAGAGAGGACGTGGCTTGGGGTTGAGGATGGTTTAT  
GGCTGGCCGAGTTTCATTTATATAAAACAAACAATATATAAAACAAGGGG  
TAAATGGCCATCTTATATGTATTTAACCGTCCTCTTTTTTTTTTTTTTTT  
TTTTTTTTTTTTTTTTTTTGTAAATTTAAGAAGGGGTATACCAGTGTGAGC  
25 CTCTTATTCCCAACCAGTCAAATAGGGACTTAGGTTGTTTGGAAACAGTT  
CCGTGAGACCGTGACTTGGATGGTAGATAAATTTAGTAACTTAACCCTT  
CAATTAACCTACCTTTTTCTTATTAACCTCAATTTCAACCTAAATTCTGAT  
TCTTGTTTGAATAAGTTGCATCTTTATTTTGTATTATCTTGTTGCAT  
AGGATCCTTAGCATCTTTTAATAATTTATTTGAAGGTGAAAGATCCAAC  
30 ATTTTAAATCTGTTGACGTTTCCATCATTTGCAACTGTTTCTTGAAAAA  
AAAATACCTAAAATCAAAATAACCATTTTCAAATCCAAAATTATAAGAGA  
GAATTGTAAATGGACATGGAATCATAAATCATTAAACACAGTTCAGTAAAC  
AAGTTGCTAATTACATTTCTTGCTGTGCAGATTGAAATTCTATCAGAGAA  
AGAGACATTACAAGAAGCCACTGGCAGTATTCAAATCTTGATTCCCAT  
35 CCTGTCTCATGCACTCTTTTCATAACCTCCGTGTGCTTACATTGGATAAT  
TATGAAGGAGTGGAGGTGGTGTGTTGAGATAGAGAGTGAGAGTCCAACAAG  
TAGAGAATTGGTAACAACCTCACAATAACCAACAACAGCCTATTATACTTC  
CCTACCTCCAGGAATTGTATCTAAGGAATATGGACAACACGAGTCATGTG  
TGGAAAGTGCAGCAACTGGAATAAATTCTTCACTCTTCCAAAACAACAATC  
40 AGAATCACCATTCCACAACCTCACAACCATAGAAATGAGATGGTGTGATG  
GCTTTAGGTACTTGTTTTCGCCTCTCATGGCAGAACTTCTTTCCAACCTA  
AAGAAAGTCAAGATACTTGGGTGTGATGGTATTAAAGAAGTTGTTTCAAA  
CAGAGATGATGAGGATGAAGAAATGACTACATTTACATCTACCCACAAAA



CCACCAACTTGTTCCCTCATCTTGATTCTCTCACTCTAAACCAACTGAAG  
AATCTGAAGTGTATTGGTGGAGGTGGTGCCAAGGATGAGGGGAGCAATGA  
AATATCTTTCAATAATACCACTGCAACGACTGCTGTTCTTGATCAATTTG  
AGGTATGCTTTGTACATATTCAATTATTTATTTAATTCCTTTTTTATTT  
5 GCAATATTCTATAAATAATACATTTTATACCCACTATACTAAGATAATAA  
TTACCTAGAGGGATGGATGCTATGACACAGCTGCTACACTTCAGAACTC  
TAGTAAGGGCAGTTATGGAAGTTCAATAAAATGATAATGGCATCTTTTGA  
TGGGTAATATAGGCAATTTAAGTTTTATTTCTGTAAAGCAGTATTTAGC  
AAGTACTGGCCAGTAGGAGAGGAGAATATCACCTTTTGTGAAAATCTGGT  
10 CATTGTACCCAGAATTTAGTTAAATGTAACATTTTAGATATTAGGGGTTA  
TCAGGTGACAGATATTGTAGAATAGAACATATGTAATATTACCCAAAAC  
TATTTTTTCTAAGGTTGCTCTGTAAATATGTGCTTTCTTGATTTTCATTG  
AATTTGCATTCCCTATATTTTAGGTGGTAAAGTGATTGTCTCTTCAATAAA  
TCCCGAAATTAATTAACAAAAAACAAGTAAATTTTGTATATGGA  
15 GAGCACTGGTATCATTTAGTATATAAAAAAACTAGATTTTGAATTAAGTT  
TCTTATATAAAAGCTGTGTATATAGTTTAATTAGTTTTACATCATTTTC  
CATGTGGTGTTGCAGTTGTCTGAAGCAGGTGGTGTTTCTTGGAGCTTATG  
CCAATACGCTAGAGAGATAAAAAATAGGCAACTGCCATGCATTGTCAAGTG  
TGATTCCATGTTATGCAGCAGGACAAATGCAAAAGCTTCAAGTGCTGAGA  
20 GTAATGGCTTGCAATGGGATGAAGGAGGTATTTGAACTCAATTAGGGAC  
GAGCAGCAACAAAAACAACGAGAAGAGTGGTTGTGAGGAAGGAATTCCAA  
GAGTAAATAACAATGTTATTATGCTTCCCAATCTAAAGATATTAAGTATT  
GGAATTTGTGGGGGTTTGGAACATATATTACATTCTCTGCACTTGAAAG  
CCTGAGACAGCTCCAAGAGTTAACGATTAAAGGGTTGCTACAGAATGAAAG  
25 TGATTGTGAAGAAGGAAGAAGATGAATATGGAGAGCAGCAAACAACAACA  
ACAACAACGAAGGGGGCATCTTCTTCTTCTTCTTCTTCTAAGAAGGTGGT  
GGTCTTTCCTTGCTAAAGTCCATTGTATTGGTCAATCTACCAGAGCTGG  
TAGGATTCTTCTTGGGGATGAATGAGTTCGGGTTGCCCTTCATTAGATAAA  
CTTATCATCGAGAAATGCCCAAAAATGATGGTGTTTACAGCTGGTGGGTC  
30 CACAGCTCCCCAACTCAAGTATATACACACAAGATTAGGCAAACATACTC  
TTGATCAAGAATCTGGCCTTAACCTTTCATCAGGTACATATATATTCCTTT  
AATTGGCATCATCTAATTAAGAAAGATATCATTCCCTGCCAAGTAAATTTA  
CTTCAAACACATTACACTAGTTTTCAGTCCAAGTTTATGTTGTTCTAGGA  
AGGCCAAAATGGGAAAGCAAGATAGGGAAAAATAGAGTATTTCAGTGGAA  
35 AGGGTATTTTAGGTATTTTCTGTCAAAAATTGTTATTGCAGGCTTTTTAG  
TACCTGGAAGAGCATGATTATTCTCGATTTGCTTGTTTCTTTATCATTTT  
TCTTAGCCTAGCATGATTTTCAATGAAATCTTCCCTGTTACTCCATTTG  
ATTGTTGTTCTTCATGGTTCTAAGTGAGTTAGTGGCTCATCTGTTACTTC  
TTTTGATTGTTATTTTCATAGCATGTTGTCACTTGAATCAAGCTTTTCCA  
40 TTTTCAACAAGGACAAAAGGTCAAACTAACCTACTTTATGAGATCAAAA  
ATAGCAACCCATCGGATAACTTTTAGTTGGAGTTAATACTTACAATTACC  
ATTGTGATTAATAATTATAATATCTTGTATTAATTCATAAAAATTGGTAC  
AGCACATATATGACATTTCAAAGGTTTTTGTGTTGACATATATATGCCTCT

GGCGTTTTCTTTATTGGACATGCAGACTTCATTCCAAAGTTTATACGGTG  
ACACCTTGGGCCCTGCTACTTCAGAAGGGACAACCTGGTCTTTTCATAAC  
TTTATCGAATTAGATGTGAAATCTAATCATGATGTTAAAAAGATTATTCC  
ATCCAGTGAGTTGCTGCAACTGCAAAAGCTGGTAAAGATTAATGTAATGT  
5 GGTGTAAGGGTAGAGGAGGTATTTGAAACTGCATTGGAAGCAGCAGGG  
AGAAATGGAAATAGTGAATTGGTTTTGATGAATCGTCACAAACAACCTAC  
CACTACTCTTGTCAATCTTCCAAACCTTGGAGAAATGAAGTTACGGGGTC  
TCGATTGTCTGAGGTATATGGAAGAGCAATCAGTGGACAGCATTGAG  
TTTCCAAACCTAACAAGAGTTGAAATTTATGAATGTAATTCATTAGAACA  
10 TGTATTTACTAGTTCATGGTTGGTAGTCTATTGCAACTCCAAGAGCTAG  
AGATTGGTTTGTGCAACCATATGGAGGTCGTGCATGTTTCAGGATGCAGAT  
GTTTCTGTAGAAGAAGACAAAGAGAAAGAATCTGATGGCAAGATGAATAA  
GGAGATACTTGTGTTACCTCATCTAAAGTCATTGAAATTACTACTTCTTC  
AAAGTCTTAAGGGGTTTAGCTTGGGGAAGGAGGATTTTTCATTCCCATT  
15 TTGGATACTTTGGAATCTACGAATGCCAGCAATAACCACCTTCACCAA  
GGGAAATTCCGCTACTCCACAGCTAAAAGAAATGGAAACAAATTTTGGCT  
TCTTTTATGCTGCAGGGGAAAAAGACATCAACTCCTCTATTATAAAGATC  
AAACAACAGGTAAACCAGATCTTTGTTGCTTTAATAATTCTTAAACTACA  
TTTGAAGAGCTTCATGCAAGTTTTTTTTTGTATATTGTCAAAAACCGCAA  
20 CCTACATTTTCAGCTTTATATTTATGTACTTTATGCAGGATTTCAAACAA  
GACTCTGATTAATGTGAAGTGAATATTAAGGTAAATTATATTTTCATGT  
TCCTAGTTGCCTATTAATTAAAGGCCTTTTAGTTCGTGATTTTGGATGT  
ATTCTTCATGATGATGTCAATCTTCTAATACCCCATTCATTGTTTGGTTG  
AATGTTGACTCTATGTCAGGATGAATATTCAAGGGAAGAATTGTTTCATCA  
25 TATGAAGGACATTAAAGAACATGGTGCTAT

RG2C deduced polypeptide sequence (SEQ ID NO:92)

MAMETANEIKQVVPVLMVPINDYLRYLVSCKRYISDMDLKMKEAKDNVEEH  
KNHNISNRLEVPAAQVQSWLEDVEKINAKVETVPKDVGCCFNLKIRYRAGRDAFNI  
30 IEEIDSVMRRHSLITWTDHPIPLGRVDSVMASSTLSTEHNDFQSREVRFSEALKALE  
ANHMIALCGMGGVGKTHMMQRLKKVAKEKRKFGYIIEAVIGEISDPIAIQQVVADY  
LCIELKESDKKTRAELRQGFKAKSDGGNTKFLIILDDVWQSVLEDIGLSPSPNQG  
VDFKVLTSRDEHVCVSMGVEANSIINVGLLIEAEAQRLFQQFVETSEPELHKIGEDI  
VRRCCGLPIAIKTMACTLRNKRKDAWKDALSRQLQHDIGNVATAVFRTSYENLPD  
35 KETKSVFLMCGLFPEDFNIPTEELMRYGWGLKLFDRVYTHIARNRLNNTCIDRLVQT  
NLLIGSDNGVHVKMHDLVRAFVLGMYSEVEQASIVNHGNMPGWPDENMIVHSC  
KRISLTCKGMIEFPVDLKFPLTILKLMHGDKSLKFPQEFYEGMEKLRVISYHKMKY  
PLLPLAPQCSTNIRVLHLTECSLKMFDSCIGNLSNLEVLFSFANSIEWLPSTVRNLK  
KLRLDLRLCYGLRIEQGVLSLVKLEEFYIGNAYGFIDDNCKEMAERSYNLSALEF  
40 AFFNKAIEVKNMSFENLERFKISVGCSTGDNINMSSHSYENMLRLVTNKGVDLDSK  
LNLFLKTEVLFLSVHGMNDLEDVEVKSTHPTQSSSFCNLKVLISKVELRYLFLK  
NVANTLSRLEHLEVCKCKNMEELIHTGIGGCGETITFPKLKFLSLSQLPKLSGLCH

NVNIIGLPHLVDLKLKGIPGFTVIYPQNKLRSSLLKEEVVIPKLETQIDDMENLEEI.  
WPCELSGGEKVKLREIKVSSCDKLVNLFPRNPMSLLHHLEELTVENC GSIESLFNID  
LDCVGAIGEEDNKSLLRSINVENLGKLRVWRIKGADNSHLINGFQAVESIKIEKCK  
RFRNIFTPITANFYLVALLEIQIEGCGGNHESEEQIEILSEKETLQEATGSISNLVFPSC  
5 LMHSFHNLRVLTLDNYEGVEVVFEIESESPTSRELVTTHNNQQQPILPYLQELYLR  
NMDNTSHVWKC SNWNKFFTL PKQQSESPFHNLT TIEMRWCHGFRYLFSP LMAELL  
SNLKKVKILGCDGIKEVVS NRDD EDEEMTFTSTHKT TNLFPHLDSLTLNQLKNLK  
CIGGGGAKDEGSNEISFNNTTATTAVLDQFELSEAGGVSWSLCQYAREIKIGNCHAL  
SSVIPCYAAGQMOKLQVLRVMACNGMKEVFETQLGTSSNKNNEKSGCEE GIPRVN  
10 NNVTMLPNLKILSIGNCGGLEHIFTSALESRLQLQELTIKGCYRMKVIVKKEEDEY G  
EQQTTTTTTKGASSSSSSSKKVVFPC LKSI VLVNLP ELVGFFLGMNEFRLPSLDKLI  
EKCPKMMVFTAGGSTAPQLKYIHTRLGKHTLDQESGLNFHQTSFQSLYGD TLGPAT  
SEGTTWSFHNFIELDVKS NHDVKKIIPSELLQLQKLVKINVMWCKRVEEVFETALE  
AAGRNGNSGIGFDESSQTTTTLVNLPNLGEMKLRGLDCLRYWKS NQWTA FEFPN  
15 LTRVEIYECNSLEHVFTSSMVGSLLQLQELEIGLCNHMEVVHVQDADVSVEEDKEK  
ESDGKMNKEILVLP HLKSLKLLLLQSLKGFS LGKEDFSFPLD TLEIYEC PAITTF TK  
GNS.ATPQLKEMETNFGFFYAAGEKDINSSI KIKQQDFKQDSD.

RG2D polynucleotide sequence (SEQ ID NO:93) and (SEQ ID NO:94)

20 ACGACCACTATAGGGCGAATTGGGCCCCGACGTCGCATGCTCCCGGCCGCC  
ATGGCCGCGGGATGTAAAACGACGGCCAGTCAATCGTAACCGTTCGTAC  
GAGAATCGCTGTCCTCTCCTTCAACCATTTAATGTATATGAGCTAAATTG  
AAACATCTACTATCATGTTTAAATTTATAAACTTTTTCCTTTAGATTAC  
TTGTCTGGATGTGTTTAATAAAACCCAATTTCCCACATGCGTAGAGATCA  
25 TAG.ATGTAAC TATTGTTAATCAATTTTGCCTGCCAAGTTTAAATAATTAT  
ACTTGGATATTAACAAAAC TTTATCTAACGACCAAGGTAATATTA AAAAT  
AGGTTATTATTCTTCATGCTAATTA AAAGATGGGTTGCAAAAGTGAGACC  
ATG. AAACATTAACACGTTGATATTTTCAACTTTTATTCTTT CATATTCA  
CCATATTTTTTACTTTCTGATTGATTAATCATCTTTCAATCACAGGCTCC  
30 TTGGCAAAAAGTCAGATCTATTAACAAATACTTCCATGTGGTTGCAAATT  
ACAAGGATTTCAACATAATTACCAAAACATAGCATTATCATAAGATCGAA  
TAATAATCAAATTC TTCTATAATATTACACAAAGGTAACGTCATTAATTA  
ATTACGATACGAGACAGACTTTTTCACTCGTGACATCAACGGTCTATTCT  
AACTTTACTTAATTAATGAATCTAGGATGTGCTCATATGCATGTAATAT  
35 TTGCTACCGTCATCTTTCAAATGACCATATTTTTATGTATTTATAATGAA  
TCAATGAAAAACCGGATTTCTATTTAAAATTCTTAAACTTCATCTTTTA  
AGCCAGGGTGAATACAATTGTAGATCCACTGTTAATTTCCATCGATTATG  
CGTGATCAATTGTTGGCTGCATACGATGCAGGTGCTACCACAAGAATATG  
GCCATGGAACTGCTAATGAAATTATAAAACAAGTTGTTCCAGTTCTCAT  
40 GGTTCCCTATTAACGATTACCTACGCTACGTCGTTTCCTGCAGAAAGTACA  
TCAGTGACATGGATTTGAAAATGAAGGAATTA AAAAGAAGCAAAAGACAAT  
GTTGAAGAGCACAAGAATCATAACATTAGTAATCGTCTTGAGGTTCCAGC

AGCTCAAGTCCAGAGCTGGTTGGAAGATGTAGAAAAGATCAATGCAAAAG  
TGGAAACTGTTCTTAAAGATGTCGGCTGTTGCTTCAATCTAAAGATTAGG  
TACAGGGCCGGAAGGGATGCCTTCAATATAATTGAGGAGATCGACAGTGT  
CATGAGACGACACTCTCTGATCACTTGGACCGATCATCCCATTCTTTGG  
5 GAAGAGTTGATTCCGTGATGGCATCCACCTCTACGCTTCAACTGAACAC  
AATGACTTCCAGTCAAGAGAGGTAAGGTTTAGTGAAGCACTCAAAGCACT  
TGAGGCCAACCACATGATAGCATTATGTGGAATGGGGAGAGTGGGGAAGA  
CCCACATGATGCAAAGGCTGAAGAAGGTTGCCAAAGAAAAGAGGAAGTTT  
GGTTATATCATCGAGGCAGTTATAGGGGAAATATCGGACCCCATTGCTAT  
10 TCAGCAAGTTGTAGCAGATTACCTATGCATAGAGCTGAAAGAAAGCGATA  
AGAAAACAAGAGCTGAGAAGCTTCGTCAAGGGTTCAAGGCCAAATCAGAT  
GGAGGTAACACTAAGTTCCTCATAATATTGGATGATGTCTGGCAGTCCGT  
TGATCTAGAAGATATTGGTTTAAGCCCTTCTCCCAATCAAGGTGTGCACT  
TCAAGGTCTTGTGACTTCACGAGACGAACATGTTTGCTCAGTGATGGGG  
15 GTTGAAGCTAATTCAATTATTAACGTGGGACTTCTAATTGAAGCAGAAGC  
ACAAGATTGTTCCAGCAATTTGTAGAACTTCTGAGCCCGAGCTCCACA  
AGATAGGAGAAGATATTGTTAGGAGGTGTTGCGGTCTACCCATTGCCATC  
AAAACCATGGCGTGTACTCTAAGAAATAAAAAGAAAGGATGCATGGAAGGA  
TGCACCTTCTCGTTTACAACACCATGACATTGGTAATGTTGCTACTGCAG  
20 TTTTGTAGAACCAGCTATGAGAATCTCCCGGACAAGGAGACAAAATCTGTT  
TTTTTGATGTGTGGTTTGTTCCTCGAAGACTTCAATATTCCTACCGAGGA  
GTTGATGAGGTATGGATGGGGCTTAAAGTTATTTGATAGAGTTTATACAA  
TTATAGAAGCAAGAAACAGGCTCAACACCTGCATTGAGCGACTGGTGCAAG  
GCAAATTTACTAATTGGAAGTGATAATGGTGTACACGTCAAGATGCATGA  
25 TCTGGTCCGTGCTTTTGTTCCTGAGGATGTATTCTGAAGTCGAGCAAGCTT  
CAATTGTCAACCATGGTAATATGCCTGGGTGGCCTGATGAAAATGATATG  
ATCGTGCCTCTTGCAAAAGAATTTTCAATTAACATGCAAGGGTATGATTGA  
GATTCCAGTAGACCTCAAGTTTCTTAACTAACGATTTTGAACTTATGC  
ATGGAGATAAGTCTCTAAAGTTTCTTCAAGAATTTTATGAAGGAATGGAA  
30 AAGCTCCAGGTTATATCATACGATAAAAATGAAGTACCCATTGCTTCTTT  
GGCACCTCAATGCTCCACCAACATTGCGGTGCTTCATCTCACTGAATGTT  
CATTAAAGATGTTTGATTGCTCTTCTATCGGAAATCTATCGAATCTGGAA  
GTGCTGAGCTTTGCTAATTCTCGCATTGAATGGTTACCTTCCACAGTCAG  
AAATTTAAAGAAGCTAAGGTTACTTGATCTGAGATTTTGTGATGGTCTCC  
35 GTATAGAACAGGGTGTCTTGAAAAGTTTGGTCAAACCTGAAGAATTTTAT  
ATTGGAAATGCATATGGGTTTATAGATGATAACTGCAAGGACATGGCAGA  
GCGTTCTTACAACCTTTCTGCATTAGAATTCGCGTTCTTTAATAACAAGG  
CTGAAGTGAAGAAATATGTCATTTGAGAATCTTGAACGATTCAAGATCTCA  
GTGGGGTGCTCTTTTGATGGAAATATCAGTATGAGTAGCCACTCATACGA  
40 AAACATGTTGCAATTGGTGACCAACAAAGGTGATGTATTAGACTCTAAAC  
TTAATGGGTTATTTTGAAGACAGAGGTGCTTTTTTAAAGTGTGCATGGC  
ATGAATGATCTTGAAGATGTTGAGGTGAAGTCGACACATCCTACTCAGTC  
CTCTTCATTCTGCAATTTAAAAGTCCGTATTATTCAAAGTGTGTAGAGT

TGAGATACCTTTTCAAACCTCCATGTTGCAAACACTTTGTCAAGCCTTGAG  
CATCTAGAAGTTTGTGGATGCGAAAATATGGAAGAACTCATACATACTGG  
GATTGGGGGTTGTGGAGAAGAGACAATTACTTTCCCCAAGCTGAAGTCTT  
TATCTTTGAGTCAACTACCGAAGTTATCAGGTTTGTGCCATAATGTCAAC  
5 ATAATTGGGCTACCACATCTCGTAGACTTGAACTTAAGGGCATTCCAGG  
TTTCACAGTCATTTATCCGCAGAACAAAGTTGCGAACATCTAGTTTGTGTA  
AGGAAGAGGTAGATATATGTTCTTTATGTTAATAACAATTTAAATAATATT  
TTC.AACCAAAATTTTATAATATATCTGTAATTTGATTGTATGATGTGTTA  
TTGTTTATATGTGGCTATTAAGGGATGATTATTTTGCAGGTTGTGATTCC  
10 TAAGTTGGAGACACTTCAAATTGATGGCATGGAGAACTTAGAAGAAATAT  
GGCCTTGTGAGCTTAGTGGAGGTGAGAAAGTTAAGTTGAGAGAGATTAAA  
GTGAGTAGCTGTGATAAGCTTGTGAATCTATTTCCGCACAATCCCATGTC  
TCTGTTGCATCATCTTGAAGAGCTTAAAGTCAAAAATTGTCGTTCCATTG  
AGTCGTTATTCAACATCGACTTGGATTGTGTGTCAGTGCAATTGGAGAAGAA  
15 GACAACAAGAGCATCTTAAGAAGAATCAAAGTGAAGAATTTAGGGAAGCT  
AAGAGAGGTGTGGAGGATAAAAGGTGCAGATAACTCTCGTCCCCTCATCC  
ATGGCTTTCCAGCTGTTGAAAGCATAAGTATCTGGGGATGTAAGCGGTTT  
AGAAATATATTCACACCTATCACCGCCAATTTTGATCTGGTGGCACTTTT  
GGAGATTACATAGGAAATTACAGAGAAAATCATGAATCGGAAGAGCAGG  
20 TAACGCTTTCAATTTCACTTTCTTACTTAATTAAGGACTAAGCTCTTGTT  
TTTTGAATAATAAAGAGGTGGGATGACTAACTTGGGCATCACAATTGTA  
ACAAAATGTTACAAACCATGAACGTACAAACCATTTCTTGAATTAAGGTT  
TCAATACAAGTCATTTACAAATATGGCTTAAGTTTTTTTATATTTATGTA  
TCAACATTATTTTTTATTAGAGGTCATTATTATAATAGTAAGTTTAAAGC  
25 AATTTAAATTAGCACTAATTTTTTCATCATCTAACTTTAGCTAATAAATCG  
TTATAAATGTCAATAGCTAAAATAAAAATATTTGACATTCACTGAGAGCA  
ATTTTTTCTAAACATGATTGCAAATGATTAAAACTTAAATTTAAACTAAA  
AAGATTTTTATATATGTTATACAAAATTTACAAATTGAAATTGGATATGT  
TAATTAACAGTTTATAATTATTGTATTACAAAGCGATATATAATAAAAATA  
30 TATTTTTCTGTAGTCATGTATAATTGTATATGTAAATGATTTTTTAAGA  
TGGTAGAAGTGGAACCTAGTCAATCTCACTTAACTCATTGTCACACCAGT  
TTTATATCCGTTTCTCTCTCTCTCTCTTGCCTCCATCTTTTTTCAAC  
TCATAACACATAAAAATAACATATTTTCCAACACATTTAAGTCACTACCA  
CATCATTATTTTTAATTTAATTAAATTAGAAAATATAAAATTAATAAAAA  
35 CATAACATTTTTTTATTAAGGCACTAATAACAAATAAAAAGATACACGG  
TAAATAAAAAAACGATAATTAGAAAAAAAACATAATAAAAAAAGACAACA  
TTAAAAATAWAAAGCGACAATAAAATTAATAATGATCAAGAAAATTCT  
AAAACCTCCACCATAATTTTTCTGCAATTTGTCATTTATGTTCAAACACCA  
TTCGCAGAATCCCTCCTATCAAGTGATCATGTTGATTGAGAAAAAACTGT  
40 ATGTCTCTCATGTATCTCCAAGTCCAACAAGTTAGCTTTCATTTCTTC  
ATTTTCTCATGTAAGACGCAAATTTTCATCCCGATATTGTTTTCTATCTT  
CCACCTCTACTTTATTCACAGTGTGGATGAAGGAGAGGACAGCGATTCTC  
GTACGAACGGTTACGATTGCGACTGGCCGTCGTTTTACAATCCCCGCGCCA

TGGCGGCCGGGAGCATGCGACGTCGGGCCCATTTCGCCCTATAGTGGTCGT  
AATACA (SEQ ID NO:93)

## Sequence gap

5 TGAGCCTCCGATGCTTAGTCCACTTGGCACAGTTCAAGTCCAATCAACTT  
ATAACCCATTTTTCTTCAAGTTGTCTTCAAGTTAAGCCCAATTTGCCTTC  
TCCAAATCATCCATAACTTCATGGAATCGCCCCCTTCATCTTAATCCCGAA  
TGCACAATTATTCTCCCATCTTCATTTTAAGCAAGAGGCCACCTTCTTCA  
TGCTTCATCCATCAATAGTCTGTTGGAATAGTGTCTAAGGCTGCAACTAT  
10 ATTAGACAAGTATTTGACCCGTTTGTGCATGGTCCTTTTGGGTTGCCTTC  
ACCATAGCAACTTGATAGGATGATTTATTAAGAGAGAGTAAATATTATTA  
ATATATTATGAGAATAATATAATGAATAATATATTTGTTATTTGATTAAT  
ATAAGTCATAGAATTAATTAGAATTAATTTGGTGACTTAAAGAGATTAAT  
TAAATAAAGGGGTATAAACTGTCAATTGTTTGATAGTTAAGCTTTAGACT  
GTAATCCATTTGGATATGGTATGGACGAATCCTAAGGGATTTAGGATAG  
15 CTAAAATCGTCCATATGAGTTATCTAAGAAGGATTTGGATAGCCTTAAGA  
GAAGATTATCTGATAGGGACTTATCTGTAATCCTTAAGGAGTCTACAAGT  
ATAAATAGACCCTATGGCTGATGGAATTCGACACATCTCCTAAAGTAAGA  
GAGCCTTGGCCGAATTCCTCCCCCTCACCTCTCTCCTAAATCATTCTTCTT  
GCTATTGGTGTTTGTAAAGCCATTAGAGGAGTGACATTTGTGACTCTAGAA  
20 TCTCCAAGACCTCAAGATCAACAAGGAATTCAAAGGTATGATTCTAGATC  
TGTTTCAATGTTGTTATTTGTCCTAATTAGTCATTAGAAGACTTGGATTTC  
AAAGCATGTTTATTAGAAAGCCTAGATCYGAGCAATAGGGTTTTGCATGC  
GCACATAGGAAAGTTCTTATGGCTAAAACCCATCATAGTCCACTTCATGT  
ATCATCTCTACTAGTTATTTAGTCCATAATCCTTGTTGTCCTCCAAGTTT  
25 AATTACCTCCCTTAGTTTCTGTTCTGCTAGTTTCCTTAAAATTTGCTATT  
AAGATCACAGAACTAGAGAGTACCCAAAATGGTTATAAAATAACAAAAAG  
GAA-AATATGCATGAAGATTAATAAATTATAAATGTAATATGCTAAAATA  
AACTATAAAAAAAAAGTAAATAAAATGAACTATCACACTCCGACCACCC  
TTATAGGCTTGTACTGCACCCACCCTTCATTCCTTGTAACCAATATGGGAT  
30 GGAACATTATTCATTAAGCCAAAAAATAACATTTAAGGGGTGAGTGAC  
AAAGGTAAGTACTAAAGACAACAATAATCCATTTTTCTTGTACATACACA  
ACACACACATAGGGGCGGACGTAGGATTTGTAGTATGTGTTGTGGGTGAC  
ACATTTTTTCTTTTACGTAGTGACACAATAGTAGAGAAAACGAGAAATTC  
CAATTTTTTACATTGTGTTTCGAAAAAATATACAGGGGTTGCTGGTGCTAC  
35 TCTGGGCACCAAAGTGGAACCGCCCCTGCACACACACACACATAGAGGGA  
GAGAGAGAGGAGAAAGAGAGAGAGAGAGAGAGAGAGAGAGAGATTT  
TGGGATGTGATACTTCTTTTGGGAAAATGGAGCAATATCTTTAATATTGT  
ATTTTTTTAATGTAATTTATATATTTAATCATTTTAGTTTATAACTTTTA  
GTTTTTTTTATTTAATCTGTATATTTAATCATTTTCAGTTTATAAGTTTT  
40 ATTTATTTTGGTATACCAGAAAAAAGTCTTTTATGTGTTGGATTTAAC  
ATAAAAATCTAACAATATTAATCAAAAAGACCAAACATGTGGACAATTAT  
GTATATAATTAATTCTCAATGGTCTTAGTGTAACGATATAAATTTCAAAA  
CAATTTTTTCACATTAACAAAAAACACTTTCAGTCATAATTGTTATAAATTA

TCATTGTATCACAAAATCAGTTCATAACATCACATCCCAAGATCAATAAA  
GTGTAAATACTCCTCATGTGTGTAATAATCAAGCCGACGCCTTCCCGCGA  
TTCTCACTGGTACCTGAAACACGTAACATAACAACGTGTAAGCATAAAATGC  
TTAGTGAGTTCCCCAAAATACCACATACCACATATATGCCTTTCCAGGCC  
5 ATA ACTCTGTAGGATCTTCCGACCCAAGTGTCTCAGGGGACTTCCGTCCC  
GAATCCCGGTAGACCTTCCGGTCCTACCCGTATTGACCTTCCGGTCCGTA  
TCATACATAACATAACATAACACATACATATCACATAACAACATATAGCAC  
ATACATCTCATAACATAAAAGACCTTCCGGTCACATAAAGGTACCCTTCC  
AGGTACAGTATAGTGAGAACTCACCTCGTATGATGTCTAATACCTCAC  
10 GTGCTCGATATCCCTGAATCTCGAAACAATGACCTAGCCCCGCCTACTCA  
CATAAAGTAATTATTTCAAATCATTAAACGGCTCTCAAGGCTAGACTACAT  
CCCTTTCTATAAATCCACAGAAGGGTAAAAGACCATTTTACCCCTCCTTG  
ACCCAAAAGTCCAAATGTTGATCAAAAACCCAAAAGTCAACGAAAGACAA  
TGGTCAACTTTGACCCTACTCGTGGAGTGCACAAAGGTGACTCGGCAAGT  
15 ACATGCGGGTCCTCTGAATCCTTTAGTCTCTCTTGGCTCGTCGAGTCTT  
TCTTCCACCCGACGAGTTACACCTGTCATGAATCGCGGGGCAACCCCGAC  
TCGACTTGTGAGTCCGCTCATGGACTCAACGAGTTCATTCCATGCTCAC  
ACTCAAATGACCTCCTGAGGTCAGATCTGTTCCCTCTAATCCATAGATCTG  
ACCTTCCCAAGCTCAATAAACACGTAAAGGTTGAACTTGATACTCATGC  
20 AACGTCCAAATGATTCTACTTGATGATTTAGCCCCAAATACAACATCCTA  
AGTCCATACGACCTTATTTTTCTCAAATAACAACACATATATTTAATTAC  
CAATGACAGTAATAGATATCATATAAAGTATTTGTAACACTTTGTAAGAA  
CCTTGCTACTATAGGTAAAAAGAAACATTTCAAAGTACATGCCCTAATTA  
GAAAAAAAGTTATAAAAAAATAATGACTAGGGGCGTGTTTTTTTACTAG  
25 TTTGTATCAAATTATATCAAAATTTAAGGTGGAAAAGAATGACGACCACA  
TTAACCAGAAATGTAATTATTTTTTTATTTGGTAATTTTTTAATATTTGTT  
GTGATCTATGTATTTAAAAGTAAATATCAAACAAGAACATAATCCAAACC  
CTAAATTGCAAGTCTCGCCCAATTTCTCTATCACTAGTCCTCACTTACGA  
TGGCGTTACGTCGCTCTCTCACTTCCTACAACCCATTGTTGCTACTAATT  
30 AACTAACGAAAAGTTGAATATCCATATATTTATTTGGATGTGAAATTGA  
ACGAATCTCGTCAAATTTTTTATTTTGTGATGGATTTGAGTGGAAGTTT  
AGGCAGAACGGGAATGATGGTCTGCAAGTGGTTATAAACATGGGTGAAGA  
TAAATGGAGTTGTCGCCGTTGTATTATAGATCTCTTAGGGGTTTGATTC  
TGAGTTATTACTGTATACGTAGCCTCTTTACAACGACCATTCTTCCAAGT  
35 ACCATTTGATCTTTTTAGAATCCAGTTGTCTGAAACACCCTGATTTGGAT  
CAAATATCACCACAACTCTTAAGAACTGGACTAATTAATTGTTTTCTTG  
ATCTTGATAACAAGAGGAAACACGTCACCATATCTTTTATTTTAAATTTG  
CTTTTGGTGTATTTTCTTCTTCCCATTTCTTCTTGATCTGTTCCAGAT  
GGTATTTGGTGTGGATAATTTACACCTGGAGATTGTGAACGATGGGAAGG  
40 GGTATGTGATTTACAGAGGATGTGGCTTGTGGTTGAGGATGGTTTATGGC  
TGGCCGAGTCTAATTTATATTTATATAAACAATAAATATATAAAACAAG  
GGTAAAATATGTATTTAAGCGTCCTCTTTTAATGGTGACAATTTTACAG  
TTTACTCTCTTTGTTTTTTAATTGTGATGCCACGATCGAACTCATTCAT

CCCCCCCCCTTTTTTTTTTAAAAATAAAAAATTAAGAAGGGGTACCACCAT  
ATACCCGTGTCAGCTTCTTATTCCCAAGCAGTCAAATAGGGACTTAGGTT  
GTATGGAAACAGTTCCGTGACTTGGATGGCAGATAAATTTAGTAACTTA  
ACCCTTCAATTAACCTACCTTTTTCTTATTAACCTCAATTTCAAGCTAAAT  
5 TCTGATTCTTGTTTGAAAATAAGTTGCATCTTTATTTTGCATATTATCT  
TGTTGCATAGGATCCTTAGCATCTTTTAATAGTTTATTTGAAGCTGAAAG  
ATCCAACCTAGTTTTGATCTGTTGGCATTTCATCATTTGCAACTGTTTC  
TTGAAAAAAAATACCTAAAATCAAAATAACCATTTTCAAATCCAAAATTA  
TAAGAGAGAATTGTTAATGGACGTGGAATCATAAATCATTAACACAGTTC  
10 AGTACACAAGTTGCTAATTACATTTCTTGCTGTGCAGATTGAAATTCTAT  
CAGAGAAAGAGACATTACAAGAAGTCACTGATACTAATATTTCTAATGAT  
GTTGTATTATTCCCATCCTGTCTCATGCACTCTTTTCATAACCTCCATAA  
ACTTAAATTGAAAAATTATGAAGGAGTGGAGGTGGTGTGTTGAGATAGAGA  
GTGAGAGTCCAACATGTAGAGAATTGGTAACAACCTCACAATAACCAACAA  
15 CAGCCTATTATACTTCCCAACCTCCAGGAATTGTATCTAAGGAATATGGA  
CAACACGAGTCATGTGTGGAAGTGCAGCAACTGGAATAAATTCTTCACTC  
TTCCAAAACAACAATCAGAATCACCATTCCACAACCTCACAACCATAGAA  
ATGAGATGGTGTGTCATGGCTTTAGGTACTTGTTCGCTCTCATGGCAGA  
ACTTCTTTCCAACCTAAAGAAAGTCAAGATACTTGGGTGTGATGGTATTG  
20 AAGAAGTTGTTTCAAACAGAGATGATGAGGATGAAGAAATGACTACATTT  
ACATCTACCCACACAACCACCAACTTGTTCCCTCATCTTGATTCTCTCAC  
TCTAAAATACATGCACTGTCTGAAGTGTATTGGTGGAGGTGGTGCCAAGG  
ATGAGGGGAGCAATGAAATATCTTTCAATAATACCACTACAACCTACCGAT  
CAATTTAAGGTATGTTTGTACATATTTAATTATATATTTAATTTCCCTGT  
25 TAATTTCCCTTTTCTTTGCAATATTCTATGCGAACTCAAGAATGGGATTG  
GAGGCATATAAAGTTACATTCATTTGAACAAGTATTACCTTTTATTTGTT  
ATTTATCATTTTCATATCAAGTACCTATAACATTTCTTTTTTATTTTCT  
AATTAGAAGAGGTCCACATGTCTAATTAGGTTTTCCATTCTATGTGTAAC  
CTCTATTCTCTCTGTAATCAAGCATCTTAGATTATTTATCCATTTTCATA  
30 ATTGTTGTTTATTTTTACAGTTTTTTTTTTTTATTTAATTTTAATAATTTAA  
TTTTAATTTATTTATTTTTTTTTTTTGGTAATTGCAACCTGTCATATAT  
TCAAGTCTTAATGTAACATAATAATACATTTTATACCCACTATACTAAGA  
TAATAATTACCTAAAGGGATGGATGCCATGACACTGCTACACTTCAGNAA  
CTCTAGTAAGGGCAGTTATGGAAGTTCAATAAAAATGATAATGGCATCTTT  
35 TGATGGGTAATATAGGCAATTTAAGTTTTATTTCTGTAAAGCAGTATTT  
AGCTAGTAGTGGCCAGTAGGAGAGGAGAATATCACCTTTTGTCAAAATCT  
GGTCATTGTACCCAGAATTTAGTTAAATGTAACATTTTAGATATTAGGGG  
TCATCAGGTGACAGATATTGTAGAATAGAACAAATATGTAATATTACCCAA  
AACTATTTTTCTAAGGTTGCTCTGTAAATATGTGCTTTCTTGATTTCA  
40 TTGAATTTGCATTCGTATATTTTAGGTGGTAAACTGATTGTCTCTTCAAT  
AAATCCTGAAATTAATTAACAAAAAACAACAAAGTACATTTTGTATTT  
GGAGAGCACTGGTATCATTTAGTATAGAAAAAACTAGATTTTGAATTAY  
CTTCTTATATAAAAGTTGTGTATATAGTTTAATTAGTTTTACATCATTT



TTCTATGTGTTGTTGCAGTTGTCTGAAGCAGGTGGTGTGTTGTTGGAGCTT  
ATGCCAATACTCTAGAGAGATAGAGATATATAGGTGTGATGCACTGTCAA  
GTGTAATTCATGTTACGCAGCAGGACAAATGCAAAAGCTGCAAGTGCTG  
ACAGTCAGTTCTTGTAATGGTCTGAAGGAGGTATTTGAACTCAATTAGG  
5 GACGAGCAGCAACAAAAACAACGAGAAGAGTGGTTGTGAGGAAGGAATTC  
CAAGAGTAAATAACAATGTTATTATGCTTCCCAATCTAAAGATATTGGAA  
ATCTACGGTTGTGGGGGTTTGGAACATATATTACATTCTCTGCACTTGA  
AAGCCTGAGACAGCTCCAAGAGTTAACGATTAAGGGTTACTACTCTTGTC  
AATCTTCCAAACCTCAAAGAAATGAGGTTGGAGTGGCTAAGTAATCTGAG  
10 GTATATATGGAAGAGCAATCAGTGGACAGCATTTGAGTTTCCAAACCTAA  
CAAGAGTTGAAATTTGTGAATGTAATTCATTAGAACATGTATTTACTAGT  
TCCATGGTTGGTAGTCTATTGCAACTCCAAGAGCTACATATATTTAACTG  
CAGTCTGATGGAGGAGGTAATTGTAAAGGATGCAGATGTTTCTGTAGAAG  
AAGACAAAGAGAAAGAATCTGATGGCAAGACGAATAAGGAGATACTTGTG  
15 TTACCTCATCTAAAGTCCTTGAATTACAACCTTCTTCGAAGTCTTAAGGG  
GTTTAGCTTGGGGAAGGAGGATTTTTTCATTCCCATTATTGGATACTTTAG  
AAATCAAAAGATGCCCAACAATAACCACCTTCACCAAAGGAAATTCCGCT  
ACTCCACAACATAAAAGAAATACAAACAAATTTTGGCTTCTTTTATGCTGC  
AGGGGAAAAAGACATCAACTCTCTTATAAAGATCAAACAACAGGTAAATC  
20 AGATCTTTGTTGCTTTAATAATTCTTAAACTACATTTGAAAAGCTTCATG  
CAAGTTTTTTTTGTTATATTGTCAAAAACCGCAACCTACATTCAGCTTTAT  
ATTTATGTACTTTATGCAGGATTTCAAACAAGACTCAGATTAATGTGAAG  
TGAATATTAAGGTAAATTATATTTTCATGTTCCCTAGTTGCCTATTAATT  
AATGGCCTTTTAGTTCATGATTTTTTGGATGTATTCTTCATGATGATGTGA  
25 ATCTTCTAATACCCCATTCATTGTTTGGTTGAATGTTGACTCTATGTCAG  
GATGAATATTCAAGGGAAGAATTGTTTCATCAWATGAAGGACATTAAAGAA  
CATGGATGCTATGAAGATGTTGGGAAAACATATGTATCAAGTGGCAARCT  
GCTTAATGATCTAAGTTTGTGTTGGTTGANGATGTTGATTTTAATATTCAA  
ATTCATTGGTTATATGGGCTTATCAATAGTGTTAATGGGATAATGAGTGA  
30 CTTAACCTAAATTATGTTGTTGGTAAATGTTGGACAAGTATGGAAAATTA  
GGAATGACTTGTGAAAAAAAATAAAAAAAA (SEQ ID NO:94)

**RG2D deduced polypeptide sequence (SEQ ID NO:95)**

MAMETANEIKQVVPVLMVPINDYLRYVVSCRKYISDMDLKMKEAKDNVEE  
35 HKNHNISNRLEVPAAQVQSWLEDVEKINAKVETVPKDVGCCFNLKIRYRAGRDAF  
NIIIEIDSVMRHSLITWTDHPIPLGRVDSVMASSTLSTEHNDFQSREVRFSEALKA  
LEANHMIALCGMGRVVGKTHMMQRLKKVAKEKRKFGYIIEAVIGEISDPIAIQVVA  
DYLIELKESDKKTRAELRQGFKAASDGGNTKFLIILDDVWQSVLEDIGLSPSPN  
QGVDFKVLITSRDEHVCSVMGVEANSIINVGLLIEAEAQRLFQQFVETSEPELHKIG  
40 EDIVRRCCGLPIAKTMACTLRNKRKDAWKDALSRQHHDIGNVATAVFRTSYENL  
PKETKSVFLMCGLFPEDFNIPTEELMRYGWGLKLFDRVYTHIERNRLNTCIERLV  
QANLLIGSDNGVHVKMHDLVRAFVLGMYSEVEQASIVNHGNMPGWPDENMIVH

SCKRISLTCKGMIEIPVDLKF PKLTILKLMHGD KSLKFPQEFYEGMEKLQVISYDKM .  
KYPLLPLAPQCSTNIRVLHLTECSLKMFD CSSIGNLSNLEVL SFANSRIEWLPSTVRN  
LKKLRLLDLRFCDGLRIEQGVLSLVKLEEFYIGNAYGFIDNCKDMAERSYNLSA  
LEFAFFNNKAEVKNMSFENLERFKISVGCSFDGNISMSSH SYENMLQLVTNKG DVL  
5 DSKLNGLFLKTEVLF LSVHGMNDLEDVEVKSTHPTQSSSFCNLKVRIISKCVELRYL  
FKLHVANTLSSLEHLEVCGCENMEELIHTGIGGCGEETITFPKLKSLSLSQLPKLSGL  
CHNVNIIGLPHLVDLKLKGIPGFTVIYPQNKLR TSSLLKEEVVIPKLET LQIDGMENL  
EEIWPCELSGGEKVKLREIKVSSCDKLVNLFPHNPM SLLHHLEELKVKNCRSIESLF  
NIDLDCVSAIGEEDNKSILRRIKVKNLGLREVWRIKGADNSRPLIHGFPAVESISIW  
10 GCKRFRNIFT PITANFDLVALLEIHIGNYRENHESEEQIEILSEKETLQEVTD TNISND  
VVLFPSCLMHSFHNLHKLKLENYEGVEVVFEIESESPTCRELVTTHNNQQQPILPN  
LQELYL RNM DNTSHVWKCSNWNKFFTL PKQQSESPFHNLT TIEMRWCHGFRYLF S  
PLMAELLSNLKKVKILGCDGIEEVVSNR DDEDEEMTFTSTHTTTNLFP HLDSTL K  
YMHCLKCIGGGGAKDEGSNEISFNNTTTTTDQFKLSEAGGVCWSLCQYSREIEIYRC  
15 DALSSVIPCYAAGQMQLQVLTVSSCNGLKEVFETQLGTSSNKNNEKSGCEE GIPR  
VNNNVIMLPNLKILEIYGCGGLEHIFTSALESRLQLQELTIKGY YTLVNL PNLKEM  
RLEWLSNLRYTWKSNQWTA FEFPNLTRVEICECNSLEHVFTSSMVG SLLQLQELHIF  
NCSLMEEVIVKDADVSVEEDKEKESDGKTNKEILV LPHLKSLKLQLL RSLKGFSLGK  
EDFSFPLLD TLEIKRCPTITFTTKGNSATPQLKEIQTNFGFFYAAGEKDINS LIKIKQQ  
20 DFKQDSD.CEVNIK

**RG2E polynucleotide sequence (SEQ ID NO:96)**

TGGGAAGACACAATGATGCAAAGGTTGAAGAAGGTTGCTAAAGAAAATAGAAT  
GTTCAATTATATGGTTGAGGCAGTTATAGGGGAAAAGACAGACCCACTTGCTAT  
25 TCAACAAGCTGTAGCGGATTACCTTTGTATAGAGTTAAAAGAAAGCACTAAACC  
AGCAAGAGCTGATAAGCTTCGTGAATGGTTTAAGGCCAACTCTGGAGAAGGTA  
AGAATAAGTTCCTTGTAATATTTGATGATGTTTGGCAGTCCGTTGATCTGGAAG  
ACATTGGTTTAAAGTCATTTTCCAAATCAAGGTGTCGACTTCAAGGTCTTGTTGA  
CTTCACGAGACGAACATGTTTGCACAGTAATGGGGGTTGAAGCTAATTCAATTC  
30 TTAATGTGGGACTTCTAGTAGAAGCAGAAGCACAAAGTTTGTTCAGCAATTTG  
TAGAAACTTTTGAGCCCGAGCTCCATAAGATAGGAGAAGATATCGTAAGGAAG  
TGTTGTGGTTTACCTATTGCCATTAAAACCATGGCATGTACTCTAAGAAATAAA  
AGAAAGGATGCATGGAAGGATGCACTTTTGCATTTAGAGTACCATGACATTAGC  
AGTGTTGCGCCCAAAGTCTTTGAAACGAGCTACCATAATCTCCACAACAAGGAG  
35 ACTAAATCTGTGTTTTTGATGTGTGGTTTTTTTCTGAAGACTTCAATATTCCAA  
TCGAGGAGTTGATGAGGTATGGATGGGGCTTAAAGATATTTGATAGAGTTTATA  
CTATTAGACAAGCAAGAATCAGGCTCAACACCTGCATTGAGCGACTGGTGCAG  
ACAAATTTGTTAATAGAAAGTGATGATGGTGTGCACGTCAAGATGCATGATCTG  
GTCCGTGCTTTCTGTTTTGGTTATGTTTTCTGAAGTTGAACATGCTTCAATTATCA  
40 ACCATGGTAATATGCTTGGATGGCCTGAAAATTATATGACCAACTCTTGCAAAA  
CAATTTTCATTAACATGCAAGAGTATGTCTGAATTTCCGGGAGATCTCAAGTTTC  
CAAACCTAACGATTTTGAAGCTCATGCATGGAGATAAGTTGCTAAGATATCCTC

AAGACTTTTATGAAGGAATGGAAAAGCTCTGGGTTATATCATATGATGAAATGA  
AGTATCCATTGCTTCCCTCGTTACCTCAATGCTCCATCAACCTTCGAGTGCTTCA  
CCTCCATCGATGCTCATTAAATGATGTTTGATTGCTCTTGTATTGGAAATATGTTG  
AATCTGGAAGTGCTTAGCTTTGTAAATCTGGCATTGAATGGTTACCTTCCACA  
5 ATAGGAAATTTAAAGAAGCTAAGGTTACTTGATCTGAGAGATTGTTATGGTCTT  
CGTATAGAAAAAGGTGTCTTGAAAAATTTGGTGAAAATTGGAGGAATTTATATT  
GGTAGAGCAGATATTTTATAGAT

**RG2E deduced polypeptide sequence (SEQ ID NO:97)**

10 WEDTMMQRLKKVAKENRMFNYMVEAVIGEKTDLAIQQA VADYLCIELKESTKP  
ARADKLREWFKANS GEGKNKFLVIFDDVWQSV DLEDIGLSHFPNQGVDFKVLLTS  
RDEHVCTVMGVEANSILNVGLLVEAEAQSLFQQFVETFEPELHKIGEDIVRKCGL  
PIAKTMACTLRNKRKDAWKDALLHLEYHDISSVAPKVFETSYHNLHNKETKSVFL  
MCGFFPEDFNIPIEELMRYGWGLKIFDRVYTIRQARIRLNTCIERLVQTNLLIESDDG  
15 VHVKMHDLVRAFLVMFSEVEHASIINHGNMLGWPENYMTNSCKTISLTCKSMSE  
FPGDLKFPNLTILKLMHGDKLLRYPQDFYEGMEKLWVISYDEMKYPLLPSLPQCSI  
NLRVLHLHRCSLMMFDCSCIGNMLNLEVL SFVKSGIEWLPSTIGNLKKLRLLDLRD  
CYGLRIEKGVLKNLVKIGGIYIGRADIL.

**RG2F polynucleotide sequence (SEQ ID NO:98)**

CTGTGGAAGACACAATGATGCAAAGGCTGAAAAAGGTTGTGCATGAAAAGAAA  
ATGTTTAACTTTATTGTTGAAGCAGTTATAGGGGAAAAGACAGACCCCGTTGCC  
ATTCAGGATGCTATAGCAGATTACCTAGGTGTAGAGCTCAATGAAAAATCTAAG  
CAAGCAAGAGCTGATAAGCTCCGTCAAGGATTCAAGGACAAATCAGATGGAGG  
25 CAAAATAAGTTCTTTGTAATACTTGACGATGTTTGGCAGTCTGTTGATCTGGA  
AGATATTGGTTTAAAGTCCTTTTCCAAATCAAGGCGTCGACTTCAAGGTCTTGTT  
GACATCACGAGACAGACATGTTTGCACAGTGATGGGGGTGAAGCCAAATTAA  
TTCTAAACGTGGGACTTCTAATTGAAGCTGAAGCACAAAGTTTGTTCACCAAT  
TTGTTGTCACTTCTGAGCCCGAGCTCCATAAGATAGGAGAAGATATTGTAAAGA  
30 AGTGTTCGGTCTGCCAATTGCCATCAAAACCATGGCATGTACTCTACGACATA  
AAAGAAAGGATGCATGGAAGGATGCACTTTCACGTTTAGAGCACCATGACATT  
CAAAGTGTTGTGCCTAAAGTATTTGAAACGAGCTACAACAATCTCAAAGACAA  
GGAGACTAAATCCGTATTTTTGATGTGTGGTTTGTTCCTGAAGACTTGGATAT  
ACCTATCGAGGAGTTGATGAGGTATGGATGGGGCTTAAGATTATTTGATAGAGT  
35 TAATACTATTACACAAGCAAGAAACAGGCTCAACACCTGCATTGAGCGACTGG  
TGCACACAAATTTGTTAATTGAAAGTGTTGATGGTGTGCATGTCAAGATGCATG  
ATCTGGTTCGTGCTTTTGT TTTGGGAATGTTTTCTGAAGTGGAGCATGCTTCAAT  
TGTC AACCATGGTAATATGCCCAGGTGGACTGAAAATGATATGACTGACTCTTG  
CAAACAAATTCATTAAACATGCAAGAGTATGTTGGAGTTTCCTGGAGACCTCAA  
40 GTTTCCAAACCTAAAGATTTTGAAACTTATGCATGGAGGTAAGTCACTAAGGTA  
TCCTCAAGACTTTTATCAAGGAATGGAAAAGCTGGAGGTTATATCATACGATGA  
AATGAAGTATCCATTGCTTCCCTCGTTGCCTCAATGTTCCACCATCCTTCGAGTG

CTTCATCTCCATGAATGTTTCATTAAGGATGTTTGATTGCTCTTCAATCGGTAATC.  
TTTTCAACATGGAAGTGCTCAGCTTTGCTAATTCTAGCATTGAATTGTTACCTTC  
CGTAATTGGAAATTTGAAGAAGTTGCGGCTGCTAGATTTGACAACTGTTATGG  
TGTTTCGTATAGAAAAGGATGTCTTGAAAAATTTGGTGAAACTTGAAGAGCTTTA  
5 TATTAGGAATGGTCTACCAGTTTACAGAGGAT

**RG2F deduced polypeptide sequence (SEQ ID NO:99)**

VEDTMMQRLKKVVHEKKMFNFIVEAVIGEKTDPVAIQDAIADYLGVELNEKSKQA  
RADKLRQGFKDKSDGGKNKFFVILDDVWQSVLDLEDIGLSPFPNQGVDFKVLLTSRD  
10 RHVCTVMGVEAKLILNVGLLIEAEAQSLFHQFVVTSEPELHKIGEDIVKKCFGLPIAI  
KTMACTLRHKRKDAWKDALSRLEHHDIQSVVPKVFETSYNNLKDKETKSVFLMCG  
LFPEDLDIPIEELMRYGWGLRFLDRVNTITQARNRLNTCIERLVHTNLLIESVDGVH  
VKMHDLVRAFLVGMFSEVEHASIVNHGNMPEWTENDMTDSCQISLTCKSMLEFP  
GDLKFPNLKILKLMHGGKSLRYPQDFYQGMKLEVISYDEMKYPLLPSLPQCSTILR  
15 VLHLHECSLRMFDCSSIGNLFNMEVLSFANSSIPELLPSVIGNLKKLRLDLTNCYGV  
RIEKDVLKNLVKLEELYIRNGLPVYRG

**RG2G polynucleotide sequence (SEQ ID NO:100)**

GAAGACACGATGATGAAGAACTGAAGGAGGTCGTGGGACAAAAGAAATCATTC  
20 AATATTATTATTCAAGTGGTCATAGGAGAGAAGACAAACCCTATTGCAATTCAG  
CAAGCTGTAGCAGATTACCTCTCTATAGAGCTGAAAGAAAACACTAAAGAAGC  
AAGAGCTGATAAGCTTCGTAAACGGTTTGAAGCCGATGGAGGAAAGAATAAGT  
TCCTTGTAATACTTGACGATGTATGGCAGTTTGTGCGATCTTGAAGATATTGGTTT  
AAGTCCTCTGCCAAATAAAGGTGTCAACTTCAAGGTCTTGTTGACGTCAAGAGA  
25 TTCACATGTTTGCACCTCTGATGGGAGCTGAAGCAAATTCAATTCTTAATATAAA  
AGTTTTTAAAGATGTAGAAGGACAAAGTTTGTTCGCCAGTTTGCTAAAAATGC  
GGGTGATGATGACCTGGATCCTGCTTTCATGGGATAGCAGATAGTATTGCAAG  
TAGATGTCAAGGTTTGCCCATTCATCAAAACCATTGCCTTAAGTCTTAAAGG  
TAGAAGCAAGTCTGCATGGGACGTTGCACTTTCTCGTCTGGAGAATCATAAGAT  
30 TGGTAGTGAAGAAGTTGTGCGTGAAGTTTTTAAATTAGCTACGACAATCTCCA  
AGATGAGGTTACTAAATCTATTTTTTTACTTTGTGCTTTATTTCTGAAGATTTT  
GATATTCTACTGAGGAGTTGGTGAGGTATGGGTGGGGCTTGAAATTATTTATA  
GAAGCAAAAACCTATAAGAGAAGCAAGAAACAGGCTCAACACCTGCACTGAGCG  
GCTTAGGGAGACAAATTTGTTATTTGGAAGTGATGACATTGGATGTGTCAAGAT  
35 GCACGATGTGGTGCGTGATTTTGTGTTTGCATATATTCTCAGAAGTCCAACACGC  
TTCAATTGTCAACCATGGTAACGTGTCAGAGTGGCTAGAGGAAAATCATAGCAT  
CTACTCTTGTAAGAAATTTTCATTAACATGCAAGGGTATGTCTCAGTTTCCCAA  
AGACCTCAAATTTCCAAACCTTTCAATTTGAACTTATGCATGGAGATAAGTC  
ACTGAGCTTTCTGAAAACCTTTATGGAAAGATGGAAAAGGTTCAAGTAATATC  
40 ATATGATAAATTGATGTATCCATTGCTTCCCTCATCACTTGAATGCTCCACCAA  
CGTTTCGAGTGCTTCATCTTCACTTACTGTTTCATTAAGGATGTTTGATTGCTCTTCA  
ATTGGTAATCTTCTCAACATGGAAGTGCTCAGCTTTGCTAATTCTAACATTGAA

TGGTTACCATCTACAATTGGAAATTTGAAGAAGCTAAGGCTACTAGATTTGACA  
AATTGTAAAGGTCTTCGTATAGATAATGGTGTCTTAAAAAATTTGGTCAAACCTT  
GAAGAGCTTTATATGGGTGTTAATCGTCCGTATGGACAGGCCGTTAGCTTGACA  
GATGAAAA

5

**RG2G deduced polypeptide sequence (SEQ ID NO:101)**

RHDDEELKEVVGQKKSFNIIQVVIGEKTNPPIAQAVADYLSIELKENTKEARADKL  
RKRFEADGGKNKFLVILDDVWQFVDLEDIGLSPLPNKGVNFKVLLTSRDSHVCTL  
MGAEANSILNIKVLKDVEGQSLFRQFAKNAGDDDLDPAFNGIADSIASRCQGLPIAI  
10 KTIALSLKGRSKSAWDVALSRLENHKIGSEEVVREVFKISYDNLQDEVTKSIFLLCAL  
FPEDFDIPTTEELVRYGWGLKLFIEAKTIREARNRLNTCTERLRETNLLFGSDDIGCVK  
MHDVVRDFVLHIFSEVQHASIVNHGNVSEWLEENHSIYSCKRISLTCKGMSQFPKDL  
KFPNLSILKLMHGDKSLSPENFYGKMEKVQVISYDKLMYPLLPSSLECSTNVRVLH  
LHYCSLRMFDCSSIGNLLNMEVLSFANSNIEWLPSTIGNLKKLRLLDLTNCKGLRID  
15 NGVLKNLVKLEELYMGVNRPYGQAVSLTDE

**RG2H polynucleotide sequence (SEQ ID NO:102)**

TGAAGGAGGTTGTGGAACGAAAGAAAATGTTTCAGTATTATTGTTCAAGTG  
GTCATAGGAGAGAAGACAAACCCTATTGCTATTTCAGCAAGCTGTAGCAGA  
20 TTACCTCTCTATAGAGCTGAAAGAAAACACTAAAGAAGCAAGAGCTGATA  
AGCTTCGTAAATGGTTTCGAGGCCGATGGAGGAAAGAATAAGTTCCTTGTA  
ATACTTGACGATGTATGGCAGTTTGTTCGATCTTGAAGATATTGGTTTAAG  
TCCTCTGCCAAATAAAGGTGTCAACTTCAAGGTCTTGTTGACGTCAAGAG  
ATTCACATGTTTTGCACTCTGATGGGAGCCGAAGCCAATTCAATTCTCAAT  
25 ATAAAAGTTTTAACAGCTGTAGAAAGGACAAAGTTTGTTCGCCAGTTTGC  
TAAAATGCGGGTGATGATGACCTGGATCCTGCTTTCAATAGGATAGCAG  
ATAGTATTGCAAGTAGATGTCAAGGTTTGCCCATTGCCATCAAAACCATT  
GCCTTAAGTCTTAAAGGTAGAAAGCAAGCCTGCGTGGGACCATGCGCTTTC  
TCGTTTGGAGAACCATAAGATTGGTAGTGAAGAAGTTGTGCGTGAAGTTT  
30 TTAAAATTAGCTATGACAATCTCCAAGATGAGATTACTAAATCTATTTTT  
TTACTTTGTGCTTTATTTCTGAAGATTTTGATATTCCTACTGAGGAGTT  
GATGAGGTATGGATGGGGCTTGAAATTATTTATAGAAGCAAAAACCTATAA  
GAGAAGCAAGAAACAGGCTCAACACCTGCACTGAGCGGCTTAGGGAGACA  
AATTTGTTATTTGGAAGCGATGACATTGGATGCGTCAAGATGCACGATGT  
35 GGTGCGTGATTTTGTTTTGCATATATTCTCAGAAGTCCAGCACGCTTCAA  
TTGTCAACCATGGTAACGTGTCAGAGTGGCTAGAGGAAAATCATAGCATC  
TACTCTTGTAAGAATTTTCATTAACATGCAAGGGTATGTCTGAGTTTCC  
CAAAGACCTCAAATTTCCAAACCTTTCAATTTTGAACTTATGCATGGAG  
ATAAGTCGCTGAGCTTTCCTGAAAACCTTTATGGAAAGATGGAAAAGGTT  
40 CAGGTAATATCATATGATAAATTGATGTATCCATTGCTTCCCTCATCACT  
TGAATGCTCCACTAACGTTTCGAGTGCTTCATCTCCATTATTGTTTATTAA  
GGATGTTTGATTGCTCTTCAATTGGTAATCTTCTCAACATGGAAGTGCTC

AGCTTTGCTAATTCTAACATTGAATGGTTACCATCTACAATTGGAAATTT  
GAAGAAGCTAAGGCTACTAGATTTGACAAATTGTAAAGGTCTTCGTATAG  
ATAATGGTGTCTTAAAAAATTTGGTCAAACCTGAAGAGCTTTATATGGGT  
GTTAATCATCCGTATGGAC

5

**RG2H deduced polypeptide sequence (SEQ ID NO:103)**

KEVVERKKMFSIIVQVVIGEKTNP IAIQQA VADYLSIELKENTKEARADKLRKWFEA  
DGGKNKFLVILDDVWQFVDLEDIGLSPLPNKGVNFKVLLTSRDSHVCTLMGAEAN  
SILNIKVLTAVEGQSLFRQFAKNAGDDDLDPAFNRIADSIASRCQGLPIAIKTIALSLK  
10 GRSKPAWDHALSRLENHKIGSEEVVREVFKISYDNLQDEITKSIFLLCALFPEDFDIP  
TEELMRYGWGLKLFIEAKTIREARNRLNTCTERLRETNLLFGSDDIGCVKMHDVVR  
DFVLHIFSEVQHASIVNHGNVSEWLEENHSIYSCKRISLTCKGMSEFPKDLKFPNLSI  
LKL.MHGDKSLSFPENFYGKMEKVQVISYDKLMYPLLPSLECSTNVRVLHLHYCSL  
RMFDCSSIGNLLNMEVLSFANSNIEWLPSTIGNLKKLRLLDLTNCKGLRIDNGVLKN  
15 LVKLEELYMGVNHPYG

**RG2I polynucleotide sequence (SEQ ID NO:104)**

AAG.AAGAGCTGAAGGAGGTTGTGGAACAAAAGAAAACGTTCAATATTATT  
GTTCAAGTGGTCATAGGAGAGAAGACAAACCCTATTGCTATTCAAGCAAGC  
20 TGTAGCAGATTCCTCTCTATAGAGCTGAAAGAAAACACTAAAGAAGCAA  
GAGCTGATAAGCTTCGTAAATGGTTCGAGGCTGATGGAGGAAAGAATAAG  
TTCCTCGTNATACTTGACGATGTATGGCNGTTTGTGATCTTGAAGATAT  
TGGTTTAAGTCCTCATCCAAATAAAGGTGTCANCTTCAAGGTCTTGTGGA  
CGTCAAGAGATTACATGTTTGCACCTCTGATGGGAGCTGAAGCCAATTCA  
25 ATTCTCAATATAAAAGTTTTTAAAGATGTAGAAGGAAAAAGTTTGTTCG  
CCAGTTTGCTAAAAATGCGGGTGATGATGACCTGGATCCTGCTTTCATTG  
GGATAGCAGATAGTATTGCAAGTAGATGTCAAGGTTTGCCCATGCCATC  
AAAACCATTGCCTTAAGTCTTAAAGGTAGAAGCAAGTCTGCATGGGACGT  
TGC.ACTTTCTCGTCTGGAGAATCATAAGATTGGTAGTGAAGAAGTTGTGC  
30 GTG.AAGTTTTTAAATTAGCTATGACAATCTCCAAGATGAGGTTACTAAA  
TCT.ATTTTTTTACTTTGTGCTTTATTTCTGAAGATTTTGATATTCCTAC  
TGAGGAGTTGGTGAGGTATGGGTGGGGCTTGAAATTATTTATAGAAGCAA  
AACTATAAGAGAAGCAAGAAACAGGCTCAACACCTGCACTGAGCGGCTT  
AGGGAGACAAATTTGTTATTTGGAAGTGATGACATTGGATGCGTCAAGAT  
35 GCACGATGTGGTGCGTGATTTTGTGTTTGCATATATTCTCAGAAGTCCAGC  
ACGCTTCAATTGTCAACCATGGTAATGTGTCAGAGTGGCTAGAGGAAAAT  
CATAGCATCTACTCTTGTAAGAATTTTCAATTAACATGCAAGGGTATGTC  
TGAGTTTCCCAAAGACCTCAAATTTCCAAACCTTCAATTTTGAACTTA  
TGC.ATGGAGATAAGTCGCTGAGCTTTCTGAAAACCTTTATGGAAAGATG  
40 GAAAAGGTTCAAGTAATATCATATGATAAATTGATGTATCCATTGCTTCC  
CTC.ATCACTTGAATGCTCCACCAACCTTCGAGTGCTTCATCTCCATGAAT  
GTTCAATTAAGGATGTTTGATTGCTCTTCAATTGGTAATCTTCTCAACATG

GAAGTGCTCAGCTTTGCTAATTCTGGCATTGAATGGTTACCATCTACAAT  
TGGAAATTTGAAGAAGCTAAGGCTACTGGATCTGACAGATTGTGGAGGTC  
TTCATATAGATAATGGCGTCTTAAAAAATTTGGTCAAACCTGAAGAGCTT  
TATATGGGTGCTAATCGTCTGTTTGGAAAGTGCCAT

5

**RG2I deduced polypeptide sequence (SEQ ID NO:105)**

EELKEVVEQKKT FNII VQV VIGEKTNP IAIQQAVADSL SIELKENTKEARADKLRKWF  
EADGGKNKFLVILDDVW?FVDLEDIGLSPHPNKG V?FKVLLTSRDSHVCTLMGAEA  
NSIL\_NIKVLKDVEGKSLFRQFAKNAGDDDLDPAFIGIADSIASRCQGLPIAKTIALSL  
10 KGRSKSAWDVALSRLENHKIGSEEVVREVFKISYDNLQDEVTKSIFLLCALFPEDFDI  
PTEELVRYGWGLKLFIEAKTIREARNRLNTCTERLRETNLLFGSDDIGCVKMHDVV  
RDFVLHIFSEVQHASIVNHGNVSEWLEENHSIYCKRISLTCKGMSEFPKDLKFPNLS  
ILKLMHGDKSLSPENFYGKMEKVQVISYDKLMYPLLPSSLECSTNLRVLHLHECSL  
RMFDCSSIGNLLNMEVLSFANSIGIEWLPSTIGNLKKLRLLDLTDCGGLHIDNGVLKN  
15 LVKLEELYMGANRLFGKCH

**RG2J polynucleotide sequence (SEQ ID NO:106) and (SEQ ID NO:107)**

ATGTCCGACCCAACAGGGATTGTTGGTGCCATTATTAACCCAATTGCTCA  
AACGGCCTTGGTTCCCCTTACAGACCATGTAGGCTACATGATTTCTCTGCA  
20 GAAAATATGTGAGGGACATGCAAATGAAAATGACAGAGTTAAATACCTCA  
AGAATCAGTGCAGAGGAACACATTAGCCGGAACACAAGAAATCATCTTCA  
GATTCATCTCAAATTAAGGATTGGTTGGACCAAGTAGAAGGGATCAGAG  
CGAATGTTGCAAACCTTTCCAATTGATGTCATCAGTTGTTGTAGTCTCAGG  
ATCAGGCACAAGCTTGGACAGAAAGCCTTCAAGATAACTGAGCAGATCGA  
25 AAGTCTAACGAGACAAAATTCGCTGATTATCTGGACTGATGAACCTGTTC  
CCCTGGGAAGAGTTGGTTCCATGATTGCATCCACCTCTGCAGCATCAAGT  
GATCATCATGATGTCTTCCCTTCAAGAGAGCAAATTTTTAGGAAAGCACT  
AGAAGCACTTGAACCCGTCCAAAAATCCACATAATAGCCTTATGGGGGA  
TGGGCGGAGTGGGGAAGACCACGATGATGAAGAAGCTGAAAGAGGTCGTG  
30 GAACAAAAGAAAACGTGCAATATTATTGTTCAAGTGGTCATAGGAGAGAA  
GACAAACCCTATTGCTATCCAGCAAGCTGTAGCAGATTACCTCTCTATAG  
AGCTGAAAGAAAACACTAAAGAAGCAAGAGCTGATAAGCTTCGTAAACGG  
TTCGAAGCCGATGGAGGAAAGAATAAGTTCCTTGTAACTTGACGATGT  
ATGGCAGTTTTTCGATCTTGAAGATATTGGTTTAAGTCCTCTGCCAAATA  
35 AAGGTGTCAACTTCAAGGTCTTGTGACGTCAAGAGATTACATGTTTGC  
ACTCTGATGGGAGCTGAAGCCAATTCTATTCTCAATATAAAAGTTTTAAA  
AGATGTAGAAGGAAAAAGTTTGTTCGCCAGTTTGCTAAAAATGCGGGTG  
ATGATGACCTGGATCCTGCTTTCATTGGGATAGCAGATAGTATTGCAAGT  
AGATGTCAAGGTTTGCCCATGCAAAACCATTGCCTTAAGTCTTAA  
40 AGGTAGAAGCAAGTCTGCATGGGACGTCGCACTTCTCGTCTGGAGAATC  
ATAAGATTGGTAGTGAAGAAGTTGTGCGTGAAGTTTTTAAATAGCTAT  
GACAATCTCCAAGATGAGGTTACTAAATCTATTTTTTTACTCTGTGCTTT

ATTTCTGAAGATTTTGATATTCCTATTGAGGAGTTGGTGAGGTATGGGT  
GGGGCTTGAAATTATTTATAGAAGCAAAAACATAAGAGAAGCAAGAAAC  
AGGCTCAACAACTGCACTGAGCGGCTTAGGGAGACAAATTTGTTATTTGG  
AAGTCATGACTTTGGGTGCGTCAAGATGCACGATGTGGTGCGTGATTTTG  
5 TTTTGCATATGTTTTCAGAAGTCAAGCATGCTTCAATTGTCAACCATGGT  
AACATGTCAGAGTGGCCAGAGAAAAATGATACCAGCAACTCTTGTA AAAAG  
AATTTCAATTAACATGCAAGGGTATGTCTAAGTTTCCTAAAGACATCAACT  
ATCCAAACCTTTTGATTTTGAACTTATGCATGGAGATAAGTCGCTGTGC  
TTTCCTGAAAACTTTTATGGAAAGATGGAAAAGGTTTCAGGTAATATCATA  
10 TGATAAAATTGATGTATCCATTGCTTCCCTCATCACTTGAATGCTCCACTA  
ACGTTGAGTGTCTCATCTCCATTATTGTTTCAATTAAGGATGTTTGATTGC  
TCTTCAATTGGTAATCTTCTCAACATGGAAAGTGCTCAGCTTTGCTAATTC  
TAACATTGAATGGTTACCATCTACAATTGGAAATTTGAAGAAGCTAAGGC  
TACTAGATTTGACAAATTGTAAAGGTCTTCGTATAGATAATGGTGTCTTA  
15 AAAAATTTGGTCAAACCTTGAAGAGCTTTATATGGGTGTTAATCGTCCGTA  
TGGACAGGCCGTTAGCTTGACAGATGAAAACCTGCAATGAAATGGTAGAAG  
GTTCCAAAAAATCTTGTGCACTAGAATATGAGTTGTTTAAATACAATGCT  
CAAGTGAAGAATATATCCTTCGAGAATCTTAAACGATTCAAGATCTCAGT  
GGGATGTTCTTTACATGGATCTTTTCAGTAAAAGCAGGCACTCATACGAAA  
20 ACACGTTGAAGTTGGCCATTGACAAAGGCGAACTATTGGAATCCCGAATG  
AACGGGTTGTTTGAGAAAACGGAGGTTCTTTGTTTAAAGTGTGGGGGATAT  
GTATCATCTTTTCAGATGTAAAGGTGAAGTCCTCTTCGTTCTACAATTTAA  
GAGTCCTTGTCGTTTCAGAGTGTGCAGAGTTGAAACACCTCTTCACACTT  
GGTGTTGCAAATACTTTGTCAAAGCTTGAGCATCTTAAAGTCTACAAATG  
25 CGATAATATGGAAGAACTCATACATACCGGGGGTAGTGAAGGAGATACAA  
TTACATTCCCCAAGCTGAAGCTTTTATATTTGCATGGGCTGCCAAACCTA  
TTGGGTTTGTGTCTTAATGTCAACGCAATTGAGCTACCAAACTTGTGCA  
AATGAAGCTTTACAGCATTCCGGGTTTCACAAGCATTATCCGCGGAACA  
AGTTGGAAGCATCTAGTTTGTGAAAGAAGAGGTACATATACATATAGTT  
30 TATGTTAATACATTTTAAACAATCTTTTCAACTAAAAGTTTCAGAATATA  
TCTGTATTTTGATTGTATGATGTGTTAGTGTGTTGGATGTGGCTATTAAAG  
GATAATTATTTGGCAGGTTGTGATTCCCTAAGTTGGATATACTTGAAATTC  
ATGACATGGAGAATTTAAAGGAAATATGGCCTAGTGAGCTTAGTAGAGGT  
GAGAAAGTTAAGTTGAGAAAGATTAAAGTGAGAAATTGTGATAAACTTGT  
35 GAATCTATTTCCACACAATCCCATGTCTCTGCTGCATCATCTTGAAGAGC  
TTATAGTCGAGAAATGTGGTTCCATTGAAGAGTTGTTCAACATCGACTTG  
GATTGTGCCAGTGTAATTGGAGAAGAAGACAACAACAGCAGCTTAAGAAA  
CATCAATGTGGAGAATTCAATGAAGCTAAGAGAGGTGTGGAGGATAAAAAG  
GTGCAGATAACTCTCGTCCCCTCTTTTCGTGGCTTTCAAGTTGTTGAAAAG  
40 ATAATCATTACGAGATGTAAGAGGTTTACAAATGTATTCACACCTATCAC  
CACAAATTTTGATCTGGGGGCACTTTTGGAGATTTTCAGTTGATTGTAGAG  
GAAATGATGAATCAGACCAAAGTAACCAAGAGCAAGAGCAGGTATGGATT  
TCAATTTTACTCTTTTACTTAATTAATGATTAAGCCCCTGCTTTTTAATA



AAAAGGGGACAAACCATTCTTGACTTAATGTTGCAATACAAGTCATGTA  
TAAGAGTGATTAACCTTTTTTTTATTATAAAATAACTACAAAACATGTTT  
TTTCATTATAGATCATGTATAAATGTGACTAATTTTTTTTCATCGCCTAAC  
TTTTGTTGATAAATCATTAGAAATGTCACTAATTACTTTTTTAGTATTTAT  
5 AAAATAACTACAAAACATGTTTTTTTCATTATAGATCATGTATATATCAAC  
TAAAAATATTATTCCTTACACAAAAAAGGTTCAAGAAAGCCTGTA  
TTTCGAAATAACTAAAAAGAAAATATTTGATATTCCTAAGAGAAATTTT  
TTTCTAAACATGATCGCAAATGATTAAACTTAAATTAAACTAAAAAGA  
TTTTTATATATGTTATNCAAAATTAATAATTTGAAATTAAGTTTATAATTC  
10 TNGTNTCACAAAGGGATATATATAGTAAATATTATTTTTTTGCGATCAT  
GCATAGTTGTATTTTTAAATGATTTATTAACGTGGTAGGAGTGGAACCA  
CTCAATCTAGTAGACCCACTATCACATGTCACATCAGCTTTACATCTATT  
TTTCTTTCTCCTTTTTTTCATCTTTTTAACTCATAACACNTAAAANTANC  
ATATTTTCCAACACACTNAACTCATTGTCACATTATTATTTTAAATTTAA  
15 TTAAATTNGAAAATTAATAAANTAAANCNTAACATTTTTTAATTAATAA  
AATATTAATCCAAATAAAAANTNCACGATAAATTAATAANGTTTANTTTG  
GAAAAAANCC (SEQ ID NO:106)

Sequence gap

20 ATAACCCTTTCAAGGGTCAACTCAAGTCCAAGTTAAAGTCAAGGTCAAAA  
CCTTGGTTAAAGTCAACTTTGGTCAAAGTCAACATCTACTTGACTCACCT  
CACCGAGTTGGTCCACCAACTTGTCGAGTCCCTTAATCCACAACTTCAA  
GAACTTCGATCCTACTCGTCGAGTCTTTCAAGAACTCTTCGAGTTTCCAT  
TACACAGAATCGGGACCTTTTGCTCATGACTCGCCGAGTTCATCCTTGAA  
CTTGTCGAGTCTAGCTTCATACGAGTTCGAGTGTTTAGTCCTTGACTCGT  
25 CGAGTTCTTCCTTGAACCTCGTCGAGTCCATCTTCGTATAGTTGGGACATT  
GCCTTGAACCTACCGAGTTCATCATTGAACCTCATCGAGTCTTCGATCTT  
CAAGTCCATAATCCTGTCCATCTTGTTGAGTCTCTTAGACTCAACCA  
GATTCCTCAGAAACAGAAAAGGTTAGGGAACCATTACCTGACTCGCCGAG  
TCCCAAGAACGAATCCCCGAGTCCCCCAATGTCCATGACCATAACAATCGA  
30 TTTTCGTTGGGCTCATTGCATCCAAAGCATAGATCTAACCTCCTAGGGTC  
CATATTACACGTAAAGCTACGAACTTGACGTCCATGCATGGGGGATTTGG  
CTCAAATGGCATTAAAATGGGGTTTATCTGATGCATGGGACTCCCATGGC  
CATAAAGTTAACACCTTTATGCCATGGGAATCCTCAATGGTTCCATATCT  
GAAGTTAACTCTACAATATGTTCTAAACCCGAAGGTGGCTTAGAAATG  
35 CCCCCAAATGGCAAGATTCAAGCCTTAAAGGAGATCTAACAAATGATAAG  
TCAAGGTTCAAGCTTTTTACCTTGAATAAGCTGGAAATGAAGCAAAATCT  
CTGGATCCACTTGCTTCTTCAAGAACCCCCAAGCTTCCACTTCTTCTTC  
AAGTTTCAAACAACTTTAAACACTCAAAAATGGCTCAAGAACACTCAAAA  
AGCTTTAGGGTTTCGAGTTAGGGCTTTTTGGAAGCGAGAGGGACGATGGG  
40 GGCTGAAATGAGGCTAGAAAAAGTGTTTAAATAGGGGGCAAACCCTAAAT  
ATTAGGGTTTCATCCAGGCAGCCCTACTCGTCGAGTCGGGCTCCCGACTC  
GTCGAGTAGGTCACTTAAAACCCGCGTCCATAATCCAGTCTACTCGACGA  
GTTGGGCCTCCAACCTCGTCGATTCCGAGTGCAAAACGTTCAATTACTTAA

ATTTAAATATGTACCAGGAACCGGGTGTACAGTTGAGACTTTATACCTC  
CATAAGATAGATCTAGGTGCACATAGCCTGGATCCACAAGCTCCATGTCA  
ACAAGCGACTCTTCAAGAAGTTCATTCTTCCTCCTTAAGCACCAAAAAAC  
ACACAAAATCACCATGAAGCTCAAGAAATACTCAAATAGAGGATAGGGTT  
5 TCGTTCGTAGGGTTAGAGAGGATGGAGGCTAGAGGAAATGAGGGATAGAG  
GCGAGTTAAGGTCTTTAAATAGGGTCCAAGACCCTAAATTAGGGTTTTAA  
TCTGGCCAGACGAACGCAGGGTGTCCCAAATGCATATGTGTCCAAATTC  
TCGTGTGCGCCATGCGTACCTCCCTTGTACGCCATGTGTACCGGGTTTGG  
TCCAAACCCTTCTAACTTCAAATGATCATAACTTGCACCCCTTATCTGTT  
10 TTCGATGTTCTTTATATCCACGGAAAGGTAACAAGAAGCCCTATACTTCT  
ATAAACTTTATTTAATCTGAAAACCAACCGAAATTAAATCCAAAATTCAT  
AAAAGTCCCGAACCAACACATTTACCGATACCCTTGGGCTCCAAAACACA  
AATTGAAAACCCGGATCATCCAACTACATCATCCACCTCCAAATGAGCC  
CAAACCTCAATTATTCAAGGGTCTAAGCCTGTTAATGCCCACTCCTCGAT  
15 TACCACCCCGCAATGGGAACGATTCAAACAGGGCGTTACATAATTTGT  
TGTGGTTTTGTATTTTTTATTTCCGGTGAAGGTGAAAGATCCAACATTTT  
TTAATCTGTTGGCATTTTCCATCATTGCAACTGTTTCTTGAAAAAAAAA  
TACCTAAAATCAAATAACCATTTTCAAATCCAAAATTATAAGAGAGAAT  
TGTAATGGACATGGAATCTTAAATCATTAAACACAGTTCAGTACACAAGT  
20 TGCTAATTACATTTCTTGCTGTGCAGATTGAAATTCTATCAGAGAAAGAG  
ACATTACAAGAAGCCACTGACAGTATTTCTAATGTTGTATTCCCATCCTG  
TCTCATGCACTCTTTTCATAACCTCCAGAACTTATATTGAACAGAGTTA  
AAGGAGTGGAGGTGGTGTTTGAGATAGAGAGTGAGAGTCCAACAAGTAGA  
GAATTGGTAACAACCTCACCATAACCAACAACAGCCTGTTATATTTCCCAA  
25 CCTCCAGCATTTGGATCTAAGGGGTATGGACAACATGATTTCGCGTGTGGA  
AGTGCAGCAACTGGAATAAATTCTTCACTCTTCCAAAACAACAATCAGAA  
TCCCCATTCCACAACCTCACAACCATAAATATTGATTTTTGCAGAAGCAT  
TAAGTACTTGTTTTACCTCTCATGGCAGAACTTCTTTCCAACCTAAAGA  
AAGTCAATATAAAATGGTGTATGGTATTGAAGAAGTTGTTTCAAACAGA  
30 GATGATGAGGATGAAGAAATGACTACATTTACATCTACCCACACAACCAC  
CATCTTGTTCCCTCATCTTGATTCTCTCACTCTAAGTTTCCTGGAGAATC  
TGAAGTGTATTGGTGGAGGTGGTGCCAAGGATGAGGGGAGCAATGAAATA  
TCTTTCAATAATACCACTGCAACTACTGCTGTTCTTGATCAATTTGAGGT  
ATGCTTTGTTTCATATTCAATTATTTATTTAATTTCTTTTTTTATTTGCAA  
35 TATTCTATAAATAATACATTTTATACCCACTATACTAAGATAATAATTAC  
CTAGAGGGATGGATGCTATGACACAGCTGCTACACTTCAGAACTCTAGT  
AAGGGCAGTTATGGAAGTTCAATAAAATGATAATGGCATCTTTTGATGGG  
TAATATAGGCAATTTAAGTTTTATTTCTGTAAAGCAGTATTTAGCAAGT  
ACTGGCCAGTAGGAGAGGAGAATATCACCTTTTGTGAAAATCTGGTCATT  
40 GTACCCAGAATTTAGTTAAATGTAACATTTTAGATATCAGGGGACATCAG  
GTGACAGATATTGTAGAATAGAACAATATATAATATTACCCAAAACCTATT  
TTTTCTAAGGTTTTTCTGTAAATATGTGCTTCTTGATTTCATTGAATT  
TGCATTCCCTATATTTTAGGTGGTAAAGTGATTGTCTCTTCAATAAATCCC

GAAATTAATTAAAAAAAAAAAAAAAAAACAAAAGTAAATTTTTGATATGGAGA  
GCACTGGTATCATTTAGTATATAAAAAAACTAGATTTTGAATTAAGTTTC  
TTATATAAAAGCTGTGTATATAGTTTAATTAGTTTTACATCATTTTTCCA  
TGTGGTGTTCAGTTGTCTGAAGCAGGTGGTGTTCCTTGGAGCTTATGCC  
5 AATACGCTAGAGAGATAAGTATAGAATTCTGCAATGCATTGTCAAGTGTG  
ATTCCATGTTATGCAGCAGGACAAAATGCAAAAGCTTCAAGTGCTGACAGT  
CAGTTCTTGTAAATGGTCTGAAGGAGGTATTTGAAACTCAATTAAGGAGGA  
GCAGCAACAAAAACAACGAGAAGAGTGGTTGTGATGAAGGAAATGGTGGA  
ATTCCAAGAGTAAATAACAATGTTATTATGCTTTCTGGTCTGAAGATATT  
10 GGAAATCAGCTTTTGTGGGGGTTTGGAAACATATATTCACATTCTCTGCAC  
TTGAAAGCCTGAGACAGCTCGAAGAGTTAACGATAATGAATTGCTGGTCA  
ATGAAAGTGATTGTGAAGAAGGAAGAAGATGAATATGGAGAGCAGCAAAAC  
AACAAACAACAACGAAGGGGACTTCTTCTTCTTCTTCTTCTTCTTCTTCTT  
CTTCTTCTTCTTCTTCTTCTCCTCCTTCTTCTTCTAAGAAGGTTGTGGTC  
15 TTTCTTGTCTAAAGTCCATTGTATTGGTCAATCTACCAGAGCTGGTAGG  
ATTCTTCTTGGGGATGAATGAGTTCGGGTTGCCTTCATTAGATGAACTTA  
TCATCGAGAAATGCCCAAAAATGATGGTGTTCACAGCTGGTGGGTCCACA  
GCTCCCCAACTCAAGTATATACACACAAGATTAGGCAAAACATACTATTGA  
TCAAGAATCTGGCCTTAACCTTTCATCAGGTATATATGTTTCTTTAATTGG  
20 CATCATCTAATTAAGAAAGATATCATTCTGCCAAGTAAATTTACTTCAA  
ACACATTACACTGGTTTCAGTCTAAGTTTATGTTGTTCTAGGAAGGCCA  
AAATGGGAAAGCAAGATAGGGAAAAATAGTGTATTTCAAGTGGAAGGGTA  
TTTTAGGTATTTTCTGTCAAAAGTTGTTATTGCAGGCTTTTATGACCTG  
GAATCGTGTGTGGGAGGAGCATTATTCTGATTGCTTGTTCCTTAT  
25 CATTTTTTCTTAGCCTCTCGAACAGCTAGAAACCCTTTTAATCTTTTGAT  
TTTAAATGACAAAATTTTTCCCTGTTACTCTATTTGATTGTTGTTCTTCA  
TGGTTCTAAGTGAGTTATTGGCTCATCTGTTACTTCTTTTGATTGTTATT  
TTCATAGCATGTTAGTCACTTGAATCAAGCTTTTTTCATTTTCAACCAGGG  
CAAAAGGTCAAAAGTAACCTACTTTATGAGATCAAAAACAGCAACCCATC  
30 GGATAACTTTTAGTTGGAGTTAATAGTTACAATTACCATTGTGATTAATA  
ATTATAATATCCTGTATTAATTCATAAAAAATTGGTACAGCACATATATGA  
CATTTCAAAGGTTTTTGTGTTGACATATATATGCCTCTGGCGTTTTCTTTA  
TTGGACTTGACAGACCTCATTCCAAAGTTTATACGGTGACACCTTGGGCCC  
TGCTACTTCAGAAGGGACAACCTTGGTCTTTTCATAACTTGATTGAATTAG  
35 ATGTGAAATTTAATAAGGATGTTAAAAAGATTATTCCATCCAGTGAGTTG  
CTGCAACTGCAAAAGCTGGAAAAGATAAATATAAACAGTTGTGTTGGGGT  
AGAGGAGGTATTTGAAACTGCATTGGAAGCAGCAGGGAGAAATGGAATA  
GTGGAATTGGTTTTGATGAATCGTCACAAACAACCTACCACTACTCTTGTC  
AATCTTCCAAACCTTAGAGAAATGAACTTATGGGGTCTAGATTGTCTGAG  
40 GTATATATGGAAGAGCAATCAGTGGACAGCATTTGAGTTTCCAAAACATA  
CAAGAGTTGAAATTAGTAATTGCAACAGTTTAGAACATGTATTTACTAGT  
TCCATGGTTGGTAGTCTATCGCAACTCCAAGAGCTACATATAAGTCAGTG  
CAAACTTATGGAGGAGGTGATTGTTAAGGATGCAGATGTTTCTGTAGAAG

AAGACAAAGAGAAAGAATCTGATGGCAAGATGAATAAGGAGATACTTGCG  
TTACCTAGTCTAAAGTCCCTGAAATTAGAAAGCTTACCATCTCTTGAGGG  
GTTTAGCTTGGGGAAGGAGGATTTTTCATTCCCATTATTGGATACTTTAA  
GAATTGAGGAATGCCCAGCAATAACCACCTTCACCAAGGGAAATTCCGCT  
5 ACTCCACAATAAGAGAAATAGAAACAAGATTTGGCTCGGTTTATGCAGG  
GGAAGACATCAAATCCTCTATTATAAAGATCAAACAACAGGTAAATCAGA  
TCATTGTTGGTTTAATAATTCTTAAACTACATTTGAAAAGTTTCATGTAA  
GTTTTTTATTATTGTCAAAAGCCGCAACCTATATTTTCAACTTTATATTT  
ATGTACTTTATGCAGGATTTCAAAAAGCCCAGGACTCTATTTAATGTGA  
10 AGTAAATACTAGAAGAGGTAAATTCTATTTACATGTCTCCTGATTGCCTA  
TTAATTAATGGCCTTTCAGTTCATGGTTTTTGGATGTATTCTTCATGATG  
ACGTGAATGTTTAAATACCCCACTAGTTAATTGTTAGGTTGAATGTTGAT  
GACCAAAGGACTATATGTCGGGAAGAATATTCAAGGAAAGAATTGTTTCAT  
CATATGAAGGGCATTAAATTAAGAAGAACATGGATGCTATGAAGATGTTG  
15 GGAATAATATATGAATCAAATAACAAGCTACTCACTTATCTAAGTTTGTG  
GTTGAGGATGTTGATTTTAATATTTCAAATTCATTGGTATCATTATATGG  
GTTTATCAGTAGTGTTAATGGGATAATGAGCAACTTAACCTTAAATTATG  
CTGTTGGTAAATGTTGGACTCAAGTATGGAAAATTAGGAATAACTTGTGA  
AAAATATATGCAAAAGTAGGATTGAGATTTTCAATGAAAAAAATTATGAA  
20 ACTATACTACTATAGTATATAAATAAATTCAACTTACTGTTGGGTATATT  
GGAAGCACATATCATGAAAGTAAGTAGAAGCAGAATTTGTTCCCATCTTC  
ATCTACTTATAGTTTCCATTTCTTACTTGTAATAATCTGATTAACTTTA  
GAGTATTTTCTATTTTTTACCAACCAAAATTTTCATATAAAGGCCACAAG  
T (SEQ ID NO:107)

25

**RG2J deduced polypeptide sequence (SEQ ID NO:108)**

MSDPTGIVGAIINPIAQTALVPLTDHVGYMISCRKYVRDMQMKMTELNTSRISAEHH  
ISRNTRNHLQIPSIKDWLDQVEGIRANVANFPIDVISCCSLRIRHKLQKAFKITEQI  
ESLTRQNSLIWTDEPVPLGRVGSMAISTSAASSDHHDVFPSREQIFRKALEALEPVQ  
30 KSHIALWGMGGVGKTTMMKKLKEVVEQKKTCNIIVQVVIGEKTNPPIAQAVADY  
LSIELKENTKEARADKLKRFEADGGKNKFLVILDDVWQFFDLEDIGLSPLPNKGV  
NFKVLLTSRDSHVCTLMGAEANSILNIKVLKDVEGKSLFRQFAKNAGDDDLDPFI  
GIADSIASRCQGLPIAKTIALSLKGRSKSAWDVALSRLENHKIGSEEVVREVFKISYD  
NLQDEVTKSIFLLCALFPEDFDIPIELVRYGWGLKLFIEAKTIREARNRLNNECTERL  
35 RETNLLFGSHDFGCVKMHDVVRDFVLHMFSEVKHASIVNHGNMSEWPEKNDTSN  
SCKRISLTCKGMSKFPKDINYPNLLILKLMHGDKSLCFPENFYGKMEKVQVISYDKL  
MYPLLPSSLECSTNVRVLHLHYCSLRMFDCSSIGNLLNMEVLSFANSNIEWLPSTIG  
NLKKLRLLDLTNCKGLRIDNGVLKNLVKLEELYMGVNRPYGQAVSLTDENCNEM  
VEGSKKLLALEYELFKYNAQVKNISFENLKRKISVGC SLHGSFSKSRHSYENTLKL  
40 AIDKGELLESRMNGLFEKTEVLCLSVGDMYHLSDVVKVSSSFYNLRLVLVSECAEL  
KHLFTLGVANTLSKLEHLKVYKCDNMEELIHTGGSEGDTITFPKLKLLYLHGLPNL  
LGLCLNVNAIELPKLVQMKLYSIPGFTSIYPRNKLEASSLLKEEVVPEELIVEKCGSI  
EELFNIDLDCASVIGEEDNSSLRNINVENSMKLEVVRIKGADNSRPLFRGFQVVE

KIITRCKRFTNVFTPITTNFDLGALLEISVDCRGNDESDQSNQEQEQIEILSEKETLQE  
ATDSISNVVFPSCLMHSFHNLOKLILNRVKGVFVFEIESESPTSRELVTTHNQQQP  
VIFPNLQHLDLRGMDNMIRVWKCSNWNKFFTLPKQQSESPFHNLTINIDFCRSIKY  
LFSPLMAELLSNLKKVNIKWCYGIEEVVSNRDEDEEMTTFTSTHTTTILFPHLDSL  
5 TLSFLENLKCIGGGGAKDEGSNEISFNNTTATTAVLDQFELSEAGGVSWSLCQYAR  
EISIEFCNALSSVIPCYAAGQMOKLQVLTVSSCNGLKEVFETQLRRSSNKNNEKSGC  
DEGNGGIPRVNNNVIMLSGLKILEISFCGGLEHIFTSALESRLQLEELTIMNCWSMK  
VIVKKEEDEYGEQQTNTTTKTGSSSSSSSSSSSSSSSSSSSSSKKVVFPCLSIVLVNLP  
ELVGFFLGMNEFRLPSLDELIEKCPKMMVFTAGGSTAPQLKYIHTRLGKHTIDQES  
10 GLNFHQDIYMPLAFSLDLQTSFQSLYGDTLGPATSEGTTWSFHNLIELDVKFNKD  
VKKIIPSELLQLQKLEKININSCVGVVEVFETALEAAGRNGNSGIGFDESSQTTTTTL  
VNLPLNREMNLWGLDCLRYIWKSQWTAFEFPLTRVEISNCNSLEHVFTSSMVGS  
LSQLQELHISQCKLMEEVIVKDAADVSEEDKEKESDGKMNKEILALPSLKSLKLESL  
PSLEGFSLGKEDFSFPLDTRLIEECPAITTFTKGNSATPQLREIETRFSGSVYAGEDIKS  
15 SIIKIKQQDFKKAQDSI.CEVNTR

**RG2K polynucleotide sequence (SEQ ID NO:109) and (SEQ ID NO:110)**

TGGGATTCCATATATAAAAACATATATTTTTATAAAGTGGGATTCCATTG  
TTTATATAGATTTTTATTACCAATAGACAATAGATTAAAAAAGATATA  
20 AAAACATGTCGGCTTTTGACTAAAAATATAGATTTTTATGAATAGAATAT  
TCAATTTGCTTAACTCGTTTAAAAAAAATGAAAAAGATGTCGATATAAAA  
TCTCATATGGGCCTTCTTTACCATTCAAATAGTAAAATAGTAAAAGATAC  
TTGTTTGGGGCATGAACTGACCATAGTCAAACCCATACAAAATCAAACGA  
ATCCACATGGATGATGACGATGGGGTCGCAGTAAATGTGTTTTGGTCCT  
25 TTTTTTCGAGAGAACAGAAGCTTCTGCTCTTCATCTTCTTAGATTTTG  
GGGATTTTCTGGTTTCAGGGGTTGTGAGTGGAACTAAATTGAAGCAA  
AAAGTATGGTATAATTGGTTGCTAGTGAAATTGATGCTTTCTATTACTAT  
CATCTTTAAAATTGTCAAAACATTATGTATTAAATTATGAGATCGAAAGT  
GGTCTATGGGCCAAAGGTAATACAAGCTTACTCAATGAAATGAATCTAGG  
30 ATGCATCATGCATGTATTGGTTAGATTAAAGATTTTCATCAAATTTCTT  
TATCAAATTGTTGTATACCATGTTATGTAGGTGCTACCACAAGCCATAAC  
ATCGAGCAATGGAGTGTATTACTGGCATCTTTAGCAACCCGTTTGCTCAG  
TGTCTCATCGCTCCTGTGAAAGAACACCTTTGCCTTCTGATTTTCTATAC  
ACAATATGTAGGGGATATGCTTACTGCAATGACGGAGTTGAATGCTGCAA  
35 AAGACATTGTTGAAGAGCGGAAGAATCAAAACGTAGAAAAATGTTTTGAG  
GTTCCAAACCATGTCAACCGTTGGTTGGAAGATGTTCAAACAATCAACAG  
AAAAGTGGAACGTGTTCTTAACGATAATTGCAATTGGTTCAATCTATGTA  
ATAGGTACATGCTCGCAGTGAAAGCCTTGGAGATAACTCAGGAGATCGAT  
CATGCCATGAAACAACTCTCTCGGATAGAATGGACTGATGATTCAGTTCC  
40 TTTGGGAAGAAATGATTCCACAAAGGCATCCACCTCTACACCATCAAGTG  
ATTACAATGACTTCGAGTCAAGAGAACACACTTTTAGGAAAGCACTTGAA  
GCACTTGATCCAACACACATCCACATGGTAGCCTTATGGGGGATGGG

TGGAGTTGGGAAGACCACGATGATGAAGAGGCTGAAAAATATTATTAAG  
AAAAGAGGACGTTTCATTATATTGTTTTGGTGGTTATAAAGGAAAATATG  
GATCTCATTTCATCCAGGATGCTGTAGCAGATTATCTGGATATGAAGCT  
AACAGAAAGCAATGAATCAGAAAGAGCCGATAAACTTCGTGAAGGGTTTC  
5 AGGCCAAATCAGATGGAGGTAAGAATAGGTTCCCTCATAATACTGGATGAT  
GTATGGCAATCTGTTAATATGGAAGATATTGGTTTAAGTCCTTTCCGAA  
TCAAGGTGTCGACTTCAAGGTCTTGTTGACCTCGGAAAACAAAGATGTTT  
GTGCAAAAATGGGAGTTGAAGCTAATTTAATTTTCGACGTGAAATTCTTA  
ACAGAAGAAGAAGCACAAAGTTTGTTTTATCAATTTGTAAAAGTTTCTGA  
10 TACCCACCTTGATAAGATTGGAAGCTATTGTAAGAACTGTGGTGGTC  
TACCCATTGCCATCAAACCATAGCCAATACTCTTAAAAATAGAAACAAG  
GATGTATGGAAGGATGCACTTTCTCGTATAGAGCATCATGACATTGAGAC  
AATTGCACATGTTGTTTTTCAAATGAGCTACGACAATCTCCAAAACGAAG  
AAGCTCAATCCATTTTTTTGCTTTGTGGATTGTTTCCTGAAGACTTTGAT  
15 ATTCCTACTGAGGAATTGGTGAGGTATGGATGGGGATTGAGAGTATTTAA  
TGGAGTGTATACTATAGGAGAAGCAAGACACAGGTTGAACGCCTACATCG  
AGCTGCTCAAGGATTCTAATTTATTGATTGAAAGTGATGATGTTCACTGC  
ATCAAGATGCATGATTTAGTTTCGTGCTTTTGTGGTGGATACGTTAATAG  
ATTCAAGCATTCTTTGATTGTTAACCATGGTAATGGTGGTATGTTAGGGT  
20 GGCCTGAAAATGATATGAGTGCCTCATCTTGCAAAAGAATTTCAATTAATA  
TGCAAGGGCATGTCCGATTTTCTAGAGACGTAAAGTTTCCAAATCTCTT  
GATTTTGAACTTATGCATGCAGATAAGTCTTTGAAGTTTCTCAAGACT  
TTTATGGAGAAATGAAGAAGCTTCAGGTTATATCATAACGATCACATGAAG  
TATCCCTTGCTTCCAACATCACCTCAATGCTCCACCAACCTTCGTGTGCT  
25 TCATCTTCATCAATGCTCATTGATGTTTGATTGCTCTTCTATTGGAAATC  
TGTTGAATCTGGAAGTGCTCAGCTTTGCTAATTCTGGTATTGAGTGGTTG  
CCTTCCACAATCGGAAATTTGAAGGAGCTAAGGGTACTAGATTGACAAA  
TTGTGATGGTCTTCGTATAGATAATGGTGTCTTAAAGAAATTGGTGAAC  
TTGAAGAGCTTTATATGAGAGTTGGTGGTCGATATCAAAAGGCCATTAGC  
30 TTCCTGATGAAAATGCAATGAAATGGCAGAGCGTTCAAAAAATCTTTC  
TGCATTAGAATTTGAGTTCTTCAAAAACAATGCTCAACCAAGAATATGT  
CATTTGAGAATCTTGAACGATTCAAGATCTCAGTGGGATGTTATTTTAAG  
GGAGATTTTCGGTAAGATCTTTCCTCTTTTGAACACGTTGCGGTTGGT  
CACCAACAGAACTGAAGTTCTTGAATCTAGGCTTAATGAGTTGTTTGAGA  
35 AAACAGATGTTCTTTATTTAAGTGTGGGAGATATGAATGATCTTGAAGAT  
GTTGAGGTAAAGTTGGCACATCTTCCTAAATCCTCTTCCTTCCACAATTT  
AAGAGTCCTTATCATTCTGAGTGTATAGAGTTGAGATACCTTTTCACAC  
TTGATGTTGCAACACTTTGTCAAAGCTTGAGCATCTTCAAGTTTACGAA  
TGCGATAATATGGAAGAAATCATACATACAGAGGGTAGAGGAGAAGTGAC  
40 AATTACATTCCCAAAGCTGAAGTTTTTATCATTGTGTGGGCTACCAAATC  
TGTTGGGTTTGTGTGGTAATGTGCACATAATTAATCTACCACAACTCACA  
GAGTTGAACTTAATGGCATTCCAGGTTTCACAAGCATATATCCTGAAAA  
AGATGTTGAAACATCTAGTTTGTGAATAAAGAGGTAAATGTGTTTTATG

TTAATACAATACAATCTTTTCAATTAACCGTTTCAAAATATATTGTATGA  
TTTATTTTTGTTTGGATGGGGTTATTAATGGGTGATTATTTCTCAGGTTG  
TAATTCCTAATTTGGAGAACTTGATATTAGTTATATGAAGGATTTGAAA  
GAGATATGGCCTTGTGAATTAGGGATGAGTCAGGAAGTTGATGTTTCTAC  
5 GTTGAGAGTGATTAAAGTAAGCAGTTGTGATAATCTTGTGAATCTATTCC  
CGTGCAATCCTATGCCATTGATACATCACCTTGAAGAGCTTCAAGTGATA  
TTTTGTGGTTCCATTGAAGTGTTATTCAACATTGAGTTGGATTCTATTGG  
TCAAATTGGAGAAGGCATCAACAATAGCAGCTTGAGAATCATCCAATTGC  
AGAAGTTAGGGAAGCTAAGTGAGGTGTGGAGGATAAAAGGTGCGGATAAC  
10 TCTAGTCTTCTCATCAGTGGCTTTCAAGGTGTTGAAAGCATTATCGTTAA  
CAAATGCAAGATGTTTAGAAATGTATTCACACCTACCACCACCAATTTTG  
ATCTGGGGGCACTTATGGAGATTCGGATACAAGATTGTGGAGAAAAGAGG  
AGAAACAACGAATTGGTAGAGAGTAGCCAAGAGCAAGAGCAGGTATGGCT  
TTCAATTTTCACTTTTCTTACTTAATGAAGGATTAAGCTCCTGCTTTTTGAA  
15 TAAAAAGTGGATGAATGACTAAATTCGGGAATGCCACCCGGAAAGTTATC  
AACCATTAGCTACACCATTTTTTGAACATAATGTTGCAATAAATGCATAA  
TATAATTAAAAATGGTCATTGATAAATGTAAACCAACCTTTTTTATTTA  
TTAAAATGTCTACAATAAATGATTTTCTTTATTATATATCATTTTATAAC  
AATAAGCTTAAAGATGTTTAAATAGCCAATGTCAGTTATAGATCGTAACT  
20 AATTTTTTATTAAGTATTTTAGTTAAGATATCACTCATTATTATTTTAA  
TAGAAAAAAGACAAGATTGGCTAATCCTCATAAGAATTTGGAAGATTTAA  
GCAAAATATAGAGCTTTTCCAAACATAGCCAATAGTTTCTTTTGCAGGTC  
CCATCTACGAAATTATCAATAGATTTGCGATTTTTTTTTTGGCACCCGGA  
AATTTCCATTAAATTAAGGTTCAAGCCATTTTGTAGTTGGCACCTG  
25 CAAAATGGTAGTTTGCACCTGCGGAAATCACCTTTCACCATTTTCGCATCT  
ATGACTTGTGAAAATGTTAATTTGTGAAATGGTCATGTGCACCTCATGAG  
AAATACGAAATGGTCAGTAATATGACTTTTTTATATAAATATGATGGTGG  
CATATATTTATAGGAAAATATAGCTGCACGATATTAATTAATAGTGAAAT  
TAGTTAACTGTATACGATAAGTATACAAAATTTATATGTATGAAGTATAC  
30 TCAATTTAGGACGACTCGGGCAATGAAATCATCATTTAATAGGAGCAATG  
AAATCATTTTCGAAAAATGTTTACAAATGAATAAAATATTAAATTAACT  
TAAACATTTTGTAGTAGTTTGAATTTACAACTGAAATTTGTTGTAT  
TTATTAACATTTATAAATGTTGTACTATGATTTTTTCTTGTGTTGCAAAT  
ATTCCTTAAAAATCCACCTAAAAATCAAAATAATTAATCTTTTTCAAGTTG  
35 AAAAATGAAAATCGTATGATATAACCGTGTATGGATGTGGAATTATATAT  
CAGTTACTAATTACATTTTTTGTGTTGGGATATATGTGCGCAGATTGATATT  
GCAATCCCATTCACTCTCACACACTCTTCCAAAACCTCCGTAACTTGC  
TTTGGAAAAGTATGAAGGAGTGGAGGTGGTGTGTTGAGATAGAGAGTCCAA  
CAAGTAGAGAATTGATAACAATTCACCATAATCAACAACCACTACTTCCC  
40 AACCTTGAGTTATTGGATATAAGTTTATGGACAGCATGAGTCATGTATG  
GAAGTGCAACTGGAATAAATCTTCATTCTTCAAAAACAACAGTCAGAAT  
CCCCATTCTGTAATCTCACAACCATACATATTCAATATTGCCAAAGCATT  
AAGTACTTGTGTTTCAACTCTCATGGCAAACTTCTTTCCAACCTAAAGAA

GGTCGAGGTAAGAGAGTGTTCATGGTATTGAAGAAGTTGTTTCGAACAGAG  
ATGATGAAGATGAGGAAAAGACTACATTTACATCTACATCTTCTGAAAAA  
AGCACTAATTTGTTCCCTCGTCTTGAATCTCTCGCTCTTTATCAACTTCC  
AAATCTCAAGTGTATTGGTGGTGGTGGTCTGCCAACAGTGGAACAATG  
5 AAATATCTCTTGATAATCCACTACTACTTCTTTTGTGATCAATCT  
AAGGTATGTTTTTTTTTTNGTTNCCCTT (SEQ ID NO:109)

Sequence gap

CCTCCCTAATAACATGTTATGCACACTATACTAACATATTAGACACGT  
AAAGGATAAATGCTATGCCTCATATAATACGTTATATTTATAATCTTTAA  
10 ACAATCAAATTTATTAAACAAATAACTAAGTGTGAGCAAAGGCAGGTACC  
CGACTAAATTGCCCAAACCAGTCTGGTGGTTCGTGGAATGTTGGGCCAG  
GTCGTAAAACGTCTACACACCGGTTCTTTAAATCACAGATCCGCTTCTC  
ATACTGTGAACCCGGTTTTAATTTTAAAAGAAAATTCATTATAAAGTAA  
ATGACTTAAACCATTACAAACAACAAAATTTACCATTACAATGTTGGAC  
15 TATCATTATTTGCAACATAAACTGAAAATACACATATTCCTTCTGATA  
TCAGCATGAGTGGCTGGTGGCTAACCCAAAAATCCATGCATTGTAGATG  
TGTGTTACAACACATAGTATCAATGAAAGGCATATTTTAGGCTAGAATT  
TAACAATCTGTAATAATATCCCTAAAATAATATCATCATCAACCAACT  
AATATAAAACCATTGGGTTCGTCAATTTTAGGTACAAAACATAGATTTTTC  
20 TAAGCTTGTGTATTTAAACATATGCTTTCTAACTTAATTGATTTTGCA  
TTCCAAAATTTTAGGTTGTAAAGTGGTATGTCATTTGTTGTCTTTTCAAC  
ATTAAATTGTACAAAACCAAACTACATAATTGATGTAGATATCATAACA  
ATTGTGTTATTTAGTATATAAACTAAATTTGAATTGAATTTCTTATA  
CAAAAGTTGTGTCTATGTATACATGTTTATGTAGGTAATAGACAATTAGT  
25 CTCTGTTAAGTATATGGAGTTTAAATTTTAGACTAATTTTCATGTGTTG  
CAGTTTTATCAGGCAGGTGGCGTTTTTTGGACGTTATGCCAATACTCCAG  
AGAGATAAATATAAGGGAGTGTTATGCATTGTCAAGTGTAATTCCATGTT  
ATGCAGCAGGACAGATGCAAAATGTTCAAGTGCTGAATATATACAGGTGC  
AACTCAATGAAGGAGTTATTTGAACTCAAGGGATGAACAACAACATGG  
30 TGACAGTGGTTGTGATGAAGGAAATGGTTGTATACCAGCAATTCCAAGAC  
TAAATAACGTTATTATGCTACCCAATCTAAAGATATTGAAGATTGAAGAT  
TGTGGTCATCTGGAACATGTATTACATTCTCTGCACTTGGAAGCCTGAG  
ACAGCTCGAAGAGTTAACGATAGAGAAATGCAAGGCAATGAAAGTGATAG  
TGAAGGAAGAAGATGAATATGGAGAGCAAACAACAAGGCATCTTCGAAG  
35 GAGGTTGTGGTCTTTCCTCGTCTCAAGTCCATTGAACTGGAAAATCTACA  
AGAGCTCATGGGTTTCTACTTAGGGAAGAATGAGATTCAGTGGCCTTCAT  
TGGATAAGGTTATGATCAAGAATTGCCCGAGAAATGATGGTGTGTTGCACCT  
GGTGAGTCCACAGTTCCTCAAGCGCAAGTATATAAATACAAGCTTTGGCAT  
ATATGGGATGGAGGAGGTACTTGAACTCAAGGGATGAACAACAATAATG  
40 ATGACAATTGTTGTGATGATGGAATGGTGGAAATCCAAGACTAAATAAC  
GTTATTATGTTTCAAATATAAAGATATTGCAAATCAGCAATTGTGGCAG  
TTTGGAACATATATTCACATTCTCTGCACTTGAAAGCCTGATGCAGCTCA  
AAGAGTTAACAATAGCGGATTGCAAGGCAATGAAAGTGATTGTGAAGGAG



GAATATGATGTAGAGCAAACAAGGGTATTGAAGGCTGTGGTATTTTCTTG  
TCTAAAGTCCATTACACTATGCCATCTACCAGAGTTGGTGGGTTTCTTCT  
TGGGGAAGAATGAGTTCTGGTGGCCTTCATTGGATAAGGTTACCATCATT  
GATTGCCCACAAATGATGGGGTTCACACCTGGTGGGTCAACAACTTCCCA  
5 CCTCAAGTACATACACTCAAGCTTAGGCAAACATACTCTTGAATGTGGCC  
TTAATTTCAAGTCACAACTACTGCATATCATCAGGTATAATTATTATTCT  
TTNACACCATCTAATTATGGAATCATGACGCTAATTACAGTATTAAACAC  
(SEQ ID NO:110)

10 **RG2K deduced polypeptide sequence (SEQ ID NO:111)**

MECITGIFSNPFAQCLIAPVKEHLCLLIFYTQYVGDMLTAMTELNAKDIVEERK  
NQNVKEKCFEVPNHVNRWLEDVQTINRKVERVLNDNCNWFNLCNRYMLAVKAL  
EITQEIDHAMKQLSRIEWTDDSVPLGRNDSTKASTSTPSSDYNDFESREHTFRKAL  
EALGSNHTSHMVALWGMGGVGKTTMMKRLKNIIEKRTFHYIVLVVIKENMDL  
15 ISIQDAVADYLDMLKTESNESERADKLREGFQAKSDGGKNRFLIILDDVWQSVN  
MEDIGLSPFPNQGVDFKVLITSENKDVCAKMGVEANLIFDVKFLTEEEAQSIFY  
QFVKVSDTHLDKIGKAIVRNCGLPIAKTIANLTKNRNKDVWKDALSRIEHHD  
IETIAHVVFQMSYDNLQNEEAQSIFLLCGLFPEDFDIPTTEELVRYGWGLRVFNGV  
YTIGEARHRLNAYIELLKDSNLLIESDDVHCIMHDLVRAFVLDTFNRFKHSLIV  
20 NHGNGGMLGWPENDMSASSCKRISLICKGMSDFPRDVKFPNLLILKLMHADKS  
LKFPQDFYGMKKLQVISYDHMKYPLLPTSPQCSTNLRVLHLHQCSLMFDCSSI  
GNLLNLEVLFSFANGIEWLPSTIGNLKLRLVLDLTNCDGLRIDNGVLKKLVKLEELY  
MRVGGRYQKAISFTDENCNEMAERSKNLSALEFEFFKNNAPKNMSFENLERFKIS  
VGCYFKGDFGKIFHSFENTLRLVTNRTEVLESRLNELFEKTDVLYLSVGDMNDLED  
25 VEVKLAHLPKSSSFHNLRLVLIIECEIERYLFTLDVANTLSKLEHLQVYECNMEIEI  
HTEGRGEVTITFPKLKFLSLCGLPNLLGLCGNVHIINLPQLTELKLNIGIPGFTSIYPEK  
DVETSSLLNKEVVIPNLEKLDISYMKDLKEIWPCELGMSQEVDVSTLRVIKVSSCDN  
LVNLFPCNPMPLIHHLEELQVIFCGSIEVLFNIELDSIGQIGEGINSSLRRIQLQNLGK  
LSEVWRIKGADNSSLLISGFQGVESIIVNKCKMFRNVFTPTTTNFDLGALMEIRIQDC  
30 GEKRRNNELVESSQEQEQ

**RG2L polynucleotide sequence (SEQ ID NO:112)**

GGAAGACACAATGATGCAAAGACTGAAGAAGGTTGCCAAAGAAAATAGAA  
TGTTTCAGTTACATGGTCGAGGCAGTTATAGGGGAAAAGACAGACCCAATT  
35 GCTATTCAACAAGCTGTAGCCGATTACCTTCGTATACAGTTCAAAGAAAG  
CACTAAACCAGCAAGAGCTGATAAGCTTCGTGAATGGTTCAAGGCCCACT  
CTGNAGACGGTAAGAATAAGTTCCTCGTAATATTTGATGACGTCTGGCAG  
TCCGTTGATCTGGAAGATATTGGNTTAAGTCCTTTTCCAAATCAAGGTGT  
CGACTTCAAGGTCTTGTTGACTTCACGAGACGAACACGTTTGACAATGA  
40 TGGGGGTTGAAGCTAATTCAGTTATTAATGTGGGACTTCTAACTGAAGTA  
GAAGCACAAAGTCTGTTCCAGCAATTTGTAGAACTTTTGAGCCCGAGCT  
CTGTAAGATAGGAGAAGTTATCGTAAGAAAGTGTGCGGTCTACCTATTG

CCATCAAACCATGGCGTGTA CTCTAAGAAATAAAAGAAAGGATGCATGG  
AAGGATGCACTTTCACGTATAGAGCACTATGACATTCGTAGTGTTGCGCC  
TAAAGTCTTTGAAACAAGCTATCACAATCTCCAAGACAGGGAGACTAAAT  
CCGTGTTTTTGTATGTGTGGTTTGTTCCTGAAGACTTCAATATTCCTACC  
5 GAGGAGTTGATGAGGTATGGATGGGGCTTAAAGCTATTTGACAGAGTTTA  
TACAATTAGAGAAGCAAGAACCAGGCTCAACACCTGCATTGAGCGACTTG  
TGCAGACAAATTTGTTAATTGAAAGTGATGATGTTGGGTGTGTCAAGATG  
CATGATCTGGTGCCTGCTTTTGTTCCTGAAGTTCGAGCA  
TGCTTCAATTGTCAACCATGGTAATATGCATGGGTGGACTAAAAATGATA  
10 TGAACGACTCTTGCAAAACAGTTTCTTTAACATGCGAGAGTGTTGTCTGAG  
TTTCCAGGAGACCTCAAGTTTCCAAACCTAAAGCTTTTGAACTTATGCA  
TGGAGATAAGATGCTAAGGTTTTCTCAAGACTTTTATGAAGGAATGGAAA  
AGCTCCAGGTAATATCATACCATAAAATGAAGTATCCATTGCTTCCCTCG  
TCACCTCAATGCTCCACCAACCTTCGAGTGCTTCATCTTCATCGGTGTTT  
15 ATTACGGATGCTTGATTGCTCTTGATCGGAAATTTGACGAATCTGGAAG  
TGTTGAGCTTCGCTAATTCTGGCATTGAACGGATACCTTCAGCAATCGGA  
AATTTGAAGAAGCTTAGGCAACTTGATCTGAGAGGTCGTTATGGTCTTTG  
TATAGAACAGGGTGTCTTGAAAAATTTGGTCGAACTTGAAGAACTTTATA  
TTGGAAATGCATCTGCGTTTAGAGATTATAACTGCAATGAGATGGCAG  
20

**RG2L deduced polypeptide sequence (SEQ ID NO:113)**

EDTMMQRLKKVAKENRMFSYMVEAVIGEKTDPPIAQQAVADYLRIQFKESTKPAR  
ADKLREWFKAHS?DGKNKFLVIFDDVWQSVLDLEDIGLSPFPNQGVDFKVLLTSRDE  
HVCTMMMGVEANSVINVGLL TEVEAQSLFQQFVETFEPELCKIGEIVVRKCCGLPIAI  
25 KTMACTLRNKRKDAWKDALSRIEHYDIRSVAPKVFETSYHNLQDRETKSVFLMCG  
LFPEDFNIPTEELMRYGWGLKLFDRVYTIREARTRLNTCIERLVQTNLLIESDDVGC  
VKMHDLVRAFVLGMYSEVEHASIVNHGNMHGWTKNMNDSCKT VSLTCEVSVEF  
PGDLKFPNLKLLKLMHGDKMLRFSQDFYEGMEKLQVISYHKMKYPLLPSSPQCST  
NLRVLHLHRCSLRMLDCSCIGNLTNLEVLSFANS GIERIPSAIGNLKKLRQLDLRGR  
30 YGLCIEQGV LKNLVELEELYIGNASAFRDYCNEMA

**RG2M polynucleotide sequence (SEQ ID NO:114)**

GGGGAAGACACAATAGATGCAAAGGCTGAAGAAGTTGCCAAAGAAAAGAG  
AATGTTTCAGTTATATCATTGAGGCGGTTATAGGGGAAAAGACAGACCCCA  
35 TTTCCATT CAGGAAGCTATATCATATTACCTTGGTGTAGAGCTCAATGCA  
AATACTAAGTCAGTAAGAGCTGATATGCTTCGTCAAGGGTTCAAGGCCAA  
ATCTGATGTAGGTAAGGATAAATTCTTAATAATACTCGACGATGTATGGC  
AGTCTGTTGATTGGAAGATATTGGATTAAGTCCATTTCCAAATCAAGGT  
GTTAACTTCAAGGTCCTGTTAACATCACGAGACCGACATATTTGCACTGT  
40 GATGGGGGTTGAAGGTCATTCGATTTTAAATGTGGGACTTCTCACAGAAG  
CAGAATCAAAAAGATTGTTCTGGCAGTTTGTAGAAGGTTCTGATCCTGAG  
CTCCATAAGATAGGAGAAGATATTGTAAGTAAGTGTGTGGTCTACCCAT

TGCCATTAAAACCATGGCATGTACACTTAGAGATAAAAGTACGGATGCAT  
GGAAGGATGCACTGTCTCGTTTAGAGCATCATGACATTGAAAATGTTGCC  
TCTAAAGTTTTTAGAGCGAGCTATGACCATCTCCAAGACGAGGAGACTAA  
ATCCACTTTTTTCTATGTGGATTGTTTCCAGAAGATTCCAATATTCCTA  
5 TGGAGGAGTTGGTGAGGTATGGGTGGGGATTGAAATTATTTAAAAAAGTG  
TATACCATAAGAGAAGCAAGAACTAGGCTCAACACTTGCATTGAGCGGCT  
CATCTATACCAATTTGTTGATAAAAGTTGATGATGTTTCAGTGCATCAAGA  
TGCATGATCTCATCCGTTCTTTTGTGTTTGGATATGTTTTCTAAAGTTGAG  
CATGCTTCGATTGTCAACCATGGTAATACGCTAGAGTGGCCTGCAGATNA  
10 TNTGCACGACTCTTGTAAGGGCTTTCATTAACATGCAAGGGTANATGTG  
AGTTTTGTGGAGACCTNAANTTTCCAACCCTAATGATTTTAAACTTATG  
CATGGAGATAAATCGCTAAGGTTT

**RG2M deduced polypeptide sequence (SEQ ID NO:115)**

15 GEDTIDAKAEVAKERMFYSYIEAVIGEKTDPISIQEASYYLGVELNANTKSVRAD  
MLRQGFKAQSDVGKDKFLILDDVWQSVLEDIGLSPFPNQGVNFKVLLTSRDRHI  
CTVMGVEGHSIFNVGLLTEAESKRLFWQFVEGSDPELHKIGEDIVSKCCGLPIAKT  
MACTLRDKSTDAWKDALSRLEHHDNIENVASKVFRASYDHLQDEETKSTFFLCGLFP  
EDSNIPMEELVRYGWGLKLFKKVYTIREARLNTCIERLIYTNLLIKVDDVQCIKM  
20 HDLIRSFVLDMFSKVEHASIVNHGNTLEWPA?HDSCKGLSLTCKG?CEFCGDL?F  
PTLMILKLMHGDKSLRF

**RG2N polynucleotide sequence (SEQ ID NO:116)**

AGGTAAAATCCATAACCCTAAATGTTGGTACGCTCATATATCAAATTGCG  
25 TGTTTTGTTGAATGAAAAAAGCATGCTCAAAAAACCAGTGTAAGGCACGG  
TATATGACATATTTATAGTTACTGATAACAAATTATGATAATTTGGGTT  
TACRTAAGTTAGGATTCGTACTTCAACCAAATGTAATAGTTTTTGTGAGT  
CTATCTATGATTTGGGGAATCACATTAGCAACGGGATTGTACTAGTAAT  
TCG.AAAAAGTCTTTTAAATAATTTTTCTGTTTATAATTTATGAATAGTTT  
30 TAGCGACATCTAATATTAATAAGAATGTATCTGATATTGAATTAATGTCC  
TTAATGTGAACATAGACCTTTTCCATTTACTAATGCCTAATTATTAGTTT  
CTAATCAATAAATTTTAATTTCTGTTTTATGCTTCTAAGACAATAAAAAAT  
CCATGATTTACCTTTAAATATTAACAAAAATGACCATAAATAAATAAAAA  
ATTAGGATACCAAACCCCCCGCCATGCCCAATGTCTAAATATTCTTGAT  
35 GCTTTTGCTTTTCCCTCTTTTCCTTGTTAGTCTATTATTCTGGAGAGTTT  
GAGAGAGTTTCATACAAGAAAATTTCAAGAAGAAAGCAAAGGTCCAGGTA  
TTCTCTTTTCTTAATTATGTATTAACCTTACAAGCATTTTTTTACACGATCC  
ATGGTTTTTTGTGTATGTTTTTCAAATTGAACTAGATTGGGACTTTTGC  
CCTTGATGATTCATAAGATATTGCATGGAGTTGAGATTGTGTAAGAAAAG  
40 TGGTGAATAGAAAGAGCAAGTGAATCCAGATATAGTATTGGTAATATATG  
ATGATGAGATAGAGATATGTTAAACTGGCTAGAAAATTGTTTTAATTTG  
AAATTTAGGTKGTTGAATTTGAAAGATACCAAGCTAATAACTAATTAGTT

ATGCTAAWTAGTTATAAAGAACAACAACTCTTAGTTTTTTTTTCATGA  
TTTTCAACCTCTTTGTACCAAATAAATTATAGCAAAATTGAATATCATT  
CTCTGCAATCAATCTTAACCTTTTGTATTATCATCATGTCTAAAATTGCC  
ACAAGTTTATTTTCAAAGTCATATTGGATTATGAAAGGACTATTTTACC  
5 AATTACATCTTTACTTTATGGGCCAAAGCTAATACAATCCGACTAAACTA  
AAGGAATATGGGATGCATATAGTTTGCTTCCCGATTATAGATTTCTATCT  
AATTTGTCTATTGTACTAATTTAGGTGCCACCACAAGTAAATTTGTTAAA  
TGGATATCGTTAATGCCATTCTTAAACCAGTTGTCGAGACTCTCATGGTA  
CCCGTTAAGAAACACATAGGGTACCTCATTTCCTGCAGGCAATATATGAG  
10 GGAAATGGGTATCAAAATGAGGGGATTGAATGCTACTAGACTTGGTGTCTG  
AAGAGCATGTGAACCGGAACATAAGCAACCAGCTTGAGGTTCCAGCCCAA  
GGCAGGGGTTGGTATGAAGAAGTAGGAAAGATCAATGCAAAAGTGAAAAA  
TTTTCTAGCGATGTTGGCAGTTGTTTCAATCTTAAGGTTAGACACGGGG  
TCGGAAAGAGAGCCTCCAAGATAATTGAGGACATCGACAGTGTCTATGAGA  
15 GAACACTCTATCATCATCTGGAATGATCATTCCATTCTTCTAGGAAGAAT  
TGATTCCACGAAAGCATCCACCTCAATACCATCAACCGATCATCATGATG  
AGTTCCAGTCAAGAGAGCAAACCTTTCACAGAAGCACTAAACGCACTCGAT  
CCTAACCACAAATCCCACATGATAGCCTTATGGGGAATGGGCGGAGTGGG  
GAAGACGACAATGATGCATCGGCTGAAAAAGGTTGTGAAAGAAAAAGAAA  
20 TGTTTAATTTTATTGTTGAGGCGGTTGTAGGGGAAAAAACAGACCCCAT  
GCTATTCAATCAGCTGTGGCAGATTACCTAGGTATAGAGCTCAATGAAAA  
AACTAAACCAGCAAGAAGCTGAGAAGCTTCGTAAATGGTTTGTGGACAATT  
CTGCTGGTAAGAAGATCCTAGTCATACTCGACGATGTATGGCAGTTTGTG  
GATCTGAATGATATTGGTTTAAAGTCCTTTACCAAATCAAGGTGTGCACTT  
25 CAAGGTGTTGTTGACATCACGAGACAAAGATGTTTGCACTGAGATGGGAG  
CTGAAGTTAATTCAACTTTTAATGTGAAAAATGTTAATAGAAACAGAAGCA  
CAAAGTTTATTCCACCAATTTGTAGAAATTTCCGATGATGTTGATCGTGA  
GCTCCATAATATAGGAGTGAATATTGTAAGGAAGTGTGGCGGTCTACCCA  
TTGTCATCAAAACCATGGCGTGTACTCTTAGAGGAAAAAGCAAGGATGCA  
30 TGAAGAATGCACTTCTTCGTTTAGTGAACACTACAACATTGAAAATATAGT  
GAATGGAGTTTTTAAAATGAGTTACGACAATCTCCAAGATGAGGAGACTA  
AATCCACCTTTTTGCTTTGTGGAATGTTTCCCGAAGACTTTAATATTCT  
ACCGAGGAGTTGGTGAGGTATGGATGGGGGTTGAAATTATTTAAAAAGT  
GTATACTATAGGAGAAGCAAGAATCAGGCTCAACACATGCATTGAGCGGC  
35 TCATTCATACAAATTTGTTGATTGAAGTTGATGATGTTAGGTGCATCAAG  
ATGCATGATCTTGTCCGTGCTTTTGTGTTGGATATGTATTCTAAAGTCGA  
GCATGCTTCCATTGTCAACCATGGTAATACACTAGAGTGGCATGTGGATA  
ATATGCACAACTCTTGTAAGAACTTTTATTAAACATGCAAGGGTATGTCT  
AAGTTTCTACAGACCTCAAGTTTCCAAACCTCTCGATTTGAACTTAT  
40 GCATGAAGATATATCATTGAGGTTTCCAAAAACTTTTATGAAGAAATGG  
AGAAGCTTGAGGTTATATCCTATGATAAAATGAAATATCCATTGCTTCCC  
TCATCACCGCAATGCTCCGTCAACCTTTGCGTGTTTCATCTCCATAAATG  
CTCGTTAGTGATGTTTGACTGCTCTTGTATTGGAAATCTGTCTGAATCTAG

AAGTGCTTAGCTTTGCTGATTCTGCCATTGACCTGTTGCCTTCCACAATC  
GGAATTTTGAAGAAGCTAAGGCTACTGGATTGACAAATTGTTATGGTCT  
TTGTATAGCTAATGGTGTCTTTAAAAAATTGGTCAAACCTGAAGAGCTCT  
ATATGACAGTGGTTAATGGAGGAGTTCGAAAGGCGATCAGCCTCACTGAG  
5 GATAACTGCAATGAGATGGCAGAACGTTCAAAAGACCTTTCTGCATTAGA  
ACTTGAGTTCTTTGAAAACAATGCTCAGCCAAAGAATATGTCATTTGAGA  
AGCTACAACGATTCCAGATCTCAGTGGGGTGCTATTTATATGGAGCTTCC  
ATAAAGAGCAGGCACTCGTATGAAAACACATTGAAGTTGGTTATTGACAA  
AGGTGAATTATTTGAATCTTGAATGAACGGCCTGTTTAAGAAAACAGAGG  
10 TGTTATGTTTAAGTGTGGGAGATATGAATGATCTTGAAGATRTTGAGGTT  
AAGTCATCCTCACAACYTCTTCAATCTTCTTCGTTCAACAATTTAAGAGT  
CCTTGTCGTTTCAAAGTGTGCAGAGTTGAAACACTTCTTCACACCTGGTG  
TTGCAAACACTTTAAAAAAGCTTGAGCATCTTGAAGTTTACAAATGTGAT  
AATATGGAAGAACTCATACGTAGCAGGGGTAGTGAAGAAGAGACGATTAC  
15 ATCCCCCAAGCTGAAGTTTTTATCTTTGTGTGGGCTACCAAAGCTATCGG  
GTTTGTGCGATAATGTCAAAATAATTGAGCTACCACAACCTCATGGAGTTG  
GAACTTGACGACATTCCAGGTTTCACAAGCATATATCCCATGAAAAAGTT  
TGAAACATTTAGTTTGTGAAGGAAGAGGTAATATAAATTTTTAATGCT  
AATACATTACAAAGGATCTTTTCAGTTAAATCTTTCAAAATATATTGTAA  
20 TTTGATTGTATGGGGTATTATTGTTGGATGGGACTATTAATAAATGATTA  
TCTTGCAAGTTCTGATTCTTAAGTTAGAGAACTGCATGTTAGTAGTATG  
TGGAATCTGAAGGAGATATGGCCTTGCGAATTTAATATGAGTGAGGAAGT  
TAAGTTCAAGAGAGATTAAAGTGAGTAACTGTGATAAGCTTGTGAATTTGT  
TTCCGCACAAGCCCATATCTCTGCTGCGTCATCTTGAAGAGCTTAAAGTC  
25 AAGAATTGTGGTTCCATTGAATCGTTATTCAACATCCATTTGGATTGTGC  
TGGTGCAACTGGAGATGAATACAACAACAGTGGTGTAAGAATTATTAAG  
TGATCAGTTGTGATAAGCTTGTGAATCTCTTTCCACACAATCCCATGTCT  
ATACTGCATCATCTTGAAGAGCTTGAAGTCGAGAATTGTGGTTCCATTGA  
ATCGTTATTCAACATTGACTTGGATTGTGCTGGTGCAATTGGGCAAGAAG  
30 ACAACAGAAGCAGCTTAAGAAACATCAAAGTGGAGAATTTAGGGAAGCTA  
AGAGAGGTGTGGAGGATAAAAGGTGGAGATAACTCTCGTCCCCTTGTTC  
TGGCTTTCAATCTGTTGAAAGCATAAGGGTTACAAAATGTAAGAGGTTTA  
GAAATGTATTACACCTACCACCACAAATTTTAATCTGGGGGCACTTTTG  
GAGATTTCAATAGATGACTGCGGAGAAAACAGGGAAAATGACGAATCGGA  
35 AGAGAGTAGCCATGAGCAAGAGCAGGTAAGGATTTCAATTTCACTTTCKT  
ACTTAATTAATGATTAAGCTCCTGCTTTTTRAATAAAAAAGGGACAAACC  
ATTTTCATGACTTAATGTAGCAATACAAGTCATGTATAAGAGTGACCAACT  
CTTTTTTATTTATAAAATGACTACAAAATATTTTTTTTCATTAGAGATCA  
TGTATAAATGTGACTAATTTTTCATCACCTAACTTTAGTTGATAAATCTT  
40 TATAAATGTCACTAGTTACTTTTCAGTAAAATAACAAATTTAATAAATTA  
TCAACAAAAAGCATCAACTAAAAAATCCCACAACCCGTAATAATTTAAA  
ATAAAAGGATTTAACATCTAATACGAACAATTTTTTTTCTAAACATGATT  
TGGACCAAATATCACCAGCAACTCAAGTTTGAATCGATTCAGCTTAAAA

CTTGACCARCATAATTAGATAGATGAGAGTTGAAGCTAAAGTGCCTATAT  
AAGTTCGTTTCATCTTTTTTCTTGATCTTGATAGCAAGTTGAATSATTTT  
CTTCTTCAAAATTGATAAAAAATCTACATTATAAAGAGACTAGCTTGAAAA  
AAAATGGTCTAGGTGGGTCTTGGGTCTGGTAGATGAAGATGGAAGGGAGA  
5 GTAGATTTCAAAGACACAAACACATCTTCATTTTATTTATTTATTTATTA  
TTATTATTTTTTGATATCTTGCTCATATTTGTTACAGATATGTGAGGTCT  
ATTAATCTTTTTAAATATATAAAAAATAAATACATAAATGAGAAAAATTA  
ATAAAGAATAAATTAATAAGGGCACAATAGTCTTTTTTGGTAAGACAAGG  
ACCAAAAGCGCAACAAAAGTAAACAGTAGGGACCATCCGATTTAAAAAAT  
10 TAATTAGGGACCAAAAACATAAATTCCCCCAAACCATAGGGACCATTTCGT  
GTAATTTACTCTTGCTTTTCGTTTTGTTTCATATTTGGGTAACATTTTTT  
TTGTACATATCTAGGTAACGAACTTGTTGAAAGTGTTACATCTACGATG  
TGACCTACTACAACCGATCATAATGGTCATATATGAACACTTCCAACAAG  
TTTGTTATCTAGGTGTGTACAAAAAACGATAGTTACCATGATGTGAACA  
15 TACCAAAAAATTAATTACCTTAGCAAGTTATTTTCCCATTTAGGTTGTAT  
GGAAACAGTTCCGTGAGACCGTGACTTGGATGGTAGATAAATTTAGTAA  
CTTAACCCTTCAATTAACCTACCTTTTTCTTATTAACTCAATTTCAAGCT  
AAATTCTGATTCTTGTTTGAAGTAAGTTGCATCTTTATGTTTGTATTAT  
CTTGTTGCATAGGATCCTTAGCATCTTTTAATAATTTATTTGAAGGTGAA  
20 AGATCCAACATTTTTTAATCTGTTGGCATTTCATCATTTGCAACTGTT  
TCTTGAAAAAAA::TACCTAAAATCAAAATAACCATTTTCATATCCAAAA  
TTATAAGAGAGAATTGTTAACGGACATGGAATCATAAATCATTAAACACAG  
TTCAGTACACAGGTTGCTAATTACATTTCTTGCTGTGCAGATTGAAATTC  
TATCAGAGAAAGAGACATTACAAGAAGCCACTGGCAGTATTTCAAATATT  
25 GTATTCCCATCCTGTCTCATGCACTCTTTTCATAACCTCCATAAACTTAA  
CTTGAACAGAGTTGAAGGAGTGGAGGTGGTGTGAGATAGAGAGTGAGA  
GTCCAACAAGTAGAGAATTGGTAACAACCTACCATAACCAACAACAACCT  
ATTATACTTCCCAACCTCCAGGAATTGATTCTATGGAATATGGACAACAT  
GAGTCATGTGTGGAAGTGCGGCAACTGGAATAAATTCTTCACTCTTCCAA  
30 AAGAACAATCAGAATCCCCATTCCACAACCTCAGTAACATACATATTTAT  
GAATGCAAAAGCATTAAGTACTTGTTTCACCTCTCATGGCAGAACTTCT  
TTCCAACCTAAAGCATATCGAGATAAGAGAGTGTGATGGTATTGAAGAAG  
TTGTTTCAAAAAGAGATGGTGAGGATGAAGACATGACTACATCTAC:::  
:::GCACACAACCACCACTTTTTCCCTCATCTTGATTCTCTCACTCTAAA  
35 GCAACTGAAGAATCTGAAGTGTATTGGTGGAGGTGGTGCCAAGGATGAGG  
GGAGCAATGAAATATCTTTCAATAATACCACTGCAACTACTGCTGTTCTT  
GATCAATTTGAGGTATGCTTTGTACATATTCAATTATTTATTTAATTTCC  
TTGTTAATTTCTTTTTTCTTTGCAATATTCTATGAAAAAATCACCAAA  
TCACAAATAAGAGATTTAACTTTTATTTACACCCATGCGGACTCAAGA  
40 ATGGGATTTGGAGGCATATAAAGTTACATTCATTTGAACAAGTATTACCA  
TTT.ATTTGTTATTTATCATTTTCATATCATTTACTGATAACATTTCTTTT  
TTACTTTTCTAATTAGAAAAGGTCCACATGTCTAATTAGGTTTTCCATTC  
TATGTGAATCCTCTATTCTGTCTGTAATCAAGCATCTTAGATTATTTATC

CATTTTCATAATTGTGTTTATATTGACAGTTTTTTTCTTTTATAGTTGT  
AATTGCAACCTGTCATATWTTMWWKCKWWATKYWMWWARTAATACATTT  
TATACCCWCTATACTAAGATA

5 **RG2N deduced polypeptide sequence (SEQ ID NO:117)**

LGKTTMMHRLKKVVKEKKMFNFIVEAVVGEKTDPIAIQSAVADYLGIELNEKTKPA  
RTEKLRKWFVDNSAGKKILVILDDVWQFVDLNDIGLSPLNQGVDFKVLLTSRDKD  
VCTEMGAENVSTFNVKMLIETEAQSLFHQFVEISDDVDRELHNIGVNIVRKCGGLPI  
VIKTMACTLRGKSKDAWKNAALLRLVNYNIENIVNGVFKMSYDNLQDEETKSTFLL  
10 CGMPEDFNIPTEELVRYGWGLKLFKKVYTIGEARIRLNTCIERLIHTNLLIEVDDVR  
CIKMHDLVRAFVLDMYSKVEHASIVNHGNTLEWHVDNMHNSCKRSLTCKGMSK  
FPTDLKFPNLSILKLMHEDISLRFKPNFYEEMEKLEVISYDKMKYPLLPSSPQCSVNL  
CVFHLHKCSLVMFDCSCIGNLSNLEVLFSADSAIDLLPSTIGILKKLRLDLTNCYGL  
CIANGVFKKLVKLEELYMTVVNGGVRKAISL

15

**RG2O polynucleotide sequence (SEQ ID NO:118)**

TTGTAAAACGACGGCCAGTCGAATCGTAACCGTTCGTACGAGAATCGCTG  
TCCTCTCCTTCATTTGAATCATGATATTTGAATATCGATACTTTTGA CTG  
TAGCTTTTGGGTCGATTTTTTAGCAAGATACATAACTGGCCAAACCCATT  
20 GGCTATTTTAGCCCAAATATGAAATGGACTGGATTGTTTTTTCCTTTC  
TAACACGCACACATCTGGCGATCAGTATCACTCCATTATGAAGACCTAGT  
CAAATTCATTAACGTTCACTCGTTCCTTCAAAGTTTCAAAGTTCCAATT  
CCAATTCCCTCTTTTTTTTTTCTTTCCTCGATTCTGATTGTAATCCGAT  
TCTGCGACGAAGGAGAGCTTGGTCAGAGGGCTGTGATTCTTGAGTCTTGA  
25 CCTCCGAATCTAGCTGGATTATTTTCGACACACCAGACCACGTATCAGGT  
TGCTCATCCCGAAATACTGCTTTGCAAAGTGTGTATCATCGCCTAGGAA  
ATTAAAGTTTCTTTTTTGGCTCTGTTACTGAATCAGTAGCTTTGCAACTTG  
CTCATTATAAGCTGATCCATATTTTACATATCTTTTGAAGAATAATAGGT  
ACTGACTTTACCTTTCTGATGAGAGCGATTAAAGAGATACCTCTGTAAAA  
30 TCCATTTTTGTGAAGGGATCTGGGTTAGTTTTTAAAGGATTTGCTACAAC  
AGTATCCCAACAAACGATCTATTTCCCATTTNACTCATCCGCTCAAGATCT  
ATCCACCTTTATATATGTTAATTGGGAGTCTTCCATGGTGCAATGAATCT  
AGGATGCATTTAGAAGCCCAATCCATTACAAGTTTTCATCCAATTTTCATG  
TGACAAGTTGTTGGTTACTATGTAGGTACTTCCACAATTAAGAATTTCCA  
35 GCAATGGATGTTGTTAATGCCATTCTTAAACCAGTTGCCGAGACACTTAT  
GGAACCTGTTAAGAAACATCTAGGCTACATCATTTCAGCACAAAACATG  
TGAGGGATATGAGTAACAAAATGAGGGAGTTGAACGCTGCAAGACATGCT  
GAAGAAGACCACTTGGACAGGAACATAAGAACTCGTCTTGAGATTTCAA  
TCAAGTTAGGAGTTGGTTAGAAGAAGTAGAAAAGATCGATGCAAAAAGTAA  
40 AAGCCCTTCCTAGTGATGTCACCGCTTGTTGCAGTCTCAAGATCAAACAT  
GAAGTCGGAAGGGAAGCCTTGAAGCTAATTGTGGAGATTGAAAGTGCCAC  
AAGACAACACTCTTTGATCACCTGGACTGATCATCCCATTCCTCTGGGAA

AAGTTGATTCCATGAAGGCATCGATGTCCACAGCATCAACCGATTACAAT  
GACTTTCAGTCAAGAGAAAAAAGTTTACTCAAGCATTGAAAGCACTTGA  
ACCAAACAACGCTTCCCACATGATAGCGTTATGTGGGATGGGTGGAGTGG  
GGAAGACCACAATGATGCAAAGACTAAAAAAGTTGCTAAACAAAATAGA  
5 ATGTTTCAGTTATATGGTTGAGGCAGTTATAGGGGAAAAGACGGACCCAAT  
TGCTATTCAACAAGCTGTAGCGGATTACCTTCGTATAGAGTTAAAAAGAA  
GCACTAAACCAGCAAGAGCTGATAAGCTTCGTGAATGGTTCAAGGCCAAC  
TCTGGAGAAGGTAAGAATAAATTCCTTGTAATACTTGATGACGTCTGGCA  
GTCTGTTGATCTAGAAGATATTGGTTTAAAGTCCTTTTCCAAATCAAGGTG  
10 TCGACTTCAAGGTCTTATTGACTTCACGAGACGAACATGTTTGCACAGTA  
ATGGGAGTTGGATCTAATTCAATTCTTAATGTGGGACTTCTAATAGAAGC  
AGAAGCACAAAGTTTGTTCACAATTTGTAGAACTTCTGAGCCCGAGC  
TCCATAAGATAGGAGAAGATATTGTAAGGAAGTGTGCGGTCTACCTATT  
GCCATCAAAACCATGGCATGTACTCTTAGAAATAAAAGAAAGGATGCTTG  
15 GAAGGATGCACTTTCGCGTATAGAGCACTATGACCTTCGCAATGTTGCGC  
CTAAAGTCTTTGAAACGAGCTACCACAATCTCCATGACAAAGAGACTAAA  
TCAGTGTTTTTGATGTGTGGTTTGTTCGGAAGACTTCAATATTCCTAC  
TGAGGAGTTGATGAGGTATGGATGGGGATTAAAGATATTTGATAGAGTCT  
ATACATTTATAGAAGCAAGAAACAGGATCAACACCTGCATTGAGCGACTG  
20 GTGCAGACAAATTTGTTAATTGAAAGTGATGATGTTGGGTGTGTCAAGAT  
GCATGATCTGGTCCGTGCTTTTGTTTTAGGTATGTATTCTGAAGTAGAGC  
ATGCTTCAGTTGTCAACCATGGTAATATACCTGGATGGACTGAAAATGAT  
CCGACTGACTCTTGTAAGCAATTCATTAAACATGCGAGAGTATGTCTGG  
AAACATTCCAGGAGACTTCAAGTTTCCAAACCTAACGATTTTGAACTTA  
25 TGCATGGAGATAAGTCGCTAAGATTTCCACAAGACTTTTATGAAGGAATG  
GAAAAGCTCCAGGTTATATCATACGATAAAATGAAGTATCCAATGCTTCC  
CTTGTCTCCTCAATGCTCCACCAACCTTCGAGTGCTTCATCTCCATGAAT  
GTTCAATTAAGATGTTTGATTGCTCTTGTATTGGAAATATGGCGAATGTG  
GAAGTGTTGAGCTTTGCTAATTCTGGCATTGAAATGTTACCTTCCACTAT  
30 CGGAAATTTAAAGAAGCTAAGGTTACTTGATTAAACAGATTGTCATGGTC  
TTCATATAACACACGGTGTCTTTAACAATTTGGTCAAACCTGAAGAGTTG  
TATATGGGATTTTCTGATCGACCTGATCAAACCTCGTGGTAATATTAGCAT  
GACAGATGTCAGCTACAATGAATTAGCAGAACGTTCAAAGGCCTTTCTG  
CATTAGAGTTCCAGTTCTTTGAAAACAATGCCCAACCAAATAATATGTCG  
35 TTTGGGAAACTTAAACGATTCAAGATCTCAATGGGATGCACTTTATATGG  
AGGATCAGATTACTTTAAGAAAACGTATGCTGTCCAAAACACATTGAAGT  
TGGTTACTAACAAAGGTGAAGTATTGGACTCTAGAATGAACGAGTTGTTT  
GTTGAAACAGAAATGCTTTGTTTAAAGTGTTGATGATATGAATGATCTTGG  
TGATGTTTGTGTGAAGTCCTCACGTTCTCCTCAACCTTCTGTGTTCAAAA  
40 TTCTAAGAGTCTTTGTCTGTTTCCAAGTGTTGAGTTGAGATACCTTTTC  
ACAATTGGTGTAGCCAAGGATTTGTCAAATCTTGAGCATCTTGAAGTTGA  
TTCATGTAATAATATGGAACAACTCATATGTATTGAGAATGCTGGAAAAG  
AGACAATTACATTCCTAAAGCTGAAGATTTTATCTTTGAGTGGGCTACCA



AAGCTTTTCGGGTTTGTGCCAAAATGTCAACAACTTGAGCTACCACAACT  
CATAGAGTTGAAACTTAAGGGCATTCCAGGGTTCACATGCATTTATCCGC  
AAAACAAGTTGGAAACATCTAGTTTGTGAAGGAAGAGGTAGATATATGT  
5 TATATCTATATGTCTATAATTTGATTATATGATGTATTAGTGTGGATG  
TGGCTATTAAGGGATGATTATTTTGCAGGTTGTGATTCCTAAGTTGGAGA  
CACTTCAAATTGATGAGATGGAGAATTTAAAGGAAATATGGCATTATAAA  
GTTAGTAATGGTGAGAGAGTTAAGTTGAGAAAGATTGAAGTGAGTAACTG  
TGATAAGCTTGTGAATCTATTTCCACACAACCCCATGTCTCTGCTGCATC  
10 ATCTTGAAGAGCTTGAAGTCAAGAAATGTGGTTCCATTGAATCGTTATTC  
AACATCGACTTGGATTGTGTTGATGCCATAGGAGAAGAAGACAACATGAG  
GAGCTTAAGAAACATTAAAGTGAAGAATTCATGGAAGTTAAGAGAAGTGT  
GGTGTATAAAAGGTGAAAATAACTCTTGCCCCCTTGTTTCTGGCTTTCAA  
GCTGTTGAAAGCATAAGCATTGAAAGTTGTAAGAGGTTTAGAAATGTATT  
15 CACACCTACCACCACCAATTTTAATATGGGGGCACTTTGGAGATATCAA  
TAGATGACTGTGGAGAATACATGGAAAATGAAAATCGGAAAAGAGTAGC  
CAAGAGCAAGAGCAGGTATGGATTTCAATTTCACTTTCTTACTTACTTAA  
GGATTAAGCTTCTGTTTTTTTGAATAAAAAAGGGACATCTTCTAATAATG  
CACATCTTAAATTA AAAAGTATTTAATTGTTGCATAGCAGCGTATAACAT  
20 CTTCTAATAATTTATCTGAAGGTGAAAGATCCAATACTTCTAATTTGTT  
AAC.AATTTCAATCATTGTGCAATGTTCTTAAAAAATTAATTACCTGAAA  
TCAAAACAATCTTCTTCAAATCCAAAATTATGAGACAGAATTGAGAAGGG  
ATGTGAAATTATAAACCATTAAACAAATTCCATGCTCACGTTACTAATTA  
CATTCTTGTGGGATATATATGTACAGACTGATATTTTGTGAGAGGAAG  
25 TGA.AATTACAAGAAGTCACTGATACTATTTCTAATGTTGTATTACATCG  
TGTCTCATACACTCTTTTATAACAACCTCCGTAACTCACTTGGAGAA  
GTATGGAGGAGTTGAGGTTGTGTTTGAGATAGAGAGTTCAACAAGTAGAG  
AATTGGTAACAACATACCATAAACAACAACAACAACAACCTATATTT  
CCC.AACCTTGAGGAATTATATCTATATTATATGGACAACATGAGTCATGT  
30 ATGGAAGTGCAACAACTGGAATAAATTTTACAACAATCAGAATCCCCAT  
TCC.ACAACCTCACAACCATAACATGTCCGATTGCAAAAGCATTAAAGTAC  
TTGTTTTACCTCTCATGGCAGAACTTCTTCCAACCTAAAGAGAATCAA  
TATTGACGAGTGTGATGGTATTGAAGAAATTGTTTCAAAAAGAGATGATG  
TGG.ATGAAGAA

35

**RG2O deduced polypeptide sequence (SEQ ID NO:119)**

MDVVNAILKPVAETLMEPVKKHLGYIISSTKHVRDMSNKMRELNAARHAEEDHLD  
RNIRTRLEISNQVRSWLEEVKIDAKVKALPSDVTACCSLKIKHEVGREALKLIVEIE  
SATRQHS�ITWTDHPIPLGKVDSMKASMSTASTDYNDFQSREKFTTQALKALEPNN  
40 ASHMIALCGMGGVGKTTMMQRLKKVAKQNRMFSYMVEAVIGEKTDPJAIQQAVA  
DYLRIELKESTKPARADKLREWFKANSGEKKNKFLVILDDVWQSVLEDIGLSPFP  
NQGVDFKVLTSRDEHVCTVMGVGSNSILNVGLLIEAEAQSLFQQFVETSEPELHKI

GEDIVRKCCGLPIAIKTMACTLRNKRKDAWKDALSRIEHYDLRNVAPKVFETSYHN  
LHDKETKSVFLMCGLFPEDFNIPTEELMRYGWGLKIFDRVYTFIEARNRINTCIERL  
VQTNLLIESDDVGCVKMHDLVRAFVLGMYSEVEHASVVNHGNIPGWTENDPTDSC  
KAISLTCEMSGNIPGDFKFPNLTILKLMHGDKSLRFPQDFYEGMEKLQVISYDKMK  
5 YPMLPLSPQCSTNLRVLHLHECSLKMFDSCIGNMANVEVLSFANSNGIEMLPSTIGN  
LKKLRLLDLTDCHGLHITHGVFNNLVKLEELYMGFSDRPDQTRGNISMTDVSNE  
LAERSKGLSALEFQFFENNAQPNMNSFGKLKRFKISMGCTLYGGSDYFKKTYAVQ  
NTLKLVTNKGELLSRMNELFVETEMLCLSVDDMNDLGDVCVKSSRSPQSPVFKIL  
RVFVVSKCVELRYLFTIGVAKDLSNLEHLEVDSCNNMEQLICIENAGKETITFLKIKI  
10 LSLSGLPKLSGLCQNVNKLLELPQLIELKLKGIPGFTCIYPQNKLETSSLLKEEVVIPKL  
ETLQIDEMENLKEIWHYKVSNGERVKLRKIEVSNC DKLVNLFPHNPSLLHHLEEL  
EVKKCGSIESLFNIDLDCVDAIGEEDNMRSRLNIKVKNSWKLREVWCIKGENNSCPL  
VSGFQAVESISIESCKRFRNVFTPTTTNFMGALLEISIDDCGEYMEKSEKSSSEQ  
EQTDLSEEVKLQEVTDITISNVVFTSLIHSFYNNLRKLNLEKYGGVEVVFEIESSTS  
15 RELVTTHYHKQQQQQPIFPNLEELYLYMDNM SHVWKCNNWNKFLQQSESPFHN  
LTTIHMSDCKSIKYLFSPLMAELLSNLKRINIDECGI

**RG2P polynucleotide sequence (SEQ ID NO:120)**

CCCATTGCTATTTCAGGAAGCAGTAGCAGATTACCTCNGTATAGAGCTCAA  
20 AGAAAAAACTAAATCNGCAAGAGCTGATATGCTTCGTAAAATGTTAGTTG  
CCAAGTCCGATGGTGGTAAAAATAAGTTCCTAGTAATACTTGACGATGTA  
TGGCAGTTTGTTGATTTAGAAGATATCGGTTTAAGTCCTTTGCCAAATCA  
AGGTGTTAACTTCAAGGTCTTGCTAACATCACGGGATGTAGATGTTTGCA  
CTATGATGGGAGTCGAAGCCAATTCAATTCTCAACATGAAAATCTTACTA  
25 GATGAAGAAGCACAAAGTTTGTTCATGGAGTTTGTACAAATTTGAGTGA  
TGTTGATCCCAAGCTTCATAAGATAGGAGAAGATATTGTAAGAAAGTGTT  
GTGGTTTGCCTATTGCCATCAAAACCATGGCCCTTACTCTTAGAAATAAA  
AGCAAGGATGCATGGAGTGATGCACTTTCTCGTTTAGAGCATCATGACCT  
TCACAATTTTGTGAATGAAGTTTTTGAATTAGCTACGACTATCTTCAAG  
30 ACCAGGAGACTAAATATATCTTTTGTCTTGTGGATTGTTTCCCGAAGAC  
TACAATATTCCTCCTGAGGAGTTAATGAGGTATGGATGGGGCTTAAATTT  
ATTTAAAAAAGTGTATACTATAAGAGAAGCAAGAGCCAGACTCAACACCT  
GCATTGAGCGGCTTATCCATACCAATTTGTTGATGGAAGGAGATGTTGTT  
GGGTGTGTAAAGATGCATGATCTAGCACTTGCTTTTGTTATGGATATGTT  
35 TTCTAAAGTGCAGGATGCTTCAATTGTCAACCATGGTAGCATGTCAGGGT  
GGCCTGAAAATGATGTGAGTGGCTCTTGCCAAAGAATTCATTAACATGC  
AAGGGTATGTCTGGGTTTCTATAGACCTCAACTTTCCAAACCTCACAAT  
TTTAAACTTATGCATGGAGATAAGTTTCTCAAGTTTCTCCTCCAGACTTTT  
ATGAACAAATGGAAAAGCTTCAAGTTGTATCGTTTCATGAAATGAAATAT  
40 CCGTTTCTTCCCTCGTCTCCTCAATATTGCTCCACCAACCTTCGAGTTCT  
TCATCTCCATCAATGCTCATTGATGTTTGATTGCTCTTGATTGGAAATC  
TGTTTAATCTGGAAGTGTTGAGCTTTGCTAATTCTGGCATTGAATGGTTA

CCTTCCAGAATTGGAAATTTGAAGAAGCTAAGGCTACTAGATTTGACAGA  
TTGTTTTGGTCTTCGTATAGATAAGGGTGTCTTAAAAAATTTGGTCAAAC  
TTGAAGAGGTTTATATGAGAGTTGCTGTTCGAAGCAAAAAGCCGGAAT  
AGAAAAGCCATTAGCTTTCACAGATGATAACTGCAATGAGATGGCAGAGCG  
5 TTC

**RG2P deduced polypeptide sequence (SEQ ID NO:121)**

PIAIQEAVADYL?IELKEKTKSARADMLRKMLVAKSDGGKNKFLVILDDVWQFVDL  
EDIGLSPLPNQGVNFKVLLTSRDVDVCTMMGVEANSILNMKILLDEEAQSLFMEFV  
10 QISSDVDPKLHKIGEDIVRKCCGLPIAKTMALTLRNKSKDAWSDALSRLHHDLHN  
FVNEVFGISYDYLQDQETKYIFLLCGLFPEDYNIPPEELMRYGWGLNLFKKVYTIRE  
ARARLNTCIERLIHTNLLMEGDVVGCVKMHDLLALAFVMDMFSKVQDASIVNHGS  
MSGWPENDVSGSCQRISLTCKGMSGFPIDLNFPNLTKLMHGDKFLKFPDFYEQ  
MEKLQVVSFHEMKYPFLPSSPQYCSTNLRVLHLHQCSLMFDCSCIGNLFNLEVLSF  
15 ANSGIEWLPSRIGNLKKLRLLDLTDCFGLRIDKGV LKNLVKLEEVYMRVAVRSKKA  
GNRKAISFTDDNCNEMAERS

**RG2Q polynucleotide sequence (SEQ ID NO:122)**

TGGGGAAGACACAGTGATAGAAAARAAAAAGAATGTTGTGGAAAAGAGGA  
20 AAATGTTTGATTATGCTGTTGTGGCGGTTATAGGGGAAAAGACGGACCCT  
ATTGCTCTTCAGAAAAGTGTTCGGGATTACTTGCATATTGAGCTAAATGA  
AAGCACTAACTAGCAAGAGCAGATAAACTTTGCAAATGGTTCAAGGACA  
ACTCGGATGGAGGTAAGAAAAAGTTCCTCGTAATACTCGACGATGTTTGG  
CAATCTGTTGATTTGGAAGATATTGGTTTAAGTACTCCTTTTCCAAATCA  
25 AGGTGTCAACTTCAAGGTTTTGTTGACATCACGAAAGAGAGAAATTTGCA  
CAATGATGGGAGTTGAAGCTGATTTAATTCTCAATGTCAAAGTCTTAGAA  
GAAGAAGAAGCACAAAAGTTGTTCTCCTCCAGTTTGTAGAAATTGGTGACCA  
ATACCACGAGCTTCATCAGATAGGGGTACATATAGTAAAGAAGTGTTATG  
GTTTACCCATTGCCATTAAACCATGGCTCTTACTTTAAGAAATAAAAGA  
30 AAGGATTCATGGAAGGACGCACTCTCTCGTTTAGAGGACCATGACACTGA  
AAATGTTGCAAATGCAGTTTTTCGAGATGAACTACCGCAATCTACAAGATG  
AGGAGACCAAAGCCATTTTTTTGCTTTGCGGTTTGTTCCTCCGAAGACTTT  
GAT.ATTCCTACTGAGGAGTTGGTGAGGTATGGATGGGGCTTAAATCTATT  
TAAAAAAGTGTATACCATAAGAAAGGCAAGAACGAGATCGCATACATGTA  
35 TTGAGCGACTCTTGATTCAAATTTGTTGATTGAAAGTAACGATATTCGG  
TGCGTCAAGATACACGATCTGGTGCGCGCTTTTGTGTTTGGATATGTATTG  
TAAAGTTGAGCATGCTTCAATTGTCAACCATGGTAATATGCGGACCGAAT  
ATAATATGGCTGACTCTTGCAAAACAATTTCAATTAACATACAAGAGTATG  
TCTGGGTTTGAGTTTCCAGGAGACCTCAAGTTTCCAAACCTAACAGTTTT  
40 GAAACTTATGCANGGAGATAAGTCTCTAAGGTTTCTCAAGACTTTTATC  
AATCAATGGAAAAACTTCGGGTTATATCATATGATAAAATGAAGTATCCA  
TTGCTTCCCTCATCACCTCAATGCTCCACTAACATCCGAGTGCTTCGTCT

CCATGAATGTTTCATTAAGGATGTTTGATTGCTCTTGTATTGGAAAGCTAT  
TGAATTTGGAAGTCCTCAGCTTTTTTAATTCTAACATTGAATGGTTACCT  
TCCACAATCAGAAATTTAAAAAAGCTAAGGCTACTAGATTTGAGATATTG  
TGATCGTCTTCGTATAGAACAAGGTGTCTTGAAAAATTTGGTCAAACCTG  
5 AAGAACTTTATACTGGATATACATCAGCGTTTACAGA

**RG2Q deduced polypeptide sequence (SEQ ID NO:123)**

GEDTVIEKKKNVVEKRKMFDYAVVAVIGEKTDPIALQKTVADYLHIELNESTKLAR  
ADKLCCKWFKDNSDGGKKKFLVILDDVWQSVLEDIGLSTPPNQGVNFKVLLTSR  
10 KREICTMMGVEADLILNVKMLEEEEAQKLFLQFVEIGDQYHELHQIGVHIVKKCYG  
LPIAIKTMALTLRNKRKDSWKDALSRLEDHDTENVANAVFEMNYRNLQDEETKAI  
FLLCGLFPEDFDIPEELVRYGWGLNLFKKVYTIRKARTRSHTCIERLLDSNLLIESN  
DIRCVKIHDLVRAFVLDMYCKVEHASIVNHGNMRTEYNMADSKTISLTYKSMSG  
FEFPGDLKFPNLTVLKLMDGDKSLRFPQDFYQSMEKLRVISYDKMKYPLLPSSPQCS  
15 TNIRVLRLHECSLRMFDCSCIGKLLNLEVLFFNSNIEWLPSTIRNLKKLRLLDLRYC  
DRLRIEQGV LKNLVKLEELYTGYSAFTE

**RG2S polynucleotide sequence (SEQ ID NO:124)**

ATTTGGGGTTTTACATTTAATTTTTTGTGCATGAATGTGAAAATAGACTG  
20 CTTATTGATTCTTTGTGTTTCATTGAGTTGATTTTCATTATTACTACCTT  
ACAAATTGCTCAGTGATAGATTTCCATTAATTTGCTAATTCGGTTGCTTC  
TAAATATGTAGGAGCTACTAAAAGCAAAAATATCGAGCAATGTCGGACCC  
AACGGGGATTGCTGGTGCCATTATTAACCCAATTGCTCAGAGGGCCTTG  
TTCCCGTTACAGACCATGTAGGCTACATGATTTCTGCAGAAAATATGTG  
25 AGGGTCATGCAGACGAAAATGACAGAGTTGAATACCTCAAGAATCAGTGT  
AGAGGAACACATTAGCCGGAACACAAGAAATCATCTTCAGATTCCATCTC  
AAATTAAGGATTGGTTGGACCAAGTAGAAGGGATCAGAGCAAATGTGGAA  
AACTTTCCGATTGATGTCATCACTTGTGTAGTCTCAGGATCAGGCACAA  
GCTTGGACAGAAAGCCTTCAAGATAACTGAGCAGATTGAAAGTCTAACAA  
30 GACAGCTCTCCCTGATCAGTTGGACTGATGATCCAGTTCCTCTAGGAAGA  
GTTGGTTCCATGAATGCATCCACCTCTGCATCATCAAGTGATGATTTCCC  
ATC.AAGAGAGAAAACTTTTACACAAGCACTAAAAGCACTCGAACCCAACC  
AAC.AATTCCACATGGTAGCCTTGTGTGGGATGGGTGGAGTAGGGAAGACT  
AGAATGATGCAAAGGCTGAAGAAGGCCGCTGAAGAAAAGAAATTGTTTAA  
35 TTATATTGTTAGGGCAGTTATAGGGGAAAAGACGGACCCCTTTGCCATTC  
AAGAAGCTATAGCAGATTACCTCGGTATACAACCTCAATGAAAAAACTAAG  
CCAGCAAGAGCTGATAAGCTTCGTGAATGGTTCAAAAAGAATTCAGATGG  
AGGTAAGACTAAGTTCCTCATAGTACTTGACGATGTTTGGCAATTAGTTG  
ATCTTGAAGATATTGGGTAAAGTCCTTTTCCAAATCAAGGTGTCGACTTC  
40 AAGGTCTTGTGACATCAGGAGACTCACAAGTTTGCACTATGATGGGGGT  
TGAAGCTAATTCAATTATTAACGTGGGCCTTCTAACTGAAGCAGAAGCTC  
AAAGTCTGTTCCAGCAATTTGTAGAACTTCTGAGCCCCGAGCTCCAGAAG

ATAGGAGAGGATATCGTAAGGAAGTGTTGCGGTCTACCTATTGCCATAAA  
AACCATGGCATGTACTCTTAGAAATAAAAGAAAGGATGCATGGAAGGATG  
CACTTTCGCGCATAGAGCACTATGACATTCACAATGTTGCGCCCAAAGTC  
TTTGAAACGAGCTACCACAATCTCCAAGAAGAGGAGACTAAATCCACTTT  
5 TTTAATGTGTGGTTTGTTCCTCGAAGACTTCGATATTCCTACTGAGGAGT  
TGATGAGGTATGGATGGGGCTTGAAGCTATTTGATAGAGTTTATACGATT  
AGAGAAGCAAGAACCAGGCTCAACACCTGCATTGAGCGACTGGTGCAGAC  
AAATTTGTTAATTGAAAGTGATGATGTTGGGTGTGTCAAGATGCATGATC  
TGGTCCGTGCTTTTGTTCCTGGGTATGTTTCTGAAGTCGAGCATGCTTCT  
10 ATTGTC AACCATGGTAATATGCCCAGTG GACTGAAAATGATATAACTGA  
CTCTTGCAAAAAGAATTCATTAAACATGCAAGAGTATGTCTAAGTTTCCAG  
GAGATTTCAAGTTTCCAAACCTAATGATTTTGAAACTTATGCATGGAGAT  
AAGTCGCTAAGGTTTCTCAAGACTTTTATGAAGGAATGGAAGGCTCCA  
TGTTATATCATACGATAAAATGAAGTACCCATTGCTTCCTTTGGCACCTC  
15 GATGCTCCACCAACATTCGGGTGCTTCATCTCACTAAATGTTCAATAAG  
ATGTTTGATTGCTCTTGATTGGAAATCTATCGAATCTGGAAGTGCTGAG  
CTTTGCTAATTCTCGCATTGAATGGTTACCTTCCACAGTCAGAAATTTAA  
AGAAGCTAAGGTTACTTGATCTGAGATTTTGTGATGGTCTCCGTATAGAA  
CAGGGTGTCTTGAAAAGTTTAGTCAAACCTGAAGAATTTTATATTGGA  
20 TGCATCTGGGTTTATAGATGATAACTGCAATGAGATGGCAGAGCGTTCTG  
ACAACCTTTCTGCATTAGAATTCGCGTTCTTTAATAACAAGGCTGAAGTG  
AAAAATATGTCATTTGAGAATCTTGAACGATTCAAGATCTCAGTGGGACG  
CTCTTTTGATGGAAATATCAATATGAGTAGCCACTCATACGAAAACATGT  
TGCAATTGGTGACCAACAAAGGTGATGTATTAGACTCTAACTTAATGGG  
25 TTATTTTGAACAAAGGTGCTTTTTTTAAGTGTGCATGGCATGAATGA  
TCTTGAAGATGTTGAGGTGAAGTCGACACATCCTACTCAGTCCTCTTCAT  
TCTGCAATTTAAAAGTTCTTATTATTTCAAAGTGTGTAGAGTTGAGATAC  
CTTTTCAAACCTCAATCTTGCAAACACTTTGTCAAGACTTGAGCATCTAGA  
AGTTTGTGAATGCGAGAATATGGAAGAACTCATACATACTGGAATTTGTG  
30 GAGAAGAGACAATTACTTTCCCTAAGCTGAAGTTTTATCTTTGAGTCAA  
CTACCGAAGTTATCAAGTTTGTGCCATAATGTCAACATAATTGGGCTACC  
ACATCTCGTAGACTTGATACTTAAGGGCATTCCAGGTTTCACAGTCATTT  
ATCCGCAGAACAAGTTGCGAACATCTAGTTTGTGGAAGGAAGAGGTAGAT  
ATATGTTCTTTATGTTAATAACAATTTAAATAATATTTTCAACCAAATTT  
35 CATAATATATCTGTAATTTGATTGTATGATGTGTTATTGTTTATATGTGG  
CTATTAAGGGATGATTATTTTGCAGGTTGTGATTCCTAAGTTGGAGACAC  
TTCAAATTGATGACATGGAGAACTTAGAAGAAATATGGCCTTGTGAACTT  
AGTGGAGGTGAGAAAGTTAAGTTGAGAGAGATTAAAGTGAGTAGCTGTGA  
TAAGCTTGTGAATCTATTTCCGCGCAATCCCATGTCTCTGTTGCATCATC  
40 TTGAAGAGCTTAAAGTCAAGAATTGCGGTTCCATTGAATCGTTATTCAAC  
ATTGACTTGGATTGTGTGCGGTGCAATTGGAGAAGAAGACAACAAGAGCCT  
CTTAAGAAGCATCAACATGGAGAATTTAGGGAAGCTAAGAGAGGTGTGGA  
GGATAAAAGGTGCAGATAACTCTCATCTCATCAACGGTTTTCAAGCTGTT

GAAAGCATAAAGATTGAAAAATGTAAGAGGTTTAGCAATATATTCACACC  
TATCACCGCCAATTTTTATCTGGTGGCACTTTTGGAGATTCAGATAGAAG  
GTTGCGGAGGAAATCACGAATCAGAAGAGCAGGTAACGCTTCAATTTAA  
CTTTCTTAAGTAATTAAGGACTAACCTCCTGTTTTTTGAATAATAAAGAG  
5 GTGGGATGACTAAACTTGGGCATCACAATTGCAACAAAATGTTACAAACC  
ATGAAACGTTCAAACCATTTCTTGAATTAAGGTTTCAATACAAGTCATTT  
AAAAATATGGCTTAAATTTTTTTATATTTATGTATCAACATGATTTTTCA  
TTAGAGATCATTATTATAATAGTAAGTTTAAAGCAATTTAAATTAGAACT  
AATTCTAACTTTAGCTAATAAATCGTTATAAATGTAAATAATTACTTTTT  
10 AGTGAAATAAGCAACGGATTTAATAAGTTAACAACCTTAAATGTCATTTCC  
TAACAAAAAAAACCTATTTGGTTCAGAAGAACCGTAATTCAAGATAACTAA  
AATAAAAAATATTTGACATTCACTAAGAGCATTTTTTTTTCTAAATATGAT  
TGCAAATGAATAAAACTTAAATTTATACAGAAAAGATTTTTATATATGTT  
ATACAAAATTTACAAATTGAAACTGGATATGTTAATTAACGGTTTATAAT  
15 TCTGGTATCACAAAGGGATATATAATAAAATATTATTTCTGTAGTCATT  
TATAATTGTACTAGTTTATAACCCGTGGGAACCATGAGTTCTAAAATTAG  
TTAAACTTTTCATAATAAAAATTTATAATTATTATTTATTTTAAATAAATT  
ATTAAATTAAGAGATGTATCAAAAATTTAAAGTTATTATAACTTCAAATTT  
AACATATAATTAGAAAATATATGATCATAACTTTCCGCAACTCTTCTTTT  
20 GTATTAAAATGCCAGAGAAGCTCTTAGTAYATTTTCTAAATCAAAGTCA  
CAAACTAATGAAGCATATAATTTTGTGAAAATCAATTAGCATTAGGTTT  
TAAGAGTCACCAAATTCAAAGAGTAATCCAATGCTTTCATTACCACTATG  
GAGAAAATATTTTCTTAGTTTAAATGAAATGAAAACAAACATTCAAACCTA  
ATTGTTGCTTACTAAACCAAAGACCCATTACTTAGCCAAGAGTTTAACCA  
25 AAAAAAATTACATTCATGTATCATTATTCATGACTAGATATATATGAACA  
TGAAGGGAGTTTTTATAGAAAATATAATCATAGATATTCAACATAACTTC  
ATGGAATTCCTCAAAATAACCAAGTTATTCAAGAAATTACATCCAAGTCA  
ACCAAAGAGAAGTTTAGCCTAGCATGGCTAAACTCAAGAAAATAAAATAA  
GGATTAGAAGTACCAAACATGTAGTAAGAATCACAGTAAAAGATGATGTT  
30 GTTCTTGATGTTCTTCTAAGTTCTTCAAGTCTCCAGTTGCTCCTAATAAT  
GCAAAGGAGAGCCATTAAATTCGTATGTATTGATCCCTTCAAAGCTGCA  
CCAACCTCCCTTAAATAACACTCAAAGCAAAAATGACAAAATTGCCCTG  
AAGGACCCTATGCGGGTGCCTTGCGCGGGTGGAGCTGAATACGAAAGGTC  
TTTGGTCTTTGTGAGGGTGATGCTGTGCGGGTTAGCTTGTGCGCATGCTTC  
35 CGCGCGGTTGCGGCACATGTGCACAAGTGATGCATGGTGTGTACGTTCTT  
GAGTTTTGAGCCTCCGATGCTTAGTCCATTTGGCCCAATTCGAGTCCAAT  
CAGCTTATGACCCATTTTTCTTCAAGTTATCTTCAAGTTATCTTCAAGTT  
AAGCCCAAATTGCCTTCTCCAAATCATCCATAACTTCACAAAATCGCCCG  
TTCATCTTAATCCCGAATGCACAATTATTCTCCTGTCTTCCTTTTAAGCA  
40 AGATACCACCTTCTTCATGCTTCATCCATCAATAGTACACTTCATGTATC  
ATCTCTACTAGTTATTTAGTCCACAATCCTTATTGTCCTCCAAATTTAAT  
TATCTCATTTAGTTCCCGTCCACTAGTTTCCTTAAAATTTGCAATTAAG  
CTC.ACACAAATATTAAGTACCTGAAATGGTCATAAAAATAACAAAAGGAA

AAT.ATGCATGAAGATTAAGTAAATGATGAACGAAATATGCTAAAATAGAC  
TATAAAATGAAGTAAATAAAATGAAATTATCGCACTCCGACCACCCTTAT  
AGGCTTGTAGTCCATCCACCCTTCATTCCCTGTACCAATATGGGATGGAA  
ACATCATTAATTAAGCCAAAAAACTAACATATAAGGGGTGAGTGACAAAG  
5 GTA.AGTACTAAAGATGAAAATAATCCATTTTTTGTATATACACAACAC  
ACACATAGGGGCAGACGTAGGATTCATAGTACAGATTGTTGGTGGCACA  
TAAGTGTGCTGGTGACACTTTTTTTCTTTTACGTAGTGGCACAACAG  
TAG.AAAAAACGARAAATTCGAAATTTTTTACAATGTGTSTAAAAAAAAYA  
GTGGTTGTTGGTGCCACTATGGACACCAAAGTTGAACTGCCCCCTGCGCGC  
10 RCACACACACACATAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAG  
ARAGWAWGRRRGAKAKARMCSMSYTTGGGATGTGATACTTCTTTTAGGAA  
AATGGAGTTATATCTTTGATATTGTATTTTTTTAATGTAATTTATATATT  
TAATCATTTTTAGTTTATAAGTTTTATTTATTTTGATATGAAAAAAAAGT  
CTTTTATACATTGGATTTAACATAAAAAATCCAACAATATTAATCAAAAAG  
15 ACC.AMACATGTGGACAMWTATGTATATAAWTAATTCACAATAGTCTTTAG  
GAATAGNATTATATATATAATTAATTCTCAATGGTCTTAGGAATAGTAAG  
TTCTTATATTTCAAACCTTNGCCACAATTCTTTGKTTACTTWGACACTTY  
CCTCTCTCTAATTATATATATATATATATATATATATATATATATACACA  
CAC.ACACACACACACTAGATGTGTGCCCGCGCAAAGCAGTGACGTNNNGG  
20 AGA.ANACTTTCTTAAGCATAAATAATTATTATTTTTTTATTGGGTATTA  
TATA.AATAAAAAATTACAACCTTTAAATAAAATATTTATGTTTATACTTTA  
TATTTATATTGCTTGTATACTATTAATATAATAAATTAATATTTATGTCT  
AATTTATGAAATGTAAATTAATTTAAATACATGAATTTAATATTTTTTAAA  
ATTTTCAGTTTGCTTCAAATTGAGTTTCTTAATTATTTTTTTTAAATTCAN  
25 GTATTCAAACCTTTTGGTAAGTATTAAGAATTATTTATGCACAATTGATT  
TAT.ACAAAAAAATTTGTAACCTTATACATCTTAAAATTCAAGATATAACTA  
ACATGTTTTACAATATATATATATATATATATATATATATATATATATAT  
ATATATATATATATATAGTAAAGCGCANAGGTCATAGGNANAGANTATTT  
TCT.ATTATTCTACGTTTTGCCACAAAAGTTTGAACACTTTGCCACTTTTT  
30 GTCCCTCCTTAACCTTTTCAATGTTTTGCGACAAAAGTTCCAAAACCTTG  
CCACTTTGATCATTCCTCAACTTTTCACCGCATTAGTTTGTGGAGTTGGC  
AGTTTTGGTCCCCCTAACTTCGATATTTTCTCCTGCTAGCCAAAAAGGGT  
TCC.AGAGTTTCACANTTTTGGTCCCTGACAATAACCAAATGTGAGATGTC  
AAA.TTTTTGCCACATTAGTTTGTGGAGTTGTCCCTTTTGGTCCCCCACA  
35 TTCGATATTCTACTATACGACCTTATTTTTCTCAAATAACAACACGTATA  
TTT.AATTACCAATGATAGAAATAGATATCAAATAAAGTATTTGTAACACC  
GTGTAAGAACGGTGCTACTATAGGTAAAAATAAACATTTCAAAGTACGAT  
GTCCTAATTGGAAAAAGAGTTTTTAAAAAATAACAACCTAGGGGCGAGTTT  
TTTTTACAAGTTTGTATCAAATCATATCAAAATTTAAGGTGGAACGGTGA  
40 CCACATTAACCAGAAATGTAATTTATTCTTTGATTTTGATAATTTTTAAT  
ATTTTGTGTGATCTATGTATTTAAAAGTAAACAACAAAGAACATAATCC  
AAA.ACCCTAAATTGCAAGTCTCGCCCAATTTCTCTATCACTAGTCGTCAC  
TTACGATGGCGTTACGTCGCTCTCTCACTTCTTACAACCCTTTGTTGCTA

CTCATTACAATAACGAAAAGTTGAATATCCATATATTTATTTGGATGTGG  
AATTGAACAAATCTCGTCAAATTTTGGATTTTGTGATGGATTTGAGTAG  
AAGTTTGGGCAGAACGGGAATGATGGTCTGCAAGTGGTTATAAACTTGAT  
TCTGAGTTATTACTATATATGTAGCCTCTTTACAACGACCAAGGTTTCTT  
5 CCAGGTACCATTTGATCTTTTTAGAACCCAGTTGTCTGAAACACCCTGAT  
TTGGATCAAATATCACCAACAACCTCTTAAAAACTTGATTAATCAATTGTT  
TTCTTCATCTTGATAACAAGTGGAAATGATTTTCTACTTAGATTAACCTGA  
AAAAAAGGTCCATGTGCGTCTGGTGGATCTGGTAAATGAAGATGGAAGG  
GAGAGCTGACTTTAAAGACACAAACACGTCACCATATCTTTTATTTTATT  
10 TTAATTTGCTTTTTTTCCTATTTCTTTCTTTCTTGATCTCCAGATGGTAT  
GTGGTGTGGATAATTTACACATAGAGATTGGGAACGACTGTGTTTTAGAG  
AGGACGTGGCTTGGGGTTGAGGATGGTTTATGGCTGGCCGAGTTTCATTT  
ATATAAACAAACAAATATATAAAACAAGGGGTAAAATGGCCATCTTATAT  
GTATTTAACCGTCCTTTTTTATTTTTTTTTTATTTTTTAAATTTAAGAAGG  
15 GGTATACCAGTGTGAGCCTCTTATCCCAACCAGGCAACCAGTCAAATAG  
GGACTTAGGTTGTTTGGAAACAGTTCCGTGAGACCGTGACTTGGATGGTA  
GATAAATTTAGTAACTTAACCCTTCAATTAACCTACCTTTTTCTTATTA  
ACTCAATTTCAACCTAAATTCTGATTCTTGTTTGAAAATAAGTTGCATCT  
TTATGTTTGTATTATCCTGTTGCATAGGATCCTTAGCATCTTTTAATAAT  
20 TTATTTGAAGGTGAAAGATCCAACCTATTTTTTAGCTGTTGGCATTTTCCA  
TCATTTGCAACTGTTTCTTGAAAAAAAATACCTAAAATCAAATAACCA  
TTTTCAAATCCAAAATTATAAGAGAGAATTGTTAATGGACGTGGAATCGT  
AAATCATTAACACAGTTCAGTACACAAGTTGCTAATTACATTTCTTGCTG  
TGCAGATTGAAATTCTATCAGAGAAAGAGACATTACAAGAAGTCACTGAT  
25 ACTAATATTTCTAATGATGTTGTATTATTCCCATCCTGTCTCATGCACTC  
TTTTCATAACCTCCATAAACTTAAATTGGAGAGAGTTAAAGGAGTGGAGG  
TGGTGTGTTGAGATAGAGAGTGAGAGTCCAACAAGTAGAGAATTGGTAACA  
ACTCACCATAACCAACAACATCCTATTATACTTCCCAACCTCCAGGAATT  
GGATCTAAGTTTTATGGACAACATGAGTCATGTGTGGAAGTGCAGCAACT  
30 GGAATAAATTCTTCACTCTTCCAAAACAACAATCAGAATCCCCATTCCAC  
AACCTCACAACCATAACATGTTTCACTGTCAGAGAGCATTAAAGTACTTGTT  
TTCGCTCTCATGGCAGAACTTCTTTCCAACTAAAGGATATCTGGATAA  
GTGGGTGTAATGGTATTAAAGAAGTTGTTTCAAAGAGAGATGATGAGGAT  
GAAGAAATGACTACATTTACATCTACCCACACAACCACCATCTTGTTCCC  
35 TCATCTTGATTCTCTCACTCTAAGACTACTGGAGAATCTGAAGTGATTG  
GTGGAGGTGGTGCCAAGGATGAGGGGAGCAATGAAATATCTTTCAATAAT  
ACCCTGCAACTACTGCTGTTCTTGATCAATTTGAGGTATGCTTTGTACA  
TATTCAATTATTTATTTAATTTCTTTTTCTTTGCAATATTCTATAAAT  
AATACATTTTATACCCACTATACTAAGATAATAATTACCTAGAGGGATGG  
40 ATGCTATGACACAGCTGCTACACTTCAGAACTCTAGTAAGGGCAGTTAT  
GGAAGTTCAATAAAATGATAATGGCATCTTTTGATGGGTAATATAGGCAA  
TTTAAAGTTTTATTTCTGTAAAGCAGTATTTAGCAAGTACTGGCCAGTAG  
GAGAGGAGAATATCACCTTTTGTGAAAATCTGGTCATTGTACCAAGAAT



TTAGTTAAATGTAACATTTTAGATATCAGGGGACATCAGGTGACAGATAT  
TGTAGAATAGAACAATATATAATATTACCCAAAACATTTTTTCTAAGGT  
TATTCTGTAAATATGTGCTTTCTTGATTTTCATTGAATTTGCATTCCCTAT  
ATTTTAGGTGGTAAAGTGATTGTCTCTTCAATAAATCCCGAAATTAATTA  
5 AAAAAAAAAAAAAAAACAAAAGTAAATTTTTGATATGGAGAGCACTGGTATCA  
TTTAGTATATAAAAAAACTAGATTTTGAATTAAGTTTCTTATATAAAAGC  
TGTGTATATAGTTTAATTAGTTTTACATCATTTTTTCCATGTGGTGTGCA  
GTTGTCTGAAGCAGGTGGTGTCTTGGAGTTTATGCCAATACGCTAGAG  
AGATAGAGATATCTAAGTGTAATGTATTGTCAAGTGTGATTCCATGTTAT  
10 GCAGCAGGACAAATGCAAAAGCTTCAAGTGCTGAGAGTAACGGGTTGTGA  
TGGCATGAAGGAGGTATTTGAACTCAATTAGGGACGAGCAGCAACAAAA  
ACAGAAAGGGTGGTGGTGAAGGAAATGGTGGAAATCCAAGAGTAAAT  
AAC.AATGTTATTATGCTTCCCAATCTAAAGACATTGAAAATCTACATGTG  
CGGGGGTTTGGAACATATATTACATTCTCTGCACTTGAAAGCCTGACAC  
15 AGCTCCAAGAGTTAAAGATAGTGGGTGCTACGGAATGAAAGTGATTGTG  
AAGAAGGAAGAAGATGAATATGGAGAGCAGCAACAACAACAACAAC  
AACGAAGGGGGCATCTTCTTCTTCTTCTTCTTCTTCTTCTAAGAAGGTTG  
TGGTCTTTCCCGTCTAAAGTCCATTGAACTATTCAATCTACCAGAGCTG  
GTAGGATTCTTCTTGGGGATGAATGAGTTCCGGTTGCCTTCATTGGAAGA  
20 AGTTACCATCAAGTATTGCTCAAAAATGATGGTGTTCGAGCTGGTGGGT  
CCACAGCTCCCCAACTCAAGTATATACACACAAGATTAGGCAAACATACT  
CTTGATCAAGAATCTGGCCTTAACCTTCATCAGGTATATATATATTCCTT  
TAATTGGCATGATCTAATTAAGAAAGATATCATTCCCTGCCAAGTAAATTT  
ACTTCAAACACATTCACTGGTTTCAGTCTAAGTTTATGTTGTTCTAGG  
25 AAGGCCAAAATGGGAAAGCAAGATAGGGAAAAATAGTGTATTCAGTGGA  
AAGGGTATTTTAGGTATTTTCTGTCAAAAGTTGTTATTGCAGGCTTTTTTA  
GTACCTGGAATCGTGTGTGGGAGGAGCGTTATTATTCTGATTTGCTTGT  
TCTTTATCATTTTTTCTTAGCCTCTCGAACAGCTAGAAACCCTTTTAATC  
TTTTGATTTTAAATGACAAAATTTTTCCCTGTTACTCTATTTGATTGTTG  
30 TTCTTCATGGTTCTAAGTGAGTTATTGGCTCATCTGTTACTTCTTTTGAT  
TGTTATTTTCATATCATGTTGTCCTTTGAATCAAGCTTTTCCATTTTCAA  
CCAGGGCAAAGGTCAAAGTAACCTACTTTATGAGATCAAAAACAGCAA  
CCCATCGGATAACTTTTAGTTGGAGTTAATAGTTACAATTACCATTGTGA  
TTAATAATTATAATATCTTGATTAATTCATTAATAATTGGTACAGCACAT  
35 ATATGACATTTTAAAGGTTTGTGTTTGTGTTGACATATATATGCCTCTGGC  
GTTTTCTTTATTGGACATGCAGACCTCATTCCAAAGTTTATACGGTGACA  
CCTCGGGCCCTGCTACTTCAGAAGGGACAACCTGGTCTTTTCATAACTTG  
ATCGAATTAGATATGGAATTAATAATTATGATGTTAAAAAGATTATCCATC  
CAGTGAGTTGCTGCAACTGCAAAAGCTGGAAAAGATTGATGTGAGTAGTT  
40 GTTATTGGGTAGAGGAGGTATTTGAACTGCATTGGAAGCAGCAGGGAGA  
AATGGAAATAGTGGAAATGGTGTGATGAATCGTCACAACTACTACTAC  
TACTACTCTTTCAATCTTCGAAACCTCAGAGAAATGAAGTTGCATTTTC  
TACGTGGTCTGAGGTATATATGGAAGAGCAATCAGTGGACAGCATTGAG

TTTCCAAACCTAACAAGAGTTCATATAAGTAGGTGTAGAAGGTTAGAACA  
TGTATTTACTAGTTCCATGGTTGGTAGTCTATTGCAACTCCAAGAGCTAG  
ATATTAGTTGGTGCAACCATATGGAGGAGGTGATTGTTAAGGATGCAGAT  
GTTTCTGTTGAAGAAGACAAAGAGAGAGAATCTGATGGCAAGACGAATAA  
5 GGAGATACTTGTGTTACCTCGTCTAAAATCCTTGAAATTAAAATGCCTTC  
CATGTCTTAAGGGGTTTAGCTTGGGGAAGGAGGATTTTTCATTCCCATT  
TTGGATACTTTAGAAATCTACAAATGCCCAGCAATAACGACCTTCACCAA  
GGGAAATTCTGCTACTCCACAGCTAAAAGAAATAGAAACAAGATTTGGCT  
CGTTTTATGCAGGGGAAGACATCAACTCCTCTATTATAAAAAGATCAAAC  
10 AACAGGTAAATCAGATCTTTGTTGCTTTAATAATTCTTAAACTACATTTG  
AAAAGCTTCATGCAAGTTTTTTTTTGTATATTGTCAAAAACCGCAACCTA  
CATTTTCAGCTTTATATTTATGTACTTTATGCAGGAGTTCAAACAAAAC  
CTGATTAATGTGAAGTGAATATTAAGGTAAATTATATTTTCATGTTCTT  
AGTTGCCTATTAATTAATGGCCTTTTAGTTCRTGATTTTTGGATGTAGTY  
15 WTCATGATGATGTGAATCTTCTAATACCCCATTCATTGTTTGGTTGAATG  
TTGACTCTATGTCAGGATGAATATTCAAGGGAAGAATTGTTTCATCATATG  
AAGGACATTAAAGAACATGGATGCTATGAAGATGTTGGAARAC

**RG2S deduced polypeptide sequence (SEQ ID NO:125)**

20 MSDPTGIAGAIINPIAQRALVPVTDHVGYMISCRKYVRVMQTKMTELNTSRISVEEH  
ISRNTRNHLQIPSQIKDWLDQVEGIRANVENFPIDVITCCSLRIRHKLKGQKAFKITEQI  
ESLTRQLSLISWTD DDPVPLGRVGS MNASTSASSDDFPSREKTFTQALKALEPNQQF  
HMYALCGMGGVGKTRMMQRLKKA AEEKL FNYIVRAVIGEKTDPFAIQEAIADYL  
GIQLNEKTKPARADKLREWFKNSDGGKTKFLIVLDDVWQLVDLEDIGLSPFPNQG  
25 VDFKVL LSRDSQVCTMMGVEANSIINVGLL TEAEAQSLFQQFVETSEPELQKIGED  
IVRKCCGLPIAKTMACTLRNKRKDAWKDALSRIEHYDIHNVAPKVFETSYHNLQE  
EETKSTFLMCGLPEDFDIPTEELMRYGWGLKLFDRVYTIREARLNTCIERLVQT  
NLLIESDDVGCVKMHDLVRA FVLGMFSEVEHASIVNHGNMPEWTENDITDSCKRIS  
LTCKSMSKFP GDFKFPNLMILKLMHGD KSLRFPQDFYEGMEKLHVISYDKMKYPLL  
30 PLAPRCSTNIRVLHLTKCSLKMFD CSCIGNLSNLEVLSFANSRIEWLPSTVRNLKKLR  
LLDLRFCDGLRIEQGV LKSLVKLEEFYIGNASGFIDN CNEMAERSDNL SALEFAFF  
NNKAEVKNMSFENLERFKISVGRSFDGNINMSSH SYENMLQLVTNKG DVLD SKLN  
GLFLKTKVLFLSVHGMNDLEDVEVKSTHPTQSSSFCNLKVLISKVELRYLFKLN  
ANTLSRLEHLEVCECENMEELIHTGICGEETITFPKLKFLSLSQLPKLSSLCHNVNIIG  
35 LPHLVDLILKGIPGFTVIYPQNKLR TSSLLKEEVVIPKLET LQIDDMENLEEIWPCELS  
GGEKVKLREIKVSSCDKLVNLFPRNPMSLLHHLEELKVKNCGSIESL FNIDLCVGA  
IGEEDNKSLRSINMENLGKLREVWRIKGADNSHLINGFQAVESIKIECKRFSNIFT  
PITANFYLVALLEIQIEGCGGNHESEEQIEILSEKETLQEVTD TNISNDV VLFPSCLMH  
SFHNLHKLKLERVKGVVVFEIESESPTSRELVTTHNQHPILPNLQELDSL FMD  
40 NM SHVWKCSNWNKFFTL PKQQSES PFHNLTTIHMFSRSIKYLF SPLMAELLSNLK  
DIWISGCNGIKEV VSKR DDEDEEMTTFTSTHTTTILFPHLDSLTLRLLENLKCIGGGG  
AKDEGSNEISFNNTTATTAVLDQFELSEAGGVSWSLCQYAREIEISKCNVLSSVIPCY

AAGQMQKLQVLRVTGCDGMKEVFETQLGTSSNKNRKGGGDEGNNGGIPRVNNNVI  
MLPNLKTLYMCGGLEHIFTFSALES LTQLQELKIVG CYGMKVIVKKEE DEYGEQ  
QTTTTTTTKGASSSSSSSSKVVVFPRLKSIELFNLPELVGFFLGMNEFRLPSLEEVT  
IKYCSKMMVFAAGGSTAPQLKYIHTRLGKHTLDQESGLNFHQTSFQSLYGDTSGPA  
5 TSEGTTWSFHNLIELDMELNYDVKKIIPSELLQLQKLEKIHVSSCYWVEEVFETAL  
EAAGRNGNSGIGFDESSQTTTTTTLFNLRLNREMKLHFLRGLRYTWKSNQWTAFEF  
PNLTRVHISRCRRLEHVFTSSMVGSLLQLQELDISWCNHMEEVIVKDADVSVEEDK  
ERESDGKTNKEILVLPRLKSLKLCLPCLKGFSLGKEDFSFPLDLEIYKCPAITFTT  
KGN SATPQLKEIETRFGSFYAGEDINSSIIKRSNNRSSNKT LINVK .ILK

10

**RG2T polynucleotide sequence (SEQ ID NO:126)**

GGAAGACGACAATGGTGCAACGGTTGAAGAAGGTTGTGAAAGATAAGAAG  
ATGTTCCATTATATTGTCGAGGTGGTTGTAGGGGCAAACACTGACCCCAT  
TGCTATCCAGGATACTGTTGCAGATTACCTCAGCATAGAACTGAAAGGAA  
15 ATACGAGAGATGCAAGGGCTTATAAGCTTCGTGAATGCTTTAAGGCCCTC  
TCTGGTGGAGGTAAGATGAAGTTCCTAGTAATTCTTGACGATGTATGGAG  
CCCTGTTGATCTGGATGATATCGGTTTAAGTTCCTTGCCAAATCAAGGTG  
TTG.ACTTCAAGGTCTTGCTGACATCACGCAACAGTGATATCTGCATGATG  
ATGGGAGCTAGTTTAATTTTCAACCTCAATATGTTAACAGACGAGGAAGC  
20 ACATAATTTTTTCCGTCGATACGCAGAAATTTCTTATGATGCTGATCCCCG  
AGCTTATTAAGATAGGAGAAGCTATTGTAGAGAAATGTGGTGGTTTACCC  
ATTGCCATCAAACTATGGCCGTTACTCTTAGAAATAAACGCAAAGATGC  
ATGGAAAGATGCACTTTCTCGTTTAGAGCACCGTGACACTCATAATGTTG  
TGGCTGATGTTCTTAAATTGAGCTACAGCAATATCCAAGACGAGGAGACT  
25 CGGTCGATTTTTTTTGCTATGTGGTTTGTTCCTGAAGACTTTGATATTCC  
TACCGAAGACTTAGTGAGGTATGGATGGGGATTGAAAATATTTACCAGAG  
TGT.ATACTATGAGACATGCAAGAAAAAGGTTGGACACGTGCATTGAGCGG  
CTT.ATGCATGCCAACATGTTGATAAAAAGTGATAATGTTGGATTTGTCAA  
GATGCATGATCTGGTTCGTGCTTTTGTGTTGGGCATGTTATCTGAAGTCG  
30 AGCATGCATCAATTGTCAACCATGGGGATATGCCAGGGTGGTTTGAAACT  
GCAAATGATAAGAACAGCTTGTGCAAAAGAATTCATTAACATGCAAAGG  
TATGTCTGCGATTCTGAAGACCTCACGTTTCCAAACCTCTCGATCCTGA  
AATTAATGGATGGAGACGAGTCACTGAGGTTTCCTGAAGGCTTTTATGGA  
GAAATGGAAAACCTTCAGGTTATATCATATGATAACATGAAGCAGCCATT  
35 TCTTCCACAATCACTTCAATGCTCCAATGTTTCGAGTGCTTCATCTCCATC  
ACTGCTCATTAATGTTTGATTGCTCTTCTATTGGAAATCTTTGAATCTC  
GAGGTGCTCAGCATTGCTAATTCTGCCATTAAATTGTTACCTCCACTAT  
TGGAGATCTGAAGAAGCTAAGGCTCCTGGATTTGACAAATTGTGTTGGTC  
TCTGTATAGCTAATGGCGTCTTTAGAAATTTGGTCAAACCTGAAGAGCTT  
40 TAT.ATGAGAGTTGATGATCGAGATTCGTTTTTTGTGAAAGCTGATGACAG  
CAAGACCATTACCT

**RG2T deduced polypeptide sequence (SEQ ID NO:127)**

KTTMVQRLKKVVKDKKMFHYIVEVVVGANTDPIAIQDTVADYLSIELKGNTRDAR  
AYKLRECFKALSGGGKMKFLVILDDVWSPVDLDDIGLSSLPNQGVDFKVLLTSRNS  
DICMMMGLIFNLNMLTDEEAHNFFRRYAEISYDADPELIKIGEAIVEKCGGLPIAI  
5 KTMAVTLRNRKDAWKDALSRLEHRDTHNVVADVLKLSYSNIQDEETRSIFLLCG  
LFPEDFDIPTEDLVRYGWGLKIFTRVYTMRHARKRLDTCIERLMHANMLIKSDNVG  
FVKMHDLVRAFVLGMLSEVEHASIVNHGDMPGWFETANDKNSLCKKRISLTCKGMS  
AIPEDLTFPNLSILKMDGDESLRFPEGFYGEMENLQVISYDNMKQPFLPQSLQCSN  
VRVLHLHHCSLMFDCSSIGNLLNLEVLSIANSIAIKLLPSTIGDLKKLRLLDLTNCVGL  
10 CIANGVFRNLVKLEELYMRVDDRDSFFVKADDSKTTT

**RG2U polynucleotide sequence (SEQ ID NO:128)**

GCCTTGTGTGGGATGGGTGGAGTGGGAAAGACCACTGTGATGAAGAAGCT  
GAAGGAGGTTGTGGTAGGAAAGAACTGTTTAATCATTATGTTGAGGCGG  
15 TTATAGGGGAAAAGACAGACCCCATTTGCTATTCAACAAGCTGTTGCCGAG  
TACCTTGGTATAAGTCTAACCGAAACCACTAAACCAGCAAGAAGCTGATAA  
GCTCCGTACATGGTTTGCAAACAACCTCAAATGGAGGAAAGAAGAAGTTCC  
TGGTAATACTAGACGATGTATGGCAACCAGTTGATTTGGAAGATATTGGT  
TTAAGTCGTTTTCCAAATCAAGATGTTGACTTCAAGGTCTTGATTACATC  
20 ACGGGACCAATCAGTTTGCCTGAGATGGGAGTTAAAGCTGATTTAGTTC  
TCAAGGTGAGTGTCCTGGAGGAAGCGGAAGCACACAGTTTGTTCCTCCAA  
TTTTTAGAACCTTCTGATGATGTCGATCCTGAGCTCAATAAAATCGGAGA  
AGAAATTGTAAAGAAGTGTGCGAGTACCCATTGCTATCAAACCATGG  
CCTGAACTCTTAGAAGTAAAGTAAGGATACATGGAAGAATGCCCTTTCT  
25 CGTTTACAACACCATGACATTAACACAATTGCGTCTACTGTTTTCCAAAC  
TAGCTATGACAATCTCGAAGACGAGGTGACTAAAGCTACTTTTTTGCTTT  
GTGGTTTATTTCCGGAGGACTTCAATATTCCTACCGAGGACCTATTGAGG  
TATGGATGGGATTGAAGTTATTCAAGGAAGTAGATACTATACGAGAAGC  
AAGATCCAAGTTGAAAGCCTGCATTGAGCGGCTCATGCATACCAATTTGT  
30 TGATCGAAGGTGATGATGTTAGGTACGTAAAGATGCATGATCTGGTGCGT  
GCTTTTGTGTTTGGATATGTTTCTAAAGCCGAGCATGCATCTATTGTCAA  
CCATGGTAGTAGTAAGCCAAGGTGGCCTGAAACTGAAAGTGATGTGAGCT  
CCTCTTGCAAAGAATTTTCATTAACATGCAAGGGTNTG

**RG2U deduced polypeptide sequence (SEQ ID NO:129)**

ALCGMGGVGKTTVMKKLKEVVVGKKLFNHYVEAVIGEKTDPIAIQQA VAEYLGIS  
LTETTKPARTDKLRTWFANNSNGGKKKFLVILDDVWQPVLDLEDIGLSRFPNQDVD  
FKVLITSRDQSVCTEMGVKADLVLKVSVLEEAHSLFLQFLEPSDDVDPELNKIGE  
EIVKKCCRLPIAIKTMA.TLRSKSKDTWKNALSRLQHHDINTIASTVFQTSYDNLEDE  
40 VTKATFLLCGLFPEDFNIPTEDLLRYGWGLKLFKEVDITREARSKLKACIERLMHTN

LLIEGDDVRYVKMHDLVRAFVLDMFSKAEHASIVNHGSSKPRWPETESDVSSCKR-  
ISLTCKG?

**RG2V polynucleotide sequence (SEQ ID NO:130)**

5 CTGTGGAAGACACGAATGATSAAGAAGCTGAAGGAGGTCGTGGAACAAAA  
GAAAATGTTCAATATTATTGTTCAAGTGGTCATAGGAGAGAAGACAAACC  
CTATTGCTATTCAGCAAGCTGTAGCAGATTACCTCTCTATTGAGCTGAAA  
GAAAACACTAAAGAAGCAAGAGCTGATAAGCTTCGTNAATGGTTCGAGGA  
CGATGGAGGAAAGAATAAGTTCCTTGTAATACTTGATGATGTATGGCAGT  
10 TTGTGCGATCTTGAAGATATTGGTTTAAAGTCCTCTGCCAAATAAAGGTGTC  
AACTTCAAGGTCTTGTGACGTTAAGAGATTCACATGTTTGCACCTCTGAT  
GGGAGCTGAAGCCAATTCAATTCTCAATATAAAAGTTTTAAAGATGTTN  
AAGGACAAAGTTTGTTCGCCAGTTTGCTAAAAATGCAGGTGATGATGAC  
CTGGATCCTGCTTTCATGGGATAGCAGATAGTATTGCAAGTAGATGTCA  
15 AGGTTTGCCCATTTGCCATCAAACCATTGCCTTAAAGTCTTAAAGGTAGAA  
GCAAGCCTGCGTGGGACCATGCGCTTTCTCGTTTGGAGAACCATAAGATT  
GGTAGTGAAGAAGTTGTGCGTGAAGTTTTTAAAATTAGCTATGACAATCT  
CCAAGATGAGGTTACTAAATCTATTTTTWTACTTTGTGCTTTATTTCTTG  
AAGATTTTGATATTCCTATTGAGGAGTTGGTGAGGTATGGGTGGGGCTTG  
20 AAATTATTTATAGAAGCAAAAACCTATAAGAGAAGCAAGAAACAGGCTCAA  
CACCTGCACTGAGCGGCTTAGGGAGACAAATTTGTTATTTGGAAGTGATG  
ACATTGGATGCGTCAAGATGCACGATGTGGTGCGTGATTTTGTTTGGTAT  
ATATTCTCAGAAGTCCAGCACGCTTCAATTGTCAACCATGGTAATGTGTC  
AGAGTGGCTAGAGGAAAATCATAGCATCTACTCTTGTAAGAATTTTCAT  
25 TAACATGCAAGGGTATGTCTGAGTTTCCCAAAGACCTCAAATTTCCAAAC  
CTTTCATTTTGAAACTTATGCATGGAGATAAGTCGNTGAGCTTTCCTGA  
AGACTTTTATGGAAAGATGGAAAAGGTTTCAGGTAATATCATATGATAAAT  
TGATGTATCCATTGCTTCCCTCATCACTTGAATGCTCCACTAACGTTCTGA  
GTGCTTCATCTCCATTATTGTTTCAATTAAGGATGTTTGATTGCTCTTCAAT  
30 TGGTAATCTTCTCAACATGGAAGTGCTCAGCTTTGCTAATTCTAACATTG  
AATGGTTACCATCTACAATTGGAAATTTGAAGAAGCTAAGGCTACTAGAT  
TTGACAAATTGTAAAGGTCTTCGTATAGATAATGGTGTCTTAAAAAATTT  
GGTCAAACCTGAAGAGCTTTATATGGGTGTTAATGTCCGTATGGACCAGG  
CCGT

35

**RG2V deduced polypeptide sequence (SEQ ID NO:131)**

LWKTRM?KKLKEVVEQKKMFNIIVQVVIGEKTNPPIAQQAVADYLSIELKENTKEAR  
ADKLR?WFEDDGGKNKFLVILDDVWQFVDLEDIGLSPLPNKGVNFKVLLTLRDSH  
VCTLMGAEANSILNIKVLKDV?GQSLFRQFAKNAGDDDLDPAFNGIADSIASRCQGL  
40 PIAIKTIALSLKGRSKPAWDHALSRLNHNKIGSEEVVREVFKISYDNLQDEVTKSIF?L  
CALFPEDFDPIEELVRYGWGLKLFIEAKTIREARNRLNTCTERLRETNLLFGSDDIG

CVKMHDEVVRDFVWYIFSEVQHASIVNHGNVSEWLEENHSIYSCKRISLTCKGMSEF  
PKDLKFPNLSILKLMHGDKS?SFPEDFYGKMEKVQVISYDKLMYPLLPSSLECSTNV  
RVLHLHYCSLRMFDCSSIGNLLNMEVLSFANSNIEWLPSTIGNLKKLRLLDLTNCKG  
LRIDNGVLKNLVKLEELYMGVNVVRMDQAV

5

**RG2W polynucleotide sequence (SEQ ID NO:132)**

TTGGGAAAGAGACAATGATGAAGAATTGAAAGAGGTTGTGGTTGAAAAGA  
AAATGTTTAATCATTATGTGGAGGCGGTTATAGGGGAGAAGACGGACCCC  
ATTGCTATTTCAGCAAGCCGTTGCAGAGTACCTTGGTATAATTCTAACAGA  
10 AACCATAAGGCAGCAAGAACCGATAAGCTACGTGCATGGCTTTCTGACA  
ATTCAGATGGAGGAAGAAAGAAGTTCCTAGTAATACTAGACGATGTATGG  
CATCCGGTTGATATGGAAGATATTGGTTTAAGTCGTTTCCCAAATCAAGG  
TGTCGACTTCAAGGTCTTGATTACATCACGGGACCAAGCTGTTTGCCTG  
AGATGGGAGTTAAAGCTGATTTCAGTTATCAAGGTGAGTGTCTAGAGGAA  
15 GCTGAAGCACAAAGCTTATTCTGCCAACTTTGGGAACCTTCTGATGATGT  
CGATCCTGAGCTCCATCAGATTGGAGAAGAAATTGTAAGGAAGTGTGTG  
GTTTACCCATTGCAATAAAAACCATGGCCTGCACTCTTAGAAGTAAAAGC  
AAGGATACATGGAAGAATGCACTTTCTCGTTTACAACACCATGACATTAA  
CACAGTCGCGCCTACTGTTTTTCAAACCAGCTATGACAATCTCCAAGATG  
20 AGGTGACTGGAGATACTTTTTTGCTATGTGGTTTGTTCGGGAGGACTTC  
GATATTCCTACTGAAGACTTATTGAAGTATGGATGGGGCTTAAATTATT  
CAAGGGAGTGGATTCTGTAAGAGAAGCAAGATACCAGTTGAACGCCTGCA  
TTGAGCGGCTCGTGCATACCAATTTGTTGATTGAAAGTGATGTTGTTGGG  
TGCGTCAAGTTGCACGATCTGGTGCGTGCTTTTATTTTGGATATGTTTTG  
25 TAAAGCGGAGCATGCTTCGATTGTCAACCATGGTAGTAGTAAGCCTGGGT  
GGCCTGAAACTGAAAATGATGTGATCAGGACCTCCTGCAAAAGAATCTCA  
TTAACATGCAAGGGTATGATTGAGTTTTCTAGTGACCTCAAGTTTCCAAA  
TGTCTTGATTTTAAACTTATGCATGGAGATAAGTCGCTAAGGTTT

**RG2W deduced polypeptide sequence (SEQ ID NO:133)**

WERDNDEELKEVVVEKKMFNHYVEAVIGEKTDPPIAQQAVAEYLGILTETTKAAR  
TDKLRAWLSDNSDGGRRKKFLVILDDVWHPVDMEDIGLSRFPNQGVDFKVLITSRD  
QAVCTEMGVKADSVIKVSVLEEAEQSLFCQLWEPSSDDVDPELHQIGEEIVRKCCG  
LPIAIKTMACTLRSSKDTWKNAISRLLQHHINTVAPTQTSYDNLQDEVTGDTF  
35 LLCGLFPEDFDIPTEDLLKYGWGLKLFKGVDSVREARYQLNACIERLVHTNLLIESD  
VVGCVKLHDLVRAFILDMFCKAEHASIVNHGSSKPGWPETENDVIRTSCKRISLTCK  
GMIEFSSDLKFPNVLILKLMHGDKSLRF

**RG5 polynucleotide sequence (SEQ ID NO:134)**

40 GGGGGGGTGGGGAAGNCGACTCTAGCCCAGAAAGNTCTATAATGACCATAA  
AATAAAAGGAAGCTTTAGTAAACAAGCATGGATCTGTGTTTCTCAACAAT

ATTCTGATATTTCAAGTTTTGAAAGAAGTCCTTCGGAACATCGGTGTTGAT  
TATAAGCATGATGAAACTGTTGGAGAACTTAGCAGAAGGCTTGCAATAGC  
TGTCGAAAATGCAAGTTTCTTTCTTGTGTTGGATGATATTTGGCAACATG  
AGGTGTGGACTAATTTACTCAGAGCCCCATTAAACACTGCAGCTACAGGA  
5 ATAATTCTAGTAACAACTCGTAATGATACAGTTGCACGAGCAATTGGGGT  
GGAAGATATTCATCGAGTAGAATTGATGTCAGATGAAGTAGGATGGAAAT  
TGCTTTTGAAGAGTATGAACATTAGCAAAGAAAGTGAAGTAGAAAACCTA  
CGAGTTTTAGGGGTTGACATTGTTCTGTTGTGTGGTGGCCTCCCCCTAGC  
CTT

10

**RG5 deduced polypeptide sequence (SEQ ID NO:135)**

GGVGKTTLAQK?YNDHKIKGSFSKQAWICVSQQYSDISVLKEVLNIGVDYKHDET  
VGELSRRLAIAVENASFLLVDDIWQHEVWTNLLRAPLNTAATGILVTRNDTVA  
RAIGVEDIHRVELMSDEVGWKLLLKSMNISKESEVENLRVLGVDIVRLCGGLPLAL

15

**RG7 polynucleotide sequence (SEQ ID NO:136)**

GGTGGGGTTGGGAAGACAACGGGCACAAGGAGGCGACTGCCAATACTTCC  
GACTTTTATTCATAGAGATGACGAGTCTTATTTTCTACTACTATAGGGA  
GGATATTTGGTTGCGCGAGACGATTGCGCGAAGGGATTCTATCCTT  
20 CTTTTTTTCCGCGAAGACTTCGTTCCGGAGGACGGGCTATATTCCCTTTA  
ATATTAGTCTAGCCCAGTCTAGGCCAACCATATGGCGATGCGGTAGACCT  
CCCAGAGATAGATACTTGATCTTAGAGGATTACACGTTCAATGGTGGAA  
ACTTAAGGAACCGGCTAAGAGTGACTAAACGGAAAAACCCTATTCATTCC  
ATAGCCTCATCCGGTCGAGGCATTAAACAATCCATCCCAATCCTCTTTCC  
25 TTTGGTCTACTCTAATGATGTGCCCCTTCGTTGGTGGAATATCTCTTTAT  
ACCGACGATTTATATGGGGATTGCCACTAGCGTTG

30

The above examples are provided to illustrate the invention but not to limit its scope. Other variants of the invention will be readily apparent to one of ordinary skill in the art and are encompassed by the appended claims. All publications, patents, and patent applications cited herein are hereby incorporated by reference.

WHAT IS CLAIMED IS:

1. An isolated nucleic acid construct comprising an RG polynucleotide which encodes an RG polypeptide having at least 60% sequence identity to an RG polypeptide from an RG family selected from the group consisting of: an RG1 polypeptide, an RG2 polypeptide, an RG3 polypeptide, an RG4 polypeptide, an RG5 polypeptide, and an RG7 polypeptide.
2. The nucleic acid construct of claim 1, wherein the RG polynucleotide encodes an RG polypeptide comprising an leucine rich region (LRR).
3. The nucleic acid construct of claim 1, wherein the RG polynucleotide encodes an RG polypeptide comprising a nucleotide binding site (NBS).
4. The nucleic acid construct of claim 1, wherein the polynucleotide is a full length gene.
5. The nucleic acid construct of claim 1, wherein the further encodes a fusion protein.
6. The nucleic acid construct of claim 1, wherein the RG1 polypeptide is encoded by an RG1 polynucleotide sequence.
7. The nucleic acid construct of claim 6, wherein the RG1 polypeptide is encoded by a polynucleotide sequence selected from the group consisting of SEQ ID NO:1 (RG1A), SEQ ID NO:2 (RG1B), SEQ ID NO: 3 (RG1C), SEQ ID NO:4 (RG1D), SEQ ID NO:5 (RG1E), SEQ ID NO:6 (RG1F), SEQ ID NO:7 (RG1G), SEQ ID NO:8 (RG1H), SEQ ID NO:9 (RG1I), and SEQ ID NO:10 (RG1J).
8. The nucleic acid construct of claim 1, wherein the RG2 polypeptide is encoded by an RG2 polynucleotide sequence.
9. The nucleic acid construct of claim 8, wherein the RG2 polypeptide is encoded by a polynucleotide sequence selected from the group consisting of: SEQ ID NO:21 (RG2A);



SEQ ID NO:23 (RG2B); SEQ ID NO:25 (RG2C); SEQ ID NO:27 (RG2D); SEQ ID NO:29 (RG2E); SEQ ID NO:31 (RG2F); SEQ ID NO:33 (RG2G); SEQ ID NO:35 (RG2H); SEQ ID NO:37 (RG2I); SEQ ID NO:39 (RG2J); SEQ ID NO:41 (RG2K); SEQ ID NO:43 (RG2L); SEQ ID NO:45 (RG2M); SEQ ID NO:87 (RG2A); SEQ ID NO:89 (RG2B); SEQ ID NO:91 (RG2C); SEQ ID NO:93 (RG2D) and SEQ ID NO:94 (RG2D); SEQ ID NO:96 (RG2E); SEQ ID NO:98 (RG2F); SEQ ID NO:100 (RG2G); SEQ ID NO:102 (RG2H); SEQ ID NO:104 (RG2I); SEQ ID NO:106 (RG2J) and SEQ ID NO:107 (RG2J); SEQ ID NO:109 (RG2K) and (SEQ ID NO:110 (RG2K); SEQ ID NO:112 (RG2L); SEQ ID NO:114 (RG2M); SEQ ID NO:116 (RG2N); SEQ ID NO:118 (RG2O); SEQ ID NO:120 (RG2P); SEQ ID NO:122 (RG2Q); SEQ ID NO:124 (RG2S); SEQ ID NO:126 (RG2T); SEQ ID NO:128 (RG2U); SEQ ID NO:130 (RG2V); and, SEQ ID NO:132 (RG2W).

10. The nucleic acid construct of claim 1, wherein the RG3 polypeptide is encoded by an RG3 polynucleotide sequence.

11. The nucleic acid construct of claim 10, wherein the RG3 polypeptide is encoded by a polynucleotide sequence as set forth in SEQ ID NO:68.

12. The nucleic acid construct of claim 1, wherein the RG4 polypeptide is encoded by an RG4 polynucleotide sequence.

13. The nucleic acid construct of claim 12, wherein the RG4 polypeptide is encoded by a polynucleotide sequence as set forth in SEQ ID NO:69.

14. The nucleic acid construct of claim 1, wherein the RG5 polypeptide is encoded by an RG5 polynucleotide sequence.

15. The nucleic acid construct of claim 14, wherein the RG5 polypeptide is encoded by a polynucleotide sequence as set forth in SEQ ID NO:134.

16. The nucleic acid construct of claim 1, wherein the RG7 polypeptide is encoded by an RG7 polynucleotide sequence.
17. The nucleic acid construct of claim 16, wherein the RG7 polypeptide is encoded by a polynucleotide sequence as set forth in SEQ ID NO:136.
18. The nucleic acid construct of claim 1, further comprising a promoter operably linked to the RG polynucleotide.
19. The nucleic acid construct of claim 18, wherein the promoter is a plant promoter.
20. The nucleic acid construct of claim 19, wherein the plant promoter is a disease resistance promoter.
21. The nucleic acid construct of claim 19, wherein the plant promoter is a lettuce promoter.
22. The nucleic acid construct of claim 18, wherein the promoter is a constitutive promoter.
23. The nucleic acid construct of claim 18, wherein the promoter is an inducible promoter.
24. The nucleic acid construct of claim 18, wherein the promoter is a tissue-specific promoter.
25. A nucleic acid construct comprising a promoter sequence from an RG gene linked to a heterologous polynucleotide.
26. A transgenic plant comprising a recombinant expression cassette comprising a promoter operably linked to an RG polynucleotide.

27. The transgenic plant of claim 26, wherein the plant promoter is a plant promoter.
28. The transgenic plant of claim 26, wherein the plant promoter is a viral promoter.
- 5 29. The transgenic plant of claim 26, wherein the plant promoter is a heterologous promoter.
30. The transgenic plant of claim 26, wherein the plant is lettuce.
- 10 31. The transgenic plant of claim 26, wherein the RG polynucleotide is selected from the group consisting of SEQ ID NO:1 (RG1A), SEQ ID NO:2 (RG1B), SEQ ID NO: 3 (RG1C), SEQ ID NO:4 (RG1D), SEQ ID NO:5 (RG1E), SEQ ID NO:6 (RG1F), SEQ ID NO:7 (RG1G), SEQ ID NO:8 (RG1H), SEQ ID NO:9 (RG1I), and SEQ ID NO:10 (RG1J).
- 15 32. The transgenic plant of claim 26, wherein the RG polynucleotide is selected from the group consisting of SEQ ID NO:21 (RG2A); SEQ ID NO:23 (RG2B); SEQ ID NO:25 (RG2C); SEQ ID NO:27 (RG2D); SEQ ID NO:29 (RG2E); SEQ ID NO:31 (RG2F); SEQ ID NO:33 (RG2G); SEQ ID NO:35 (RG2H); SEQ ID NO:37 (RG2I); SEQ ID NO:39 (RG2J); SEQ ID NO:41 (RG2K); SEQ ID NO:43 (RG2L); SEQ ID NO:45 (RG2M); SEQ ID NO:87 (RG2A); SEQ ID NO:89 (RG2B); SEQ ID NO:91 (RG2C); SEQ ID NO:93 (RG2D) and SEQ ID NO:94 (RG2D); SEQ ID NO:96 (RG2E); SEQ ID NO:98 (RG2F); SEQ ID NO:100 (RG2G); SEQ ID NO:102 (RG2H); SEQ ID NO:104 (RG2I); SEQ ID NO:106 (RG2J) and SEQ ID NO:107 (RG2J); SEQ ID NO:109 (RG2K) and (SEQ ID NO:110 (RG2K); SEQ ID NO:112 (RG2L); SEQ ID NO:114 (RG2M); SEQ ID NO:116 (RG2N); SEQ ID NO:118 (RG2O); SEQ ID NO:120 (RG2P); SEQ ID NO:122 (RG2Q); SEQ ID NO:124 (RG2S); SEQ ID NO:126 (RG2T); SEQ ID NO:128 (RG2U); SEQ ID NO:130 (RG2V); and, SEQ ID NO:132 (RG2W).
- 20 33. The transgenic plant of claim 26, wherein the RG polynucleotide is selected from the group consisting of SEQ ID NO:68 (RG3) and SEQ ID NO:69 (RG4).
- 25 30

34. The transgenic plant of claim 26, wherein the RG polynucleotide comprises a sequence as set forth in SEQ ID NO:134 (RG5).

5 35. The transgenic plant of claim 26, wherein the RG polynucleotide comprises a sequence as set forth in SEQ ID NO:136 (RG7).

36. The transgenic plant of claim 26, wherein the RG polynucleotide encodes an RG1 polypeptide selected from the group consisting of SEQ ID NO:11 (RG1A), SEQ ID NO:12 (RG1B), SEQ ID NO: 13 (RG1C), SEQ ID NO:14 (RG1D), SEQ ID NO:15 (RG1E), SEQ  
10 ID NO:16 (RG1F), SEQ ID NO:17 (RG1G), SEQ ID NO:18 (RG1H), SEQ ID NO:19 (RG1I), and SEQ ID NO:20 (RG1J).

37. The transgenic plant of claim 26, wherein the RG polynucleotide encodes an RG2 polypeptide selected from the group consisting of SEQ ID NO:22 and SEQ ID NO:41  
15 (RG2A); SEQ ID NO:24 and SEQ ID NO:42 (RG2B); SEQ ID NO:43 (RG2C); SEQ ID NO:44 (RG2D); SEQ ID NO:45 (RG2E); SEQ ID NO:46 (RG2F); SEQ ID NO:47 (RG2G); SEQ ID NO:48 (RG2H); SEQ ID NO:49 (RG2I); SEQ ID NO:50 (RG2J); SEQ ID NO:51 (RG2K); SEQ ID NO:52 (RG2L); SEQ ID NO:53 (RG2M); SEQ ID NO:88 (RG2A); SEQ ID NO:90 (RG2B); SEQ ID NO:92 (RG2C); SEQ ID NO:95 (RG2D); SEQ  
20 ID NO:97 (RG2E); SEQ ID NO:99 (RG2F); SEQ ID NO:101 (RG2G); SEQ ID NO:103 (RG2H); SEQ ID NO:105 (RG2I); SEQ ID NO:108 (RG2J); SEQ ID NO:111 (RG2K); SEQ ID NO:113 (RG2L); SEQ ID NO:115 (RG2M); SEQ ID NO:117 (RG2N); SEQ ID NO:119 (RG2O); SEQ ID NO:121 (RG2P); SEQ ID NO:123 (RG2Q); SEQ ID NO:125 (RG2S); SEQ ID NO:127 (RG2T); SEQ ID NO:129 (RG2U); SEQ ID NO:131 (RG2V); and, SEQ ID  
25 NO:133 (RG2W).

38. The transgenic plant of claim 26, wherein the RG polynucleotide encodes an RG3 polypeptide with a sequence as set forth by SEQ ID NO:138.

30 39. The transgenic plant of claim 26, wherein the RG polynucleotide encodes an RG4 polypeptide with a sequence as set forth by SEQ ID NO:139.

40. The transgenic plant of claim 26, wherein the RG polynucleotide encodes an RG5 polypeptide with a sequence as set forth by SEQ ID NO:135.

5 41. A method of enhancing disease resistance in a plant, the method comprising introducing into the plant a recombinant expression cassette comprising a promoter functional in the plant and operably linked to an RG polynucleotide sequence.

42. The method of claim 41, wherein the plant is a lettuce plant.

10 43. The method of claim 41, wherein the RG polynucleotide encodes an RG polypeptide selected from the group consisting of SEQ ID NO:22 and SEQ ID NO:41 (RG2A); SEQ ID NO:24 and SEQ ID NO:42 (RG2B); SEQ ID NO:43 (RG2C); SEQ ID NO:44 (RG2D); SEQ ID NO:45 (RG2E); SEQ ID NO:46 (RG2F); SEQ ID NO:47 (RG2G); SEQ ID NO:48 (RG2H); SEQ ID NO:49 (RG2I); SEQ ID NO:50 (RG2J); SEQ ID NO:51  
15 (RG2K); SEQ ID NO:52 (RG2L); SEQ ID NO:53 (RG2M); SEQ ID NO:88 (RG2A); SEQ ID NO:90 (RG2B); SEQ ID NO:92 (RG2C); SEQ ID NO:95 (RG2D); SEQ ID NO:97 (RG2E); SEQ ID NO:99 (RG2F); SEQ ID NO:101 (RG2G); SEQ ID NO:103 (RG2H); SEQ ID NO:105 (RG2I); SEQ ID NO:108 (RG2J); SEQ ID NO:111 (RG2K); SEQ ID NO:113 (RG2L); SEQ ID NO:115 (RG2M); SEQ ID NO:117 (RG2N); SEQ ID NO:119 (RG2O);  
20 SEQ ID NO:121 (RG2P); SEQ ID NO:123 (RG2Q); SEQ ID NO:125 (RG2S); SEQ ID NO:127 (RG2T); SEQ ID NO:129 (RG2U); SEQ ID NO:131 (RG2V); and, SEQ ID NO:133 (RG2W).

25 44. The method of claim 41, wherein the RG polynucleotide encodes an RG polypeptide selected from the group consisting of SEQ ID NO:138 (RG3); SEQ ID NO:139 (RG4); and SEQ ID NO:135 (RG5).

45. The method of claim 41, wherein the promoter is a tissue-specific promoter or a plant disease resistance promoter.

46. The method of claim 41, wherein the promoter is a constitutive promoter or an inducible promoter.

47. A method of detecting RG resistance genes in a nucleic acid sample, the method  
5 comprising:  
    contacting the nucleic acid sample with an RG polynucleotide to form a  
hybridization complex; and,  
    wherein the formation of the hybridization complex is used to detect the RG  
resistance gene in the nucleic acid sample.

10

48. The method of claim 47, wherein the RG polynucleotide is an RG1 polynucleotide.

49. The method of claim 47, wherein the RG polynucleotide is an RG2 polynucleotide.

15 50. The method of claim 47, wherein the RG polynucleotide is an RG3 polynucleotide, an RG4 polynucleotide, an RG5 polynucleotide or an RG7 polynucleotide.

51. The method of claim 47, wherein the RG resistance gene is amplified prior to the step of contacting the nucleic acid sample with the RG polynucleotide.

20

52. The method of claim 51, where the RG resistance gene is amplified by the polymerase chain reaction.

53. The method of claim 47, wherein the RG polynucleotide is labeled.

25

54. An RG polypeptide having at least 60% sequence identity to a polypeptide selected from the group consisting of: an RG1 polypeptide, an RG2 polypeptide, an RG3 polypeptide, an RG4 polypeptide, an RG5 polypeptide, and an RG7 polypeptide.

## INTERNATIONAL SEARCH REPORT

International application No.  
PCT/US98/00615

<b>A. CLASSIFICATION OF SUBJECT MATTER</b>														
IPC(6) : Please See Extra Sheet.														
US CL : 435/6, 91.2, 418, 419; 530/350; 536/23.1, 23.6, 24.1; 800/205														
According to International Patent Classification (IPC) or to both national classification and IPC														
<b>B. FIELDS SEARCHED</b>														
Minimum documentation searched (classification system followed by classification symbols)														
U.S. : 435/6, 91.2, 418, 419; 530/350; 536/23.1, 23.6, 24.1; 800/205														
Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched														
Electronic data base consulted during the international search (name of data base and, where practicable, search terms used)														
APS, DIALOG														
<b>C. DOCUMENTS CONSIDERED TO BE RELEVANT</b>														
Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.												
Y	PARAN et al. Development of Reliable PCR-Based Markers Linked to Downy Mildew Resistance Genes in Lettuce. Theor. Appl. Genet. 1993. Vol. 85, No. 8, pages 985-993, see entire article.	1-6, 8, 10, 12, 14, 16, 18-30, 41-42, 45-54												
Y	KESSELI et al. Analysis of a Detailed Genetic Linkage Map of Lactuca sativa (Lettuce) Constructed From RFLP and RAPD Markers. Genetics. April 1994. Vol. 136, No. 4, pages 1435-1446, see entire document.	1-6, 8, 10, 12, 14, 16, 18-30, 41-42, 45-54												
Y	MICHELMORE, RW. Isolation of Disease Resistance Genes from Crop Plants. Current Opinion in Biotechnology. 1995. Vol. 6, No. 2, pages 145-152, see entire document.	1-6, 8, 10, 12, 14, 16, 18-30, 41-42, 45-54												
<input checked="" type="checkbox"/> Further documents are listed in the continuation of Box C. <input type="checkbox"/> See patent family annex.														
<table border="0"> <tr> <td>* Special categories of cited documents:</td> <td>*T* later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention</td> </tr> <tr> <td>*A* document defining the general state of the art which is not considered to be of particular relevance</td> <td>*X* document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone</td> </tr> <tr> <td>*B* earlier document published on or after the international filing date</td> <td>*Y* document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art</td> </tr> <tr> <td>*L* document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)</td> <td>*A* document member of the same patent family</td> </tr> <tr> <td>*O* document referring to an oral disclosure, use, exhibition or other means</td> <td></td> </tr> <tr> <td>*P* document published prior to the international filing date but later than the priority date claimed</td> <td></td> </tr> </table>			* Special categories of cited documents:	*T* later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention	*A* document defining the general state of the art which is not considered to be of particular relevance	*X* document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone	*B* earlier document published on or after the international filing date	*Y* document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art	*L* document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)	*A* document member of the same patent family	*O* document referring to an oral disclosure, use, exhibition or other means		*P* document published prior to the international filing date but later than the priority date claimed	
* Special categories of cited documents:	*T* later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention													
*A* document defining the general state of the art which is not considered to be of particular relevance	*X* document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone													
*B* earlier document published on or after the international filing date	*Y* document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art													
*L* document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)	*A* document member of the same patent family													
*O* document referring to an oral disclosure, use, exhibition or other means														
*P* document published prior to the international filing date but later than the priority date claimed														
Date of the actual completion of the international search		Date of mailing of the international search report												
14 MARCH 1998		13 APR 1998												
Name and mailing address of the ISA/US Commissioner of Patents and Trademarks Box PCT Washington, D.C. 20231		Authorized official PHUONG BUI												
Facsimile No. (703) 305-3230		Telephone No. (703) 308-0196												

# INTERNATIONAL SEARCH REPORT

International application No.  
PCT/US98/00615

## C (Continuation). DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
Y	PARAN et al. Recent Amplification of Triose Phosphate Isomerase Related Sequences in Lettuce. Genome. 1992. Vol. 35, No. 4, pages 627-635, see entire document.	1-6, 8, 10, 12, 14, 16, 18-30, 41-42, 45-54
Y	PARAN et al. Identification of Restriction Fragment Length Polymorphism and Random Amplified Polymorphic DNA markers linked to Downy Mildew Resistance Genes in Lettuce, Using Near-Isogenic Lines. Genome. 1991. Vol. 34, No. 6, pages 1021-1027, see entire document.	1-6, 8, 10, 12, 14, 16, 18-30, 41-42, 45-54



## INTERNATIONAL SEARCH REPORT

International application No.  
PCT/US98/00615**Box I Observations where certain claims were found unsearchable (Continuation of Item 1 of first sheet)**

This international report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. ☐ Claims Nos.:  
because they relate to subject matter not required to be searched by this Authority, namely:
2. ☒ Claims Nos.: 7, 9, 11, 13, 15, 17, 31-40, 43-44  
because they relate to parts of the international application that do not comply with the prescribed requirements to such an extent that no meaningful international search can be carried out, specifically:  
  
these claims are drawn to numerous sequences identified by SEQ ID NOs. However, since no computer readable form was submitted, no meaningful search could be carried out.
3. ☐ Claims Nos.:  
because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

**Box II Observations where unity of invention is lacking (Continuation of Item 2 of first sheet)**

This International Searching Authority found multiple inventions in this international application, as follows:

1. ☐ As all required additional search fees were timely paid by the applicant, this international search report covers all searchable claims.
2. ☐ As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee.
3. ☐ As only some of the required additional search fees were timely paid by the applicant, this international search report covers only those claims for which fees were paid, specifically claims Nos.:
4. ☐ No required additional search fees were timely paid by the applicant. Consequently, this international search report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:

Remark on Protest

- ☐ The additional search fees were accompanied by the applicant's protest.  
☐ No protest accompanied the payment of additional search fees.

**INTERNATIONAL SEARCH REPORT**

International application No.  
PCT/US98/00615

**A. CLASSIFICATION OF SUBJECT MATTER:**  
IPC (6):

A01H 1/00; C07H 21/04; C07K 14/00; C12N 5/04, 5/10; C12P 19/34; C12Q 1/68